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Abstract 
Hypothesis: Polyphenols in apples cause specific molecular changes in vascular 
endothelial cell which can lead to improvements in vascular function.  
 
Results: First, changes in polyphenol concentrations in apples with respect to fruit 
growth and maturity and seasonal variations were assessed in order to allow the 
optimisation of harvest dates and predict the effects of weather on polyphenol yields 
and composition. The data showed that the polyphenol concentration decreases during 
fruit growth while the content increases due to an increase in fruit weight. It was also 
shown that the mean temperature is negatively correlated with polyphenol content and 
concentration while the total amount of rainfall and the total hours of sunshine are 
positively correlated.  
 
Next, simple strategies to achieve a high-yielding polyphenol-rich apple extract were 
tested. Heat treatment of whole apples prior to pressing failed to decrease the loss of 
polyphenols observed during pressing. However, hot water extraction of apple pomace, 
a by-product of apple juice production, was shown to be a very effective method of 
extracting polyphenols retained in the pomace (extraction yield 51 % with 17 % of the 
polyphenols retained in the pomace). In a randomised human intervention trial, it was 
shown that a pre-commercial apple polyphenol extract caused small but significant 
improvements in vascular stiffness index, in keeping with the original hypothesis.  
 
Treatment of human umbilical vein endothelial cells with vascular endothelial growth 
factor (VEGF) and apple procyanidin, but not epicatechin, resulted in an inhibition of 
VEGF-induced migration. It was therefore hypothesised that apple procyanidins inhibit 
VEGF signalling. It was shown that certain polyphenols specifically inhibited VEGF-
induced VEGFR-2 phosphorylation at physiological concentrations, and it was shown 
for the first time that polyphenols were able to inhibit VEGF signalling by interacting 
with the VEGF molecule and not the receptor. The interaction between the polyphenols 
and VEGF was the result of a non-covalent slow binding of one or more molecules of 
polyphenol to the VEGF protein resulting in the formation of a tightly bound VEGF-
polyphenol complex. Using a human whole genome gene array, it was confirmed that 
the apple procyanidin fraction completely negated the cellular effects of VEGF. Further, 
the procyanidin fraction regulated the expression of many other genes (e.g. KLF2) that 
are involved in angiogenesis and inflammation independently of VEGF. 
 
Conclusions: These findings are significant because they provide a plausible link 
between consumption of dietary polyphenols and an improvement of vascular function. 
More importantly this data shows a novel mechanism of how polyphenols inhibit VEGF-
induced VEGFR-2 phosphorylation. While this research has only shown an interaction 
with VEGF, it raises the possibility that polyphenols can affect other signalling 
pathways by interacting with other signalling peptides such as growth factors and 
hormones.  
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Chapter 1 : General introduction 
1.1 Structure of the thesis 
This thesis contains the results of a research project that spanned apple polyphenol 
content and composition and the effect of seasonal variation, through apple processing 
techniques for extracting polyphenols, to in-vitro and human studies focussed on 
biological effects of apple polyphenols and mechanisms of action at the cellular and 
molecular levels. The purpose of this general introduction is to introduce polyphenols; 
their bioavailability, metabolism and absorption; their health related properties; and to 
detail the overall aim and specific objectives of the thesis. As the objectives of each of 
the results chapters focus on different aspects of apple polyphenols and their impact on 
vascular endothelial cells, each results chapter will also provide an overview of the 
literature relevant to the research aims of that chapter.  
 
1.2 What are polyphenols? 
Polyphenols are one of the most numerous and widely distributed groups of secondary 
metabolites in the plant kingdom (Bravo, 1998; Ross and Kasum, 2002). Polyphenols 
are the result of secondary metabolism in plants and are derived from both the 
shikimate (phenylalanine) pathway and the acetate-malonate (malonyl-CoA) pathway 
via several enzymatic steps (Bravo, 1998; Awad et al., 2001a; Golding et al., 2001; 
Ross and Kasum, 2002; Arts and Hollman, 2005). The transformation of phenylalanine 
to cinnamic acid by the enzyme phenylalanine ammonia-lyase (PAL) is the first step in 
the biosynthesis of polyphenols (Figure 1.1) (Awad et al., 2001a).  
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Figure 1.1: A schematic representation of the biosynthetic route of polyphenols in plants. 
Genes encoding enzymes for each step are shown in italics. The shared genes of phenolic acid synthesis 
are PAL = phenylalanine ammonia-lyase; C4H = cinnamate hydroxylase; and 4CL = 4-coumarate CoA 
ligase. The shared genes for anthocyanin synthesis are CHS = chalcone synthase; CHI = chalcone 
flavanone isomerise; F3H = flavanone-3-hydroxylase; DFR = dihydroflavonol-4-reductase; ANS = 
anthocyanidin synthase; and 3GT = cyanidin/flavonol 3-O-glucosyl transferase. The branch genes: FLS = 
flavonol synthase and 3GT for flavonol synthesis; LAR = leucoanthocyanidin reductase and ANR = 
anthocyanidin reductase for synthesis of catechin and epicatechin oligomers.  
 
1.2.1 Classification of polyphenols 
There are more than 8000 polyphenol structures which can be divided into different 
groups based on their chemical structure (the number of phenol rings that they contain 
and to the structural elements that bind these rings to one another) (Manach et al., 
2004; D'Archivio et al., 2007). The main groups of polyphenols are flavonoids, phenolic 
acids, lignans and stilbenes (Figure 1.2).  
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Figure 1.2: Chemical structures of polyphenols. 
 
1.2.1.1 Flavonoids 
Flavonoids are the most common and widely distributed group of polyphenols that are 
present in plants, with more than 4000 different varieties of flavonoids. They are also 
the most abundant polyphenols in our diet accounting for two-thirds of the total 
polyphenol intake (Scalbert and Williamson, 2000). Flavonoids share a common basic 
carbon backbone structure, the diphenylpropane skeleton. The diphenylpropane 
skeleton (C6-C3-C6) consists of two benzene rings (A and B) linked by a three-carbon 
chain. This three carbon chain forms a closed pyran ring (C) (Figure 1.2). Different 
Flavonoids 
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degrees of hydroxylation and oxidation of the heterocyclic C pyran ring gives rise to six 
subclasses of flavonoids: flavonols, flavones, flavanols, flavanones, anthocyanins and 
isoflavones (Figure 1.3).  
 
 
Figure 1.3: Chemical structures of flavonoids 
 
Flavonols are the most commonly occurring flavonoids in foods with quercetin being 
the main flavonol found in the human diet. Other flavonols include kaempferol, fisetin 
and myricetin. In plants, flavonols are present in their glycosylated forms and the 
commonly attached sugars are glucose or rhamnose but other sugars may be involved 
such as galactose, arabinose and xylose (Manach et al., 2004). Flavonol synthesis is 
stimulated by light; therefore they accumulate more so in the skin and leaves of fruits 
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and vegetables (Manach et al., 2004; D'Archivio et al., 2007). The richest sources of 
flavonols in the human diet are blueberries, onions, leeks, broccoli, curly kale, red wine 
and tea (Scalbert and Williamson, 2000; D'Archivio et al., 2007).  
 
Flavones are the least common flavonoid and they are not widespread in the human 
diet. The most common flavones found in plants consist of glycosides of luteolin which 
are found in sweet red peppers and artichokes and apigenin which are found in celery 
(Scalbert and Williamson, 2000; Manach et al., 2004; D'Archivio et al., 2007). The 
flavones apigenin and luteolin are also common in cereal grains and aromatic herbs 
(parsley, rosemary and thyme) (Peterson and Dwyer, 1998; Pietta, 2000). 
 
Flavanols exist in both the monomer form (catechins) and the polymer form 
(proanthocyanidins) and unlike other flavonoids they are not glycosylated in foods 
(Scalbert and Williamson, 2000). Catechins are widely distributed in plants and are 
found in many fruits such as apples, apricots and cherries as well as in chocolate, tea 
and red wine (Pietta, 2000). Catechin and epicatechin are the main flavanols found in 
fruits while gallocatechin, epigallocatechin and epigallocatechin gallate are the main 
flavanols found in tea (Manach et al., 2004). Proanthocyanidins, which are also known 
as condensed tannins, are dimers, oligomers and polymers of catechins that are bound 
together by links between C4 and C8 or C6. Proanthocyanidins are found in fruits (e.g. 
apples, grapes, and cranberries), cocoa and beverages (e.g. red wine and tea). 
 
Flavanones are found in high concentrations in citrus fruit, but are also present in 
tomatoes and certain aromatic plants such as mint (Manach et al., 2004). The main 
flavanones are naringenin (found in grapefruit), hesperidin (found in oranges) and 
eriodictyol (found in lemons). They are generally glycosylated by either neohesperidose 
(which gives a bitter taste) or rutinose (which is flavourless) (Peterson and Dwyer, 
1998).  
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Anthocyanins are water soluble pigments that are responsible for the red, blue and 
purple colours of plants and fruits (D'Archivio et al., 2007). Anthocyanins are the 
glycosylated forms of anthocyanidins. Anthocyanins are widespread in the human diet; 
they are most abundant in fruits but are also found in red wine, certain cereals, certain 
leafy and root vegetables (Manach et al., 2004; D'Archivio et al., 2007). Anthocyanins 
include cyanidin (most common anthocyanidin in foods), delphinidin, petunidin, 
pelargonidin, peonidin and malvidin.  
 
Isoflavones are classified as phytoestrogens because of their structural similarities to 
estrogens and their ability to bind to estrogen receptors (Peterson and Dwyer, 1998; 
Manach et al., 2004; D'Archivio et al., 2007). Isoflavones are found most often in 
leguminous plants including soybeans, black beans, green beans and chickpeas with 
soya and its products being the main source in the human diet (Peterson and Dwyer, 
1998; Pietta, 2000; Manach et al., 2004). The main isoflavones are genistein, daidzein 
and to a lesser extent glycitein.  
 
1.2.1.2 Phenolic acids 
Phenolic acids are abundant in foods and account for one-third of the total intake of 
polyphenols in the diet (Scalbert and Williamson, 2000). Phenolic acids present in 
plants are hydroxylated derivatives of benzoic acid and cinnamic acid (Manach et al., 
2004; D'Archivio et al., 2007). 
 
Hydroxybenzoic acids are found in a few plants that are consumed in the human diet. 
Edible plants containing hydroxybenzoic acids generally have very low contents of 
hydroxybenzoic acids with the exception of certain red fruits (e.g. blackberries), black 
radishes and onions (Manach et al., 2004; D'Archivio et al., 2007). Hydroxybenzoic 
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acids include gallic acid and protocatechuic acid. Tea is an important source of gallic 
acid and raspberries are an important source of protocatechuic acid. 
 
Hydroxycinnamic acids consist mainly of p-coumaric, caffeic, ferulic and sinapic acids. 
They are rarely found in their free form and their bound forms are glycosylated 
derivatives or esters of quinic, shikimic or tartaric acid (Manach et al., 2004). The most 
frequently encountered hydroxycinnamic acids are caffeic and ferulic acid and caffeic 
acid is the most abundant phenolic acid in fruits while ferulic acid is the most abundant 
phenolic acid in cereals. Caffeic and quinic acid combine to form chlorogenic acid 
which is found in many types of fruits as well as in coffee.  
 
1.2.1.3 Lignans 
Lignans are formed by oxidative dimerization of two phenylpropane units. Lignans 
include secoisolariciresinol, matairesinol, pinoresinol and lariciresinol. The richest 
dietary source of lignans are linseed and linseed oil, which contain secoisolariciresinol 
and matairesinol (Manach et al., 2004). Other cereals, grains, fruits and certain 
vegetables also contain traces of these lignans but in smaller concentrations than that 
found in linseed. Lignans are also phytoestrogens due to their estrogen agonist and 
antagonist properties (Scalbert and Williamson, 2000). 
 
1.2.1.4 Stilbenes 
Stilbenes are not widespread in food plants and are only found in low quantities in the 
human diet. The main representative of stilbenes is resveratrol which has received a lot 
of interest due to its anti-carcinogenic properties (Scalbert and Williamson, 2000; 
Manach et al., 2004). Resveratrol is found in grapes, red wine and grape juice.   
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1.2.2 Dietary intake of polyphenols 
Several studies have estimated the polyphenol intakes in various countries including 
Australia (Johannot and Somerset, 2006), Denmark (Justesen et al., 1997), Finland 
(Hirvonen et al., 2000; Knekt et al., 2002; Ovaskainen et al., 2008), France 
(Commenges et al., 2000), Greece (Vasilopoulou et al., 2005; Dilis and Trichopoulou, 
2010), Japan (Arai et al., 2000), Ireland (Beking and Vieira, 2011), Mexico (Hervert-
Hernández et al., 2010), Spain (Garcia-Closas et al., 1999), The Netherlands (Hertog 
et al., 1993b; Arts et al., 2001a; Boker et al., 2002), the United Kingdom (Beking and 
Vieira, 2011) and the United States (Rimm et al., 1996; de Kleijn et al., 2001; Wu et al., 
2002; Gu et al., 2004; Chun et al., 2007; Wang et al., 2011). A summary of the reported 
polyphenol intakes in these countries is described in Table 1.1. The reported 
polyphenol consumption varies substantially between these populations groups. The 
actual polyphenol intakes are likely to be higher than the reported values because the 
data provided in these reports do not represent the total polyphenol intake but only 
estimates of the intake of selected analysed polyphenols. Therefore the dietary intake 
methodologies, the foods analysed, the method used for quantification of dietary intake 
of polyphenols and the selected polyphenols analysed all contribute to the differences 
observed between countries (Johannot and Somerset, 2006; Chun et al., 2007). 
Dietary habits and food preferences of different cultures also play a part in the 
variability of the mean polyphenol intakes between countries (Beecher, 2003). The 
growing conditions (e.g. cultivar, climate conditions, seasonal variations and date of 
harvesting) of the fruit and vegetable also contribute to the variability in polyphenol 
consumption between countries. For further information on how the cultivar, climate 
conditions and seasonal variations affect the polyphenol content in apples, refer to 
Chapter 2 (Introduction).  
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Table 1.1: Estimated mean polyphenol consumption (mg/day) in different countries. 
Country Estimated mean 
polyphenol intake 
(mg/day) 
Polyphenols analysed Richest sources of polyphenol 
intake 
Reference 
Australia 454 Flavanols (93 % of intake), flavonols (4.6 %), flavanones 
(1.6 %), anthocyanidins (0.6 %) and flavones (0.1 %) 
Tea, oranges, citrus fruits, grapes, 
wine, apples and leaf and stalk 
vegetables 
Johannot and Somerset 
(2006) 
Denmark 26 Flavanones and Flavonols Tea, onions, apples, oranges and 
orange juice 
Justesen et al. (1997) 
 
Finland 8 Flavonols and Flavones n/a Hirvonen et al. (2000) 
 
 24.2 Flavones, flavonols, flavanols and isoflavones Apples Knekt et al. (2002) 
 863 Phenolic acids (75 % of intake), flavanols (14 %), 
anthocyanidins (6 %) and other flavonoids (4 %) 
Phenoic acids = coffee 
Anthocyanidins = berries and berry 
products 
Flavonoids = apples, berries, tea, 
chocolate and citrus fruit 
Ovaskainen et al. (2008)  
France 14.4 Flavones and flavonols  Fruits, vegetables, wine and tea Commenges et al. (2000) 
Greece 118.6 Flavanones (32 % of intake), flavanols (28 %), flavonols (22 
%), anthocyanidins (9 %), flavones (8 %) and isoflavones (1 
%) 
Oranges, red wine and apples Vasilopoulou et al. (2005) 
 161 Flavonoids = 53% of intake (flavones, flavanols, flavanones, 
flavanols, anthocyanidins, isoflavones), Procyanidins = 47% 
of intake 
Grapes, wine and peaches Dilis and Trichopoulou 
(2010) 
Ireland 177 Flavanols, flavanols, flavanones, flavones, and 
anthocyanidins 
n/a Beking and Vieira (2011) 
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Table 1.1: Estimated mean polyphenol consumption (mg/day) in different countries continued.  
Country Estimated mean 
polyphenol 
intake (mg/day) 
Polyphenols analysed Richest sources of 
polyphenol intake 
Reference 
Japan 63.9 Flavonoids = 2.0 – 42 mg/day (flavones and flavonols) 
Isoflavones = 12 – 119 mg/day 
Flavonoids = onions, molokheya 
and apples 
Isoflavones = tofu, natto and miso 
Arai et al. (2000) 
Mexico 842 Analysed extractable polyphenols, hydrolysable polyphenols and 
proanthocyanidins 
n/a Hervert-Hernández et al. 
(2010) 
Spain 9 Flavonols n/a Garcia-Closas et al. 
(1999) 
The Netherlands 23 Flavonols and flavones Tea, onions and apples Hertog et al. (1993b) 
 50 Flavanols Tea, apples and pears Arts et al. (2001) 
 < 1  Isoflavones n/a Boker et al. (2002) 
United Kingdom 182  Flavanols, flavanols, flavanones, flavones, and anthocyanidins n/a Beking and Vieira (2011) 
United States 20.1 Flavonols, flavones Tea, onions, apples and broccoli Rimm et al. (1996) 
 < 1 Isoflavones n/a (de Kleijn et al. (2001) 
 12 Isoflavones n/a Wu et al. (2002) 
 57.7 Procyanidins (polymers = 73.9 %, trimers = 7.8 %, dimers = 11.2 
% and monomers = 7.1 % of intake) 
Apples, chocolate and grapes Gu et al. (2004) 
 189.7 Flavanols (83.5 % of intake), flavanones (7.6 %), flavonols (6.8 
%), anthocyanidins (1.6 %), flavones (0.8 %), and isoflavones 
(0.6 %) 
Tea, citrus fruit juices, wine and 
citrus fruits 
Chun et al. (2007) 
 95 Procyanidins (polymers = 30 %, monomers = 22 %, dimers = 16 
%, 4-6 mers = 15 %, 7-10 mers = 11 % and trimers = 5 % of 
intake) 
Tea, legumes and wine Wang et al. (2011) 
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1.3 Polyphenols found in apples 
Polyphenols are ubiquitous in plants and plant derived foods, but in the majority of 
Western populations the main dietary sources of polyphenols are fruits, tea, red wine 
and chocolate. This thesis is concerned with apple polyphenols. Apples are widely 
consumed and are one of the main contributors to polyphenol intakes in several 
countries including the UK (Hertog et al., 1993a; Rimm et al., 1996; Hertog et al., 
1997b; Justesen et al., 1997; Knekt et al., 1997; Price et al., 1999; Arai et al., 2000; 
Arts et al., 2001a; Knekt et al., 2002; Boyer and Liu, 2004; Gu et al., 2004; 
Vasilopoulou et al., 2005; Johannot and Somerset, 2006; Ovaskainen et al., 2008; 
Perez-Jimenez et al., 2010). The consumption of apples has also been associated with 
a reduced risk of cancer, cardiovascular disease, asthma and diabetes (Boyer and Liu, 
2004). Therefore further investigation of polyphenols derived from apples may be 
beneficial in the understanding of how dietary polyphenols reduce the risk of chronic 
diseases.  
 
There are five main classes of polyphenols found in apples: (1) flavanols (present in 
their monomeric [epicatechin and catechin] and in their oligomeric forms 
[procyanidins]); (2) hydroxycinnamic acids (caffeoylquinic acid and p-coumaroylquinic 
acid); (3) dihydrochalcones (phloretin glycosides = phloridzin and phloretin aglycone); 
(4) flavonols (quercetin-3-glycosides [galactoside, glucoside, xyloside, arabinoside and 
rhamnoside]); and (5) anthocyanins (cyanidin3-galactaside) (Awad et al., 2000; Awad 
et al., 2001b; Tsao et al., 2003; Alonso-Salces et al., 2004; Chinnici et al., 2004; Marks 
et al., 2007a; Renard et al., 2007). The anthocyanins are present in higher quantities in 
the apple skin of red varieties (Guyot et al., 2003). The flavanols are the most abundant 
polyphenol in apples, followed by hydroxycinnamic acids, and present in lower 
concentrations are the flavonols, dihydrochalcones and anthocyanins (Alonso-Salces 
et al., 2004; Vrhovsek et al., 2004). 
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Polyphenols found in apples play an important role in the nutritional, organoleptic and 
commercial properties of apples and apple products (Podsędek et al., 2000; Alonso-
Salces et al., 2004; Renard et al., 2007). Polyphenols are responsible for the taste 
(bitterness and astringency), flavour and colour of apples and their derived foodstuffs 
(Chinnici et al., 2004; Marks et al., 2007a). They are also involved in the formation of 
hazes and sediments in apple juices and ciders and in the browning phenomena 
contributing to their colour (Alonso-Salces et al., 2004). The dihydrochalcones, 
flavonols and anthocyanins contribute to the pigmentation of apples (Guyot et al., 1998; 
Alonso-Salces et al., 2004) and in fruit processing, and the hydroxycinnamic acids and 
catechins are involved in the browning phenomena contributing to the colour of apple 
juices and ciders (Guyot et al., 1998; Marks et al., 2007b; Renard et al., 2007).  
 
1.4 Bioavailability, absorption and metabolism of polyphenols 
The health benefits of polyphenols are affected by their absorption, metabolism and 
bioavailability in the human body. For polyphenols to induce their protective effects 
in-vivo, they must be absorbed from the diet and transported into the blood in a 
bioactive form to their target sites. The following sections will give a brief overview of 
the bioavailability, absorption and metabolism of polyphenols.   
 
1.4.1 Bioavailability 
An important aspect when considering the role of polyphenols in human health is the 
evaluation of their bioavailability from foods. Bioavailability is defined as the fraction of 
an ingested nutrient or compound that reaches the systemic circulation and specific 
sites where it can exert its biological action (Porrini and Riso, 2008). Polyphenol 
bioavailability is usually assessed from the plasma pharmacokinetics and / or urinary 
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excretion. Evidence from bioavailability studies has shown that polyphenols are present 
in systemic circulation after the ingestion of a polyphenol-rich meal. This indicates that 
at least a portion of the ingested dose can be absorbed.  
 
An excellent review of polyphenol bioavailability is reported by Manach et al. (2005). 
The authors report mean values of the pharmakonetic data (maximal plasma 
concentration [Cmax], time to reach the maximal plasma concentration [Tmax], area under 
the plasma concentration-time curve [AUC], elimination half-life and relative urinary 
excretion) from human bioavailability studies for 18 major polyphenols. To allow for 
comparisons between polyphenols, the data was normalised such that the 
pharmakonetic data was representative of a 50 mg dose (aglycone equivalent). Gallic 
acid represented the most bioavailable polyphenol (Cmax = 4 µM) followed by the 
isoflavones (Cmax = ~2 µM) and anthocyanins were the least bioavailable polyphenol 
(Cmax = 0.03 µM) (Manach et al., 2005). The time to reach Cmax for the majority of the 
polyphenols is approximately 2 hours, however for rutin and isoflavones Tmax is 
reached approximately 6 hours after ingestion (Manach et al., 2005). Urinary excretion 
is also used to measure the bioavailability of polyphenols. The urinary excretion ranged 
from 0.3 % to 42 % for the analysed polyphenols (Manach et al., 2005). Therefore a 
major proportion of the polyphenols ingested are not found in the urine which implies 
that they have either not been absorbed through the gut barrier; have been absorbed 
but have been excreted via the bile; or have been metabolized by colonic microflora 
(Scalbert and Williamson, 2000). As a large proportion of polyphenols are excreted in 
the bile, the urinary excretion values underestimate the bioavailability of polyphenols 
(Manach et al., 2005). The elimination half-lives for catechins are also low indicating 
that the catechins do not accumulate in the plasma with repeated ingestion (Manach et 
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The bioavailability of flavanol monomers has been widely reported and the majority of 
the flavanol bioavailability studies with human volunteers involved the consumption of 
flavanol monomers from cocoa or tea. Manach et al. (2005) reported that the mean 
Cmax, from the available bioavailability studies, is 0.4 µM for epicatechin, 0.12 µM for 
epigallocatechin gallate (EGCG), 1.10 µM for epigallocatechin (EGC), 4 µM for gallic 
acid, and 0.02 µM for proanthocyanidin dimers. However the values for the flavanol 
monomers are underestimated in this review because the methylated metabolites were 
not taken into account in all bioavailability studies (Rein et al., 2000; Manach et al., 
2005). Following the ingestion of flavanol monomers from cocoa, the concentration of 
flavanol monomers have been reported to be between 4.92 and 5.92 µM for 
epicatechin and 0.16 µM for catechin (Baba et al., 2000; Holt et al., 2002a). 
Concentrations of epicatechin, EGCG and EGC, after the consumption of four cups of 
green tea, have been reported to be between 0.28 and 0.65 µM, 0.17 and 0.71 µM, 
and 0.67 and 1.79 µM, respectively (Lee et al., 1995; Yang et al., 1998b; Lee et al., 
2002). The wide variability of the plasma concentrations of flavanol monomers are 
probably a result of different doses given in the intervention trials as well as the lack of 
a standardized method available for analysing plasma concentration levels and 
problems with the detection of certain metabolites.  
 
The bioavailability of flavanol polymers has been less widely investigated. Human 
plasma concentrations of procyanidin dimer B2, after the consumption of cocoa, has 
been reported to be 0.041 µM (Holt et al., 2002a) and human plasma concentrations of 
procyanidin dimer B1, after the consumption of a grape seed extract, has been 
reported to be 0.011 µM (Sano et al., 2003). It was previously assumed that the 
procyanidins were degraded into monomers in the acidic environment of the stomach, 
however it was shown, in-vivo, that procyanidins from cocoa were not degraded in the 
stomach and that the procyanidins were able to reach the small intestine intact (Rios et 
al., 2002b). It was also shown that after the consumption of grape seed extract, in rats, 
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the procyanidins were not degraded into monomers and they reached the small 
intestine (Tsang et al., 2005). It has also recently been shown, in the small intestine of 
rats, that procyanidins are slightly absorbed but are not conjugated or methylated like 
their flavanol monomer counterparts (Appeldoorn et al., 2009b). The bioavailability of 
procyanidin trimers have been determined in rat plasma with a concentration of 4 µM 
after a high dose (1000 mg/kg of an apple procyanidin extract) (Shoji et al., 2006a), 
after the consumption of 300 mg/kg grape seed extract (amount not quantified) 
(Prasain et al., 2009) and after the consumption of 1 g/kg grape seed procyanidin 
extract (8.55 µM detected in plasma) (Serra et al., 2009). Procyanidin dimers and 
trimers have been shown to be absorbed through a Caco-2 cell monolayer (used as a 
model of intestinal epithelium), thus suggesting that these compounds may be 
absorbed (Déprez et al., 2001). However, human plasma concentrations of procyanidin 
trimers, tetramers and higher oligomers have yet to be detected. Low bioavailability of 
procyanidins with increasing (epi)catechin units (Déprez et al., 2001) and limited 
sensitivity of mass spectrometry analysis (Shikha Saha, IFR, unpublished work) are 
some of the factors involved with the difficulty in detecting human procyanidin plasma 
concentrations.  
 
1.4.2 Absorption 
Polyphenols exist in foods and beverages in various chemical forms, and the chemical 
structure plays an important role in the rate and extent of the absorption, metabolism 
and bioavailability of polyphenols circulating in the plasma (Scalbert and Williamson, 
2000). The first step in the absorption of dietary polyphenols is deglycosylation as 
flavonoids, with the exception of flavanols, are present in the diet as glycosides. 
Depending on the sugar residue attached, hydrolysis and absorption of flavonoids may 
occur in the small intestine (Hollman et al., 1999; Arts et al., 2004). In the small 
intestine, lactase phloridzin hydrolase (LPH) and cystolic β-glucosidase (CBG) are the 
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two β-glucosidases present which are capable of hydrolysing flavonoid glycosides (Day 
et al., 2003; Németh et al., 2003). LPH is exposed to the lumen and is situated on the 
brush boarder of the small intestine epithelial cells and hydrolysis of the flavonoid 
glycosides occurs extracellularly prior to passive diffusion of the flavonoid aglycone 
across the membrane (Day et al., 1998; Day et al., 2000; Day et al., 2003; Németh et 
al., 2003). On the other hand, CBG is located intracellularly. It has been proposed that 
glucose transporters such as the sodium-dependent glucose transporter (SGLT1) 
transport the polyphenol-glucose molecules across the membrane before hydrolysis by 
CBG can occur (Gee et al., 1998; Day et al., 2003; Németh et al., 2003). In the case of 
flavonoids which are not absorbed in the small intestine (e.g. flavonoids with 
rhamnose-substitutions [e.g. rutin] and phenolic acid-esters), these pass through the 
small intestine to the colon and then are hydrolysed by colonic microflora before being 
absorbed (Hollman et al., 1997). A schematic drawing of the absorption and 
metabolism of polyphenols is provided in Figures 1.4 and 1.5.  
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Figure 1.4: Absorption and metabolism of polyphenols in the small intestine. 
Polyphenols are either hydrolysed in the small intestine by LPH before passively diffusing through the 
membrane or are transported into the cells by SGLT1 (or other sugar transporters) and hydrolysed 
intracellularly by CBG. Conjugation (methylation, sulfation, glucuronidation) of the flavonoid aglycones 
occurs in the small intestine epithelial cells before passing into the blood supply.  
 
1.4.3 Metabolism 
Following absorption, polyphenols (which are now aglycones) are subjected to 
conjugation in the small intestine and/or in the liver. All polyphenols are subjected to 
three main types of conjugation: methylation, sulfation and glucuronidation. The 
primary site of polyphenol metabolism is the small intestine (Spencer et al., 1999; 
Crespy et al., 2001; Donovan et al., 2001). Flavonoids are metabolized by uridine-5’-
diphosphate glucuronosyl-transferases, sulfotransferases and catechol-O-
methyltransferases in the small intestine (Rice-Evans, 2001; Kroon et al., 2004). The 
conjugates are then transported via the portal vein to the liver and are subjected to 
further conjugation (Olthof et al., 2003). Following conjugation in the liver, flavonoid 
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metabolites are transported around the body in the blood bound to plasma proteins 
(Manach et al., 1995). Conjugated polyphenols can also be secreted from the liver into 
the bile resulting in the transport back into the small intestine for further deconjugation 
or passage into the colon (Das and Griffiths, 1969; Donovan et al., 2001). Once 
reaching the colon, polyphenols are metabolised by the colonic microflora where the 
resulting metabolites are reabsorbed or are excreted in the faeces (Sfakianos et al., 
1997). Flavonoid metabolites can also be secreted by the kidneys via the urine.  
 
 
Figure 1.5: Absorption and metabolism of polyphenols. 
Polyphenols are either hydrolysed in the small intestine or the colon depending on their chemical structure 
and the resulting aglycones are absorbed. Conjugation (methylation, sulfation and glucuronidation) occurs 
in the small intestine before passing into the liver where further conjugation occurs. From the liver the 
polyphenols are either secreted into the bile and transported back into the liver for further deconjugation or 
the polyphenol metabolites are transported around the body in the blood bound to plasma proteins  and/or 
are secreted by the kidneys via the urine.  
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1.5 Polyphenols and cardiovascular disease 
A high consumption of fruits and vegetables has been linked with a reduced risk of 
chronic diseases including cardiovascular disease (CVD). Polyphenols present in fruits 
and vegetables have been implicated as playing a significant role in the protective 
effects of these foods (Bravo, 1998). Therefore understanding how polyphenols reduce 
the risk of CVD is important as CVD is one of the primary chronic diseases afflicting 
industrialised countries (Epstein and Ross, 1999; Steinberg et al., 2003; Boyer and Liu, 
2004).  
 
1.5.1 Epidemiological associations 
Higher intakes of polyphenols have been associated with a reduced risk of CVD in 
several epidemiological studies (Hertog et al., 1993a; Knekt et al., 1996; Hertog et al., 
1997b; Yochum et al., 1999; Geleijnse et al., 2002; Knekt et al., 2002; Mink et al., 
2007; Janszky et al., 2009; Buijsse et al., 2010) while other studies have shown no 
association between the consumption of polyphenols and a reduced risk of CVD (Rimm 
et al., 1996; Hertog et al., 1997a; Sesso et al., 2003).  
 
In the Zutphen Elderly Study, flavonoid intake was inversely associated with coronary 
heart disease (CHD) and total mortality (Hertog et al., 1993a; Hertog et al., 1997b) and 
apples, which contributed 10% of the flavonoid intake, were also inversely related to 
coronary heart disease (CHD) mortality but with a weaker association (Hertog et al., 
1993a). In the Finnish Mobile Clinic Health Examination Survey, the consumption of 
flavonoids and apples were inversely associated with total mortality and coronary 
mortality (Knekt et al., 1996) and ischemic heart disease and cerebrovascular disease 
(Knekt et al., 2002). The intake of flavanols and flavones was also inversely associated 
with CHD mortality in the Iowa Women’s Health Study (Yochum et al., 1999) and 
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recently further investigation of the Iowa Women’s Health Study showed that the intake 
of flavanones and anthoycanidins and apples were also inversely associated with CHD 
and CVD mortality after multivariate adjustment (Mink et al., 2007). An inverse 
relationship between the consumption of tea and flavonoids and myocardial infarction 
was observed in the Rotterdam Study cohort (Geleijnse et al., 2002). In the Stockholm 
Heart Epidemiological Program (Janszky et al., 2009) and in a middle-aged German 
cohort (Buijsse et al., 2010) the consumption of chocolate was related to a lower risk of 
CVD. In the Stockholm Heart Epidemiological Program, chocolate consumption had a 
strong inverse relationship with cardiac mortality (Janszky et al., 2009) and in the 
German cohort chocolate consumption had a stronger inverse relationship with stroke 
than myocardial infarction (Buijsse et al., 2010). 
 
In contrast, three cohort studies found no association between flavonoid consumption 
and CVD risk (Hertog et al., 1997a). In the Health Professionals Follow-up Study 
(Rimm et al., 1996) and the Women’s Health Study (Sesso et al., 2003), the intake of 
flavonoids was not associated with a reduced risk of CVD. The intake of flavonols, from 
tea to which milk was added, was also not associated with the incidence of ischemic 
heart disease in the Caerphilly Study (Hertog et al., 1997a). No association found 
between flavonoid consumption and CVD risk in these cohorts may be attributed, in 
part, on younger ages, greater ratio of women to men, lower risk factors, population 
group studied (Graf et al., 2005) and/or other factors such as the tendency to consume 
tea with milk in the Caerphilly Study and not accounting for appropriate confounding 
factors (Hertog et al., 1997a; Graf et al., 2005). Milk has been suggested to impair the 
bioavailability of flavonoids (Graf et al., 2005). Therefore, the majority of the 
epidemiological studies indicate that higher intakes of flavonoids are associated with a 
reduced risk of CVD.  
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1.5.2 Intervention studies 
Cardiovascular disease is associated with the development of atherosclerotic plaques 
and thrombosis and atherosclerosis is the main cause of myocardial infarction and 
stroke. Endothelial dysfunction, inflammatory response, modified lipids and 
lipoproteins, and activated platelets are all involved in the development of CVD 
(Epstein and Ross, 1999; Steinberg et al., 2003). A number of human intervention trials 
have shown a positive relationship between the consumption of flavonoids and 
reductions in biomarkers of cardiovascular risk (Taubert et al., 2007; Hooper et al., 
2008). A systematic review of the effectiveness of different flavonoid subclasses and 
flavonoid-rich food sources on CVD risk factors (endothelial function, blood pressure 
and lipoproteins) was conducted by Hooper et al. (2008). Endothelial function was one 
of the risk factors assessed because the vascular endothelium plays an important role 
in the regulation of vascular homeostasis and endothelial dysfunction is an indication of 
the initial development of atherosclerosis (Hashimoto et al., 1999; McEniery et al., 
2006). Assessing endothelial function by flow-mediated dilation (FMD) is the gold 
standard, for further information regarding endothelial function refer to Chapter 3. The 
oxidation of low density lipoproteins (LDL) has also been implicated in the development 
of atherosclerosis (Hollman and Katan, 1997; Yochum et al., 1999) and the formation 
of foam cells and atherosclerotic plaques is due to the oxidation of LDL cholesterol 
which is taken up more quickly by macrophages (Yochum et al., 1999).  
 
The majority of the dietary intervention trials, described in the systematic review by 
Hooper et al. (2008), assessed the effects of soy- or soy isoflavone-products or the 
effects of flavanols from red wine, grapes, chocolate, cocoa, black tea or green tea. 
The consumption of chocolate or cocoa increased FMD and reduced systolic and 
diastolic blood pressure after acute and chronic consumption but had no effect on low 
density lipoprotein (LDL) or high density lipoprotein (HDL) cholesterol (Hooper et al., 
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2008). Reduced systolic and diastolic blood pressure was also shown in a meta-
analysis of five randomized controlled studies (Taubert et al., 2007) and ten 
randomized controlled intervention trials after the consumption of flavanol-rich cocoa 
(Desch et al., 2010). While the meta-analysis of 13 intervention trials showed that the 
consumption of dark chocolate reduced systolic blood pressure in hypertensive 
subgroups and diastolic blood pressure in pre-hypertensive subgroups (Ried et al., 
2010). Reduction of LDL cholesterol after cocoa consumption was only significant in 
subjects with CVD risk factors as shown in a meta-analysis of eight controlled 
intervention trials (Jia et al., 2010). 
 
Acute consumption of black tea caused an increase in systolic and diastolic blood 
pressure, increased FMD response, but had no effect on LDL or HDL cholesterol while 
the consumption of green tea reduced LDL cholesterol but had no effect on systolic or 
diastolic blood pressure and no published data on FMD effects were available (Hooper 
et al., 2008). The consumption of tea (black or green) showed no significant effect on 
blood pressure in a meta-analysis of five randomized controlled studies (Taubert et al., 
2007) but tea consumption was found to substantially enhance FMD in a meta-analysis 
of nine human intervention studies (Ras et al., 2011). Soy protein isolate, but not other 
soy groups, significantly reduced diastolic blood pressure and LDL cholesterol and the 
consumption of grapes or red wine had no significant effects on FMD, systolic or 
diastolic blood pressure, and LDL or HDL cholesterol (Hooper et al., 2008).  
 
The results from the meta-analyses suggest that some flavonoid subclasses or 
flavonoid-rich foods have clinically relevant effects on CVD risk factors. However, there 
is still limited intervention trial data for some flavonoid subclasses and flavonoid-rich 
foods.  
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1.5.3 In-vitro studies and cellular mechanisms 
In order to understand the mechanisms related to the clinically relevant effects of 
dietary polyphenols the in-vitro investigation of polyphenols have been conducted. 
Numerous reports of the potential cellular mechanisms of polyphenols have been 
reported, but the most convincing in-vitro results of the cellular mechanisms of 
polyphenols come from their ability to (1) increase nitric oxide (NO) by inducing nitric 
oxide synthase (NOS) and inhibiting NADPH oxidase activity; (2) induce cellular 
antioxidant mechanisms and scavenge free radicals; and (3) inhibit vascular 
endothelial growth factor (VEGF) induced angiogenesis.  
 
1.5.3.1 Polyphenols increase nitric oxide synthase 
The ability of polyphenols to improve endothelial function, in-vivo, has been attributed 
to their ability to increase NO-dependent vasorelxation (Heiss et al., 2003; Grassi et al., 
2005b). NO is produced from L-arginine in a reaction catalyzed by the enzyme NOS 
(Leikert et al., 2002; Appeldoorn et al., 2009a). This enzyme is present in different 
isoforms: endothelial (eNOS), neuronal (nNOS) and inducible (iNOS). Endothelial-
dependent NO is produced by eNOS. Therefore the in-vitro investigation of NO 
expression focuses on the capability of polyphenols to increase eNOS. EGCG (Lorenz 
et al., 2004; Appeldoorn et al., 2009a; Lorenz et al., 2009b), epicatechin (Ramirez-
Sanchez et al., 2010), epicatechin gallate (Appeldoorn et al., 2009a), theaflavins 
(theaflavin-3-monogallate, theaflavin-3’-monogallate and theaflavin-3,3’-digallate) 
(Lorenz et al., 2009b), black tea polyphenols (Anter et al., 2004), resveratrol (Wallerath 
et al., 2002; Nicholson et al., 2008; Appeldoorn et al., 2009a), red wine polyphenols 
(Wallerath et al., 2003; Wallerath et al., 2005), red wine polyphenol extract (Leikert et 
al., 2002), grape skin extract (Madeira et al., 2009) and procyanidins (Karim et al., 
2000) have been shown to increase eNOS expression in endothelial cells. 
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Procyanidins were also found to exert a non-significant increase in eNOS in endothelial 
cells (Appeldoorn et al., 2009a).  
 
The increase of NO bioavailability by polyphenols has been reported to be due to their 
ability to inhibit NADPH oxidase activity (Steffen et al., 2007). Epicatechin metabolites 
(3’- and 4’-O-methyl epicatechin), epicatechin glucuronide, procyanidin dimer B2, ECG, 
EGC, EGCG and resveratrol were shown to inhibit NADPH oxidase (Steffen et al., 
2007; Steffen et al., 2008). However, the majority of the in-vitro investigation of the NO 
preserving-effect of polyphenols has been shown at concentrations ranging from 10 µM 
to 100 µM (Karim et al., 2000; Wallerath et al., 2002; Appeldoorn et al., 2009a; Lorenz 
et al., 2009b) and concentrations of 4 µM to 16 µM for their NADPH oxidase activity 
inhibition (Steffen et al., 2008). The physiological concentrations of dietary polyphenols 
do not exceed 10 µM and thus the effects of in-vitro concentrations of > 10 µM are 
generally not valid (Williamson and Manach, 2005). However, the NO-preserving effect 
of epicatechin has been observed at a concentration of 1 µM (Ramirez-Sanchez et al., 
2010) and the ability of certain polyphenols to inhibit NADPH oxidase activity has been 
observed at concentrations less than 10 µM (Steffen et al., 2008). Therefore this 
mechanism is applicable in-vivo and the intervention studies assessing endothelial 
function support this mechanism. The ability of polyphenols to increase NO 
bioavailability and inhibit endothelial NADPH oxidase activity is therefore an important 
mechanism in the cardio-protective effects as NO has also been shown to improve 
insulin sensitivity, decrease platelet aggregation and adhesion, decrease oxidation of 
LDL cholesterol and increase HDL cholesterol (Holt et al., 2002b; Wallerath et al., 
2003; Grassi et al., 2005b; Baba et al., 2007).  
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1.5.3.2 Antioxidant effects of polyphenols 
The ability of polyphenols to protect against CVD may be due to their ability to act as 
antioxidants. Polyphenols, especially flavonoids, have been reported to act as 
antioxidants through their ability to (1) scavenge free radicals and (2) suppress reactive 
oxygen species formation through the inhibition of enzymes responsible for superoxide 
anion production and chelating trace elements involved in free radical production 
(Bravo, 1998; Pietta, 2000). Polyphenols interfere with the oxidation of lipids and other 
molecules by donating a hydrogen atom to the free radicals and the efficiency of 
polyphenols to act as antioxidants is therefore dependent on their structure and 
number of hydroxyl groups (Bravo, 1998). The following foods rich in flavanols are an 
example of some of the foods which have been reported to be powerful antioxidants: 
black and green tea (Henning et al., 2003), cocoa (Vinson et al., 1999), red wine 
(Fuhrman et al., 2001) and apples (Eberhardt et al., 2000). The antioxidant effects of 
flavanols are due to their ability to stimulate nuclear factor-(erythroid-derived)-related 
factor 2 (Nrf2) protein expression (Yeh and Yen, 2006; Jung and Kwak, 2010). Nrf2 is a 
transcription factor that has been identified as an antioxidant response element-binding 
protein (Yeh and Yen, 2006; Na and Surh, 2008). EGCG (Na et al., 2008; Na and Surh, 
2008), epicatechin (Granado-Serrano et al., 2010), gallic acid (Yeh and Yen, 2006), 
and resveratrol (Kode et al., 2008) have been reported to increased Nrf2 expression 
in-vitro.  
 
The antioxidant capability of these foods have been investigated in-vitro, however the 
ability of the flavanols to inhibit LDL oxidation only resulted through the use of high 
doses that do not take into account what is seen in-vivo. For example, green or black 
tea inhibited LDL oxidation in plasma after the incubation of very high amounts of green 
or black tea in-vitro and the consumption of six cups per day for four weeks of green or 
black tea did not affect serum lipid concentrations or resistance to LDL cholesterol but 
only slightly increased the total cholesterol antioxidant activity of plasma in-vivo (van 
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het Hof et al., 1997). The consumption of a green tea supplement also only resulted in 
a small but significant increase in plasma antioxidant activity compared with when tea 
polyphenols were consumed as black tea or green tea (Henning et al., 2004).Therefore 
based on this evidence, the antioxidant effects of polyphenols is not a plausible 
mechanism.  
 
1.5.3.3 Inhibition of vascular endothelial growth factor-induced angiogenesis by 
polyphenols 
Physiological and supraphysiological concentrations of polyphenols have been found to 
have an effect on and influence VEGF-induced phosphorylation of VEGF receptor-2 in 
endothelial cells (Kondo et al., 2002b; Lamy et al., 2002; Tang et al., 2003; Neuhaus et 
al., 2004; Labrecque et al., 2005; Lamy et al., 2006; Mojzis et al., 2008; Wen et al., 
2008; Lu et al., 2010). Further information regarding VEGF and its receptors and the 
effect of polyphenols on inhibition of VEGF-induced VEGF receptor-2 (VEGFR-2) 
phosphorylation is described in Chapter 4 and 5.  
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1.6 Aims of the thesis 
The overall aims of this thesis were to (1) assess the potential of apples as a rich 
source of extractable bioactive polyphenols and (2) investigate the bioactivity of apple 
polyphenols with a focus on understanding mechanisms of action in the vascular 
endothelium.  
 
Polyphenols found in different apple cultivars have been well documented in the 
literature; however it has become evident that there is a lack of information (i.e. the 
quantification of the full apple polyphenol profile) on how apple polyphenols are 
affected by growth and maturity and seasonal variations. Therefore, the quantification 
of the full profile of polyphenols found in apples was conducted over an eight week 
growing season over a three year period (Chapter 2). The knowledge of how individual 
polyphenols are affected by growth and seasonal variations is useful in identifying the 
harvest time that is optimal for polyphenol yield or polyphenol concentration for fruit 
consumption, fruit processing or if the fruit were to be used as a source of polyphenols 
for extraction.  
 
As polyphenols are known to be associated with a reduced risk of cardiovascular 
disease and have been shown to: improve endothelial function by increasing the 
bioavailability of NO by inhibiting NADPH oxidase; exhibit antioxidant effects; and 
inhibit VEGF-induced angiogenesis the supplementation of apple polyphenols in foods 
may provide health protecting effects. In order to supplement foods with polyphenols, 
the polyphenols first needs to be efficiently extracted from the apples. The current 
extraction methods available do not provide an overall high extraction yield or affect the 
characteristics of the juice. Therefore the investigation of an efficient extraction method 
of polyphenols from apple pomace, a by-product of apple juice production, was 
conducted and the effect of the consumption of an apple polyphenol-rich extract 
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supplemented drink on the improvement of vascular function in human subjects was 
also studied (Chapter 3).  
 
From the data presented by García-Conesa et al. (2009), it was shown that the majority 
of biological processes influenced by an apple procyanidin fraction were most likely 
related to VEGF signalling. Certain polyphenols have been previously shown to inhibit 
VEGF-induced VEGFR-2 signalling, however the mechanisms of this action has not 
been investigated. As a result the examination of the ability of procyanidins, isolated 
from apples, and other flavanols to inhibit VEGF-induced VEGFR-2 signalling and the 
underlying mechanism(s) behind the inhibitory action were investigated (Chapter 4). It 
was discovered that certain flavanols were able to inhibit VEGF-induced VEGFR-2 
phosphorylation by interacting with the VEGF molecule. This finding led to the 
subsequent characterization of the binding interactions between certain flavanols and 
VEGF (Chapter 5).  
 
The results also showed that a procyanidin fraction isolated from apples was able to 
completely inhibit VEGF-induced VEGFR-2 phosphorylation at physiological 
concentrations (Chapter 4). Hence, the global analysis of the genes influenced by 
VEGF and the procyanidin fraction were investigated (Chapter 6). It was revealed that 
the apple procyanidin fraction not only blocks VEGF-regulated genes but also regulates 
genes that are independent of VEGF. One of the genes that was induced by the 
procyanidin fraction was Krüppel-like factor 2 (KLF2). As KLF2 is an important 
transcription factor implicated in the suppression of pro-inflammatory and pro-
atherosclerotic genes as well as inducing antithrombotic genes and regulating 
angiogenesis, further investigation of how the apple procyanidin fraction induces KLF2 
expression was conducted (Chapter 7).  
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Finally the main findings are summarized in Chapter 8 and suggestions for the direction 
of future research are given in this chapter as well.  
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Chapter 2 : Apple polyphenol analysis over the growing 
season 
2.1 Abstract 
The understanding of how the content and composition of apple polyphenols changes 
during the growing season and between seasons is beneficial as it allows the 
identification of when the total or individual content is the greatest and how variable the 
polyphenol content is between seasons. This knowledge is useful in identifying the 
harvest time that is optimal for polyphenol yield or polyphenol concentration for fruit 
consumption, fruit processing or if the fruit were to be used as a source of polyphenols 
for extraction. The effect of seasonal variation on the polyphenol concentration and 
content and percentages of individual polyphenols in the apple fruit were therefore 
investigated in the years 2007, 2009 and 2010 from an apple orchard located in 
Herefordshire. Apples were collected from the same three trees in each year and were 
sampled from the north, south, east, west, top, bottom, inner and outer positions of the 
tree. This allowed for the direct comparison between the years as well as assessing the 
variability in the polyphenol concentration of the apples located on the same tree. The 
results from this chapter have shown that the polyphenol concentration, content and 
percentage of quercetin glycosides and total flavanol monomers in the apple fruit of two 
varieties grown in an orchard in Herefordshire are affected by (1) growth and maturity 
(the polyphenol concentration decreases during growth while the content increases due 
to an increase in fruit weight); (2) seasonal variations (mean temperature is negatively 
correlated with polyphenol content and concentration while total amount of rainfall and 
total hours of sunshine are positively correlated with content and concentration); (3) 
location in the orchard; and (4) may be affected by the location on the tree as a large 
variation is observed from apples collected from the same tree. This is also the first 
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time that a complete quantitative HPLC analysis of the polyphenols found in apples 
was conducted as well as the first time an analysis of the direct effect of seasonal 
variation on individual apple trees has been investigated. 
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2.2 Introduction 
The understanding of how the content and composition of apple polyphenols changes 
during the growing season and between seasons is useful because it allows the 
identification of when the total or individual polyphenol content is the greatest and the 
determination of how variable this is between seasons. This knowledge could be used 
to identify the harvest time that is optimal for polyphenol yield or polyphenol 
concentration for fruit consumption, fruit processing or if the fruit were to be used as a 
source of polyphenols for extraction.  
 
The concentrations of polyphenols in apples and apple derived products show a large 
variation depending on the cultivar (Pérez-Ilzarbe et al., 1991; Guyot et al., 1998; 
Podsędek et al., 2000; Guyot et al., 2003; Vrhovsek et al., 2004; Cheynier, 2005; 
Marks et al., 2007a; Marks et al., 2007b; Renard et al., 2007), distribution within the 
fruit (Guyot et al., 1998; Chinnici et al., 2004; Cheynier, 2005; Lata, 2007; Marks et al., 
2007a; Renard et al., 2007), growth and maturation (Lister et al., 1994; Mayr et al., 
1995; Awad et al., 2001a; Kondo et al., 2002a; Guyot et al., 2003; Takos et al., 2006; 
Renard et al., 2007), seasonal variations (Awad et al., 2001b; van der Sluis et al., 
2001; Guyot et al., 2003), climate conditions (Awad et al., 2000; Awad et al., 2001a; 
Awad et al., 2001b; Takos et al., 2006) and food preparation, processing and storage 
(Ju et al., 1996; Awad and de Jager, 2000; Golding et al., 2001; Lattanzio et al., 2001; 
Aherne and O'Brien, 2002). These literature reports relating to various agronomic, 
climatic and genetic factors to the polyphenol content and composition of apples are 
described in the following sections.  
 
2.2.1 Cultivar 
Several reports have shown that there is substantial inter-cultivar variation in the 
concentration of polyphenols in apples (Pérez-Ilzarbe et al., 1991; Escarpa and 
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Gonzalez, 1998; Guyot et al., 1998; Price et al., 1999; Podsędek et al., 2000; Guyot et 
al., 2003; Vrhovsek et al., 2004; Cheynier, 2005; Marks et al., 2007a; Marks et al., 
2007b; Renard et al., 2007). Cider apples and dessert apples contain the same 
polyphenols but cider apples contain higher concentrations of polyphenols than dessert 
apples. There is also a large variation in polyphenol concentration within the dessert 
and cider apple varieties. According to the data presented in Table 2.1, the reported 
polyphenol concentrations in dessert apples range from 662 mg/kg to 3240 mg/kg fresh 
weight while the polyphenol concentration in cider apples range from 1899 mg/kg to 
10183 mg/kg fresh weight.  
 
2.2.2 Distribution within the fruit 
The composition and concentration of polyphenols in apples also vary greatly between 
the apple peel and the apple flesh (Escarpa and Gonzalez, 1998; Guyot et al., 1998; 
Price et al., 1999; Lata et al., 2005; Marks et al., 2007a). The apple flesh and peel 
contain the same polyphenols, with the exception of anthocyanins which are 
predominately located in the apple peel. However the apple flesh has higher 
concentrations of flavanols and dihydrochalcones while the apple peel has higher 
concentrations of flavonols, hydroxycinnamic acids and anthocyanins (Chinnici et al., 
2004; Cheynier, 2005; Lata et al., 2005; Renard et al., 2007). Overall, higher 
concentrations of polyphenols are found in the apple peel (546 mg/kg to 6306 mg/kg) 
compared to the apple flesh (230 mg/kg to 5065 mg/kg) (Table 2.1). However, when 
examining the content of polyphenols in the entire apple (Kermerrien cider apples) the 
greatest polyphenol content was located in the apple flesh (65 %) than the skin (24 %), 
core (10 %) or seeds (1 %) (Guyot et al., 1998). This is because there is a greater 
proportion of flesh in an apple than skin, core or seeds and therefore the largest 
amount of polyphenols would be located in the flesh.  
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Table 2.1: Polyphenol content in apple varieties (mg/kg fresh weight) 
Variety Total phenolics Flesh Peel 
Dessert Apples 
Alwa1 2800 ± 300 n/a n/a 
Braeburn3 754 n/a n/a 
Boskoop1 3570 ± 340 n/a n/a 
Close1 2290 ± 250 n/a n/a 
Elstar1 2520 ± 290 n/a n/a 
Fuji3 662 ± 131 n/a n/a 
Idared1 2730 ± 340 n/a n/a 
Jonagold1 3100 ± 190 n/a n/a 
Golden Delicious4 776 230 ± 16 546 ± 43 
Golden Delicious3 863 ± 75   
Granny Smith3 1210 n/a n/a 
Lobo1 2900 ± 250 n/a n/a 
Morgenduft3 1058 n/a n/a 
Papierόwka1 3240 ± 300 n/a n/a 
Red Delicious3 1311 ± 138 n/a n/a 
Renetta3 2119 ± 138 n/a n/a 
Royal Gala3 839 ± 120 n/a n/a 
Szampion1 2970 ± 70 n/a n/a 
Warta1 3240 ± 310 n/a n/a 
Cider Apples  
Ashton Bitter4 6903 2798 ± 29 4105 ± 254 
Avrolles2 -- 3182 ± 297 n/a 
Bedan2 -- 3441 ± 223 n/a 
Brown Snout4 4484 1693 ± 37 2791 ± 50 
Browns Apple4 3680 893 ± 28 2787 ± 120 
Broxwood Foxwhelp4 2379 640 ± 42 1739 ± 80 
Bulmers Norman4 7315 2294 ± 19 5021 ± 113 
Chisel Jersey4 6967 2474 ± 15 4493 ± 65 
Dabinett4 5163 1653 ± 57 3510 ± 88 
Dous Möen2 -- 3161 ± 433 n/a 
Ellis Bitter4 4116 1243 ± 39 2873 ± 114 
Harry Masters Jersey4 6007 2862 ± 101 3145 ± 14 
Kermerrien2 -- 5065 ± 550 n/a 
Major4 3197 1418 ± 50 1779 ± 25 
Medaille d’Or4 10448 4920 ± 20 5528 ± 46 
Michelin4 4145 1754 ± 38 2391 ± 162 
Petit Jaune2 -- 1899 ± 186 n/a 
Reine des Hâtives4 2746 931 ± 19 1815 ± 34 
Somerset Redstreak4 3273 1372 ± 35 1901 ± 120 
Sweet Coppin4 1251 485 ± 4 766 ± 12 
Taylors Sweet4 3958 1122 ± 23 2836 ± 103 
Tremletts Bitter4 6685 2746 ± 24 3939 ± 102 
Vilberie4 4933 2093 ± 59 2840 ± 143 
Yarlington Mill4 10183 3877 ± 103 6306 ± 117 
Data obtained from (Podsędek et al., 2000; Guyot et al., 2003; Vrhovsek et al., 2004; Marks et al., 2007a) 
n/a = not available 
1 Polyphenol concentration determined by the Folin-Ciocialteu method and (+)-catechin was used as the 
standard (Podsędek et al., 2000) 
2 Polyphenol concentration determined by HPLC analysis and the procyanidins were determined by 
thiolysis followed by HPLC analysis. Quantified (+)-catechin, (-)-epicatechin, procyanidin B2, total 
procyanidins, caffeoylquinic acid, p-coumaroylquinic acid, phloretin xyloglucoside, phloridzin (Guyot et al., 
2003). 
3 Polyphenol concentration determined by the Folin-Ciocialteu method (Vrhovsek et al., 2004). 
4 Polyphenol concentration determined by HPLC analysis. Quantified (+)-catechin, (-)-epicatechin, 
procyanidin B2, cyanidin-3-O-galactoside, 5-O-coumaroylquinic acid, 4-O-p-coumaroylquinic acid, 
quercetin-3-O-rutinoside, quercetin-3-O-galactoside, quercetin-3-O-glucoside, quercetin-3-O-rhamnoside, 
quercetin-3-O-xyloside, phloretin-2’-O-(2’’-O-xylosylglucoside), quercetin-3-O-arabinopyranoside, 
quercetin-3-O-arabinofuranoside, and phloretin 2’-O-glucoside (phloridzin) (Marks et al., 2007a). 
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2.2.3 Growth and maturity 
The composition and concentrations of polyphenols in apples is influenced by growth 
and the level of fruit maturity. In general, reports have shown that the highest 
concentrations of polyphenols occur early in fruit development and decline throughout 
fruit growth and maturation. The polyphenol concentration of Granny Smith and 
Splendour apples (Lister et al., 1994), Golden Delicious apples (Mayr et al., 1995), 
Jonagold and Elstar apples (Awad et al., 2001a), five French cider apple varieties 
(Avrolles, Dous Möen, Petit Jaune, Kermerrien and Bedlan) (Guyot et al., 2003), Cripps 
Red apples (Takos et al., 2006), Dous Moen, Kermerrien, Elstar and Gala apples 
(Renard et al., 2007) and Fuji, Oorin and Redfield apples (Kondo et al., 2002a) were 
highest in the early stages of fruit development and significantly decreased during fruit 
development. However, in Splendour apples an increase in quercetin glycosides and 
anthocyanin concentrations was observed during ripening (Lister et al., 1994). The 
observed decline in the concentration of polyphenols during fruit growth and maturation 
may be attributed to a dilution effect due to fruit growth (Takos et al., 2006).  
 
2.2.4 Seasonal variations 
Seasonal variations (differences in weather conditions between harvest years) may 
influence the polyphenol concentration in apple cultivars. Certain apple cultivars have 
been shown to have stable polyphenol concentrations between harvest years (Lister et 
al., 1994; Guyot et al., 2003) while other cultivars are more susceptible to seasonal 
variations (van der Sluis et al., 2001; Lata et al., 2005; Lata and Tomala, 2007; Stracke 
et al., 2009). In Granny Smith and Splendour apples (Lister et al., 1994) and five 
French apple varieties (Avrolles, Dous Möen, Petit Jaune, Kermerrien and Bedlan) 
(Guyot et al., 2003) there were no significant differences in the polyphenol 
concentrations between harvest years. van der Sluis et al. (2001) investigated the 
seasonal variation on flavonoid concentration in four apple varieties (Jonagold, Golden 
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Delicious, Cox’s Orange and Elstar) for the harvest years 1996 to 1998. In Jonagold 
apples no significant differences were observed in the concentrations of chlorogenic 
acid, total catechins, total quercetin glycosides, phloridzin and cyanidin 3-galatacoside 
between harvest years while Golden Delicious had some variation in total quercetin 
glycosides and phloridzin concentrations and Elstar apples varied in phloridzin 
concentration (van der Sluis et al., 2001). Cox’s Orange apples were most sensitive to 
seasonal variation and a significant difference in polyphenol concentrations was 
observed. A significant variation between the harvest years 2003 and 2004 was shown 
in 56 apple varieties (Lata et al., 2005). Lata and Tomala (2007) showed a significant 
variation between the harvest years 2004 and 2005, from the same tree, in 19 apple 
varieties and Stracke et al. (2009) also found a significant variation in the polyphenol 
concentration of Golden Delicious apples between the harvest years 2004 and 2006. 
Therefore differences in polyphenol concentrations between harvest years may depend 
on the cultivar investigated as well as the climate conditions between harvest years.  
 
2.2.5 Environmental factors 
Environmental factors such as climate and soil conditions also have an influence on the 
polyphenol concentration of apples. Climate refers to the weather conditions of the 
geographical region. The amount of light (sunlight) is considered to be one of the most 
important factors in the control of flavonoid synthesis (Awad et al., 2001b; Takos et al., 
2006). In Jonagold and Elstar apples, greater concentrations of cyanidin 3-galactoside 
and quercetin glycosides were found in apples positioned on the outer tree while those 
in the inner/shaded positions, with less amount of light received, had significantly lower 
concentrations of these compounds (Awad et al., 2000; Awad et al., 2001b). The 
concentration of catechins, phloridzin and chlorogenic acid were unaffected by light 
conditions. Therefore, the differences in light conditions (quantity and quality) in the 
Chapter 2 
 
39 
 
outer and inner positions of the tree explain the higher concentrations of anthocyanins 
and quercetin glycosides found in the outer fruit (Awad et al., 2001a).  
 
Temperature has also been shown to effect anthocyanin formation in apples. Low 
evening temperatures and high sunlight levels during autumn has been reported to 
increase anthocyanin content formation (Saure, 1990). Although it has been suggested 
that increases in the amount of rainfall can result in lower polyphenol concentrations 
(Stracke et al., 2009), there is a lack of literature concerned with how rainfall affects 
polyphenol content in apples. 
 
Soil nutrients are another environmental variable influencing polyphenol content in 
apples. In general, higher amounts of nitrogen in soil has a negative effect on 
anthocyanin formation in apples and the effect of other nutrients (e.g. potassium and 
phosphorous) on anthocyanin formation is inconsistent (Awad and de Jager, 2002). 
 
Therefore the difference in environmental factors between geographical regions may 
also influence the total polyphenol content of apples of the same variety. The 
polyphenol concentrations of certain cultivars (Pacific Beauty, Pacific Queen, Pacific 
Rose and Granny Smith) showed significant variation between the three regions 
investigated in New Zealand, while other cultivars (Braeburn, Royal Gala, Jazz and 
Red Delicious) showed no significant variation between regions (McGhie et al., 2005). 
Variables within the geographical region that may influence the polyphenol content of 
apples include the climate and soil nutrients.  
 
2.2.6 Storage, food preparation and processing 
Storage conditions can increase, decrease or have no effect on the polyphenols 
concentrations in foods depending on the method of storage (Awad and de Jager, 
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2000; Aherne and O'Brien, 2002). However, the polyphenol content in apples during 
cold storage is relatively stable. In Golden Delicious, Cox’s Orange, Elstar and 
Jonagold apples, cold storage did not have a significant effect on the total quercetin 
glycosides, phloridzin and cyanidin galactoside concentrations (van der Sluis et al., 
2001). In Delicious and Ralls apples no significant changes occurred in the 
concentrations of chlorogenic acid, flavonoids and anthocyanins during 4 – 5 months of 
cold storage (Ju et al., 1996). However, after transfer from cold storage to 20˚C, a rapid 
decrease in chlorogenic acid and flavonoids concentrations was observed. 
Lattinzo et al. (2001) reported that the polyphenol concentration in Golden Delicious 
apples increased in cold storage with a maximum increase after 60 days, afterward fruit 
stored for a prolonged period showed a decrease in polyphenol concentration while 
Golding et al. (2001) showed that the polyphenol concentration of Granny Smith, Lady 
Williams and Crofton apples remained relatively stable in cold storage.  
 
Food preparation and processing can also lead to a significant decrease in polyphenol 
concentration (Aherne and O'Brien, 2002; Cocci et al., 2006). Polyphenols are resistant 
to heat, oxygen and moderate degrees of acidity (Aherne and O'Brien, 2002), however 
kitchen preparation will result in polyphenol losses. Cutting or slicing apples causes 
enzymatic browning to occur through the mixture of polyphenol compounds with 
polyphenol oxidase (PPO) and the diffusion of oxygen into the tissue, which causes the 
total polyphenol content in the flesh to decrease (Cocci et al., 2006). The processing of 
apples results in a significant loss of polyphenols in the resulting apple products. For 
example, losses in polyphenols in apple juice can occur due to (1) pressing and (2) 
oxidation (Awad et al., 2000; Treutter, 2001; van der Sluis et al., 2002; Guyot et al., 
2003). During pressing, the polyphenols may bind to the cell-walls and be retained in 
the pomace (Guyot et al., 2003). Enzymatic oxidation of chlorogenic acid and 
procyanidins contribute to the colour of the juice or cider, however enzymatic oxidation 
decreases the final polyphenol concentration (Awad et al., 2000; Treutter, 2001).  
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The polyphenol concentration of apples can significantly change based on the different 
variables discussed above, however, in this chapter, the variability concerning 
seasonal variation will be further investigated. Although there have been a number of 
reports (Lister et al., 1994; van der Sluis et al., 2001; Guyot et al., 2003; Lata et al., 
2005; Lata and Tomala, 2007; Stracke et al., 2009) concerned with variations in 
polyphenol content and composition of apples in relation to seasonal variability, these 
studies lack a complete analysis of the full apple polyphenol profile. Lister et al. (1994) 
quantified flavanols (catechin, epicatechin), quercetin glycosides (quercetin-3-
rhamnoglucoside, quercetin-3-glucoside, quercetin-3-xyloside, quercetin-3-
arabinopyranoside, quercetin-3-arabinofuranoside and quercetin-3-rhamonside) 
chlorogenic acid, phloridzin, cyanidin-3-O-galactoside, and proanthocyanidins by using 
a water solvent delivery system. van der Sluis et al. (2001) quantified quercetin 
glycosides (quercetin-3-galactoside, quercetin-3-glucoside, quercetin-3-xyloside, 
quercetin-3-arabinoside and quercetin-3-rhamnoside), epicatechin, catechin, 
chlorogenic acid, phloridzin and cyanidin galactoside by HPLC. Guyot et al. (2003) 
quantified epicatechin, catechin, procyanidin B2, caffeoylquinic acid, p-coumarolyquinic 
acid, phloretin xyloglucoside and phloridzin by HPLC, and total procyanidins by 
thiolysis of the samples followed by HPLC analysis. Total phenolics (gallic acid 
standard), flavonols (quercetin standard) and anthocyanins (cyanidin-3,5-diglucoside 
standard) were measured spectrophotometerically by Lata et al. (2005) and Lata and 
Tomala (2007). Finally, Stracke et al. (2009) quantified chlorogenic acid, 
hydroxycinnamic acids (4-caffeoylquinic acid, 3-coumaroylquinic acid, 
4-coumaroylquinic acid and 5-coumaroylquinic acid) and dihydrochalcones (phloretin 
2’-xyloglucoside and phloretin-2’-glucoside), flavanols (epicatechin, catechin and 
procyanidin B2) and quercetin glycosides (quercetin-galactoside, quercetin-glucoside, 
quercetin-xyloside, quercetin-arabinoside and quercetin-rhamonoside) by HPLC 
analysis. 
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There are also flaws in the sampling design in some of the reports: in one report (van 
der Sluis et al., 2001) the sampling design included sampling the fruit from the outer 
layer of the tree only and avoided sampling fruit located on the top, bottom or inner 
positions of the tree; another report (Guyot et al., 2003) only selected the predominant 
fruit for further analysis; and finally another report (Lata and Tomala, 2007) only 
selected fruit of similar size or diameter located on the outer layer of the tree. This 
chapter, therefore, presents results of a full apple polyphenol profile between three 
seasons and the sampling preformed was representative of the whole tree.  
 
2.3 Objectives 
The overall aim of the research presented in this chapter was to investigate changes in 
the content and composition of apple polyphenols during the growing season for 
several growing seasons. The key aspects of the study design were: 1) apples were 
harvested from the same individual trees and analysed as such to allow direct 
comparisons to be made between seasons for individual trees; 2) sampling of 
individual trees was representative of the whole tree; 3) on selected occasions, 
individual apples were analysed to allow within-tree variation to be assessed; and 4) all 
of the different apple polyphenols were quantified. The resulting data was used to 
address the following questions concerning apple polyphenol content, concentration 
and composition: 1) the changes/differences in total polyphenol concentration, content 
and composition between seasons; 2) the changes/differences in total polyphenol 
concentration, content and profile within a single sampled tree between seasons; 3) the 
relationship between growth and maturity of the apple fruit and the concentration and 
content of polyphenols within a season; and 4) the extent of within-tree variation in 
polyphenol concentration.  
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2.4 Materials and methods 
2.4.1 Materials 
Methanol, acetonitrile and dichloromethane were obtained from Fisher-Scientific and 
trifuloroacetic acid, (-)-epicatechin, (+)-catechin and chlorogenic acid were purchased 
from Sigma-Aldrich (Poole, UK). The NIST Standard Reference Material 2384 baking 
chocolate (NIST chocolate standard) was sourced from the National Institute of 
Standards and Technology (NIST) (Gaithersburg, Maryland). All solvents were HPLC 
grade. The polyphenol standards, quercetin-3-O-rutinoside (rutin), quercetin-3-O-
galactoside (hyperoside), quercetin-3-O-glucoside (isoquercitrin), quercetin-3-O-
xyloside, quercetin-3-O-arabinoside, quercetin-3-O-rhamnoside, phloridzin and 
galangin were purchased from Extrasynthase (Genay, France).  
 
2.4.2 Apple samples 
The analysed apple samples were provided and collected by Richard Wood of 
Coressence Ltd (Herefordshire, UK). The apples were collected every week for eight 
weeks during the apple growing season. The apples were collected approximately 
eight weeks post bud burst. The 2007 apples were collected from the week beginning 
July 22, 2007, the 2009 apples were collected from the week commencing July 19, 
2009 and the 2010 apples were collected from the week starting July 19, 2010. Three 
trees, on the southern end of the apple orchard, were used to collect the samples. The 
treatment (i.e. use of fertilizers, pesticides, etc) of the orchard was consistent for each 
year. The orchard represents a mixed orchard, with the presence of the main cultivar 
(tree code: 07003102) and a pollinator cultivar (tree code: 0700392). Both the main 
cultivar and the pollinator cultivar were a cross of three bittersweet apple varieties. The 
main apple cultivar is planted in a ratio of 4:1 to the pollinater apple cultivar. Trees A 
and B are the main variety and tree C is the pollinator variety. The apples were 
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collected from three consecutive rows and columns and sampled from the north, south, 
west, east, top, bottom and inner positions of the tree. Once collected, the apples were 
immediately frozen and were subsequently transported to IFR using refrigerated 
transport (-20 ºC).  
 
In 2007, the apples were delivered frozen and seven apples were collected from each 
tree in Week 1, followed by six apples for the remaining weeks. In 2009, seven apples 
were collected from each week. The 2009 Week 1 apples were delivered fresh and the 
apples from Weeks 2 – 8 (2009) were delivered frozen. The 2009 Week 5 apples were 
not collected and analysis on 2009 Week 7 apples for trees A and B and 2009 Week 8 
apples for trees A, B and C were lost due to a failure in the freeze-drying equipment 
causing the fruit to defrost and rot. In 2010, seven apples were collected in each week.  
 
2.4.3 Meteorological information 
The apple orchard where the apples were harvested is located in Dewsall, 
Herefordshire (West Midlands). Meteorological information on the mean temperature, 
total rainfall and total hours of sunshine in the Midlands (Figure 2.1) was obtained from 
the Met Office (www.metoffice.co.uk). The Midlands area includes the Cotswold Hills to 
the south, the Northamptonshire uplands to the east, the Peak District to the north and 
is bounded by the Welsh border to the west (www.metoffice.co.uk). Therefore the 
presentation of the average climatic data from the Midlands is a limitation in this study 
because the climatic data covers a large geographical region rather than focusing on 
the specific geographical region where the orchard is located.  
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Figure 2.1: Mean temperature (ºC), total rainfall (mm) and sunshine (total hours) in the 
Midlands, England during 2007 to 2010. 
 
2.4.4 Sample preparation 
2.4.4.1 Preparation of apples after delivery 
Once delivered, the apples from each collection week and tree code were weighed 
individually. The apples were then cut into eight segments and four alternating 
segments were bagged for individual analysis and the other four alternating segments 
were bagged into a group bag for composite analysis. The bagged apples were re-
weighed and subsequently freeze-dried for seven days. The weight of the freeze-dried 
apples was recorded and the apples were ground into a powder using a domestic food 
processor and the powder was transferred to zip-lock plastic bags and stored at room 
temperature in the dark.  
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2.4.4.2 Apple polyphenol extraction 
Samples (40 mg, in triplicates) of freeze-dried whole apple powder were extracted 
using 950 µl of 70 % (v/v) methanol and 50 µl of internal standard (0.1 mg/ml galangin 
in methanol) at 70 ºC for 20 min. The samples were centrifuged for 10 min at 
13000 x g. The supernatants were filtered (0.22 µM) and the filtrate from each sample 
was transferred to a HPLC vial. Samples were stored at -20 ºC for up to 48 hours 
subsequent to HPLC analysis.  
 
2.4.5 High-performance liquid chromatography analysis 
Each sample was analysed using two different high-performance liquid 
chromatography (HPLC; Agilent HP1100) methods: (1) reverse-phase HPLC analysis 
and (2) normal-phase HPLC analysis. The coefficient of variation of the HPLC methods 
was below 10 % (intra-assay) for approximately 80 % of the samples analysed.  
 
2.4.5.1 Reverse-phase HPLC analysis with UV Diode Array Detection 
The reverse-phase analysis method is used for the separation and quantification of 
phenolics and flavonoids and was used to quantify the following phenolics: epicatechin, 
quercetin-3-O-rutinoside (rutin), quercetin-3-O-galactoside (hyperoside), quercetin-3-O-
glucoside (isoquercitrin), quercetin-3-O-xyloside, quercetin-3-O-arabinoside, quercetin-
3-O-rhamnoside, phloridzin, and 3-O-caffeoylquinic acid (chlorogenic acid). Phenolics 
and flavonoids were analysed using a Luna C18 column (250 x 4.5 mm2, 5 µM particle 
size) (Phenomenex, Macclesfield, UK) and a mobile phase consisting of a 65 min 
gradient ( 0 – 15  , 0 % B; 15 – 22 min, 17 % B; 22 – 30 min, 25 % B; 30 – 35 min, 
35 % B; 35 – 40 min, 50 % B; 40 – 55 min, 100 % B; 55 – 65 min, 0 % B) where 
solvent A is 0.1 % aqueous TFA and solvent B is 0.1 % TFA in acetonitrile. Phenolics 
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and flavonoids were detected by diode array detection (DAD) and the detection of 
phenolics present was established at 270 nm. Identification of phenolics and flavonoids 
were established by running standards for each flavonoid of interest. Example 
chromatograms of the standards and apple samples are shown in Figure 2.2. The limits 
of detection of the polyphenol compounds quantified are described in Table 2.2. 
 
 
Figure 2.2: Example reverse-phase HPLC chromatograms of low MW phenolics at 270nm. 
Mixed standard (A) and apple example (B: all phenolics and C: zoomed section). Peak ID: 1 = chlorogenic 
acid, 2 = epicatechin, 3 = quercetin-3-O-arabinose, 4 = quercetin-3-O-rutinoside (rutin), 5 = quercetin-3-O-
galactoside, 6 = quercetin-3-O-glucoside, 7 = quercetin-3-O-xyloside, 8 = quercetin-3-O-rhamnoside and 
9 = phloridzin.  
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2.4.5.2 Normal-phase HPLC analysis with Fluorescence Detection 
The normal-phase method is used for the quantification of polymeric flavan-3-ols 
(polymeric catechins, also termed procyanidins or condensed tannins). Procyanidin 
oligomers up to dp 10 (degree of polymerisation of 10 units) can be separated while 
those of higher dp are eluted as a ‘hump’ following the dp10 peaks. Samples of the 
NIST chocolate were run alongside apple samples to confirm peak retention times and 
were used as a quality control standard. Epicatechin and catechin standards were run 
to quantify the polymeric fractions. In the normal-phase method, flavanols were 
separated according to degree of polymerisation using a Luna silica column 
(250 x 4.6 mm2, 5 µM particle size) (Phenomenex, Macclesfield, UK) and a mobile 
phase consisting of a 65 min gradient (0 – 30 min, 14.0 – 28.4 % B; 30 – 45 min, 28.4 – 
39.6 % B; 45 – 50 min, 39.6 – 86.0 % B; 50 – 55 min, 86.0 % B; 55 – 65 min, 14.0 % B; 
with a constant 4 % of C maintained throughout the gradient) where solvent A is 
dichloromethane, B is methanol and C is acetic acid/water (1:1, v/v). Flavanols were 
detected by fluorescence emission at 316 nm, following excitation at 276 nm. The 
LC-fluorescence detection method is that described by (Gu et al., 2002) with the 
additional relative fluorescence response data by (Prior and Gu, 2005). Example 
chromatograms of the standards, NIST chocolate standard and apple samples are 
shown in Figure 2.3. The limits of detection of the polyphenol compounds quantified 
are described in Table 2.2. 
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Figure 2.3: Example normal-phase HPLC chromatograms of flavanols. 
NIST chocolate standard (A), epicatechin standard (B), catechin standard (C), and apple example (D). 
Peak ID: epi = epicatechin and cat = catechin.  
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Table 2.2 Limit of detection of the polyphenol compounds quantified using normal- and 
reverse-phase HPLC methods 
Polyphenol compounds Limit of detection (ng/ml) 
Reverse phase  
Epicatechin 19.6 
Chlorogenic acid  5.2 
Quercetin-3-O-arabinose 2.3 
Quercetin-3-O-rutinoside (rutin) 1.3 
Quercetin-3-O-galactoside 1.9 
Quercetin-3-O-glucoside 2.1 
Quercetin-3-O-xyloside 1.6 
Quercetin-3-O-rhamnoside 3.5 
Phloridzin 3.8 
Normal phase  
Epicatechin 23 
Catechin 23 
Dimers (dp 2) 36 
Trimers (dp 3) 33 
Tetramers (dp 4) 38 
Pentamers (dp 5) 41 
Hexamers (dp 6) 52 
Heptamers (dp 7) 38 
 
 
2.4.6 Statistical analysis 
Year and tree variation were analysed by analysis of variance (ANOVA). A p-value 
of < 0.05 was considered significant. The Tukey all pair-wise comparison was 
preformed if the p-value for the overall test was < 0.05. The significance of weather 
(temperature, rainfall and sunshine) was analysed by ANOVA. A p-value of < 0.05 was 
considered significant. The correlation between the area under the curve and weather 
variables (mean temperature, total rainfall, and total hours of sunshine) were analysed 
using Pearson’s correlation in SPSS (correlate: bivariate).  
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2.5 Results 
2.5.1 The effect of growth and maturity and seasonal variation on 
total polyphenol concentration and content 
Apple fruits, from one orchard, were collected during three years to investigate the 
effect of growth and maturity and seasonal variation on polyphenol concentration and 
content. For the purposes of this chapter, total polyphenols include the following 
quantified polyphenols: flavanol monomers (epicatechin and catechin), flavanol 
polymers (dp 2 – 7), quercetin glycosides (rutin, quercetin-3-O-galactoside, quercetin-
3-O-glucoside, quercetin-3-O-xyloside, quercetin-3-O-rhamnoside and quercetin-3-O-
xyloside), chlorogenic acid and phloridzin. The effects of seasonal variation and growth 
and maturity on total polyphenol concentration and content were determined between 
the three harvest years 2007, 2009 and 2010.  
 
In the case of total polyphenol concentration, each harvest year follows the same trend. 
A greater polyphenol concentration was observed in the beginning of the growing 
season (week 1) followed by a steady decrease until the end of the growing season 
(week 8) (Figure 2.4). In each year a statistically significant decrease in polyphenol 
concentration was observed at the end of the growing season compared to the first 
week of the growing season (2007, p <0.0001; 2009, p = 0.0022; 2010, p < 0.0001). A 
significant difference (p < 0.0001) was observed in polyphenol concentration over the 
different years analysed. However when comparing specific years, a significant 
difference was only observed between the years 2007 and 2009 (p < 0.0001) and the 
years 2009 and 2010 (p < 0.0001). The year 2007 was not significantly different from 
the year 2010 (p = 0.752).  
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Figure 2.4: Total polyphenol concentration in the tested apple orchard in 2007, 2009 and 
2010. 
The total polyphenol concentration was calculated on a fresh weight basis and the polyphenol content. 
Total polyphenols include: flavanol monomers (epicatechin and catechin), flavanol polymers (dp 2 – 7), 
quercetin glycosides (rutin, quercetin-3-O-galactoside, quercetin-3-O-glucoside, quercetin-3-O-xyloside, 
quercetin-3-O-rhamnoside and quercetin-3-O-xylsoide), chlorogenic acid and phloridzin. Each data point 
represents the mean ± the standard deviation of the three trees analysed (triplicate analysis). 
 
The differences between the years may be attributed to the differences in weather 
conditions (mean temperature, total rainfall and total sunshine) between the three 
growing seasons. The weather relating to the months in the growing seasons (July to 
September) were used for statistical analysis. The differences in mean temperature 
(º C) and total rainfall (mm) were correlated with total polyphenol concentration, while 
there was no correlation in the total hours of sunshine (p = 0.392).  Mean temperature 
was negatively correlated with polyphenol concentration (p < 0.0001, r2 = 0.213, 
Pearson’s correlation = -0.461) and total rainfall was positively correlated with 
polyphenol concentration (p = 0.013, r2 = 0.518, Pearson’s correlation = 0.720) 
(Figure 2.5). Therefore, the explanation why there was no significant difference 
between the years 2007 and 2010 may be due to the fact that they have a similar mean 
temperature and total amount of rainfall values. However the climatic data has to be 
interpreted with some care as the climatic data covered a wide geographical region 
rather than focussing on the location of the orchard.  
0 2 4 6 8 10
0
5000
10000
15000
2007
2009
2010
Weeks
To
ta
l p
o
ly
ph
en
o
ls
(m
g/
kg
 
fre
sh
 
w
ei
gh
t)
Chapter 2 
 
53 
 
 
 
Figure 2.5: Correlation between total polyphenol concentration and mean temperature 
and total rainfall during the months July and September. 
 (A) Correlation between total polyphenol concentration (area under the curve = AUC) and mean 
temperature (ºC), and (B) correlation between total polyphenol concentration (AUC) and total rainfall (mm). 
The correlation between the AUC and weather variables (mean temperature and total rainfall) were 
analysed using Pearson’s correlation in SPSS (correlate: bivariate). 
 
For the total polyphenol content, the three years do not follow a similar trend. In 2007, 
the polyphenol content increases from week 4, while the years 2009 and 2010 followed 
a similar trend with an apparent stable amount of total polyphenol content during the 
A 
B 
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growing season (Figure 2.6). In 2007, a statistically significant increase (p < 0.0001) in 
polyphenol content was observed in week 8 compared to week 1, while in 2010 the 
amount of total polyphenol content was not significantly different (p = 0.578) between 
week 1 and week 8. In 2009 a borderline significant difference (p = 0.048) was 
observed between the last week analysed (week 7) in the growing season and the first 
week in the growing season. Therefore the polyphenol content did not change during 
the growing season in 2010. 
 
There is a significant difference (p < 0.0001) in the polyphenol content over the three 
analysed growing seasons. When evaluating differences between the specific years 
the polyphenol content in the year 2007 was significantly different to the polyphenol 
content in the year 2009 (p < 0.0001) and 2010 (p < 0.0001). The polyphenol content 
was highest in 2007. There was no difference between the years 2009 and 2010 
(p = 0.138).  
 
 
Figure 2.6: Total polyphenol content in the tested apple orchard in 2007, 2009 and 2010. 
The polyphenol content was calculated from the fresh weight data and the mean apple weight from each 
week. Total polyphenols include: flavanol monomers (epicatechin and catechin), flavanol polymers 
(dp 2 - 7), quercetin glycosides (rutin, quercetin-3-O-galactoside, quercetin-3-O-glucoside, quercetin-3-O-
xyloside, quercetin-3-O-rhamnoside and quercetin-3-O-xylsoide), chlorogenic acid and phloridzin. Each 
data point represents the mean ± the standard deviation of the three trees analysed (triplicate analysis). 
 
The differences in total polyphenol content in 2007 may be attributed to the fruit size 
and the difference in weather conditions (temperature, rainfall and sunshine). In the 
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case of fruit size, 2007 had larger average fruit sizes than 2009 and 2010 (Table 2.3). 
A significant difference (p < 0.05) between average apple weights in 2007 and 2009 
was observed in weeks 2, 4, 6 and 7 and a significant difference (p < 0.05) in average 
apple weights was observed between 2007 and 2010 in weeks 3, 4, 5 and 7.  Weather 
is also another variable that can account for the difference in polyphenol content in 
2007. Mean temperature (ºC), total rainfall (mm) and total sunshine (hours) during the 
growing season period (July to September) were correlated with an increase in 
polyphenol content. Temperature was negatively correlated (weak association) with 
polyphenol content (p < 0.0001, r2 = 0.650, Pearson’s correlation = -0.806) while total 
rainfall (p = 0.013, r2 = 0.223, Pearson’s correlation = 0.472) and total sunshine 
(p < 0.0001, r2 = 0.666, Pearson’s correlation = 0.816) were positively correlated 
(Figure 2.7). The climatic data has to be interpreted with some caution as the climatic 
data covered a wide geographical region rather than focussing on the location of the 
orchard. 
 
Table 2.3: Apple weights (g) of Trees A, B and C collected over the eight week growing 
period in 2007, 2009 and 2010. 
 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7  Week 8 
2007         
A1 39 48 57 59 79 101 106 92 
B1 34 38 50 91 76 74 75 105 
C1 35 40 39 67 83 104 106 106 
Average 35.8 42.0 48.6 72.3 79.1 92.9 95.6 100.6 
2009         
A2 39 55 70 66 n/a 73 n/a n/a 
B2 42 50 65 62 n/a 78 n/a n/a 
C2 26 32 44 45 n/a 56 63 n/a 
Average 35.7 45.5 59.9 57.8 n/a 68.9 63 n/a 
2010         
A3 36 37 45 52 49 50 60 75 
B3 26 32 33 37 38 47 47 48 
C3 22 25 27 29 40 39 56 66 
Average 27.9 31.2 35.1 39.2 42.0 45.4 54.3 62.9 
1
 Mean apple weight (g) of the 7 apples collected in week 1 and the 6 apples collected in week 8 in 2007. 
2
 Mean apple weight (g) of the 7 apples collected in weeks 1 – 4 and week 6 and 7 in 2009. 
3
 Mean apple weight (g) of the 7 apples collected in weeks 1 – 8 in 2010.  
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Figure 2.7: Correlation between total polyphenol content and mean temperature, total 
rainfall and total sunshine during the months July and September. 
(A) Correlation between total polyphenol content (area under the curve = AUC) and mean temperature 
(ºC), (B) correlation between total polyphenol content (AUC) and total rainfall (mm), and (C) correlation 
between total polyphenol content (AUC) and total sunshine (hours). The correlation between the AUC and 
weather variables (mean temperature, total rainfall, and total hours of sunshine) were analysed using 
Pearson’s correlation in SPSS (correlate: bivariate). 
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2.5.2 The effect of growth and maturity and seasonal variation on 
individual polyphenols 
The apples in 2007, 2009 and 2010 were analysed for seventeen different polyphenolic 
compounds that were grouped together as total polyphenol concentration and content 
in Section 2.5.1. It is therefore also interesting to determine how the individual 
polyphenols are affected during growth and maturity and between seasons. The 
polyphenols were grouped into categories to which they are closely related to: total 
quercetin glycosides (rutin, quercetin-3-O-galactoside, quercetin-3-O-glucoside, 
quercetin-3-O-xyloside, quercetin-3-O-rhamnoside and quercetin-3-O-xylsoide), total 
flavanol monomers (epicatechin and catechin), total polymers (dp 2 – 7), chlorogenic 
acid and phloridzin. In this section the individual polyphenols are expressed as a 
percentage of the total amount of polyphenols present in the apples.  
 
The percentages of individual polyphenol (total quercetin glycosides, total flavanol 
monomers, total flavanol polymers, chlorogenic acid and phloridzin) for each of the 
three years follow the same pattern (Figure 2.8). In 2007, the percentage of total 
quercetin glycosides (p = 0.019), total flavanol polymers (p = 0.017) in the apples were 
significantly greater in week 8 compared to week 1, while the percentage of 
chlorogenic acid (p = 0.010) was significantly greater in week 1 compared to week 8. 
The percentage of total flavanol monomers (p = 0.153) and phloridzin (p = 0.349) in the 
apple fruit did not change significantly during the growing season. 
 
In 2009, the percentage of total flavanol polymers (p = 0.009), chlorogenic acid 
(p = 0.002), and quercetin glycosides (p = 0.040) in the apples was significantly greater 
at the end of the growing season (week 7) compared to the beginning of the growing 
season, while the percentage of total chlorogenic acid (p = 0.042), total flavanol 
Chapter 2 
 
58 
 
monomers (p = 0.003) and phloridzin (p = 0.007) was significantly greater at the 
beginning of the growing season compared to the end of the growing season.  
 
In 2010, the percentage of total quercetin glycosides (p = 0.013) and total flavanol 
polymers (p < 0.001) in the apple fruits was significantly greater in week 8 compared to 
week 1, while the percentage of total flavanol monomers (p = 0.0002) and chlorogenic 
acid (p = 0.028) was significantly greater in week 1 compared to week 8. The 
percentage of phloridzin (p = 0.108) in the apple fruit did not change significantly over 
the growing season.  
 
The overall effect of seasonal variation was significant for the percentage of total 
quercetin glycosides (p = 0.003) and total flavanol monomers (p < 0.0001) and not 
significant for the percentage of total flavanol polymers (p = 0.190), chlorogenic acid 
(p = 0.905) and phloridzin (p = 0.540). When analysing the specific seasons, the 
percentage of total quercetin glycosides in the year 2010 was significantly different to 
the year 2007 (p = 0.017) and 2009 (p = 0.003). The year 2010 had a lower amount of 
percentage of total quercetin glycosides in the fruit compared to 2007 and 2009. There 
was no significant difference in the percentage of total quercetin glycosides between 
the years 2007 and 2009 (p = 0.767). For the percentage of total flavanol monomers, 
the year 2007 was significantly different between the years 2009 (p < 0.0001) and 2010 
(p < 0.0001) with a greater percentage of total flavanol monomers in 2007. There was 
no significant difference between the years 2009 and 2010 (p = 0.794). 
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Figure 2.8: The percentage of total quercetin glycosides, total flavanol monomers, total 
flavanol polymers, chlorogenic acid and phloridzin in relation to the total polyphenol 
content in the tested apple orchard in 2007, 2009 and 2010. 
The individual polyphenols are expressed as a percentage of the total amount of polyphenols present in 
the apples. (A) total quercetin glycosides percentage (rutin, quercetin-3-O-galactoside, quercetin-3-O-
glucoside, quercetin-3-O-xyloside, quercetin-3-O-rhamnoside and quercetin-3-O-xylsoide), (B) total 
flavanol monomers percentage (epicatechin and catechin), (C) total flavanol polymers percentage 
(dp 2 - 7), (D) chlorogenic acid percentage, and (E) phloridzin percentage.  Each data point represents the 
mean ± the standard deviation of the three trees analysed (triplicate analysis). 
 
The differences in the percentages of total quercetin glycosides and total flavanol 
monomers might be related to the variations in weather conditions (mean temperature, 
total rainfall, total sunshine) over the growing seasons (July to September). In the case 
of the percentage of total quercetin glycosides, sunshine was the only weather factor 
that was correlated with the percentage of total quercetin glycosides; the relationship 
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was positively correlated (p < 0.0001, r2 = 0.266, Pearson’s correlation = 0.516) (Figure 
2.9). This is in keeping with previous reports indicating that the amount of quercetin 
glycosides present in the fruit is dependent on the amount of light that the fruit receives 
(Awad et al., 2001b). With the percentage of total flavanol monomers in the fruit, the 
effect of mean temperature, total rainfall and total sunshine were correlated with the 
percentage of total monomers. Mean temperature (p < 0.0001, r2 = 0.839, Pearson’s 
correlation = -0.916) is negatively correlated with the total monomers ratio while total 
rainfall (p < 0.0001, r2 = 0.396, Pearson’s correlation = 0.629) and total hours of 
sunshine (p < 0.0001, r2 = 0.634, Pearson’s correlation = 0.796) are positively 
correlated with the total flavanol monomers ratio (Figure 2.10). However the climatic 
data has to be interpreted with some caution as the climatic data covered a wide 
geographical region rather than focussing on the location of the orchard. 
 
 
Figure 2.9: Correlation between total quercetin glycosides percentage and total hours of 
sunshine between the months July and September. 
Correlation between total quercetin glycosides percentage (area under the curve = AUC) and total 
sunshine (hours). The correlation between the AUC and weather variables (total hours of sunshine) were 
analysed using Pearson’s correlation in SPSS (correlate: bivariate). 
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Figure 2.10: Correlation between total flavanol monomers percentage and mean 
temperature, total rainfall and total sunshine between the months July and September. 
 (A) Correlation between total flavanol monomers percentage (area under the curve = AUC) and mean 
temperature (ºC), (B) correlation between total flavanol monomers percentage (AUC) and total rainfall 
(mm), and (C) correlation between  total flavanol monomers percentage (AUC) and total sunshine (hours). 
The correlation between the area under the curve and weather variables (mean temperature, total rainfall, 
and total hours of sunshine) were analysed using Pearson’s correlation in SPSS (correlate: bivariate). 
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2.5.3 Changes in total polyphenol concentration and content and 
individual polyphenols within a single season between the three 
sampled trees 
2.5.3.1 Changes in total polyphenol concentration and content in the apples 
within a single season and between the three sampled trees 
The apples that were collected from the orchard in Herefordshire were collected from 
the same three trees (tree A, B and C) in the southern end of the orchard in 2007, 2009 
and 2010. Therefore the effect of growth and maturity and on polyphenol concentration 
and content on the three analysed trees within a season can also be investigated. 
 
The polyphenol concentration, in the three investigated trees (A, B and C), follow the 
same trend with a significantly greater (p < 0.01) concentration in the beginning of the 
growing season followed by a slow, general decline in the concentration to the end of 
the growing season (Figure 2.11A, B and C). In the years 2007, 2009 and 2010, there 
was a statistical difference (p < 0.05) between the polyphenol concentration in the 
three analysed trees (A, B and C).  
 
The polyphenol content, in the three investigated trees (A, B and C) did not follow the 
same trend (Figure 2.11D, E and F). In 2007, the general trend in polyphenol content is 
an increase in total polyphenol content (Figure 2.11D). Tree A has a borderline 
significant (p = 0.049) increase in polyphenol content between week 1 and week 8, 
while the polyphenol content in tree B is significantly greater (p = 0.007) at the end of 
the growing season compared to the beginning of the growing season. There is no 
significant difference (p = 0.096) in the polyphenol content of tree C between the 
beginning of the growing season and the end. Trees A, B and C are also statistically 
different (p < 0.01) from one another in 2007.  
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In 2009, the general trend is a decrease in polyphenol content from the beginning of 
the growing season to the end of the growing season (Figure 2.11C). However there is 
no significant difference (p > 0.05) in the polyphenol content from the beginning of the 
growing season to the end of the growing season. Trees A, B and C are statistically 
different (p < 0.01) from one another in 2009. 
 
In 2010, the general trend appears to be a relatively stable amount of polyphenol 
content during the growing season (Figure 2.11D). However, the polyphenol content 
was significantly greater (p < 0.01) at the beginning of the growing season compared to 
the end of the growing season for trees A and B, while there was no significant 
difference (p = 0.011) between the beginning and the end of the growing season in tree 
C. Trees A, B and C are statistically different (p < 0.001) from one another in 2010. 
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Figure 2.11: Total polyphenol concentration and content of Tree A, Tree B and Tree C in 2007, 2009 and 2010. 
The total polyphenol concentration was calculated on a fresh weight basis and the polyphenol content (A, B and C) and the total polyphenol content was calculated from the 
fresh weight data and the mean apple weight from each week (D, E and F). Total polyphenols include: flavanol monomers (epicatechin and catechin), flavanol polymers 
(dp 2 – 7), quercetin glycosides (rutin, quercetin-3-O-galactoside, quercetin-3-O-glucoside, quercetin-3-O-xyloside, quercetin-3-O-rhamnoside and quercetin-3-O-xylsoide), 
chlorogenic acid and phloridzin. Each data point represents the mean ± the standard deviation of the triplicate analysis of the time point. 
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2.5.3.2 Changes in the percentage of individual polyphenols in the apples within 
a single season between the three sampled trees 
When looking at the percentages of quercetin glycosides over the three years in the 
individual trees, the percentage of quercetin glycosides appears to be either stable 
during the growing season or increase slightly at the end of the growing season 
(Figure 2.12). In 2007, the percentage of quercetin glycosides in tree B was 
significantly different (p < 0.05) from trees A and C, while there was no difference 
(p = 0.608) in the percentage of quercetin glycosides between trees A and C. In 2009, 
the percentage of quercetin glycosides in tree C was significantly different (p < 0.0001) 
from trees A and B, while there was no difference (p = 0.728) in the percentage of 
quercetin glycosides between trees A and B. In 2010, the percentage of quercetin 
glycosides in tree A was significantly different (p = 0.008) between tree C, while there 
was no difference (p > 0.05) in the percentage of quercetin glycosides between trees A 
and B and between trees C and B. 
 
Figure 2.12: The percentage of total quercetin glycosides in relation to the total 
polyphenol content of the apples from trees A, B and C in 2007, 2009 and 2010. 
Total quercetin glycosides (rutin, quercetin-3-O-galactoside, quercetin-3-O-glucoside, quercetin-3-O-
xyloside, quercetin-3-O-rhamnoside and quercetin-3-O-xylsoide) are expressed as a percentage of the 
total amount of polyphenols present in the apples from tree A, B and C in 2007 (A), 2009 (B) and 2010 
(C). 
 
When looking at the percentages of total flavanol monomers over the three years in the 
individual trees, there appears to be either a stable amount of flavanol monomers 
during the growing season or they appear to be decreasing slightly at the end of the 
growing season (Figure 2.13). In 2007 and 2009, the percentages of flavanol 
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monomers in all trees were significantly different (p < 0.05), while in 2010 the 
percentage of flavanol monomers tree C was significantly different (p < 0.001) from 
trees A and B, while there was no difference (p = 0.090) in the percentage of flavanol 
monomers between trees A and B. 
 
 
Figure 2.13: The percentage of total flavanol monomers in relation to the total polyphenol 
content of the apples from trees A, B and C in 2007, 2009 and 2010. 
Total flavanol monomers (epicatechin and catechin) are expressed as a percentage of the total amount of 
polyphenols present in the apples from tree A, B and C in 2007 (A), 2009 (B) and 2010 (C). 
 
The percentage of total flavanol polymers increases from the beginning of the growing 
season to the end of the growing season (Figure 2.14). In 2007, there was no 
significant difference (p > 0.05) in the percentage of flavanol polymers in the three 
trees. In 2009, the percentage of total flavanol polymers was significantly different 
(p < 0.0001) in tree C compared to trees A and B, while there was no significant 
difference (p = 0.848) between tree A and B. In 2010, there was a significant difference 
(p < 0.05) in the percentage of total flavanol polymers in all trees.  
 
 
Figure 2.14: The percentage of total flavanol polymers in relation to the total polyphenol 
content of the apples from trees A, B and C in 2007, 2009 and 2010. 
Total flavanol polymers (dp 2 -7) percentage are expressed as a percentage of the total amount of 
polyphenols present in the apples from tree A, B and C in 2007 (A), 2009 (B) and 2010 (C). 
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The general trend of the percentage of chlorogenic acid in the apples over the growing 
season is to decline from the beginning to the end of the growing season (Figure 2.15). 
In 2007, the percentage of chlorogenic acid in tree A was significantly different 
(p = 0.016) between tree B, while there was no difference (p > 0.05) in tree C between 
trees A and B. In 2009, the percentage of chlorogenic acid was significantly different 
(p < 0.0001) in tree C between trees A and B, while there was no difference (p = 0.127) 
in the percentage of chlorogenic acid between tree A and B. In 2010, there was a 
significant difference (p < 0.05) in the percentage of chlorogenic acid in all trees.  
 
 
 
Figure 2.15: The percentage of chlorogenic acid in relation to the total polyphenol 
content in apples from trees A, B and C in 2007, 2009 and 2010. 
Chlorogenic acid is expressed as a percentage of the total amount of polyphenols present in the apples 
from tree A, B and C in 2007 (A), 2009 (B) and 2010 (C). 
 
The percentage of phloridzin in the apples is generally stable throughout the growing 
season (Figure 2.16). In 2007, there was no significant difference (p > 0.05) in the 
percentage of phloridzin in the three trees. In 2009, the percentage of phloridzin was 
significantly different (p < 0.0001) in tree C between trees A and B, while there was no 
significant difference (p = 0.480) between tree A and B. In 2010, there was a significant 
difference (p < 0.0001) in the percentage of phloridzin in all trees.  
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Figure 2.16: The percentage of phloridzin in relation to the total polyphenol content in the 
apples from trees A, B and C in 2007, 2009 and 2010. 
Phloridzin is expressed as a percentage of the total amount of polyphenols present in the apples from tree 
A, B and C in 2007 (A), 2009 (B) and 2010 (C). 
 
2.5.4 Changes in total polyphenol concentration and content and 
percentages of individual polyphenols within a single tree between 
the three sampled seasons 
2.5.4.1 Changes in total polyphenol concentration and content within a single 
tree between the three sampled seasons 
The apples were collected from the same three trees (tree A, B and C) in the southern 
end of the orchard in 2007, 2009 and 2010. Therefore the effect of growth and maturity 
on polyphenol concentration and content on the individual analysed trees over the 
three seasons can also be investigated.   
 
The polyphenol concentration, in the all three trees (A, B and C) over the three season 
(2007, 2009 and 2010) follow the same trend with a significantly greater (p < 0.01) 
concentration in the beginning of the growing season followed by a slow, general 
decline in the concentration to the end of the growing season (Figure 2.17 A, B and C). 
In trees A and B, the polyphenol concentration was significantly different (p < 0.0001) 
in 2009 between the years 2007 and 2010, and there was no difference (p > 0.05) 
between the year 2007 and 2010 (Figure 2.17A and B). In tree C, the polyphenol 
concentration was significantly different (p < 0.01) in all years (Figure 2.17C).  
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The polyphenol content, in the three investigated years (2007, 2009 and 2010) did not 
follow the same trend (Figure 2.17D, E and F). In tree A, the polyphenol content in the 
years 2009 and 2010 were generally stable throughout the growing season, while in 
2007 there was an increase in polyphenol content from week 5 up to week 7 
(Figure 2.17D). The polyphenol content in the year 2009 at the end of the growing 
season was not significantly different (p > 0.05) from the beginning of the growing 
season, while in 2010 the beginning of the growing season had a significantly greater 
(p = 0.003) amount of total polyphenol content that the end of the growing season. In 
2007, there was a borderline significant increase (p = 0.049) in polyphenol content from 
the beginning of the growing season to the end. In tree A, the polyphenol content in 
2007 was significantly different (p < 0.0001) between the years 2009 and 2010, and 
there was no difference (p = 0.561) between the years 2009 and 2010.  
 
In tree B, the polyphenol content in the years 2009 and 2010 are general stable 
throughout the growing season, while in 2007 there was an increase in polyphenol 
content (Figure 2.17E). In the year 2007, there was a significant increase (p = 0.007) in 
total polyphenol content from the beginning of the growing season to the end of the 
growing season while in the 2009 the beginning of the growing season had a 
significantly greater (p = 0.003) polyphenol content than the end of the growing season. 
There was no difference (p = 0.55) between the first week and last week in the growing 
season in the polyphenol content in the year 2009. In tree B, the polyphenol content in 
2009 was significantly different (p < 0.0001) between the years 2007 and 2010, and 
there was no difference (p = 0.057) between the years 2007 and 2010. 
 
In tree C, the polyphenol content in the years 2009 and 2010 was generally stable 
throughout the growing season, while in 2007 there was an increase in polyphenol 
content from the beginning to the end of the growing season (Figure 2.17F). In the year 
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2010, there was a significant increase (p = 0.010) in total polyphenol content from the 
beginning of the growing season to the end of the growing season while in the years 
2007 and 2009 there was no difference (p > 0.05) between the first week and last week 
in the growing season. In tree C, the polyphenol content was significantly different 
(p < 0.01) between all the analysed years. 
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Figure 2.17: Total polyphenol concentration and content of Tree A, Tree B and Tree C in 2007, 2009 and 2010. 
The total polyphenol concentration was calculated on a fresh weight basis and the polyphenol content (A, B and C) and the total polyphenol content was calculated from the 
fresh weight data and the mean apple weight from each week (D, E and F).  Total polyphenols include: flavanol monomers (epicatechin and catechin), flavanol polymers 
(dp 2 – 7), quercetin glycosides (rutin, quercetin-3-O-galactoside, quercetin-3-O-glucoside, quercetin-3-O-xyloside, quercetin-3-O-rhamnoside and quercetin-3-O-xylsoide), 
chlorogenic acid and phloridzin. Each data point represents the mean ± the standard deviation of the triplicate analysis of the time point. 
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2.5.4.2 Changes in the percentage of individual polyphenols in the apples within 
a single tree between the three sampled seasons  
When looking at the percentages of quercetin glycosides over the three years in the 
individual trees, the percentage of quercetin glycosides appears to be either stable 
during the growing season or increases slightly at the end of the growing season 
(Figure 2.18). In tree A, the percentage of quercetin glycosides between the years 
2007 and 2010 were borderline significantly different (p = 0.049) and there was no 
difference (p > 0.05) in the year 2009 between the years 2007 and 2010. In tree B, the 
percentage of quercetin glycosides in 2009 was significantly different (p < 0.0001) 
between the years 2007 and 2010, while there was no difference (p = 0.219) in the 
percentage of quercetin glycosides between the years 2007 and 2010. In tree C, the 
percentage of quercetin glycosides was significantly different (p < 0.01) in all years. 
 
 
Figure 2.18: The percentage of total quercetin glycosides in relation to the total 
polyphenol content in the apples from trees A, B and C in 2007, 2009 and 2010. 
The total quercetin glycosides (rutin, quercetin-3-O-galactoside, quercetin-3-O-glucoside, quercetin-3-O-
xyloside, quercetin-3-O-rhamnoside and quercetin-3-O-xylsoide) are expressed as a percentage of the 
total amount of polyphenols present in the apples from Tree A, B and C in 2007 (A), 2009 (B) and 2010 
(C). 
 
The percentage of total flavanol monomers in the apples either increases slightly from 
the beginning to the end of the growing season or remains relatively stable 
(Figure 2.19). In trees A, B and C, there is a significant difference (p < 0.01) in the 
percentage of total flavanols between all the years investigated.  
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Figure 2.19: The percentage of total flavanol monomers in relation to the total polyphenol 
content in the apples from trees A, B and C in 2007, 2009 and 2010. 
The total flavanol monomers (epicatechin and catechin) are expressed as a percentage of the total amount 
of polyphenols present in the apples from Tree A, B and C in 2007 (A), 2009 (B) and 2010 (C). 
 
The percentage of total flavanol polymers increases from the beginning of the growing 
season to the end of the growing season (Figure 2.20). In tree A, the percentage of 
total flavanol polymers in 2007 was significantly different (p < 0.0001) between the 
years 2009 and 2010 while there was no significant difference (p = 0.301) between the 
years 2009 and 2010. In tree B and C, the percentage of total flavanol polymers was 
significantly different (p < 0.01) in the year 2009 between the years 2007 and 2010, 
while there was no difference (p > 0.05) between the years 2007 and 2010.   
 
 
Figure 2.20: The percentage of total flavanol polymers in relation to the total polyphenol 
content in the apples from trees A, B and C in 2007, 2009 and 2010. 
The total flavanol polymers (dp 2 – 7) are expressed as a percentage of the total amount of polyphenols 
present in the apples from Tree A, B and C in 2007 (A), 2009 (B) and 2010 (C). 
 
The percentage of chlorogenic acid in the apples either declines from the beginning to 
the end of the growing season or remains stable throughout the growing season 
(Figure 2.21). In tree A, the percentage of chlorogenic acid in the year 2007 was 
significantly different (p = 0.039) between the year 2009, while there was no difference 
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(p > 0.05) in the year 2010 between the years 2007 and 2009. In tree B, the 
percentage of chlorogenic acid was significantly different (p < 0.0001) in the year 2009 
between the years 2007 and 2010, while there was no difference (p = 0.265) in the 
percentage of chlorogenic acid between the years 2007 and 2010. In tree C, there was 
a significant difference (p < 0.01) in the percentage of chlorogenic acid in all years.  
 
 
Figure 2.21: The percentage of chlorogenic acid in relation to the total polyphenol 
content in the apples from trees A, B and C in 2007, 2009 and 2010. 
Chlorogenic acid is expressed as a percentage of the total amount of polyphenols present in the apples 
from Tree A, B and C in 2007 (A), 2009 (B) and 2010 (C). 
 
The percentage of phloridzin in the apples is generally stable throughout the growing 
season (Figure 2.22). In tree A, there was a significant difference (p < 0.01) in the 
percentage of phloridzin in 2007 between the years 2009 and 2010 while there was no 
difference (p = 0.639) between the years 2009 and 2010. In tree B, the percentage of 
phloridzin was significantly different (p < 0.01) in all three years. In tree C, there was a 
significant difference (p < 0.01) in the percentage of phloridzin in 2010 between the 
years 2007 and 2009 while there was no difference (p = 0.059) between the years 
2007 and 2009.  
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Figure 2.22: The percentage of phloridzin in relation to the total polyphenol content in the 
apples from trees A, B and C in 2007, 2009 and 2010. 
Phloridzin is expressed as a percentage of the total amount of polyphenols present in the apples from Tree 
A, B and C in 2007 (A), 2009 (B) and 2010 (C). 
 
2.5.5 Total and individual polyphenol concentrations and contents 
within in a tree 
For each of the weeks in the growing seasons seven apples were collected from each 
tree, with the exception of 2007 where seven apples were collected in week 1 and six 
apples were collected in weeks 2 to 8. As polyphenol synthesis is dependent on the 
amount of sunlight received due to the location of fruit on the tree (Awad et al., 2001b), 
the analysis of the seven (or six) individual apples collected from week 1 and week 8 
were analysed to assess the variation in polyphenol concentration from apples 
collected from different positions on the same tree.   
 
In the week 1 individual analysis (data not shown), the individual apple analysis 
average was higher in all years for all of the following measurements: total polyphenol, 
total quercetin glycosides, total flavanol monomers, total flavanol polymers, chlorogenic 
acid and phloridzin concentrations compared to the composite apple analysis due to a 
systematic error. The systematic error was due to inadequate homogenization of the 
freeze-dried apple because of the small sample size. This error was not seen with the 
week 8 individual and composite apple analyses.  
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The week 8 individual apple sample averages and the week 8 composite apple sample 
averages are described in Table 2.4 for the year 2007 and Table 2.5 for the year 2010. 
There is no data for week 8 in 2009 due to a freeze-drier failure. In 2007, a greater than 
10% variation was observed in the triplicate analyses of the composite samples in tree 
A and C while in tree B and all the trees in 2010, a variation of less than 10% was 
observed between the triplicate analyses of the composite samples. The large variation 
in the composite samples in tree A and C in 2007 was difficult to determine because a 
high variation did not occur in the tree B samples which were extracted and analysed at 
the same time.  
 
In 2007 (11 – 40 %) and 2010 (14 – 47 %) a large variation was seen in the data for the 
individual apples. The large variation observed in the analysis of the individual apples 
is due to the location of the fruit on the tree. Apples were picked from the north, south, 
west, east, top, bottom and inner positions of the tree. The apples picked from different 
locations on the tree were not kept separate; therefore a link between polyphenol 
concentration and tree position can not be derived. However, it can be stated that the 
polyphenol concentration varies depending on the position of the apple fruit on the tree.  
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Table 2.4: Within tree variation of the total amount of polyphenols, quercetin-glycosides, flavanol monomers, flavanol polymers, chlorogenic acid 
and phloridzin in week 8 in the 2007 growing season. 
 2007 
 A B C 
 Week 8 
(Individual) 
Week 8 
(composite) 
Week 8 
(Individual) 
Week 8 
(composite) 
Week 8 
(Individual) 
Week 8 
(composite) 
 
      
Total polyphenols       
Mean ± standard deviation1 5337 ± 603 5046 ± 312 6161 ± 909 5137 ± 312 6519 ± 993 5269 ± 666 
Range (min-max)1 4432 – 5958 4797 – 5411 4538 – 6993 4797 – 5411 5101 – 8171 4766 – 6024 
Variance 11% 15% 15% 6% 15% 13% 
 
      
Total quercetin-glycosides 
Mean ± standard deviation1 152 ± 36 185 ± 65 135 ± 54 111 ± 4 116 ± 28 124 ± 19 
Range (min-max)1 118 – 206 120 – 250 71 – 206 106 – 113 71 – 143 102 – 138 
Variance 24% 35% 40% 4% 24% 16% 
 
      
Total flavanol monomers 
Mean ± standard deviation1 875 ± 119 838 ± 197 1102 ± 171 946 ± 74 3543 ± 793 939 ± 160 
Range (min-max)1 700 – 1035 678 – 1058 914 – 1498 873 – 1020 2216 - 4427 829 – 1123 
Variance 14% 24% 16% 7% 22% 17% 
 
      
Total flavanol polymers 
Mean ± standard deviation1 2882 ± 426 2849 ± 642 3428 ± 455 2944 ± 240 3483± 586 3157 ± 528 
Range (min-max)1 2398 – 3435  2384 – 3581 3158 – 4459  2679 – 3148 3401 – 5456  2792 – 2917 
Variance 15% 23% 13% 8% 15% 17 % 
 
      
Chlorogenic acid 
Mean ± standard deviation1 1084 ± 151 857 ± 61 1212 ± 222 978 ± 10 1096 ± 218 851 ± 68 
Range (min-max)1 797 – 1221 799 – 921 789 – 1439 967 – 988 969 – 1527 803 – 928 
Variance 14% 7% 18% 1% 20% 8% 
 
      
Phloridzin       
Mean ± standard deviation1 343 ± 93 318 ± 71 229 ± 72 158 ± 6 290 ± 75 197 ± 5 
Range (min-max)1 258 – 466 254 – 394 106 – 315 152 – 164 145 – 352 191 – 202 
Variance 27% 22% 31% 4% 26% 3% 
1Mean and standard deviation are expressed in mg per kg fresh weight. 
Week 8 (individual) is the mean, range and variance of seven apples. Week 8 (composite) is the mean, range and variance of triplicate analysis of the composite sample. 
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Table 2.5: Within tree variation of the total amount of polyphenols, quercetin-glycosides, flavanol monomers, flavanol polymers, chlorogenic acid 
and phloridzin in week 8 in the 2010 growing season. 
 2010 
 A B C 
 Week 8 
(Individual) 
Week 8 
(composite) 
Week 8 
(Individual) 
Week 8 
(composite) 
Week 8 
(Individual) 
Week 8 
(composite) 
 
      
Total polyphenols       
Mean ± standard deviation1 4882 ± 1027 4722 ±54  4779 ± 1208 4513 ± 108 4703 ± 1107 4281 ± 90 
Range (min-max)1 3063 – 5740  4660 – 4754  3479 – 6821  4402 – 4617 3668 – 6764  4192 – 4373  
Variance 21% 1% 25% 2% 24% 2% 
 
      
Total quercetin-glycosides 
Mean ± standard deviation1 96 ± 35 99 ± 5 92 ± 36 83 ± 5 91 ± 42 89 ± 6 
Range (min-max)1 55 – 154  94 – 102  33 – 130  79 – 88 39 – 138  85 – 95  
Variance 35% 5% 39% 6% 47% 6% 
 
      
Total flavanol monomers 
Mean ± standard deviation1 587 ± 167 582 ± 18 614 ± 89 585 ± 9 574 ±109  527 ± 32 
Range (min-max)1 338 – 737  561 – 596  423 – 851  575 – 591  460 – 769  491 – 554  
Variance 28% 3% 14% 1% 19% 6% 
 
      
Total flavanol polymers 
Mean ± standard deviation1 3166 ± 734 3027 ± 35 2738 ± 802 2584 ± 84 2901 ± 729 2680 ±30 
Range (min-max)1 1860 – 3891  2987 – 3053  1813 – 4044  2510 – 2675  2285 – 4285  2659 – 2714  
Variance 23% 1% 29% 3% 25% 1% 
 
      
Chlorogenic acid 
Mean ± standard deviation1 789 ± 163 754 ± 31 1159 ± 272 1113 ± 24 758 ± 198 679 ± 46 
Range (min-max)1 522 – 989 721 – 781  904 – 1674 1085 – 1132  509 – 1062 629 – 721  
Variance 21% 4% 23% 2% 26% 7% 
 
      
Phloridzin       
Mean ± standard deviation1 264 ± 38 260 ± 23 176 ± 37 146 ± 12 386 ± 118 306 ± 118 
Range (min-max)1 211 – 317 243 – 286  127 – 220 137 – 160  225 – 530 270 – 342  
Variance 14% 9% 21% 8% 31% 11% 
1Mean and standard deviation are expressed in mg per kg fresh weight. 
Week 8 (individual) is the mean, range and variance of seven apples. Week 8 (composite) is the mean, range and variance of triplicate analysis of the composite sample. 
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2.6 Discussion 
The data presented in this chapter show that the polyphenol concentration, content and 
percentage of individual polyphenols in apples of two varieties grown in an orchard in 
Herefordshire are affected by (1) growth and maturity; (2) seasonal variation; (3) 
location in the orchard; and (4) may be affected by the location on the tree as a large 
variation is observed from apples collected from the same tree. In general, the 
concentration of total polyphenols (the mass amount of polyphenols per unit mass of 
apple tissues) decreases, while the absolute amount of polyphenols increases over the 
growing season. This is also the first time that a complete quantitative analysis of the 
polyphenols found in apples was conducted as well as the first time an analysis of the 
direct effect of seasonal variations on individual apple trees has been investigated.  
 
The concentration of polyphenols (mg per kg fresh weight) was greatest at the 
beginning of the growing season and declined during fruit growth. Whereas the 
polyphenol content (the mass amount of polyphenols per unit mass of apple tissues) in 
the apples showed different trends based on the year of investigation. The polyphenol 
content in 2007 increased during the growing season from week 5 up to week 8. While 
in 2009 and 2010, the amount of polyphenols in the apples fluctuated slightly during the 
growing season but remained generally stable. The individual polyphenol compounds 
also did not behave uniformly. The percentage of quercetin glycosides and total 
flavanol polymers in the apples increased from the beginning of the growing season to 
the end of the growing season. The percentage of total flavanol monomers or 
phloridzin was either relatively stable during the growing season or had a greater 
percentage in the apple fruit at the beginning of the growing season compared to the 
end based on the year of investigation. The percentage of chlorogenic acid in the apple 
fruit was greatest at the beginning of the growing season and declined during fruit 
growth.  
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The results presented agree with a number of studies reporting that the concentration 
of polyphenols decreases during fruit growth and maturation (Lister et al., 1994; Mayr 
et al., 1995; Awad et al., 2001a; Kondo et al., 2002a; Guyot et al., 2003; Takos et al., 
2006; Renard et al., 2007) while the content increases during fruit growth and 
maturation (Lister et al., 1994; Awad et al., 2001a; Kondo et al., 2002a; Takos et al., 
2006; Renard et al., 2007).  It can be concluded that the decrease in the concentration 
of polyphenols is due to a dilution effect of these compounds caused by the 
progressive growth of the fruit (Lister et al., 1994; Awad et al., 2001a; Takos et al., 
2006; Renard et al., 2007). Therefore the reason why the polyphenol content in the 
apples in 2009 and 2010 did not increase during the growing season was because the 
size of the fruit did not increase as substantially during the growing season as it did in 
2007.  
 
The results presented for individual polyphenols also agree with the profile of individual 
polyphenols as described by Awad et al. (2001a). In their analysis of Jonagold and 
Elstar fruit, it was found that the amount of quercetin glycosides and chlorogenic acid 
increased during fruit growth; the amount of flavanol monomers slightly decreased 
before remaining relatively constant; and the amount of phloridzin increased during fruit 
growth before remaining relatively stable (Awad et al., 2001a). The only deviation 
between the results presented in this chapter and those with Awad et al. (2001a) is the 
profile of chlorogenic acid; the percentage of chlorogenic acid decreased during fruit 
growth in the results presented in this chapter whereas in those presented by Awad et 
al. (2001a) the amount of chlorogenic acid increased during fruit growth. In addition, 
data presented here show that percentage of procyanidins increased during the 
growing season.  
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The differences in the accumulation of polyphenols during fruit growth may be 
attributed to the polyphenol biosynthetic pathway. The biosynthesis of polyphenols is 
derived from two pathways, the shikimate and the acetate-malonate pathways, as 
described in Chapter 1, Figure 1.1. In the biosynthetic pathway, quercetin glycosides, 
flavanol monomers and polymers and anthocyanins are derived from phenolic acids 
and dihydrochalcones via several enzymatic steps. The decrease in the percentage of 
chlorogenic acid and phloridzin may therefore be responsible for the greater 
percentage of quercetin glycosides. However as the percentage of quercetin 
glycosides increases during fruit growth, their biosynthetic process may be regulated 
slightly differently to the other polyphenols as the accumulation of catechins, phloridzin 
and chlorogenic acid was not affected by the synthesis of quercetin glycosides (Awad 
et al., 2001a; Awad et al., 2001b). The increase in flavanol polymers corresponded with 
a decrease in flavanol monomers as the flavanol polymers are derived from the 
monomers in the polyphenol biosynthetic process. The decrease of chlorogenic acid 
and flavanol monomers in favour of quercetin glycosides and flavanol polymers was 
also observed by Mayr et al. (1995). Lister et al. (1994) concluded that the parallel 
changes in the concentration of quercetin glycosides, procyanidins and cyanidin 
glycosides during fruit growth correspond to the levels of flavonoid enzymes which alter 
in response to environmental and/or developmental changes.  
 
Environmental factors such as differences in weather (temperature, rainfall and amount 
of sunshine) can have an influence on the amount of polyphenols in the apple fruit. The 
results presented in this chapter show that the polyphenol concentration and content of 
the two apple varieties from an orchard in Herefordshire were significantly different 
between growing seasons. When investigating the effect of weather on polyphenol 
concentration, the mean temperature and total amount of rainfall, during the three 
months of the growing season, were correlated with the polyphenol concentration. 
Mean temperature was negatively correlated while total amount of rainfall was 
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positively correlated with the concentration of polyphenols in apples. In the case of 
polyphenol content, mean temperature, total amount of rainfall and total hours of 
sunshine were all correlated with the content. Mean temperature was negatively 
correlated while total amount of rainfall and total hours of sunshine were positively 
correlated with the amount of polyphenols in the apple fruit. The quercetin glycosides 
and total flavanol monomers were the only two individual polyphenol groups that were 
significantly different between growing seasons. The total hours of sunshine was 
positively correlated with the percentage of quercetin glycosides in the apple fruit. 
Mean temperature was negatively correlated while total amount of rainfall and total 
hours of sunshine were positively correlated with the percentage of total flavanol 
monomers in the apple fruit. Therefore these results show for the first time that the 
concentration and content of polyphenols in apples and the percentage of quercetin 
glycosides and total flavanol monomers are different between seasons and this 
difference is correlated with the differences in weather conditions over the years. 
However the climatic data should be interpreted with some care because the climatic 
data was represented the mean values of the geographical region of the Midlands 
rather than focussing on the precise location of the orchard.  
 
These results agree with those studies stating that certain cultivars are more 
susceptible to seasonal variations (van der Sluis et al., 2001; Lata et al., 2005; Lata 
and Tomala, 2007; Stracke et al., 2009). While there have been previous studies 
reporting the effects of the concentration and content of total and individual 
polyphenols, this is the first time that a complete quantitative HPLC analysis of the 
polyphenols found in apples was conducted. The apples were collected from all 
locations on the tree to ensure a representative sampling.  
 
Weather has also been reported to influence the accumulation of polyphenols in 
apples. It is widely known that the amount of light received is an important factor in the 
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synthesis of polyphenols (Awad et al., 2001b; van der Sluis et al., 2001; Stracke et al., 
2009). It has been shown that apple fruit located on the outer positions of the tree 
canopy had a greater concentration of cyanidin-3-galactoside and  quercetin glycosides 
than fruit which were located on the inner positions of the tree canopy due to the 
amount of light received by the fruit (Awad et al., 2001b). The concentration of 
catechins, phloridzin and chlorogenic acid were unaffected by the amount of light 
(Awad et al., 2001b). The results presented in this chapter also show that the 
percentage of quercetin glycosides in the apple fruit was correlated with the amount of 
sunshine received. However in contradiction with Awad et al. (2001b), the data in this 
chapter show that the content of polyphenols and the percentage of total flavanol 
monomers are also positively correlated with the amount of sunlight received. The data 
in this chapter also show that the there is a large variation of polyphenols sampled from 
different positions on the tree (north, east, west, south, top, bottom, outer and inner 
positions of the tree) which may also be due to the amount of sunlight received.  
 
The effect of temperature and rainfall on the content and concentration of polyphenols 
in apples has not been widely reported. It has been postulated that the differences in 
polyphenol concentration between two harvest seasons were due to the differences in 
rainfall between the two years, with a greater concentration of polyphenols in the year 
with the least amount of rainfall (Stracke et al., 2009). Low evening temperatures 
coupled with high sunlight levels during the autumnal season have been reported to 
increase the anthocyanin content formation in apples (Saure, 1990), however no 
investigation of other polyphenols has been conducted. The results presented in this 
chapter show that mean temperature, during the growing season months, was 
negatively correlated with polyphenol content and concentration and that total amount 
of rainfall was positively correlated with the concentration and content of polyphenols in 
apples.  
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During the sampling process, apples were collected from the same three trees over the 
years of investigation. This sampling procedure allowed for the direct comparison of 
how variable the concentration and content of polyphenols are within an orchard and 
how variable the concentration and content of polyphenols are in a tree over three 
years. The three trees that were selected comprised two of the main cultivar in the 
orchard and one of the pollinator variety; both were high polyphenol varieties. Despite 
the fact that two of the trees were the same variety, there was a significant difference in 
the concentration and content of polyphenols and percentages of individual 
polyphenols in all three years. A significant difference was also observed in the 
polyphenol content and concentration and percentages of individual polyphenols in the 
apple fruit in one tree over the three years investigated. Therefore, this suggests that 
further variability arises in the accumulation of polyphenols in different trees located in 
the same section of the same orchard as well as variability, in one tree, introduced by 
seasonal differences. This is the first time that the direct effect of seasonal variations 
on individual apple trees has been investigated.  
 
2.7 Conclusions 
The data presented in this chapter have shown that the polyphenol concentration, 
content and percentage of individual polyphenols in the apple fruit of two varieties 
grown in an orchard in Herefordshire are affected by (1) growth and maturity; (2) 
seasonal variations; (3) location in the orchard; and (4) may be affected by the location 
on the tree as a large variation is observed from apples collected from the same tree. 
The polyphenol concentration of apples decrease during growth and maturity, while the 
polyphenol content of apples generally increases during growth and maturity due to an 
increase in fruit size. Weather, during the growing season, also influences the 
concentration and content of polyphenols in apples. Mean temperatures are negatively 
correlated with polyphenol content and concentration, while total amount of rainfall and 
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total hours of sunshine are positively correlated with content and concentration. The 
location of the apple on the tree and ultimately the amount of sunlight the fruit received, 
causes a large variation in the concentration of polyphenols in the apple fruit, and 
significant differences in the polyphenol content and concentration were also observed 
between the trees located next to one another. Therefore the accumulation of 
polyphenols in apples is not a simple process and is dependent on a number of factors.   
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
CHAPTER THREE 
 
NOVEL ROUTES FOR PRODUCING POLYPHENOL-
RICH APPLE EXTRACTS AND THE EFFECTS OF AN 
APPLE POLYPHENOL EXTRACT ON VASCULAR 
FUNCTION IN HUMANS 
 
 
  
Chapter 3 
 
87 
 
Chapter 3 : Novel routes for producing polyphenol-rich 
apple extracts and the effects of an apple polyphenol 
extract on vascular function in humans  
3.1 Abstract 
Apples are eaten fresh as well as being processed into different apple products. 
However, the processing of apples into various products has been shown to 
substantially affect the polyphenol content of apple products such as apple juice. In 
apple juice production the losses occur in the pressing of the apples and the majority of 
the polyphenols are retained in the apple pomace. Therefore an effective method of 
extracting polyphenols from the apple pomace, a by-product of apple juice production, 
for the supplementation into food products is desirable as epidemiological and in-vivo 
studies have shown protective effects of dietary polyphenols. Therefore the objectives 
of this chapter were to investigate how to reduce the losses observed with apple juice 
production, determine if a hot water extraction of the apple pomace efficiently extracts 
polyphenols as well as investigating the effects of an apple polyphenol-rich extract 
supplemented apple juice improves vascular function in an intervention trial. The 
results from this chapter have shown that (1) a microwave-heat treatment of whole 
apple slices was not effective in increasing the yield of polyphenols in the first press 
juice or the recovery in the first press pomace; (2) a hot water extraction of the apple 
pomace was a very effective method of extracting the polyphenols retained from the 
first press and yielded a polyphenol-rich aqueous extract; (3) the hot water extraction of 
the apple pomace conducted at room temperature compared to 4 ºC was more 
effective in extracting the polyphenols retained in the apple pomace and similar losses 
of polyphenols were observed at both temperatures; and (4) consumption of an apple 
polyphenol-rich extract supplemented apple juice resulted in a small but significant 
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improvement in arterial stiffness and vascular age but not in reflective index 
(endothelial function) compared to the low polyphenol apple juice. Therefore future 
studies should investigate: (1) how to decrease the losses observed in the production 
of apple juice; (2) the possibility of using the polyphenol-rich extract as a food 
supplement; and (3) the consumption of apple polyphenol-rich foods and apple 
polyphenol supplement foods in different food matrices (i.e. solid food versus a drink) 
which will provide further evidence regarding apple polyphenols and their vasodilatory 
effects on endothelial function. 
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3.2 Introduction 
High intakes of fruits and vegetables have been linked with a reduced risk of chronic 
diseases such as cardiovascular disease and cancer and it has been suggested that 
this protective effect is due, at least partly, to polyphenols especially flavonoids. 
Epidemiological evidence of the effects of flavonoid intake on cardiovascular risk is 
mixed with some supporting studies (Hertog et al., 1993a; Knekt et al., 1996; Hollman 
and Katan, 1999; Arts et al., 2001b; Mink et al., 2007) and some studies not 
demonstrating the positive effects (Rimm et al., 1996; Yochum et al., 1999; Sesso et 
al., 2003). However, there have been a number of human intervention trials that have 
shown that consumption of flavonoids reduces risk of CVD (Hooper et al., 2008; Desch 
et al., 2010; Jia et al., 2010). Based on a meta-analysis of randomised controlled 
intervention studies, it was shown that some flavonoids or foods rich in flavonoids such 
as chocolate or cocoa and black tea reduced important risk factors of cardiovascular 
disease such as a reduction in flow-mediated dilation (FMD), reduction in systolic and 
diastolic blood pressure, and a reduction in the amount of low-density lipoprotein (LDL) 
cholesterol (Hooper et al., 2008). A meta-analysis of ten controlled intervention trials, 
has also shown that the consumption of flavanol-rich cocoa products caused a 
reduction in blood pressure (Desch et al., 2010) while a meta-analysis of eight 
controlled intervention trials showed an LDL cholesterol lowering effect in subjects with 
cardiovascular disease risk factors who consumed a low dose of cocoa (Jia et al., 
2010).  
 
Based on the published evidence, polyphenols (especially flavonoids) have been 
shown to reduce cardiovascular risk biomarkers. A reduction of FMD and blood 
pressure by flavonoids has been suggested to be attributed to the vasodilating effects 
of flavonoids by causing an increase in nitric oxide (NO) (Hooper et al., 2008; Desch et 
al., 2010). Flow-mediated dilation assesses the arterial diameter, by high-resolution 
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ultrasound, during a period of induced ischemia and is a direct method of assessing 
endothelial function (Hashimoto et al., 2003; Kobayashi et al., 2004; Wilson et al., 
2004). Endothelial function is a key determinant of vascular health, as dysfunction of 
the endothelium is an indication of the initial development of atherosclerosis 
(Hashimoto et al., 1999; McEniery et al., 2006). Flavonoids have been shown to 
improve endothelial function through an increase in nitric oxide synthase (NOS) 
expression and NO-dependent vasorelaxation (Heiss et al., 2003; Grassi et al., 2005b). 
NO has also been shown to cause improvements in insulin sensitivity (Grassi et al., 
2005b), improvements in platelet function (Holt et al., 2002b), inhibition of LDL 
oxidiation (Baba et al., 2007) and an increase in HDL cholesterol concentration (Baba 
et al., 2007). Flavanols have also been reported to increase NOS expression and 
activity in-vitro (Persson et al., 2006).  
 
Therefore the investigation of the effects of an apple-derived epicatechin-rich extract on 
vascular function was conducted in a randomised controlled human intervention pilot 
study. Apples were chosen as the fruit of interest as apples are one of the most popular 
fruits in the UK (Weichselbaum et al., 2010) and they are one of the five foods in the 
UK that supplies the majority of the flavonoids intake in the diet (Beking and Vieira, 
2011). Apple consumption has also been associated with a reduced risk of 
cardiovascular disease risk (Sesso et al., 2003), coronary mortality (Knekt et al., 1996) 
and coronary heart disease and cardiovascular disease mortality (Mink et al., 2007). 
 
The polyphenols found in apples include flavanols, hydroxycinnamic acids, 
dihydrochalcones, flavonols and anthocyanins as described in Chapter 1, Section 1.4. 
The polyphenol profile and content of apples are affected by several factors including 
cultivar, distribution within the fruit, growth and maturation, seasonal variations, 
geographical region, and food preparation, processing and storage as described in 
Chapter 2 (Introduction). As apples are consumed fresh as well as processed apple 
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products (e.g. apple juice, apple sauce and apple cider), it is important to understand 
how the processing of apples affects the final polyphenol content of the product. The 
processing of apples into apple juice has been shown to substantially affect the 
polyphenol content. Apple juice contains significantly lower concentrations of 
polyphenols compared to the fruit and a large proportion of the polyphenols remain in 
the post-press apple pomace (Pérez-Ilzarbe et al., 1991; Guyot et al., 2003; Boyer and 
Liu, 2004). During pressing, the main polyphenols to be transferred into the juice are 
the water-soluble polyphenols such as dihydrochalcones or hydroxycinnamic acids 
whereas the extraction of other polyphenols is more difficult (Bellion et al., 2010). For 
example, in the pressing of five French cider apple varieties, it was shown that 42 % of 
the polyphenols were extracted from the apples to the juice, indicating that the rest 
remained in the pomace (Guyot et al., 2003). However, analysis of the pomace was not 
conducted. In a separate study, the juice produced from three varieties of cider apples 
was shown to contain a small proportion of the flavanols (3.2 – 5.0 µg/g) while the 
majority of the flavanols (87 –113 µg/g) remained in the pomace (Price et al., 1999). In 
apple juice production, enzymatic treatment of the apple pulp is widely used to improve 
the ease of pressing, increase the juice yield and to clarify the juice (Van Buren et al., 
1976; Schols et al., 1991; van der Sluis et al., 2002). However, juices obtained by 
enzymatic treatments have been shown to have a lower content of polyphenols and 
have characteristic differences in the colour and aroma of the juice compared to the 
conventionally pressed apple juice (Van Buren et al., 1976; Spanos et al., 1990; Schols 
et al., 1991; van der Sluis et al., 2002). 
 
Different methods have been applied in apple juice production to successfully increase 
the yield of polyphenols in the juice from the apple pomace. The different methods 
include: alcohol extraction (van der Sluis et al., 2004), diffusion extraction (Spanos et 
al., 1990), liquefaction (Schols et al., 1991; Will et al., 2000; Mihalev et al., 2004) and 
microwaving (Gerard and Roberts, 2004). However these methods have certain 
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disadvantages which include loss of juice characteristics (e.g. aroma and taste), a 
greater susceptibility to browning, and having to comply with food laws (van der Sluis et 
al., 2004). Diagrams of the different apple juice production methods are shown in 
Figure 3.1. It has been suggested that a hot water extraction of the apple pomace may 
prove to be a favourable method of extraction than the other methods currently applied 
(van der Sluis et al., 2004). Due to the high levels of polyphenols present in the apple 
pomace after pressing, researchers have concluded that the extraction of polyphenols 
from the apple pomace could be commercially exploited (Lu and Foo, 1997; Price et 
al., 1999; van der Sluis et al., 2001; Schieber et al., 2003). Therefore the investigation 
of hot water extraction was undertaken on the apple pomace to determine whether an 
efficient extraction of epicatechin and other polyphenols could be achieved. 
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Figure 3.1: Apple juice extraction methods. 
(A) conventional pressing, (B) pulp enzyming, (C) alcohol pulp extraction, (D) alcohol pomace extraction, 
(E) liquefaction of the pulp, (F) liquefaction of the pomace, and (G) microwaving 
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3.3 Objectives 
The specific aims of this chapter were to: (1) determine if heat treatment before 
pressing can reduce the loss of polyphenols observed during pressing; (2) determine if 
hot water extraction of the apple pomace is an efficient method of extracting 
polyphenols; (3) determine if steeping the pomace being extracted at a lower 
temperature can reduce the loss observed during extraction; and (4) assess the effects 
of an apple polyphenol-rich extract supplemented apple juice versus a low polyphenol 
apple juice on vascular function by non-invasively assessing arterial function through 
the use of photoplethysmography.  
 
3.4 Materials and methods 
3.4.1 Materials 
Methanol, acetonitrile and dichloromethane were obtained from Fisher-Scientific and 
trifuloroacetic acid (TFA), hydrochloric acid (HCl) (-)-epicatechin, (+)-catechin and 
chlorogenic acid were purchased from Sigma-Aldrich (Poole, UK). All solvents were 
HPLC grade. The phenolic standards, quercetin-3-O-rutinoside (rutin), quercetin-3-O-
galactoside (hyperoside), quercetin-3-O-glucoside (isoquercitrin), quercetin-3-O-
xyloside, quercetin-3-O-arabinoside, quercetin-3-O-rhamnoside, phloridzin and 
galangin were purchased from Extrasynthase (Genay, France). The Harry Masters and 
Yarlington Mill cider apples were provided by Richard Wood of Coressence Ltd from 
the 2007 harvest year. TESCO-value apples were purchased from TESCO and Idared, 
Cox and Jonagold apples were from the Apple & Pear People (Hoveton, Norfolk).   
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3.4.2 Apple juice production 
The conventional method of apple juice production involves the slicing and pulping of 
apples followed by the pressing of the apple pulp into juice (Figure 3.1A). The 
experiments conducted in this chapter modify this process to try and increase the 
amount of polyphenols in the juice.  
 
3.4.2.1 Apple juice production modification one  
A 4.5 L wooden press was used for the production of apple juice (Winepress4u; 
Cheshire, UK). The apples were microwaved for 1 min to increase the core 
temperature to 100 ºC. The apples were cut into segments and pulped using a food 
processor (Magimix Cuisine System Automatic 5100) in order to increase juice yield. 
The apple pulp was then pressed and the juice collected. Samples of the apple 
pomace and juice were collected for analysis. The method is described in Figure 3.2A. 
 
3.4.2.2 Apple juice production modification two 
The apples were cut into segments and pulped using a food processor in order to 
increase juice yield. The apple pulp was then pressed and the juice collected. The 
apple pomace (the residue of the pulped and pressed apples) was then steeped in 
boiling water for 24 h at room temperature. The amount of boiling water added to the 
pomace was approximately two litres, enough water to cover all of the pomace. After 
steeping, the second press was performed. Samples of the apple pomace and juice 
were collected for analysis at the first and second pressing. The method is described in 
Figure 3.2B. 
 
3.4.2.3 Apple juice production modification three 
The apples were then cut into segments and pulped using a food processor in order to 
increase juice yield. The apple pulp was then pressed and the juice collected. The 
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apple pomace was steeped in boiling water for 24 h at 4 ºC. The amount of boiling 
water added to the pomace was approximately two litres, enough water to cover all of 
the pomace. After steeping, the second press was performed. Samples of the juice and 
pomace were collected for analysis at the first and second pressing. The method is 
described in Figure 3.2C.  
 
 
Figure 3.2: Apple juice production experimental procedures. 
(A) experimental modification 1 – microwave step prior to slicing, (B) experimental 
modification 2 – hot water extraction of the apple pomace followed by a 24 incubation at room 
temperature and re-pressing of the apple pomace; and (C) experimental modification 3 – hot 
water extraction of the apple pomace followed by a 24 h incubation at 4 ºC prior to the re-
pressing of the apple pomace. 
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3.4.2.4 Sample preparation for analysis 
3.4.2.4.1 Juice 
The juice was treated with HCl (final concentration 0.1 %) to prevent further enzymatic 
oxidation.  
 
3.4.2.4.2 Apples and pomace 
A sample of five apples, from each analysis, were weighed individually and cut into 
eight segments. The apples were bagged into a group bag for composite analysis and 
were re-weighed. The pomace samples were collected from the first press and the 
second press production steps and were weighed and bagged. This process was 
performed quickly so as to not cause an increase in enzymatic browning. The apples 
and pomace samples were then frozen (-20 ºC). Subsequently, the frozen apples and 
pomace samples were freeze-dried for seven days. The freeze-dried apples and 
pomace samples were homogenised into a powder using a domestic food processor 
and the powder was transferred to zip-lock plastic bags and stored at room 
temperature.  
 
3.4.2.5 Sample extraction for analysis 
3.4.2.5.1 Juice 
Juice samples were extracted using two methods. Two methods were applied as 
further work, by a member in the group, in the extraction of polyphenols from juice was 
found to be more precise if a greater volume was used in the extraction.  
 
Method 1: samples (300 µl, in triplicates) of the juice produced from Harry Masters and 
Yarlington Mill cider apples, TESCO value-range apples and gala apples were added 
to 700 µl of 70 % v/v methanol and 50 µl of the internal standard (0.1 mg/ml galangin in 
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100 % methanol). The samples were incubated at 70 ºC for 20 min and then 
centrifuged for 10 min at 13 000 x g. The supernatants were filtered (0.22 µm) and the 
filtrate was transferred to an HPLC vial. Samples were stored at -20 ºC for up to 24 h 
prior to HPLC analysis. 
 
Method 2: samples of Idared, Cox and Jonagold apples (3 ml, in triplicate) were added 
to 7 ml of 100 % methanol and 50 µl of the internal standard (0.1 mg/ml galangin in 
100 % methanol). The mixture was placed in an ultrasonic water bath to disperse the 
sample, incubated in an air oven at 70 º C for 20 min and then sonicated in the water 
bath for a final time. The sample was then made up to volume (10 ml) and a 1.5 ml 
sample was taken and centrifuged at 13 000 x g for 20 min. The supernatant was 
filtered (0.22 µm) and the filtrate was transferred to an HPLC vial. Samples were stored 
at -20 ºC for up to 24 h prior to HPLC analysis. 
 
3.4.2.5.2 Apples and pomace 
Apple and pomace samples were extracted using two methods. Two methods were 
applied as further work, by a member in the group, in the extraction of polyphenols 
from freeze-dried material was found to more precise if a greater mass was used in the 
extraction.  
 
Method 1: samples (40 mg, in triplicates) of freeze-dried whole apple powder or 
pomace powder from Harry Masters and Yarlington Mill cider apples, TESCO value-
range apples and gala apples were extracted using 950 µl of 70 % v/v methanol and 
50 µl of the internal standard (0.1 mg/ml galangin in 100 % methanol) at 70 ºC for 
20 min. The samples were centrifuged for 10 min at 13 000 x g. The supernatants were 
filtered (0.22 µm) and the filtrate was transferred to an HPLC vial. Samples were stored 
at -20 ºC for up to 24 h prior to HPLC analysis. 
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Method 2: samples (500 mg, in triplicate) of freeze-dried whole apple powder or 
pomace powder from Idared, Cox and Jonagold apples were extracted using 40 ml of 
70 % v/v methanol in a 50 cm2 volumetric flask. The mixture was placed in a ultrasonic 
water bath to disperse the sample, incubated in an air oven at 70 ºC for 20 min and 
then sonicated in the water bath for a final time. The sample was then made up to 
volume (50 ml) and a 1.5 ml sample was taken and centrifuged at 13 000 x g for 
20 min. The supernatant was filtered (0.22 µm) and the filtrate was transferred to an 
HPLC vial. Samples were stored at -20 ºC for up to 24 h prior to HPLC analysis. 
 
3.4.2.6 High-performance liquid chromatography analysis 
Each sample was analysed using two different high-performance liquid 
chromatography (HPLC) methods (reverse-phase HPLC analysis and normal-phase 
HPLC analysis) as described in Chapter 2, Section 2.4.5. 
 
3.4.2.7 Statistical analysis 
Where indicated, comparisons between the apples, first press pomace, first press juice, 
second press pomace and second press juice were carried out using a two tailed t-test. 
A p-value < 0.05 was considered significant.  
 
3.4.3 Human Study 
3.4.3.1 Ethics 
The human study was approved by the Institute of Food Research Human Research 
Governance Committee and the Norfolk Research Ethics Committee (reference: 
07/H0310/156).  
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3.4.3.2 Subjects 
Ten healthy, non-smoking males (aged between 19 and 64 years) were recruited by 
advertisements placed on the Norwich Research Park and from the Volunteer 
Database held at the Human Nutrition Unit (HNU) at IFR. Exclusion criteria were based 
on the following criteria: depressed or elevated blood pressure (<90/50 or 99/55 if 
symptomatic or >160/100); BMI <20 or >35; history of stroke; gastrointestinal problems; 
diagnosis of a long-term illness (e.g. diabetes, cancer); diagnosis of a metabolic 
disease; allergy to apples or birch pollen; on medications; unwillingness to discontinue 
dietary supplements one month prior and for the duration of the intervention; 
immunisation required one month prior and during the intervention; antibiotic use 
during the intervention; those who have given blood 16 weeks prior to the intervention 
and intend to donate less than 16 weeks after the last study sample; and parallel 
participation in another research project involving dietary intervention and sampling of 
blood. Potential subjects were screened for suitability and measurements of blood 
pressure, pulse, height, body weight, urine analysis, full blood count, glucose analysis 
and urea and electrolyte level were taken after an overnight fast.  
 
3.4.3.3 Design 
A randomised, double-blind, crossover study was used to compare the consumption of 
a standard apple juice (control) and apple juice supplemented with an epicatechin-rich 
apple concentrate (EvesseTM Fructose). Each of the phases lasted four days. 
Volunteers were asked to refrain from consuming foods and drinks containing high 
levels of polyphenols starting on study day one. The intervention began on study day 
three and a 24 h sample was collected on study day four. There was a minimum wash 
out period of 14 days between the two phases of the intervention.  
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3.4.3.4 Test Drink 
The flavonoid-rich apple concentrate, EvesseTM Fructose, was provided by 
Coressence Ltd. The EvesseTM Fructose was received in two batches, the first batch 
was produced on 20/02/2008 and the second batch was produced on 09/04/2008. 
Standard value-range apple juice was purchased from TESCO. The apple juice was 
purchased in bulk with the same batch number and a fresh apple juice was opened on 
each study day to ensure that there were no differences in the apple juice between 
study days.  
 
The epicatechin and polyphenol content was analysed using reverse-phase HPLC. 
Triplicate analysis was performed on three samples of each EvesseTM Fructose Batch 1 
and 2, apple juice and test drink. Analysis was preformed as described above for the 
juice samples (extraction Method 1 as described in Section 3.4.2.2.1 and the HPLC 
analysis as described in Chapter 2, Section 2.4.3).  
 
The volunteers who received EvesseTM Fructose Batch 1 were given 190 g of apple 
juice supplemented with either 60 g of water (control) or 60 g of EvesseTM Fructose to 
give ~70 mg of epicatechin. While for those volunteers who received EvesseTM Fructose 
Batch 2, 190g of apple juice was supplemented with 70g of water or 70 g of EvesseTM 
Fructose (to give ~70 mg of epicatechin).  
 
3.4.3.5 Pulse Contour Measurements 
Triplicate measurements were taken after an 8 h fast (baseline) and then at 15, 50, 70, 
100, 130, 160, 190, 220, 310, 370, 430 and 1440 min after consumption. Subjects 
rested for at least 10 min prior to the blood pressure being taken. A 
photoplethysmography probe (Pulse Trace PCA 2, Micro Medical, Kent) was then 
placed on the index finger, of the non-cannulated arm to measure the digital volume 
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pulse (DVP). Subjects were asked to stay in a relaxed state with no strenuous activity 
for the duration of the measurements as exercise can have an affect on the pulse 
contour analysis (PCA) measurements. In the case of an unstable reading, PCA 
measurements were attempted for another two attempts before abandoning the time 
point.  
 
3.4.3.6 Data Analysis 
Subject characteristics are shown as mean ± standard deviation. Differences between 
the groups were analysed using analysis of variance (ANOVA) and differences due to 
time were analysed using a Dunnett test. A power transformation of the response 
variables (SI, RI and VA) was performed in order to conform to the assumptions of 
ANOVA. 
 
3.5 Results 
3.5.1 Heat treatment of apples prior to pressing does not reduce 
losses of polyphenols and does not increase the juice polyphenol 
yield  
The processing of apples results in a significant loss of epicatechin and total 
polyphenols. In order to try and reduce the loss of polyphenols in the processing of 
apples into juice, a modification of the conventional apple juice production method was 
performed. The modification of the apple juice production method involved the use of a 
heat treatment (microwave) on the apples prior to pressing (experimental 
modification 1, Figure 3.2 A). It was hypothesised that a heat treatment would 
inactivate the polyphenol oxidase and inhibit enzymatic browning and thus reduce the 
loss of epicatechin and total polyphenols from the apples to the first press pomace and 
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juice. The application of heat was hypothesised to reduce the rate of enzymatic 
browning and polyphenol loss because the enzymes, which are proteins, are easily 
denatured by heat (El-Shimi, 1993). Therefore, whole apples were microwaved for 
1 min in order to increase the core temperature from approximately 23 ºC to 100 ºC 
prior to pulping and pressing.  
 
The polyphenols analysed included: epicatechin, catechin, procyanidin dimer B2, 
procyanidins (dp 3 – 7), chlorogenic acid, phloridzin, rutin, quercetin-3-O-rhamnoside, 
quercetin-3-O-glycoside, quercetin-3-O-glucoside, quercetin-3-O-xyloside and 
quercetin-3-O-arabinoside. Epicatechin, catechin, dimers and the procyanidins were 
analysed using normal phase HPLC and the quercetin glycosides, chlorogenic acid and 
phloridzin were analysed using reverse-phase HPLC.  
 
Pressing the fresh apples resulted in an extraction of 7 % of both epicatechin and total 
polyphenols into the juice while 59 % epicatechin and 60 % total polyphenols were 
retained in the pomace (Table 3.1 and Figure 3.3). The pressing of the apples resulted 
in a 34 % loss of epicatechin (p = 0.007) and a 32 % loss of total polyphenols 
(p = 0.004). The epicatechin and total polyphenol contents were derived from the fresh 
weight data and the mass of the apples, pomace or juice. In order to reduce the loss of 
epicatechin and total polyphenols associated with apple pressing, a microwave heat 
treatment was applied prior to pressing. 
 
The pre-pressed microwave heat treatment did not have any effect on reducing the 
pressing-induced losses of the epicatechin content or total polyphenol content. The 
effect of microwaving the apples resulted in a 35 % loss of epicatechin and a loss of 
18 % of total polyphenols in the microwaved apples compared to the fresh apples 
(Figure 3.3). Therefore the application of the heat treatment increased the loss of 
polyphenols compared to fresh apples rather than decreasing the polyphenol loss it 
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also increased the rate of enzymatic browning. Enzymatic browning occurred at a 
faster rate in the apples that had been mirowaved and a heat ring was apparent in the 
apples that were microwaved (Figure 3.4).  
 
After pressing the microwaved apples, the majority of the polyphenols was located in 
the pomace (55 % epicatechin and 48 % total polyphenols) compared to the juice 
(19 % epicatechin and 14 % total polyphenols). Therefore a further loss (26 % loss of 
epicatechin and 38 % loss of total polyphenols) of polyphenols occurred during the 
pressing of the apples. The majority of the polyphenols were also retained in the apple 
pomace (Table 3.1) 
 
Table 3.1: Polyphenol profile of Jonagold, Idared and Cox apples in the apples, 
microwaved apples, first press pomace and juice and second press pomace and juice. 
1Monomers include epicatechin and catechin 
2Polymers include procyanidins dp 2 -7 
3Quercetin glycosides include the following compounds: rutin, quercetin-3-O-rhamnoside, quercetin-3-O-
glycoside, quercetin-3-O-glucoside, quercetin-3-O-xyloside and quercetin-3-O-arabinoside 
 
 
 
Apples 
(mg) 
Apples 
microwaved 
(mg) 
First press 
 (mg) 
 First press 
(microwaved) 
(mg) 
 
  Pomace Juice  Pomace Juice 
Monomers1 244 162 154 17  88 29 
Polymers2 1712 1493 894 56  619 107 
Quercetin 
glycosides 
190 137 128 5  94 14 
Chlorogenic acid 437 350 248 67  187 99 
Phloridzin 175 123 141 11  101 33 
Total 2759 2265 1565 156  1088 282 
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Figure 3.3: Epicatechin content (mg) and total polyphenols content (mg) of the pomace 
and juice of the first and second press in microwaved apples in comparison to the 
epicatechin content (mg) of the fresh and microwaved apples. 
Jonagold, Idared and Cox apples were first microwaved whole for 1 min, cut into quarters, blended in a 
food processor to increase juice yield, and then pressed using a wooden press. The pomace was then 
steeped in boiling water for 24 h at room temperature prior to a second pressing. Samples of the fresh and 
microwaved apples, 1st press pomace and juice and 2nd press pomace and juice were analysed for 
epicatechin content (A) and total polyphenol content (B) using reverse- and normal-phase HPLC. The 
epicatechin content and total polyphenol content is the total amount of epicatechin/polyphenol in 2500 g of 
fresh or microwaved apples; the total amount of epicatechin/polyphenol in 1850 g and 650 g in the fresh 
apple pomace and juice, respectively; and the total amount of epicatechin/polyphenol in 1600 g and 850 g 
in the microwaved apple pomace and juice, respectively. Total polyphenols = epicatechin, catechin, dimer, 
procyanidins (dp 3 – 7), chlorogenic acid, phloridzin, quercetin-3-O-rhamnoside, quercetin-3-O-glycoside, 
quercetin-3-O-glucoside, quercetin-3-O-xyloside, and quercetin-3-O-arabinoside. Data represent mean ± 
standard deviation. Results are representative of triplicate analyses; * p <0.05, ** p <0.01, ** p < 0.001.  
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Figure 3.4: Comparison of apples with and without heat treatment. 
Apples were cut into eight segments from fresh apples (A) or apples that had been microwaved 
whole for 1 min prior to be cut into segments (B). Comparisons were photographed after cutting 
the apples, after 45 min and after 2.5 h.  
 
 
3.5.2 Hot water treatment of the apple pomace is an effective means 
of extracting polyphenols  
An adaptation of the conventional method of apple juice production was conducted in 
order to extract polyphenols from the pomace. The adaptation of the conventional 
method included the steeping of the apple pomace in boiling water for 24 h, at room 
temperature, before re-pressing (experimental modification 2, Figure 3.2B). The 
experiment was conducted on different types of apple varieties: (A) TESCO value 
apples; (B) a mixture of Harry Masters and Yarlington Mill cider apples; and (C) a 
mixture of Jonagold, Idared and Cox dessert apples (Figure 3.5). Different varieties of 
apples were chosen to determine if the type of apple variety had an affect on the hot 
water extraction yield. The TESCO value apples represented eating apples, the Harry 
Heat treatment No heat treatment 
0 hour 
0.75 hour 
2.5 hour 
BA 
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Masters and Yarlington Mill apples represented apples used for the production of cider 
and Jonagold, Idared and Cox apples represented varieties used for the production of 
apple juice.  
 
The dessert apple varieties (TESCO value and Jonagold, Idared and Cox apples) had 
a similar concentration of epicatechin in the fresh apples (approximately 82 mg/kg) 
while the cider apples (Harry Masters and Yarlington Mill apples) had a much greater 
concentration of epicatechin (498 mg/kg). The content of epicatechin was derived from 
the fresh weight data (mg/kg) and the total mass of the apples, pomace or juice. After 
the first pressing the extraction yield of epicatechin into the juice (4 %) was similar 
between the three varieties and therefore was not dependent on the variety or 
epicatechin concentration. On average 52 % of the epicatechin was retained in the 
pomace and a statistically significant loss of epicatechin (44 %; p < 0.0001) was 
observed during the processing of the apples.  
 
In all three experimental apple varieties, the hot water extraction efficiently extracted 
the epicatechin from the pomace into the second press juice. The different apple 
varieties had a similar extraction yield of epicatechin from the pomace to the second 
press juice that was not dependent on variety or epicatechin concentration. On 
average, 64 % of the epicatechin was extracted from the apple pomace into the second 
press juice with 17 % remaining in the pomace and a significant loss of 19 % 
(p < 0.0001) due to processing losses or oxidation.  
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Figure 3.5: Epicatechin content (mg) of the pomace and juice of the first and second 
press in comparison to the epicatechin content (mg) of the apples. 
TESCO value apples (A), Harry Masters and Yarlington Mill apples (B) and Jonagold, Idared and Cox 
apples (C) were first cut into quarters, blended in a food processor to increase juice yield, and then 
pressed using a wooden press. The pomace was then steeped in boiling water for 24 h at room 
temperature prior to a second pressing. Samples of the apples, 1st press pomace and juice and 2nd press 
pomace and juice were analysed for epicatechin content using reverse-phase HPLC. The epicatechin 
content in the TESCO value apples is derived from the total amount of apples pressed (2500 g), the weight 
of the first press products (1450 g pomace; 638 juice), and the weight of the second press products (904 g 
pomace; 1349 g juice). The epicatechin content in the Harry Masters and Yarlington Mill apples are 
derived from the total amount of apples (2000 g), the weight of the first press products (1600 g pomace; 
265 g pomace) and the weight of the second press products (1260 g pomace;  2340 g juice). The 
epicatechin content in the Jonagold, Idared and Cox apples are derived from the total amount of apples 
(2500 g), the weight of the first press products (1850 g pomace; 665 g juice), and the second press 
products (1000 g pomace; 3111 g juice). Data represent mean ± standard deviation. Results are 
representative of triplicate analyses and (C) is the average of three experiments. ** p < 0.01, *** p <0.001 
compared to the fresh apples or the first press, ††† p < 0.001 compared to the first press pomace and ‡‡‡ 
p < 0.001 compared to the first press juice. 
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For the total polyphenol content, the same pattern was observed as seen with the 
epicatechin content. The TESCO value apples were not analysed using the reverse-
phase method, therefore there is no data available on the total polyphenol content.  
 
The dessert apples (2500 mg) had substantially less total polyphenols compared to the 
cider apples (9500 mg). The extraction yield of total polyphenols in the juice (7 %) and 
in the pomace (61 %) was greater in the dessert apples compared to the cider apples 
(3 % in the juice and 35 % in the pomace). This is due to the greater losses of 
polyphenols observed in the cider apples (63 %) compared to the dessert apples 
(32 %).  
 
In the two experimental varieties, a hot water extraction efficiently extracted the 
polyphenols from the pomace into the second press juice in all experimental apple 
varieties (Figure 3.6). The majority of the polyphenols were retained in the apple 
pomace after the first press; however, after the hot water extraction of the apple 
pomace, the majority of the polyphenols were located in the second press juice 
compared to the second press apple pomace (Table 3.2). On average, 51 % of total 
polyphenols were extracted from the apple pomace into the second press juice with 
19 % remaining in the pomace and a loss of 30 % due to processing losses and 
oxidation.  
 
Therefore while a hot water extraction efficiently extracts epicatechin and total 
polyphenols from the apple pomace, a significant loss of epicatechin and total 
polyphenols are observed between the first press pomace and the second press 
(pomace plus juice).  
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Figure 3.6: Total polyphenol content (mg) of the pomace and juice of the first and second 
press in comparison to the total polyphenol content (mg) of the apples. 
Harry Masters and Yarlington Mill apples (A) and Jonagold, Idared and Cox apples (B) were first cut into 
quarters, blended in a food processor to increase juice yield, and then pressed using a wooden press. The 
pomace was then steeped in boiling water for 24 h at room temperature prior to a second pressing. 
Samples of the apples, 1st press pomace and juice and 2nd press pomace and juice were analysed for total 
polyphenol content using reverse- and normal-phase HPLC. Total polyphenols = epicatechin, catechin, 
dimer, procyanidins (dp 3 – 7), chlorogenic acid, phloridzin, quercetin-3-O-rhamnoside, quercetin-3-O-
glycoside, quercetin-3-O-glucoside, quercetin-3-O-xyloside, and quercetin-3-O-arabinoside. The total 
polyphenol content in the Harry Masters and Yarlington Mill apples are derived from the total amount of 
apples (2000 g), the weight of the first press products (1600 g pomace; 265 g pomace), and the weight of 
the second press products (1260 g pomace;  2340 g juice). The total polyphenol content in the Jonagold, 
Idared and Cox apples are derived from the total amount of apples (2500 g), the weight of the first press 
products (1850 g pomace; 665 g juice), and the second press products (1000 g pomace; 3111 g juice). 
Data represent mean ± standard deviation. Results are representative of triplicate analyses and (B) is the 
average of three experiments. ** p < 0.01, *** p <0.001 compared to the fresh apples or the first press, ††† 
p < 0.001 compared to the first press pomace and ‡‡‡ p < 0.001 compared to the first press juice. 
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Table 3.2: Polyphenol profile of Harry Master and Yarlington Mill apples and Jonagold, 
Idared and Cox apples in the apples, first press pomace and juice and second press 
pomace and juice. 
 
Apples First Press (mg) Second Press (mg) 
 
 Pomace  Juice Pomace Juice 
Harry Masters and Yarlington Mill Apples 
Monomers1 1026 398 29 70 335 
Polymers2 5829 1947 48 383 877 
Quercetin glycosides3 116 68 3 43 15 
Chlorogenic acid 1591 648 48 155 299 
Phloridzin 966 282 11 95 101 
Total 9528 3363 136 746 1627 
Jonagold, Idared and Cox apples 
Monomers1 260 154 17 20 91 
Polymers2 1494 894 56 121 469 
Quercetin glycosides3 190 128 5 41 63 
Chlorogenic acid 453 248 67 40 187 
Phloridzin 187 141 11 25 70 
Total 2584 1565 156 247 880 
1Monomers include epicatechin and catechin 
2Polymers include procyanidins dp 2 -7 
3Quercetin glycosides include the following compounds: rutin, quercetin-3-O-rhamnoside, quercetin-3-O-
glycoside, quercetin-3-O-glucoside, quercetin-3-O-xyloside and quercetin-3-O-arabinoside 
 
3.5.3 Steeping apple pomace at 4 ºC rather than room temperature 
does not improve the polyphenol yield  
In Section 3.5.2, a significant loss of epicatechin and total polyphenols was observed 
between the first press pomace due to the second press (pomace plus juice). 
Therefore a final modification of the conventional apple juice production was preformed 
in order to try and reduce the losses observed during the hot water extraction of the 
apple pomace. The experimental modification (experimental modification 3, 
Figure 3.2C) included at hot water extraction of the apple pomace at 4 ºC overnight to 
test whether reducing the standing temperature would have an affect on the polyphenol 
losses.  
 
The extraction yields of epicatechin and total polyphenols in the first press juice was 
10 % and 9 %, respectively, and the majority of the epicatechin (47 %) and total 
polyphenols (52 %) remained in the pomace. A significant loss of epicatechin (43 %, 
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p < 0.0001) and total polyphenols (38 %, p < 0.0001) was observed between the first 
press products (pomace and juice) and the apples (Figure 3.7). The majority of the 
polyphenols were retained in the apple pomace compared to the first press juice 
(Table 3.3).  
 
The hot water extraction of the apple pomace and incubation at 4 ºC efficiently 
extracted epicatechin and total polyphenols, with a significant increase (p < 0.0001) in 
both epicatechin and total polyphenol contents in the second press juice compared to 
the first press juice. However, the majority of the polyphenols were still retained in the 
second press pomace (Table 3.3). In the case of monomers and chlorogenic acid, a 
greater amount was extracted into the juice, while the majority of the polymers, 
quercetin glycosides were retained in the pomace. The same amount of phloridzin was 
located in the second press pomace (55 mg) and in the second press juice (56 mg).  
 
The incubation at 4 ºC was not as efficient as the extraction at room temperature. The 
extraction yield of epicatechin (46 %) and total polyphenols (34 %) in the juice at 4 ºC 
was significantly lower (p < 0.001) than the extraction yield of epicatechin (64 %) and 
total polyphenols (51 %) in the juice at room temperature. The losses observed from 
the first press pomace to the second press (pomace plus juice) were similar between 
the two methods; a 14 % loss of epicatechin and a 27 % loss of total polyphenols 
occurred at 4 ºC while a 19  % loss of epicatechin and a 30 % loss of total polyphenols 
occurred at room temperature. Therefore, the incubation at 4 ºC did not reduce the loss 
in polyphenols from the apple pomace during the incubation period and it was 
significantly less efficient in extracting epicatechin or total polyphenols from the apple 
pomace into the second press juice compared to the incubation period at room 
temperature.  
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Figure 3.7: Epicatechin content (mg) and total polyphenol content (mg) of the pomace 
and juice of the second press in comparison to the pomace and juice of the second 
press after a hot water extraction at 4 ºC. 
Jonagold, Idared and Cox apples were first cut into quarters, blended in a food processor to increase juice 
yield, and then pressed using a wooden press. The pomace was then steeped in boiling water for 24 h at 
4 ºC prior to a second pressing. Samples of the apples, 1st press pomace and juice and 2nd press pomace 
and juice were analysed for epicatechin content (A) and total polyphenol content (B) using reverse- and 
normal-phase HPLC.  Total polyphenols = epicatechin, catechin, dimer, procyanidins (dp 3 – 7), 
chlorogenic acid, phloridzin, quercetin-3-O-rhamnoside, quercetin-3-O-glycoside, quercetin-3-O-glucoside, 
quercetin-3-O-xyloside, and quercetin-3-O-arabinoside. The total polyphenol content in the Jonagold, 
Idared and Cox apples at room temperature are derived from the total amount of apples (2500 g), the 
weight of the first press products (1850 g pomace; 665 g juice), and the second press products (1000 g 
pomace; 3111 g juice). The total polyphenol content in the Jonagold, Idared and Cox apples at 4 ºC are 
derived from the total amount of apples (2500 g), the first press products (1700 g pomace; 1180 g juice), 
and the second press products (2300 g pomace; 1300 g juice). Data represent mean ± standard deviation. 
Results are representative of triplicate analysis.  *** p <0.001 compared to the room temperature first press 
pomace, ††† p < 0.001 compared to the 4 ºC first press pomace, ‡‡‡ p < 0.001 compared to the room 
temperature first press juice, and ±±± p <0.001 compared to the 4 ºC first press juice. 
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Table 3.3: Polyphenol profile of Jonagold, Idared and Cox apples in the apples, first 
press pomace and juice and second press pomace and juice that had been incubated at 
4 ºC. 
 
Apples First press (mg) Second press (mg) 
  
Pomace Juice Pomace Juice 
Jonagold, Idared and Cox apples 
Monomers1 290 132 68 53 64 
Procyanidins2 1681 805 52 329 224 
Quercetin3 glycosides 150 133 14 72 49 
Chlorogenic acid 479 229 112 64 98 
Phloridzin 196 163 23 55 56 
Total 2796 1464 233 572 491 
1Monomers include epicatechin and catechin 
2Polymers include procyanidins dp 2 -7 
3Quercetin glycosides include the following compounds: rutin, quercetin-3-O-rhamnoside, quercetin-3-O-
glycoside, quercetin-3-O-glucoside, quercetin-3-O-xyloside and quercetin-3-O-arabinoside 
 
3.5.4 Total polyphenol and epicatechin concentration and content in 
the EvesseTM Fructose, apple juice and test drink 
The epicatechin concentration and content, and total polyphenol content were analysed 
for the EvesseTM Fructose Batch 1 and Batch 2, apple juice and test drink using 
normal- and reverse-phase HPLC analysis. The total polyphenol content included the 
following analysed compounds: epicatechin, catechin, dimers and procyanidins 
(dp 2-7), chlorogenic acid, phloridzin, rutin, quercetin-3-O-galactoside, quercetin-3-O-
glucoside, quercetin-3-O-arabinoside, quercetin-3-O-xyloside and quercetin-3-O-
rhamnoside. Quercetin-3-O-arabinoside was not detectable in EvesseTM Fructose 
Batch 1 or 2 or in the apple juice. Catechin, procyanidins, quercetin-3-O-xyloside and 
quercetin-3-O-rhamnoside were also not detectable in the apple juice samples. 
 
The epicatechin concentration in the commercial apple juice was low (epicatechin: 
25.9 mg/L), and the EvesseTM Fructose Batches 1 and 2 had much higher 
concentrations of epicatechin; 1212.8 mg/L and 1028.8 mg/L, respectively (Table 3.4). 
The epicatechin content of EvesseTM Fructose Batch 1 in the test drink volume (250 ml) 
was 72.7 mg while the epicatechin content of EvesseTM Fructose Batch 2 in the test 
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drink volume (250 ml) was lower (61.7 mg).  Therefore, the volunteers receiving 
Batch 2 were given an extra 10 g of the apple concentrate (or water, for the control) in 
order to provide the same amount of epicatechin contents between the two batches. At 
the end of the study the epicatechin content in the test drink was analysed. The 
analysis was preformed on triplicate samples of three test drinks for both of the 
batches. The HPLC analyses showed no significant differences in the epicatechin 
content of the 60 ml of EvesseTM Fructose Batch 1 (72.7 mg) compared to the test drink 
(72.6 mg). However, surprisingly the Batch 2 epicatechin content in the test drink 
(84.0 mg) was apparently 14 mg greater than in the 70 ml of the EvesseTM Fructose 
(71.9 mg).  
 
The apparent 14 mg increase in the epicatechin content in test drink compared to the 
EvesseTM Fructose Batch 2 is most likely due to problems associated with the HPLC 
extraction method used. Following the completion of this study, further investigation on 
the HPLC extraction method had been conducted. It was found that the mass/volume 
of material used in current extraction method was sufficient for analysing low-
polyphenol apple granules however when analysing high-polyphenol apple fructose the 
extraction method underestimated the concentration of epicatechin (Dave Hart, Wendy 
Hollands & Paul Kroon, IFR, unpublished work). It was shown that using a greater 
mass/volume of high-polyphenol apple fructose or granules resulted in a greater 
precision and accuracy of the concentration of epicatechin. The analysis of the 
EvesseTM material could not be re-analysed using the new method as there was no 
more product remaining. Therefore, the likely error in the measurement of the 
epicatechin concentration and content arose from the analysis of EvesseTM Fructose 
than the test drink as the Evesse Fructose was a high-polyphenol extract compared to 
the diluted test drink.  
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The subjects were not split into two different groups based on the batch number of 
EvesseTM fructose that they received because the sample size for each group was too 
small to perform statistical analysis on the PCA data. 
 
Table 3.4: Total polyphenol and epicatechin concentration and content in reverse-phase 
HPLC data of EvesseTM Batch 1 and 2, apple juice and test drinks. 
Product Total 
polyphenol 
concentration 
(mg/L) 
Epicatechin 
concentration 
(mg/L) 
Epicatechin 
content (mg) 
in 60 g 
Epicatechin 
content (mg) 
in the test 
drink 
Total 
polyphenol 
content (mg) in 
the test drink 
EvesseTM Batch 1 
 
8242.4 1212.8 72.7 n/a n/a 
EvesseTM Batch 2 
 
5810.1 1028.8 61.7 n/a n/a 
Apple juice 
 
102.7 25.9 n/a n/a n/a 
Test drink with 
Batch 1 
1813.4 290.3 n/a 72.6 453.4 
Test drink with 
Batch 2 
2038.5 323.1 n/a 84.0 530.1 
n/a = not applicable 
Total polyphenol concentration and content only includes the following analysed polyphenols: epicatechin, 
catechin, dimers and procyanidins (dp 2-7), chlorogenic acid, phloridzin, rutin, quercetin-3-galactoside, 
quercetin-3-glucoside, quercetin-3-arabinoside, quercetin-3-xyloside and quercetin-3-rhamnoside.  
 
3.5.5 Baseline characteristics of volunteers 
Of the ten subjects recruited into the study, nine completed. One male subject was 
excluded after the first phase as he was prescribed antibiotics during the study. Paired 
data were therefore available for analysis on nine subjects. The mean age and BMI of 
the subjects was 48.3 years and 24.9 kg/m2, respectively (Table 3.5). The mean of the 
stiffness index (SI) (7.75 m/s ± 2.24), reflective index (RI) (69.70 ± 11.77) and vascular 
age (VA) (36.48 yrs ± 18.29) at baseline in the control phase was not statistically 
different (SI: p = 0.88; RI: p = 0.47; VA: p = 0.97) with the baseline measurements of 
the SI (7.58 m/s ± 2.21), RI (65.36 ± 13.6) and VA (36.78 yrs ± 17.30) in the treatment 
phase. There was also no significant difference, at baseline, in both phases between 
age and BMI.  
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Table 3.5: Baseline characteristics of the subjects 
Characteristics Mean ± Standard Deviation 
Age, y 
  48.3 ± 7.2 
Height, m 
  1.77 ± 6.2 
Weight, kg 
  78.7 ± 9.4 
BMI, kg/m2 
  24.9 ± 9.4 
Systolic BP1, mm/Hg 124.5 ± 9.7 
Diastolic BP1, mm/Hg 
  77.9 ± 7.9 
         Values are means ± SD, n = 9 
            1Values are means ± SD of baseline measurements on both phases, n = 18 
 
3.5.6 Assessment of vascular function by pulse contour analysis 
Vascular function was assessed by PCA. PCA is one of the methods available to 
measure vascular function. PCA measures the DVP by measuring the transmission of 
infrared light absorbed through the finger using a photoplethysmography probe 
(Millasseau et al., 2002). The DVP consists of two waveforms: the systolic wave and 
the diastolic wave (Figure 3.8) (Oliver and Webb, 2003; Woodman and Watts, 2003). 
The systolic wave is a direct measurement of pressure transmission from the left 
ventricle in the heart to the finger. The diastolic wave is formed during the period when 
the pressure from the pulse is reflected back up the aorta and down to the finger 
(Takazawa et al., 1998; Allen, 2007).  
 
Figure 3.8: Digital volume pulse waveform 
Two pressure waves combine to form the finger pulse. The first pressure wave is the systolic wave and it is 
a direct result of the pressure transmission from the aortic root in the heart to the finger. The second 
pressure wave is the diastolic wave and it is formed when part of the pulse is reflected back up the aorta 
and down to the finger. The time between the systolic and diastolic peaks is related to arterial stiffness and 
the height of the diastolic peak is related to the reflection index.  
Systolic    
(direct wave) 
Diastolic  
(reflective wave) 
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The DVP waveform has been used to determine the SI and RI (Mackenzie et al., 
2002). The transit time (in milliseconds) between the systolic and diastolic wave 
depends on large artery stiffness. The transit time divided by the subject’s height is 
used to obtain a stiffness index (SI), which correlates strongly with aortic pulse wave 
velocity (PWV) (Woodman and Watts, 2003). The height of the diastolic wave relates to 
the amount of wave reflection, which is related to endothelial function. The RI is defined 
as the relative height of the diastolic peak expressed as a percentage of the systolic 
peak.  
 
Across both phases of the study, triplicate measurements were recorded 85 % of the 
time, and repeated unstable readings and time constraints were responsible for two or 
fewer measurements being recorded at some time points. Unstable measurements 
which produced no recordings for a specific time point occurred less than 1 % of the 
time. An example measurement is shown in Figure 3.9.  
 
 
Figure 3.9: Example digital volume pulse waveform. 
Triplicate measurements of the digital volume pulse waveform were obtained from subjects after an 8 h 
fast (baseline) and then at 15, 50, 70, 100, 130, 160, 190, 220, 310, 370, 430 and 1440 min after the 
consumption of the control or treatment drink. SI = stiffness index, RI = reflective index, V.A. = vascular 
age, HR = heart rate. Age, height and sex are the subject’s characteristics.  
 
Test 1
Test 2
Test 3
14   ,  
Time
Signal
SI = 11.1 m/s
RI = 75 %
SI Range: [6-14] 
V.A: 68 [62-74] 
PPT = 153 ms
HR = 82 bpm
Age = 57
Height = 170 cm
Sex = Male
 
 
 
 
Chapter 3 
 
119 
 
The baseline measurement of SI during the treatment phase was not significantly 
different (p = 0.88) to the baseline measurement in the control phase. During the 
treatment phase, the SI increased after 15 min followed by a steady decrease until 
100 min when the SI slightly increased before finally levelling off back to baseline. The 
control phase SI shows a similar pattern to the treatment phase; however the increase 
up to 100 min is greater than for the treatment phase but does not reach significance at 
any individual time point (Figure 3.10).  
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Figure 3.10: Comparison of the stiffness index in the control and treatment phases. 
Triplicate measurements of the digital volume pulse were taken using a photoplethysmography probe were 
taken after an 8 h fast (baseline) and then at 15, 50, 70, 100, 130, 160, 190, 220, 310, 370, 430 and 1440 
min after consumption of the standard apple juice (control) or the EvesseTM fructose-supplemented apple 
juice (treatment). Values represent mean ± standard deviation of the nine subjects triplicate 
measurements. Differences between the groups were analysed using ANOVA and differences due to time 
was analysed using a Dunnett test. A power transformation of the response variable (SI) was preformed in 
order to conform to the assumptions of ANOVA.  
 
Age is known to be a confounding variable; therefore age was accounted for as a 
covariate during statistical analysis. The mean SI of the control phase (7.68 m/s ± 1.94) 
was significantly different (p = 0.031) to the mean SI of the treatment phase 
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(7.36 m/s ± 1.54). Therefore a statistically significant lower SI was observed after 
consumption of the test drink.  
 
The RI is an indicator of endothelial function and an increase in RI is due to an 
increase in peripheral pulse wave reflection (e.g. vasoconstriction) while a reduction in 
RI indicates vasodialtion (Kneifel et al., 2006; Alty et al., 2007). After consumption of 
the test drink, a reduction in RI measurements is expected as a NO preserving effect 
has been observed following treatment with flavonoids (Karim et al., 2000; Leikert et 
al., 2002; Wallerath et al., 2002; Anter et al., 2004; Lorenz et al., 2004; Nicholson et al., 
2008; Appeldoorn et al., 2009a; Lorenz et al., 2009b; Madeira et al., 2009; Ramirez-
Sanchez et al., 2010). While a difference in baseline is observed between the RI 
measurement in the treatment and control phase, the difference is not statistically 
significant difference (p = 0.47) and the RI measurement at 15 min in the treatment 
phase increases to the baseline measurement of the control phase (Figure 3.11).  
 
Following the consumption of the Evesse FructoseTM-supplemented drink, the RI 
increased moderately at 15 min, and then decreased substantially up to 100 min. After 
this, there was an increase to 130 min, followed by an uneven slow decline. The 
consumption of lunch (between the measurements at 210 and 310 min) may be the 
cause of the resulting decrease in RI. There was no statistically significant difference 
between the RI (all the data) of the control and treatment phases (p = 0.222), with no 
significant differences at any time point. 
 
However, the RI over time was significantly different (p = 0.022), and the greatest 
difference occurred at 310 min when compared to the baseline measurement in both 
the control and treatment phase.  
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Figure 3.11: Comparison of the reflective index in the control and treatment phases. 
Triplicate measurements of the digital volume pulse were taken using a photoplethysmography probe were 
taken after an 8 h fast (baseline) and then at 15, 50, 70, 100, 130, 160, 190, 220, 310, 370, 430 and 1440 
min after consumption of the standard apple juice (control) or the EvesseTM fructose-supplemented apple 
juice (treatment). Values represent mean ± standard deviation of the nine subjects triplicate 
measurements. Differences between the groups were analysed using ANOVA and differences due to time 
was analysed using a Dunnett test. A power transformation of the response variable (RI) was preformed in 
order to conform to the assumptions of ANOVA.  
 
Vascular age, which is a calculated value derived from the SI (PulseTrance PCA 2 
Operating Manual, Micro Medical), showed a similar pattern to that observed with the 
SI (Figure 3.10). There was no significant difference (p = 0.97) in the baseline 
measurements between the control and treatment phase. As age is a confounding 
variable, age was accounted for as a covariate during statistical analysis of the data. 
The mean VA of the control phase (36.52 yrs ± 17.21) was significantly different 
(p = 0.005) to the mean of the treatment phase (33.74 yrs ± 13.93) (Figure 3.12). 
Therefore a lower VA was observed after consumption of the test drink. The effect of 
time on VA after the consumption of the treatment phase was also significantly different 
(p = 0.009) to the control phase and the greatest difference occurred at 70 min when 
compared to the baseline.  
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Figure 3.12: Comparison of the vascular age in the control and treatment phases. 
Triplicate measurements of the digital volume pulse were taken using a photoplethysmography probe were 
taken after an 8 h fast (baseline) and then at 15, 50, 70, 100, 130, 160, 190, 220, 310, 370, 430 and 1440 
min after consumption of the standard apple juice (control) or the EvesseTM fructose-supplemented apple 
juice (treatment). Values represent mean ± standard deviation of the nine subjects triplicate 
measurements. Differences between the groups were analysed using ANOVA and differences due to time 
was analysed using a Dunnett test. A power transformation of the response variable (VA) was preformed 
in order to conform to the assumptions of ANOVA.  
 
The percentage differences of the treatment phase minus the control phase followed a 
similar pattern for the three measurements (SI, RI and VA) with the exception of a 
couple of time points (130 min and 1440 min) where the RI had a positive difference 
and the SI and VA had a negative difference in comparison to the control (Figure 3.13). 
In general, the treatment caused a decrease in the SI, RI and VA between 100 min and 
220 min compared to the control drink.  
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Figure 3.13: Differences between the control and treatment phases. 
Triplicate measurements of the digital volume pulse were taken using a photoplethysmography probe were 
taken after an 8 h fast (baseline) and then at 15, 50, 70, 100, 130, 160, 190, 220, 310, 370, 430 and 1440 
min after consumption of the standard apple juice (control) or the EvesseTM fructose-supplemented apple 
juice (treatment). Values represent the treatment phase values minus the control phase values, so that the 
change indicates the effect of the test drink, and are normalised to the highest negative value for each 
parameter. 
 
3.6 Discussion 
The data presented in this chapter show that: (1) applying a heat treatment 
(microwave) to the apples prior to pulping did not reduce the loss of polyphenols 
observed with apple pressing; (2) a hot water extraction of the pomace prior to re-
pressing efficiently extracted the majority of epicatechin and total polyphenols into the 
second press juice from the apple pomace; (3) allowing the hot water extracted 
pomace to stand at 4 ºC compared to room temperature was less effective in extracting 
the majority of the polyphenols from the apple pomace and did not reduce the 
polyphenol loss in the second press procedure; and (4) a commercially produced 
polyphenol-rich extract improved vascular function by improving arterial stiffness as 
assessed by PCA measurements. Therefore the efficient extraction of polyphenols 
from apple pomace, a by-product of apple juice production, provides a method of 
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extracting polyphenols for food supplementation which has the potential to improve 
vascular function.  
 
A number of published reports have been concerned with extracting a greater quantity 
of polyphenols from the apple pulp or apple pomace in the production of apple juice 
(Spanos et al., 1990; Schols et al., 1991; Will et al., 2000; Gerard and Roberts, 2004; 
van der Sluis et al., 2004). Alcohol extraction of the apple pulp and pomace was shown 
to enhance the polyphenol concentration of the apple juice. The levels of quercetin 
glycosides and chlorogenic in the enriched apple juice following alcohol extraction were 
between 1.4 (chlorogenic acid) and 9 (quercetin glycosides) times higher than in 
conventionally produced apple juice (van der Sluis et al., 2004). However this 
extraction method had several limitations including limitations on the amount of solvent 
that could be used in the extraction process in order to comply with food laws, as well 
as the loss of key juice characteristics (e.g. aroma) (van der Sluis et al., 2004). 
Diffusion extraction, the extraction of juice by counter-current flow of hot water through 
the fruit slices, was shown to increase the hydroxycinnamic acid concentration of the 
juice three fold, the phloretin glycosides by five fold, the flavanols up to 32 fold and the 
quercetin glycosides concentration up to 52 fold compared to conventional pressing 
(Spanos et al., 1990). The apple juice produced using this production method results in 
a more bitter and astringent juice due to the higher polyphenol content (Gerard and 
Roberts, 2004; van der Sluis et al., 2004). Liquefaction, the enzyme treatment of apple 
pulp by the use of enzymes (pectinases and cellulases), is another treatment used to 
increase the polyphenol content in apple juice. Schols et al. (1991) showed that 
liquefaction (with pectinases) of the apple pulp increased the concentration of catechin, 
epicatechin, phloridzin and chlorogenic acid up to six-fold in comparison to 
conventionally pressed apple juice, while Will et al. (1999) demonstrated that apple 
pomace subjected to liquefaction (with pectinases and cellulases) resulted in an 
increased polyphenol content (30 – 50 %) in the extracted juice. However the use of 
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cellulases in fruit juice production is prohibited by European Law (Ribeiro et al., 2010). 
The use of heat treatment prior to pressing has also been tested as a means of 
increasing the polyphenol concentration. Apples which were microwaved after pulping 
generated juices with increased polyphenol concentrations compared to conventional 
pressing (Gerard and Roberts, 2004). However, while the increase in total polyphenol 
concentration was significant, the proportion of total apple polyphenols extracted to the 
juice was low (Gerard and Roberts, 2004). 
 
Therefore, while alcohol extraction, diffusion extraction, liquefaction and a microwave 
heat-treatment of the apple pulp are effective methods in significantly increasing the 
apple juice polyphenol concentration compared to a conventional pressing method, 
these extraction methods also affected the characteristics of the juice or did not provide 
an overall high extraction yield. These methods also did not report the loss of 
polyphenols during the production of the juice from the apples to the press products 
(apple pomace and juice). Therefore, one of the aims of the studies described in this 
chapter was to investigate whether (1) applying a microwave heat treatment of the 
apple prior to pulping would reduced the loss of polyphenol observed with apple juice 
production; (2) to investigate whether a hot water extraction of the apple pomace would 
efficiently extract the epicatechin and other polyphenols from the polyphenol-rich 
pomace resulting from the first press; and (3) establish whether incubating the hot 
water extracted pomace at 4 ºC, rather than at room temperature, would improve the 
recovery of polyphenols in the second press juice.  
 
The rationale for applying a microwave-heat treatment to the whole apples prior to the 
pulping and pressing of the apples was to denature the polyphenol oxidases and 
peroxidases and thus inhibit enzymatic browning, which would be expected to reduce 
the loss of polyphenols observed in the production of apple juice. The microwave-heat 
treatment increased the core temperature of the apples from 23 ºC to 98 ºC; however it 
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was apparently ineffective in denaturing the polyphenol oxidase enzymes. Instead the 
rate of browning, on the flesh, was substantially increased compared to the non-heat 
treated apple. The heat treatment of the whole apples resulted in a loss of 35 % 
epicatechin and 18 % total polyphenols. After pulping and pressing of the heat-treated 
whole apples, a further loss of 26 % epicatechin and 38 % total polyphenols between 
the press products (apple pomace and juice) and the heat treated apples. Therefore 
the application of a heat treatment on the whole apples caused a loss of 61 % 
epicatechin and 53 % total polyphenols during the juice production process which was 
substantially greater than using non-heat treated apples (34 % loss of epicatechin and 
28 % loss of total polyphenols). Hence, microwave-heat treatment of the whole apples 
is not an effective method in reducing the loss of polyphenols during the production of 
apple juice.  
 
The second experimental modification involved the hot water extraction of the apple 
pomace to extract the polyphenols from the apple pomace as the majority of the 
polyphenols are retained in the pomace. In the three experimental varieties 
investigated, a hot water extraction of the apple pomace resulted in a significant 
increase in the epicatechin and total polyphenol content of the second press juice. The 
extraction yield of polyphenols was not dependent on the apple variety. A four to 
eleven fold increase in epicatechin content and a five to nine fold increase in total 
polyphenol content were observed in the second press juice compared to the first press 
juice. However a significant loss of 29 – 59 % of epicatechin and 33 – 63 % of total 
polyphenols was observed between the apples and the first press products and a 
significant loss of 37 – 56 % of epicatechin and 35 % of total polyphenols was 
observed between the first press pomace and the second press products. Therefore 
while a hot water extraction is an efficient method in extracting polyphenols from the 
pomace, a loss of polyphenols also occurs in the production of the second press 
products.  
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A small proportion of the loss is due to procedure losses (e.g. apple pulp remaining in 
the food processor and apple pomace remaining on the press) in the various 
processing steps while the majority of the loss is most likely due to enzymatic 
browning. Therefore in order to try and inhibit enzymatic browning a further 
modification of the conventional method was conducted. The third experimental 
modification was to incubate the hot water extracted pomace overnight at 4 ºC rather 
than at room temperature. In this instance the incubation at 4 ºC was less efficient than 
incubation at room temperature. The loss of polyphenols between the extraction at 
room temperature and the extraction at 4 ºC was also similar. Therefore, the incubation 
at 4 ºC did not reduce the losses of polyphenols from the apple pomace during the 
incubation period and it was significantly less efficient in extracting epicatechin or total 
polyphenols from the apple pomace into the second press juice, compared to the 
incubation period at room temperature.  
 
Investigation in how to reduce polyphenol losses during apple pressing needs to be 
conducted further. Polyphenol losses during apple processing may be reduced if apple 
processing is conducted in a controlled atmosphere (reduced oxygen environment) or if 
the hot water extraction incubation period was reduced to a shorter length of time 
(e.g. 1 h).   
 
An effective procedure in reducing the loss of epicatechin and other polyphenols from 
the apples during the production of apple juice and the effective extraction of 
epicatechin and other polyphenols from the apple pomace is important as the extracted 
polyphenols can be used for food supplementation. The supplementation of foods or 
beverages with apple flavanols may have an impact on human health as the intake of 
apple flavanols and flavonoids have been shown to be inversely associated with CVD 
mortality (Hertog et al., 1993a; Knekt et al., 1996; Arts et al., 2001a; Mink et al., 2007). 
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Flavonoids have been shown to have antioxidant activity, inhibit low-density lipoprotein 
oxidation, inhibit inflammatory responses; inhibit platelet aggregation, and improve 
endothelial function (Yochum et al., 1999; Boyer and Liu, 2004).  
 
Endothelial dysfunction is defined as the impairment of endothelium-dependent 
vascular relaxation and is considered to be a risk factor for the development of 
atherosclerosis. The vascular endothelium is a single layer of cells lining the blood 
vessels in the body. It is a source of vasodilators (e.g. NO) and vasoconstrictors (e.g. 
endothelin-1 and angiopoietin-2) that affect vascular tone, growth, platelet function, 
coagulation and monoycte function (McEniery et al., 2003; Nadar et al., 2004). Normal 
vascular tone is sustained when the balance between the vasodilators and 
vasoconstrictors are maintained (Pyke and Tschakovsky, 2005).  
 
Epicatechin and other flavonoids have been shown to improve endothelial function of 
arterial vessels and to lower blood pressure by increasing the rate of NOS (Schroeter 
et al., 2006). The effect on the consumption of flavanol-rich foods and beverages on 
the endothelial function has been previously investigated by FMD (Stein et al., 1999; 
Agewall et al., 2000; Chou et al., 2001; Duffy et al., 2001; Hodgson et al., 2002; Fisher 
et al., 2003; Heiss et al., 2003; Engler et al., 2004b; Heiss et al., 2005; Schroeter et al., 
2006; Auclair et al., 2010). FMD represents the gold standard for the non-invasive 
measurement of endothelial function in humans. FMD measures dilation of the vessel 
in response to altered flow, is expressed as the percentage increase in artery diameter 
after release of occlusion, is mediated by NO release in response to shear stress, and 
is used to measure endothelial function (Hashimoto et al., 2003; Kobayashi et al., 
2004; Wilson et al., 2004).  
 
The short- (2 h after consumption) and long-term (40 day) consumption of black tea 
improved brachial artery FMD in subjects with coronary heart disease (Duffy et al., 
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2001). In another tea intervention, the consumption of five cups of black tea per day for 
five weeks improved FMD in hypercholesterolemic subjects (Hodgson et al., 2002). 
The consumption of purple grape juice for 15 days (Stein et al., 1999) or 56 days (Chou 
et al., 2001) resulted in an improvement of FMD in subjects with coronary heart 
disease. The consumption of de-alcoholised red wine also resulted in an improvement 
in FMD in healthy subjects (Agewall et al., 2000). Consumption of a high flavonoid 
chocolate or cocoa improved FMD compared to a low flavonoid chocolate (Fisher et al., 
2003; Heiss et al., 2003; Engler et al., 2004b; Heiss et al., 2005; Schroeter et al., 
2006). Recently the investigation of endothelial function after the consumption of a 
polyphenol-rich re-hydrated lyophilised apple sample (Auclair et al., 2010). No 
significant difference was observed in FMD between the low-polyphenol and high-
polyphenol phases in the intervention in hypercholesterolemic subjects (Auclair et al., 
2010). 
 
Arterial stiffness is another measurement that assesses vascular function. A stiff artery 
may act as a marker for the development of future atherosclerotic disease or may be a 
direct factor in the process of atherosclerosis (Woodside et al., 2004). The main 
method of determining arterial stiffness is by PWV. PWV is calculated from 
measurements of pulse transit time and the distance travelled by the pulse between 
two recording sites (e.g. from the carotid artery to the femoral artery) (Asmar et al., 
1995). The higher the velocity recorded, the higher the stiffness of the arterial wall 
(Safar et al., 2002; Woodside et al., 2004). Flavanoid-rich foods have also been found 
to decrease arterial stiffness (Vlachopoulos et al., 2006b; Vlachopoulos et al., 2007). 
Consumption of chocolate (Vlachopoulos et al., 2006b) and cocoa (Vlachopoulos et al., 
2007) was associated with a significant decrease in arterial stiffness as assessed by 
carotid-femoral PWV. The chronic consumption of cranberry juice was also associated 
with a reduction in carotid-femoral PWV compared to the placebo beverage 
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(Dohadwala et al., 2010). While the consumption of black tea increased arterial 
stiffness, the consumption of green tea had no effect (Vlachopoulos et al., 2006a).  
 
The human intervention study presented in this chapter assessed vascular function by 
using PCA. PCA is a non-invasive method that indirectly measures endothelial function 
and arterial stiffness. The measurements of SI and RI are indirect measurements of 
arterial stiffness and endothelial function, respectively. A similarity of the relationship 
between PCA, age and blood pressure and between PWV, age and blood pressure 
has been described therefore indicating that these two measurements are influenced 
by similar factors (Millasseau et al., 2002).  
 
The results from the human intervention study described in this chapter show that 
supplementing a standard apple juice with EvesseTM Fructose (an apple polyphenol-
rich extract, epicatechin = 72 mg in Batch 1 and 84 mg in Batch 2) resulted in a 
significant improvement in the stiffness index as assessed by PCA. A significant 
difference between the control and treatment phases was observed for the SI 
(p = 0.031) (Figure 3.10). This is in agreement with the evidence in the literature which 
has shown that the consumption of flavanols causes an improvement in vascular 
function. A statistically significant difference in VA between the control and treatment 
phases (p = 0.005) was also observed (Figure 3.12). This observation was expected as 
VA is a derived value calculated from the SI. However, there was no difference 
between the control and treatment phases in regards to the RI. The RI is an indicator of 
endothelial function and an increase in RI is due to an increase in the peripheral pulse 
wave reflection (e.g. vasoconstriction) while a reduction in RI indicates vasodilation 
(Kneifel et al., 2006; Alty et al., 2007). As PCA is an indirect measure of endothelial 
function, an effect of the consumption of EvesseTM Fructose may be more observable 
when using FMD as the measurement. Auclair et al. (2010) recently investigated the 
FMD response on the consumption of 214 mg polyphenols per day in the low-
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polyphenol re-hydrated lyophilised apples phase and 1210 mg polyphenols per day in 
the high-polyphenol re-hydrate lyophilised apples phase for four weeks in 
hypercholesterolemic subjects. The FMD measured at the end of each intervention did 
not differ between the high-polyphenol and low-polyphenol apples (Auclair et al., 2010). 
There was also no difference in baseline measurements. However, they did not 
measure the short-term effect of apple polyphenol consumption. Therefore further 
investigation on the acute consumption of polyphenol-rich extract should be assessed 
by FMD. Further human intervention trials should investigate the consumption of apple 
polyphenols between young and old subjects; compromised and healthy subjects; and 
the effect of chronic and acute consumption of apple polyphenols.  
 
3.7 Conclusions 
The results from this chapter have shown that (1) a microwave-heat treatment of whole 
apples was not effective in increasing the yield of polyphenols in the first press juice or 
the recovery in the first press pomace; (2) a hot water extraction of the apple pomace 
was a very effective method of extracting the polyphenols retained from the first press 
and yielded a polyphenol-rich aqueous extract; (3) the incubation of hot water extracted 
apple pomace at room temperature compared to 4 ºC was more effective in extracting 
the polyphenols retained in the apple pomace, although similar losses of polyphenols 
were observed at both temperatures; and (4) consumption of an apple polyphenol-rich 
extract supplemented apple juice by human subjects resulted in a small but statistically 
significant improvement in arterial stiffness and vascular age but not in reflective index 
(endothelial function) compared to the low polyphenol apple juice.  
 
Therefore future studies should examine alternative strategies aimed at decreasing the 
losses of polyphenols during the production of apple juice (the pressing of apples and 
the extraction of the apple pomace) as well as measuring the acute effect of the 
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consumption of a polyphenol-rich apple extract on endothelial function as assessed by 
flow-mediated dilation.  
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Chapter 4 : Apple flavanols and VEGF signalling in 
human endothelial cells 
4.1 Abstract 
Previous work showed that when human umbilical vein endothelial cells (HUVECs) 
were treated with an apple procyanidin fraction degree of polymerisation (dp) 3.9 there 
were more than 1000 genes that had their expression levels significantly altered in both 
resting and cytokine-stimulated cells (García-Conesa et al., 2009). The apple 
procyanidin fraction dp 3.9 significantly altered the expression levels of several genes 
that are associated with key angiogenesis related functions in HUVECs. Vascular 
endothelial growth factor (VEGF) is the most important pro-angiogenic growth factor. 
Therefore it was hypothesised that apple procyanidin fraction dp 3.9 regulated key 
angiogenesis related genes by inhibiting the VEGF pathway. The overall aim was to 
investigate the ability of apple procyanidins and other polyphenols to inhibit VEGF 
signalling. It was shown that VEGF-induced VEGF receptor-2 (VEGFR-2) 
phosphorylation was inhibited almost instantly once the polyphenol and VEGF were 
mixed together and complete inhibition was observed after 5 min of incubation. It was 
also demonstrated that the inhibitory effect of the polyphenols was due to the 
polyphenol interacting with the VEGF molecule. An investigation of different polyphenol 
structures showed that the inhibition of phosphorylation was dependent on key 
structural features (epicatechin polymers with a degree of polymerisation greater than 
three; 3-galloylation; and a trihydroxy B-ring). The polyphenol was also able to inhibit 
VEGFR-2 phosphorylation at physiological concentrations. These findings are 
significant because they provide a plausible link between consumption of polyphenols 
and a reduced risk of cardiovascular disease (CVD). While this research has only 
shown an interaction with VEGF, it raises the possibility that polyphenols can affect 
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other signalling pathways by interacting with other signalling peptides including growth 
factors and hormones.  
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4.2 Introduction 
Oligomeric procyanidins have been shown to have cardioprotective attributes (Kenny et 
al., 2004b; Actis-Goretta et al., 2006; Corder et al., 2006; Ottaviani et al., 2006). In a 
microarray study investigating the effects of (-)-epicatechin, procyanidin dimer B2 and 
an apple procyanidin fraction with a mean degree of polymerization of 3.9 (dp 3.9) in 
HUVECs, it was found that there were no significant gene expression changes in 
resting or cytokine stimulated cells in response to epicatechin and procyanidin dimer 
B2 treatments (García-Conesa et al., 2009). However, more than 1000 genes had their 
expression levels significantly altered in both resting and cytokine-stimulated (tumour 
necrosis factor-alpha [TNF-α]) cells in response to the apple procyanidin fraction dp 3.9 
treatment. The main molecular functions that were influenced by apple procyanidin 
fraction dp 3.9 were cell death, cell growth and proliferation, cell migration, cell 
signalling and cell development. Cell growth and proliferation and cell migration are the 
main molecular functions involved in angiogenesis. The authors concluded that apple 
procyanidin fraction dp 3.9 significantly changed the expression levels of several genes 
that are associated with key angiogenesis-related functions in HUVECs (García-
Conesa et al., 2009).  
 
Angiogenesis, the formation of new blood vessels from pre-existing ones, has been 
proven to play an essential role in the pathogenesis of diverse chronic diseases. In 
cardiovascular disease, it has been suggested that angiogenesis plays an important 
part in the development and destabilization of atherosclerotic plaques. The role of 
angiogenesis in cardiovascular disease functions in two different manners. It can either 
(1) be a causative factor of atherosclerotic plaque formation or (2) it can be a 
therapeutic way to treat ischemic heart disease (Khurana et al., 2005; Stangl et al., 
2007; Ribatti et al., 2008). In the first instance pro-angiogenic growth factors can either 
promote atherosclerosis and cause plaque growth and destabilization with the plaques 
Chapter 4 
 
137 
 
more likely to rupture and cause myocardial infarction or stroke (Tenaglia et al., 1998; 
Moulton et al., 1999; Celletti et al., 2001; Moreno et al., 2004; Khurana et al., 2005; 
Holm et al., 2008). In the second situation pro-angiogenic growth factors can be used 
as a therapeutic factor in ischemia by restoring blood flow through the stimulation of 
new blood vessel formation (Ware and Simons, 1997; Khurana et al., 2005). 
 
Whether the role of angiogenesis is involved as the causative factor in the 
destabilization of atherosclerotic plaques or the therapeutic factor in ischemia, it is an 
important biological process under normal and disease conditions. During embryonic 
development, any impairment in angiogenic events results in early mortality due to 
growth retardation (Dulak, 2005). After birth, angiogenesis contributes to organ growth 
but in adulthood there is a lack of physiological angiogenesis, with the exception of 
menstrual cycles and pregnancy in females and wound healing and repair (Mojzis et 
al., 2008). In established blood vessels endothelial cells remain in a dormant, non-
proliferative state but they retain their ability to rapidly divide in response to physical 
stimuli (wounding and inflammation) or other pathological conditions that stimulate 
angiogenesis (Ware and Simons, 1997). Angiogenesis occurs when there is an 
imbalance between the pro-angiogenic (e.g. vascular endothelial growth factor [VEGF], 
basic fibroblast growth factor and TNF-α) and anti-angiogenic (e.g. angiostatin and 
endostatin) factors. The most important pro-angiogenic factor is VEGF (Giles, 2001; 
Dulak, 2005; Cebe-Suarez et al., 2006).  
 
4.2.1 Vascular endothelial growth factor 
VEGF is a dimeric cysteine-linked secreted glycoprotein of approximately 40 kDa and 
is characterised by the intrachain and interchain disulfide bonds between eight 
conserved cysteine residues (Giles, 2001; Matsumoto and Claesson-Welsh, 2001; 
Cebe-Suarez et al., 2006; Ng et al., 2006; Olsson et al., 2006). The structure of VEGF 
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is organised so that the two monomers are positioned in an anti-parallel fashion, with 
the receptor-binding sites located at each pole of the dimer (Muller et al., 1997). The 
VEGF family consists of five members: VEGF-A, -B, -C and –D and placental growth 
factor. VEGF-A is the predominant form and is commonly referred to as VEGF.  
 
The gene encoding VEGF, in humans, is located on the short arm of chromosome 6 
(6p21.1) (Ng et al., 2006). VEGF gene expression is up-regulated by hypoxia, growth 
factors (such as epidermal growth factor, TNF-α, transforming growth factor-beta, 
keratinocyte growth factor, insulin-like growth factor-1, fibroblast growth factor 4 and 
platelet derived growth factor [PDGF]) and inflammatory cytokines (interleukin-1 and 
interleukin-6) (Ferrara and Davis-Smyth, 1997; Neufeld et al., 1999; Cebe-Suarez et 
al., 2006). The VEGF gene comprises of eight exons, and different isoforms of VEGF 
with different biological activities are produced by alternative exon splicing (Ferrara and 
Davis-Smyth, 1997; Giles, 2001; Pan et al., 2002; Ng et al., 2006). The predominant 
isoforms of VEGF are VEGF121, 145, 165, 189 and 206. All VEGF isoforms contain exons 1 
to 5, with various combinations of the remaining exons 6 to 8. Exons 3 and 4 contain 
the VEGF receptor (VEGFR)-1 and VEGFR-2 binding domains, respectively, therefore 
all isoforms should be able to bind to these receptors and are predicted to be 
biologically active (Ng et al., 2006). VEGF165 is the predominant form of VEGF and is 
characterised by its heparin binding ability. VEGF regulates cell functions including 
mitogenesis, permeability, vascular tone and the production of vasoactive molecules by 
binding to specific endothelial cell surface receptors (VEGF receptors). 
 
4.2.2 Vascular endothelial growth factor receptors 
VEGF stimulates cellular responses by binding to type III receptor tyrosine kinases 
(VEGFRs) on the cell surface and causes the receptors to dimerize and become 
activated through transphosphorylation. There are three main VEGFRs: VEGFR-1 
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(Flt-1), VEGFR-2 (KDR/Flk-1) and VEGFR-3 (Flt-4). The VEGFRs consist of a 750 
amino acid extracellular matrix, a single transmembrane region, an intracellular 
tyrosine kinase domain that is interrupted by a kinase insert domain, and a C-terminal 
tail (Figure 4.1) (Cebe-Suarez et al., 2006; Olsson et al., 2006). The extracellular 
immunoglobulin (Ig)-like domains two and three are required for binding of VEGF to 
VEGFR-1 and -2 and the fourth Ig-like loop contains a receptor dimerization domain 
(Matsumoto and Claesson-Welsh, 2001; Cebe-Suarez et al., 2006). Similar to VEGF, 
the expression of VEGFR-1 and -2 are also up-regulated in response to hypoxia 
(Neufeld et al., 1999; Matsumoto and Claesson-Welsh, 2001).  
 
The VEGF receptors are expressed primarily on vascular endothelial cells, but are also 
expressed on vascular smooth muscle cells, hematopoietic cells, macrophages, and on 
some malignant cells (Cebe-Suarez et al., 2006; Ng et al., 2006). VEGFR-1 induces 
organizational effects on the vasculature and is crucial in embryonic angiogenesis but 
does not appear to be critical in pathogenic angiogenesis (Pan et al., 2002). VEGFR-3 
is important for lymphatic cell development and function while VEGFR-2 is the major 
mediator of the mitogenic, angiogenic and permeability enhancing effects of VEGF 
(Giles, 2001; Ferrara and Kerbel, 2005).  
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Figure 4.1: VEGF receptor binding properties. 
VEGFRs have an approximate 750 amino acid residue extracellular domain, which in VEGFR-1 and -2 is 
organised into seven immunoglobulin (Ig)-like loops. In VEGFR-3, the fifth Ig domain is replaced by a 
disulfide bridge. The extracellular domain is followed by a juxtamembrane domain, a tyrosine kinase 
domain which is interrupted by a 70 amino acid kinase insert and a C-terminal tail (Cebe-Suarez et al., 
2006). The different forms of VEGF bind to specific receptors: VEGF-A binds to VEGFR-1 and -2, VEGF-C 
and –D binds to VEGFR-2 and -3 and PIGF and VEGF-B binds to VEGFR-1.  
 
VEGFR-2 is the major signalling receptor for VEGF. VEGFR-2 is a 200 kDa 
glycoprotein which is expressed in hematopoietic, neural and retinal cells. VEGFR-2 
expression is up-regulated in response to hypoxia and down-regulated and de-
phosphorylated through internalization and degradation of the receptor by protein-
kinase C (PKC)-dependent phosphorylation of the receptor C-terminal tail (Cebe-
Suarez et al., 2006; Rahimi, 2006). There are 19 tyrosine residues present in the 
intracellular domain of VEGFR-2 and the most prominent phosphorylation sites are 
tyrosine resides (Tyr) 951, 1054, 1059, 1175 and 1214 (Figure 4.2). Tyr1175 is the 
most important phosphorylation site as it is implicated in several of the roles of 
VEGFR-2, including the activation of cell proliferation, cell migration, cell survival, 
vascular permeability, actin remodelling and gene expression. Other important 
phosphorylation sites are Tyr951 and Tyr1214. Phosphorylated Tyr951 regulates 
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vascular permeability and cell migration and phosphorylation of Tyr1214 has been 
implicated in cell migration, actin remodelling and vascular permeability.  
 
Figure 4.2: VEGFR-2 phosphorylation sites and signalling pathways. 
Binding of signalling molecules (Shb, Sck, phospholipase C-γ [PLC-γ], Shc and TSad) to certain tyrosine 
phosphorylation sites initiates signalling cascades which lead to specific biological responses. 
 
4.2.3 Vascular endothelial growth factor receptor-2 inhibition 
Inhibition of angiogenesis has been determined to be an effective strategy in the 
treatment of chronic diseases, in particular cancer. Therapeutics that function to inhibit 
the VEGF pathway have been used to target certain types of cancers. Anti-VEGF 
antibodies, aptamers (peptides that act like anti-VEGF antibodies) and small molecule 
VEGFR tyrosine kinase inhibitors have been produced and are available for the 
treatment of colon, lung, breast, kidney and liver cancer and neovascular age-related 
macular degeneration (Giles, 2001; Ferrara and Kerbel, 2005). These different 
treatments all work by inhibiting the VEGF signalling pathway.  
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Various food components also have been found to have an effect on and influence 
phosphorylation of VEGFR-2. Green tea catechins (with epigallocatechin gallate being 
the most potent) inhibited VEGFR-2 phosphorylation in a dose- and time-dependent 
manner as well as reducing VEGF-induced cell migration and proliferation (Kondo et 
al., 2002b; Lamy et al., 2002; Tang et al., 2003; Neuhaus et al., 2004; Mojzis et al., 
2008). Red wine polyphenolic compounds were also able to inhibit proliferation and 
migration of endothelial and vascular smooth muscle cells as well as inhibiting 
VEGFR-2 phosphorylation (Mojzis et al., 2008). Ellagic acid completely inhibited 
VEGF-induced VEGFR-2 phosphorylation in a time dependent manner (Labrecque et 
al., 2005). The anthocyanin delphinidin inhibited VEGF-induced phosphorylation of 
VEGFR-2 in a dose- and time-dependent manner (Lamy et al., 2006). A grape seed 
extract constituting at least 85 % w/w procyanidins (Wen et al., 2008) and purified 
procyanidin trimer and tetramer from a cinnamon extract (Lu et al., 2010) were also 
found to inhibit VEGFR-2 signalling in a dose-dependent manner, however, the 
mechanisms of this effect was not investigated. The aim of the present study was thus 
to investigate the inhibitory action of certain polyphenols on VEGFR-2 phosphorylation.  
 
4.3 Objectives 
The overall aim of this study was to investigate the ability of apple procyanidins and 
other polyphenols to inhibit VEGF-induced VEGFR-2 signalling and the underlying 
mechanism(s) behind the inhibitory actions. The specific objectives were to determine: 
(1) if apple flavanols and other phenolics have an inhibitory effect on the VEGF 
pathway; (2) if the apple procyanidin fraction causes the inhibitory action through 
interacting with the VEGF molecule or its receptors; and (3) to confirm inhibition of 
downstream signalling pathways in response to the polyphenol treatment.   
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4.4 Materials and methods 
4.4.1 Materials 
Human recombinant VEGF165 was obtained from R&D Systems Europe Ltd (Abingdon, 
UK). Purified (-)-epicatechin and (+)-catechin and procyanidin dimer B2 were 
purchased from Sigma-Aldrich and  epigallocatechin gallate (EGCG), epicatechin 
gallate (ECG), epigallocatechin (EGC), methyl gallate and gallic acid were purchased 
from Extrasynthese (Genay, France). Electrophoresis reagents were purchased from 
Invitrogen. The VEGFR-2, phospho-VEGFR-2 (Tyr 1175), PLCγ1, phospho-PLCγ1 
(Tyr 783), AKT and phospho-AKT (Ser 473) monoclonal antibodies, the anti-rabbit IgG, 
HRP-linked antibody and the PathScan phospho-VEGFR-2 (Tyr1175) sandwich ELISA 
kit were from Cell Signaling. The apple procyanidin fraction dp 3.9 was purified from a 
cider apple (Malus domestica, variety Antoniette) as previously described (Gossé et al., 
2005).  
 
The apple procyanidin fractions dp 3 and dp 4 were purified from the 2007 harvest 
apples (Chapter 3) provided by Coressence Ltd (Herefordshire, UK) as previously 
described (Yanagida et al., 1999; Shoji et al., 2005; Shoji et al., 2006b), with some 
modifications. Briefly 50 g of freeze-dried apple powder was extracted in 1250 ml of 
0.1 % potassium disulphite, shaken and left to stand for 10 min. The sample was 
centrifuged and passed through a Sepabeads SP-850 (Sigma) column 
(355 mm x 25 mm). The polyphenol fraction was eluted with 200 ml of 50 % (v/v) 
ethanol and concentrated, to approximately 60 ml, by rotary evaporation at 45 °C. The 
polyphenol fraction was adjusted to pH 6.5 with 1N sodium hydroxide and was passed 
through a Diaion HP-20ss (Sigma) column (355 mm x 25 mm). The column was rinsed 
with distilled water and the procyanidin fraction was eluted with 700 ml of 25 % (v/v) 
ethanol and concentrated by rotary evaporation. The fraction was reconstituted in 1 ml 
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of methanol and the remaining quercetin-glycosides, chlorogenic acid and phloridzin 
compounds in the fraction were removed by passing the fraction through a 50 g 
Biotage Snap FLASH Purification Cartridge HP-Sil (Biotage) on a Medium Pressure 
Liquid Chromatography (MPLC) (Gilson). The flow rate was set to 45 ml/min and the 
method used mobile phases consisting of 82 % dichloromethane, 14 % methanol and 
4 % of 50 % (v/v) acetic acid (solvent A) and 96 % methanol and 4 % of 50 % (v/v) 
acetic acid (solvent B) with a 120 min gradient (0 – 10 min, 0 % B; 10 – 15 min, 
18 % B; 15 – 18 min, 30 % B; 18 – 20 min 88 % B; 20 – 120 min, 0 % B). Procyanidins 
were fractionated according to the degree of polymerization by performing normal-
phase chromatography using an Inertsil PREP-Sil (30 mm i.d. x 250 mm) column 
(GL Sciences Inc) on the preparatory-HPLC (Gilson). The flow rate was 24 ml/min and 
the method used a mobile phase containing hexane/methanol/ethyl acetate in a 8:3:1 
ratio (solvent A) and hexane/methanol/ethyl acetate in a 2:3:1 ratio (solvent B) with a 
185 min gradient (0 – 35 min, 0 % B; 35 – 185 min, 100 % B) and was monitored at 
280 nm with a diode array detector (DAD). A more detailed description of the method is 
located in the Supplementary Information (Supplementary Information 1: Purification of 
apple procyanidin fractions dp 3 and dp 4).  
 
4.4.2 Cell culture 
Human umbilical vein endothelial cells (HUVECs) (Cambrex Bio Science, Wokingham, 
UK) were maintained in Endothelial Cell Growth Medium-2 (EGM-2) bullet kit (basal 
medium plus SingleQuot kit [foetal bovine serum (FBS); hydrocortisone; ascorbic acid; 
heparin; gentamicin; VEGF; human fibroblast growth factor; human insulin-like growth 
factor; human epidermal growth factor]) (Lonza-Cambrex). The cells were cultured at 
37 ºC under a humidified atmosphere containing 5 % CO2. For experimental purposes, 
cells were used at passage 4 (population doubling 6) and were seeded onto six-well 
plates at a density of 3500 cells/cm2. Cells were grown to confluence before serum 
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starvation and removal of growth factors (serum and growth factor free medium 
referred to as basal medium).  
 
4.4.3 Flavanol treatments 
Flavanol treatments were prepared in Universal tubes prior to adding them to the 
confluent monolayers. Appropriate concentrations of flavanols (apple procyanidin 
fractions dp 3.9, dp 3 and dp 4, (-)-epicatechin, catechin, procyanidin dimer B2, EGCG, 
EGC, ECG, methyl gallate or ellagic acid, structures of these polyphenols are 
described in Figure 4.18) were added to a Universal tube containing basal medium and 
VEGF (10 ng/ml or 25 ng/ml) and incubated at room temperature for 5 min. Control 
treatments were prepared in the same manner. HUVEC confluent monolayers were 
washed twice with warm phosphate buffered saline (PBS), to remove any residual 
growth factors, and prepared treatments were added to the respective wells and 
incubated for 5 min at 37 ºC under a humidified atmosphere containing 5 % CO2 
(Figure 4.3 A). All treatments were prepared in this manner unless otherwise stated.  
 
Two additional experimental procedures were tested in order to determine where the 
polyphenol is exerting its inhibitory effect. In the first experimental design modification 
(modification 1), confluent HUVEC monolayers were pre-treated with the polyphenol for 
4 h, then the medium was aspirated, the cells were washed with basal medium, and 
finally they were stimulated with VEGF (Figure 4.3 B). In the second experimental 
modification (modification 2), HUVEC monolayers were pre-stimulated with VEGF for 5 
min and then the VEGF-supplemented medium was treated with the polyphenol 
(Figure 4.3 C).  
 
 
                    
 Figure 4.3: Cell culture experimental procedures
Standard experimental 
procedure 
                 
 
Modification 1 Modification 1 Modification 2
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4.4.4 Migration wound assay 
Confluent HUVEC monolayers were washed with PBS and scraped once horizontally 
with a sterile 200 µl pipette tip. The wells were washed with PBS for a second time in 
order to remove the dislodged cells and debris. Fresh medium with or without the 
treatments were added to the wells to initiate the experiment (treatments as prepared 
in Section 4.4.3). Randomly selected views along the scraped line were photographed 
on each well, using a phase contrast inverted microscope and a CCD camera attached 
to the microscope. Photographs were taken after 0, 4, 24 and 48 h of incubation. The 
change in the area of the experimental condition was compared, visually, with that of 
the corresponding control.  
 
4.4.5 Flavanol treatment and VEGF stimulation in the presence of 
other growth factors 
HUVEC monolayers were treated with apple procyanidin fraction dp 3.9 (1 µM) or dp 4 
(1 µM) in three different types of medium. Full medium (EGM-2 bullet kit; FBS; 
hydrocortisone; ascorbic acid; heparin; gentamicin; VEGF; human fibroblast growth 
factor; human insulin-like growth factor; and human epidermal growth factor); basal 
medium (EGM-2 plus gentamicin provided in the kit), and basal medium plus bovine 
serum albumin (BSA) (1 mg/ml of BSA). The stock medium and the basal medium plus 
BSA were also supplemented with 10 ng/ml VEGF.   
 
4.4.6 Protein extraction 
After polyphenol treatment and VEGF stimulation, HUVECs were harvested by using 
radioimmunoprecipitation assay (RIPA) buffer (50 µl) and scraping the wells with a cell 
scraper. The cells were washed twice with cold PBS and the protein was extracted 
using ice cold RIPA buffer (50 µl of 50 mM Tris-Hcl, pH7.4; 150 mM NaCl; 1 % Triton 
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X-100; 0.5 % sodium deoxycholate; 0.2 % SDS; 200 mM sodium orthovanadate; plus 
one Roche complete protease inhibitor cocktail tablet, one Roche PhosStop 
phosphatase inhibitor cocktail tablet and Benzonase [Novagen]). The plates were left 
on ice for two min to allow the cells to detach. The cells were collected into an 
Eppendorf and vortexed three times over a 15 min period. Centrifugation was carried 
out at 13000 x g for 10 min and the supernatant was collected and the pellet discarded. 
Protein levels, from the supernatant of each lysate, were quantified using a 
Bicinchoninic Acid Kit (Sigma) according to the manufacturer’s instructions.  
 
4.4.7 VEGFR-2 phosphorylation measurement 
Phosphorylated VEGFR-2 expression was detected using Western blots or quantified 
using enzyme-linked immunosorbent assay (ELISA). Phosphorylated VEGFR-2 
expression levels were measured by ELISA following the manufacturer’s instructions. 
After the incubation, washing and labelling steps, absorption was measured at 450 nm 
using a Dynex 96 well microplate reader.  
 
Phosphorylation of VEGFR-2 was also assessed by Western blot. Proteins (30 µg) 
were reduced using DL-Dithiothreitol (DTT) (Sigma), denatured at 70 ºC for 10 min and 
separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE). Proteins were separated using NuPAGE Novex 10 % Bis-Tris gels (Invitrogen) 
in combination with NuPAGE MOPS SDS Running Buffer (Invitrogen) and NuPAGE 
antioxidant (Invitrogen). The gel was then transferred on to a 0.45 µm nitrocellulose 
membrane (Bio-Rad Laboratories). Equal protein loading was confirmed by ponceau 
red (Sigma-Aldrich) and by either total VEGFR-2, AKT or PLCγ1. Membranes were 
blocked with 5 % skimmed milk in TBST (50 mM Tris, pH 7.4; 200 mM NaCl and 0.1% 
Tween-20) for 1 h at room temperature. The membrane was washed with TBST and 
followed by an overnight incubation with the primary antibody (5 µl of phospho-
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VEGFR-2 (Tyr1175) antibody, VEGFR-2, phospho-AKT (Ser 473), AKT, phospho-
PLCγ1 (Tyr 783) or PLCγ1 in 5 ml of 5 % BSA in TBST) at 4 ºC. The membrane was 
washed with TBST and incubated with the secondary antibody (10 µl anti-rabbit IgG, 
HRP-linked antibody in 10 ml of 5 % skimmed milk in TBST) for 1 h at room 
temperature. The membranes were developed using Pierce SuperSignal West Pico 
chemiluminescent substrate (Pierce) and the fluorescence intensity was measured 
using a BioRad Fluor-S MultiImager. For re-probing of the membranes, the previous 
antibodies were stripped for 45 min at room temperature using RestoreTM
 
Western blot 
stripping buffer (Pierce).  
 
4.4.8 Statistical analysis 
Where indicated, comparisons between mean values from control and treated samples 
were carried out using a two tailed t-test. A p value < 0.05 was considered significant.  
 
4.5 Results 
4.5.1 Apple procyanidin fraction dp 3.9 inhibits endothelial cell 
migration 
Exposure of HUVECs to 8.9 µM apple procyanidin fraction dp 3.9 was shown to inhibit 
cell migration in comparison to control cells after 24 and 48 h (García-Conesa et al., 
2009). However, the data presented in this chapter expand on the García-Conesa et al. 
(2009) paper by investigating whether the apple procyanidin fraction dp 3.9, 
epicatechin and procyanidin dimer B2 are able to inhibit cell migration in the presence 
of 10 ng/ml VEGF.  
 
The most important pro-angiogenic growth factor in vascular endothelial cells is VEGF. 
Therefore the effect of flavanols on vascular endothelial cell migration was assessed 
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using a wound healing assay. The effect of flavanols in endothelial cell migration was 
investigated in two types of medium: full medium and VEGF-supplemented basal 
medium. The data presented for the full medium migration wound healing assay 
showed that after a 48 h period, the wound in the control-treated HUVECs was no 
longer visible and had completely healed (Figure 4.4 – 4.6). The 8.9 µM apple 
procyanidin fraction dp 3.9 treatment was able to inhibit endothelial cell migration 
(Figure 4.4) while the 10 µM epicatechin (Figure 4.5) and 10 µM procyanidin dimer B2 
(Figure 4.6) treatments were ineffective in inhibiting endothelial cell migration. Based 
on visual observations, the morphology of the cells was also changed in response to 
the apple procyanidin fraction dp 3.9 treatment. In the full medium cells, the apple 
procyanidin fraction dp 3.9 treated cells were more elongated and rod-shaped 
compared to the rounded-shaped control cells (Figure 4.4).  
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Figure 4.4: Effect of apple procyanidin fraction dp 3.9 on HUVEC migration in full medium 
examined by migration wound healing assay. 
The confluent HUVEC monolayers were wounded at time 0 and cultured with 8.9 µM dp 3.9 in EGM-2 
medium (full medium). Photographs of the full medium control (A, B, C) and apple procyanidin fraction 
dp 3.9 (D, E, F) treated cells were taken after 0, 4, and 48 h, (top, middle and bottom, respectively). This 
data are representative of triplicate analysis of three independent experiments.  
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Figure 4.5: Effect of epicatechin on HUVEC migration examined in full medium by 
migration wound healing assay. 
The confluent HUVEC monolayers were wounded at time 0 and cultured with 10 µM epicatechin in EGM-2 
medium (full medium). Photographs of the full medium control (A, B, C) and epicatechin (D, E, F) treated 
cells were taken after 0, 4, and 48 h (top, middle and bottom, respectively. This data are representative of 
triplicate analysis of two independent experiments. 
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Figure 4.6: Effect of procyanidin dimer B2 on HUVEC migration in full medium examined 
by migration wound healing assay. 
The confluent HUVEC monolayers were wounded at time 0 and cultured with 10 µM procyanidin dimer B2 
in EGM-2 medium (full medium). Photographs of the full medium control (A, B, C), and procyanidin 
dimer B2 (D, E, F) treated cells were taken after 0, 4, and 48 h (top, middle and bottom, respectively). This 
data are representative of triplicate analysis of two independent experiments. 
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The effect of endothelial cell migration was also investigated in VEGF-supplemented 
basal medium. The wound in the control-treated HUVECs was no longer visible in the 
VEGF-supplemented basal medium (Figure 4.7 – 4.9), while the 8.9 µM apple 
procyanidin fraction dp 3.9 treated cells was able to completely inhibit endothelial cell 
migration (Figure 4.7). Treatment of 10 µM epicatechin (Figure 4.8) and 10 µM 
procyanidin dimer B2 (Figure 4.9) were less effective in inhibiting endothelial cell 
migration. Based on visual observations, the morphology of the cells was also changed 
in response to the apple procyanidin fraction dp 3.9 treatment. In VEGF-supplemented 
basal medium, the apple procyanidin fraction dp 3.9 treated cells were rounded with a 
lot of detached floating cells in the medium, compared to the elongated and rod-shaped 
cells in the control treated cells (Figure 4.7).  
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Figure 4.7: Effect of apple procyanidin fraction dp 3.9 on HUVEC migration in VEGF-
supplemented medium examined by migration wound assay. 
The confluent HUVEC monolayers were wounded at time 0 and cultured with 8.9 µM apple procyanidin 
fraction dp 3.9 in basal medium plus 10 ng/ml VEGF. Photographs of the VEGF-supplemented basal 
medium control (A, B, C) and apple procyanidin fraction dp 3.9 (D, E, F) treated cells were taken after 0, 4, 
and 48 h (top, middle and bottom, respectively). This data are representative of triplicate analysis of three 
independent experiments. 
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Figure 4.8: Effect of epicatechin on HUVEC migration in VEGF-supplemented medium 
examined by migration wound healing assay. 
The confluent HUVEC monolayers were wounded at time 0 and cultured with 10 µM epicatechin in basal 
medium plus 10 ng/ml VEGF. Photographs of the basal medium plus VEGF control (A, B, C) and 
epicatechin (D, E, F) treated cells were taken after 0, 4, and 48 h (top, middle and bottom respectively). 
This data are representative of triplicate analysis of two independent experiments. 
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Figure 4.9: Effect of procyanidin dimer B2 on HUVEC migration in VEGF-supplemented 
medium examined by migration wound healing assay. 
The confluent HUVEC monolayers were wounded at time 0 with and cultured with 10 µM procyanidin dimer 
B2 in basal medium plus 10 ng/ml VEGF. Photographs of the basal medium plus VEGF control (A, B, C) 
and procyanidin dimer B2 (D, E, F) treated cells were taken after 0, 4, and 48 h (top, middle and bottom, 
respectively). This data are representative of triplicate analysis of two independent experiments. 
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These data confirm the results reported by García-Conesa et al. (2009), namely that 
apple procyanidin fraction dp 3.9, but not epicatechin or procyanidin dimer B2, inhibits 
endothelial cell migration, which is an angiogenesis related function. In addition, the 
data presented show, for the first time, that the apple procyanidin fraction dp 3.9 is able 
to inhibit endothelial cell migration in the VEGF-supplemented basal medium. This 
observation supports the notion that apple procyanidin fraction dp 3.9 inhibits 
endothelial cell migration by influencing the VEGF signalling pathway.  
 
4.5.2 Apple procyanidin fraction dp 3.9 inhibits VEGF-induced 
tyrosine phosphorylation of VEGFR-2 
The data from the migration wound healing assays indicates that HUVEC migration is 
stimulated by VEGF, and that the apple procyanidin fraction dp 3.9 effectively inhibits 
VEGF-induced HUVEC migration. This observation strongly suggests that the apple 
procyanidin fraction dp 3.9 is inhibiting VEGF signalling in HUVECs. Therefore the aim 
was to investigate the effects of apple procyanidin fraction dp 3.9 on VEGF signalling in 
HUVECs, specifically the phosphorylation of VEGFR-2. 
 
The assays used to establish the phosphorylation of VEGFR-2 tyrosine 1175 site was 
analysed by Western blotting and/or by ELISA. HUVECs were treated with pre-
incubated basal medium containing 10 ng/ml VEGF and either 1 µM or 8.9 µM apple 
procyanidin fraction dp 3.9 (Figure 4.10 and 4.11). In the absence of VEGF, 
phosphorylated VEGFR-2 could not be detected in HUVECs (Figure 4.11 A). However, 
when HUVECs were exposed to VEGF, VEGFR-2 was rapidly phosphorylated 
(by 1 min) and the intensity of the phosphorylated VEGFR-2 band peaked at 5 min 
(Figure 4.10). Subsequently, the intensity of the VEGFR-2 band declined between 
30 min and 24 h. This is likely due to internalization and degradation of VEGFR-2, 
which has been reported elsewhere (Cebe-Suarez et al., 2006; Rahimi, 2006). VEGF-
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induced phosphorylation of VEGFR-2 was completely inhibited within 5 min by 0.3 µM 
of apple procyanidin fraction dp 3.9 (VEGF concentration = 10 ng/ml VEGF) 
(Figure 4.11B). In a separate set of experiments it was shown that 0.5 µM apple 
procyanidin fraction dp 3.9 completed inhibited VEGF-induced VEGFR-2 
phosphorylation (VEGF = 25 ng/ml) (Figure 4.11C). 
 
 
Figure 4.10: Apple procyanidin fraction dp 3.9 inhibits phosphorylation of VEGFR-2 at 
1 min. 
HUVECs were treated with pre-incubated basal medium containing 10 ng/ml of VEGF and 1 µM (A) or 
8.9 µM (B) apple procyanidin fraction dp 3.9 for 1, 5, 30 min, 1 h and 24 h. The cells were lysed and the 
proteins were separated on a NuPAGE gel and probed for the presence of phosphorylated VEGFR-2 at the 
tyrosine 1175 site and the total VEGFR-2 levels. This data is representative of triplicate analysis of two 
independent experiments. 
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Figure 4.11: Apple procyanidin fraction dp 3.9 inhibits VEGFR-2 phosphorylation. 
HUVECs were treated with pre-incubated basal medium containing 10 ng/ml (A & B) or 25 ng/ml (C) of 
VEGF and different concentrations of the apple procyanidin fraction dp 3.9 for 5 min. The cells were lysed 
and the proteins were separated on a NuPAGE gel and probed for the presence of phosphorylated 
VEGFR-2 at the tyrosine 1175 site and for total VEGFR-2 levels (A & B) or the amount of phosphorylated 
VEGFR-2 was quantified by a phospho-VEGFR-2 (Tyr1175) ELISA (C). Bars represent means ± standard 
deviation expressed as a percentage of the stimulated cells. *p < 0.05, ** p < 0.01, *** p <0.001 compared 
to the stimulated cells. A & B is representative of triplicate analysis of two independent experiments and C 
is representation of duplicate analysis of one independent experiment.  
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induced VEGFR-2 phosphorylation. However it is not known whether this inhibition 
occurs due to the apple procyanidin fraction interacting with the VEGF molecule or by 
interacting with the endothelial cells (e.g. binding to the VEGF receptors, interacting 
with the receptor, the cell membrane or interacting with intracellular kinases) to prevent 
intracellular signalling.  
 
In the experiments described in Section 4.5.2, the polyphenol and VEGF were mixed 
together and subsequently added to the cells. Using this experimental design, it is not 
possible to determine whether polyphenols prevent VEGF-induced VEGFR-2 
phosphorylation by interacting with VEGF or with the endothelial cells. In order to 
determine where the polyphenol is exerting its inhibitory effect, two further experimental 
designs were tested. In the first experimental design, confluent HUVEC monolayers 
were pre-treated with the apple procyanidin fraction for 4 h, then the medium was 
aspirated, the cells were washed with basal medium, and finally they were stimulated 
with VEGF (modification 1, Figure 4.3). In the second experimental design, confluent 
HUVEC monolayers were pre-stimulated with VEGF for 5 min and then the VEGF 
supplemented medium was treated with the apple procyanidin fraction (modification 2, 
Figure 4.3).  
 
When the cells were pre-treated with the apple procyanidin fraction for 4 h, no inhibition 
in VEGF-induced VEGFR-2 phosphorylation was observed at any time point 
(Figure 4.12 A&B). When the cells were pre-stimulated with VEGF before the addition 
of the apple procyanidin fraction, an approximate 50 % reduction in VEGFR-2 
phosphorylation was observed at 5 min and an approximate 70 % reduction in 
VEGFR-2 phosphorylation was observed from 30 min to 24 h (Figure 4.13 A&B). As 
described previously (Section 4.5.2), the peak expression of VEGF-induced VEGFR-2 
phosphorylation occurs after 5 min and then declines between 15 min and 24 h (due to 
internalization and degradation of VEGFR-2). Therefore, for the purpose of quantifying 
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the effect of the apple procyanidins on VEGFR-2 phosphorylation, each treatment time 
point was compared to its respective stimulated cells control.   
 
The data from the two different experimental designs applied, showed that the 
inhibitory effect of the apple procyanidin fraction is not due to the apple procyanidin 
fraction binding to the receptors and therefore preventing VEGF from binding to the cell 
surface but rather by binding to the VEGF molecule. 
 
Figure 4.12: Apple procyanidin fraction dp 3.9 and dp 4 do not interact with the cell 
surface.  
HUVECs were pre-treated with 1 µM apple procyanidin fraction dp 3.9 (A) or 1 µM apple procyanidin 
fraction dp 4 (B) for 4 h, washed with serum free medium and stimulated with 10 ng/ml (A) or 25 ng/ml (B) 
VEGF for various times. The cells were lysed and the proteins were either separated on a NuPAGE gel and 
probed for the presence of phosphorylated VEGFR-2 at the tyrosine 1175 site and for total VEGFR-2 (A) or 
the total amount of phosphorylated VEGFR-2 was quantified by a phospho-VEGFR-2 (Tyr1175) ELISA (B). 
For ELISA data, values are expressed as a percentage of the stimulated cells from each time point (B). 
Bars represent means ± standard deviation. *p < 0.05, ** p < 0.01 compared to the stimulated cells. (A) is 
representative of triplicate analysis of two independent experiments and (B) is representative of duplicate 
analysis of one independent experiment.  
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Figure 4.13: Apple procyanidin fraction dp 3.9 and dp 4 interacts with the VEGF molecule.  
HUVECs were pre-stimulated with 10 ng/ml (A) or 25 ng/ml (B) VEGF for 5 min and treated with 1 µM 
apple procyanidin fraction dp 3.9 (A) or 1 µM apple procyanidin fraction dp4 (B) for the times indicated. The 
cells were lysed and the proteins were either separated on a NuPAGE gel and probed for the presence of 
phosphorylated VEGFR-2 at the tyrosine 1175 site and for total VEGFR-2 (A) or the total amount of 
phosphorylated VEGFR-2 was quantified by a phospho-VEGFR-2 (Tyr1175) ELISA (B). For ELISA data, 
values are expressed as a percentage of the stimulated cells from each time point (B). Bars represent 
means ± standard deviation. *p < 0.05, ** p < 0.01 compared to the stimulated cells. (A) is representative of 
triplicate analysis of two independent experiments and (B) is representative of duplicate analysis of one 
independent experiment. 
 
4.5.4 The binding of the apple polyphenols to VEGF is not the 
consequence of non-specific protein binding 
In the previous experiment it was shown that the apple procyanidin fraction inhibits 
VEGF-induced phosphorylation of VEGFR-2 by interacting with the VEGF molecule. 
However, procyanidins are well known for their affinity for proteins; protein binding by 
tannins (= procyanidins) is responsible for the oral astringency experienced when 
drinking a tannic red wine or eating dark chocolate, and is the basis for tanning leather. 
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This protein binding activity is generally non-specific as it is largely independent of the 
nature of the protein. Therefore, to determine whether the apple procyanidin fraction 
has a specific affinity for VEGF or if the binding to VEGF is non-specific, the ability of 
apple procyanidin fraction-treated VEGF to phosphorylate VEGFR2 was investigated in 
HUVECs in the presence and absence of high concentrations of serum proteins 
(Figure 4.14).  
 
When incubated with the apple procyanidin fraction in EGM-2 medium (containing 2 % 
foetal calf serum as well as other serum proteins), VEGF-induced phosphorylation of 
VEGFR-2 was still inhibited. The intensity of the phosphorylated VEGFR-2 band was 
lower than in the basal medium and basal medium plus BSA samples because no 
additional VEGF was added to the medium. The EGM-2 medium contains between 0.8 
and 2.8 ng/ml VEGF (Lonza). In the presence of basal medium plus BSA (1 mg/ml), the 
apple procyanidin fractions were able to inhibit the VEGF-induced phosphorylation of 
VEGFR-2, although it was slightly less potent than when the procyanidin fractions were 
applied in only VEGF-supplemented basal medium. A complete inhibition was 
observed with a treatment of 1 µM apple procyanidin fraction in VEGF-supplemented 
basal medium whereas an approximate 75 % inhibition was observed with the same 
treatment in BSA and VEGF-supplemented medium (Figure 4.14 B).  
 
The concentration of VEGF in the treatments was either 10 ng/ml (0.26 nM) or 25 ng/ml 
(0.66 nM), whereas the concentration of BSA (1mg/ml or 15000 nM) was 4-5 orders of 
magnitude higher. These data show that the apple procyanidin fractions effectively 
inhibit the VEGF-induced phosphorylation of VEGFR-2 even in the presence of excess 
quantities of serum proteins. These observations indicate that the binding of apple 
procyanidins to VEGF or VEGFR-2 is specific, and not the result of non-specific protein 
binding.  
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Figure 4.14: Apple procyanidin fractions are able to inhibit VEGFR-2 phosphorylation in 
the presence of other growth factors and in an excess of BSA.  
(A) HUVECs were treated with either pre-incubated basal medium containing 10 ng/ml VEGF or BSA 
(1 mg/ml) plus 10 ng/ml VEGF in the presence or absence of 1 µM apple procyanidin fraction dp 3.9. (B) 
HUVECs were treated with either pre-incubated basal medium containing 25 ng/ml VEGF or BSA (1mg/ml) 
plus 25 ng/ml VEGF in the presence or absence of 1 µM apple procyanidin fraction dp 4. For the EGM-2 
medium treatment, treatments were prepared in the same manner, but no additional VEGF was added. The 
cells were lysed and the proteins were separated on a NuPAGE gel and probed for the presence of 
phosphorylated VEGFR-2 at the tyrosine 1175 site and for total VEGFR-2 (A) or the amount of 
phosphorylated VEGFR-2 was quantified by a phospho-VEGFR-2 (Tyr1175) ELISA (B). Unstimulated = 
treatment with basal medium, stimulated = treatment with basal medium supplemented with 25 ng/ml 
VEGF. Bars represent means ± standard deviation expressed as a percentage of the stimulated cells. *** p 
<0.001 compared to the respective medium controls. Unstimulated = no VEGF, stimulated = 25 ng/ml 
VEGF. The data is representative of triplicate analysis of two independent experiments.  
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4.5.5 Apple procyanidin fraction inhibits phosphorylation of PLCγ1 
but activates AKT 
In Sections 4.5.1, 4.5.2 and 4.5.3 it was shown that apple procyanidin fractions are 
able to interact with VEGF and as a consequence inhibit endothelial cell migration and 
VEGF-induced VEGFR-2 phosphorylation. Phosphorylation of VEGFR-2 normally 
leads to intracellular signalling through the activation of other signalling molecules.  In 
order to confirm that downstream signalling of VEGFR-2 is inhibited by the apple 
procyanidin fraction treatment two downstream signalling events were investigated. 
The downstream signalling events that were chosen were phosphorylation of 
phospholipase C gamma (PLCγ) and of serine/theronine kinases AKT/PKB (AKT).  
 
PLCγ was selected because it is one of the first signalling proteins to become 
phosphorylated in response to VEGFR-2 phosphorylation. PLCγ binds to the 
phosphorylated Tyr 1175 site on the C-terminus and mediates the activation of the 
mitogen-activated protein kinase (MAPK) / extracellular signal regulated kinase 1/2 
(ERK 1/2) cascade which drives proliferation of endothelial cells. The data presented in 
Figure 4.15 show that treatment of HUVECs with VEGF induced PLCγ1 
phosphorylation. Peak expression of PLCγ1 phosphorylation occurred at 10 min and 
the levels of phosphorylated PLCγ1 slowly decreased at 30 min and 1 h. When 
exposed to the apple procyanidin fraction dp 3.9 treatment, VEGF-induced 
phosphorylation of PLCγ1 was significantly reduced at all time points. These data 
confirm that the apple polyphenol-mediated inhibition of the VEGF-induced activation of 
VEGFR-2 also prevents downstream signalling through PLCγ1.  
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Figure 4.15: Apple procyanidin fraction dp 3.9 inhibits phosphorylation of PLCγ1 
HUVECs were treated with pre-incubated basal medium containing 40 ng/ml of VEGF and 1 µM apple 
procyanidin dp 3.9 for 10, 30 min and 1 h. The cells were lysed and the proteins were separated on a 
NuPAGE gel and probed for the presence of phosphorylated PLCγ1 at Tyr 783 and for total PLCγ1. The 
data is representative of triplicate analysis of three independent experiments.  
 
The second point in the pathway that was investigated was AKT. AKT is activated 
downstream of phosphoinositide 3-kinase and mediates survival of endothelial cells as 
well as regulating nitric oxide production. AKT activation is further downstream in the 
VEGF signalling cascade and can also be activated through several other signalling 
pathways. The data presented show somewhat surprisingly that, VEGF stimulation did 
not cause AKT (Ser 473) to become phosphorylated (Figure 4.16). This was a 
repeatable observation (five independent experiments were conducted). However, AKT 
was phosphorylated when treated with apple procyanidin fraction dp 3.9, in the 
presence or absence of VEGF. The observation that AKT is not phosphorylated in the 
presence of VEGF is in disagreement with reports from the literature as it has been 
shown that VEGF causes the activation of AKT through VEGFR-2 phosphorylation 
(Zhang et al., 2003; Blanes et al., 2007). 
 
Figure 4.16: Apple procyanidin dp 3.9 promotes phosphorylation of AKT.  
HUVECS were treated with pre-incubated basal medium containing 10 ng/ml of VEGF and 1 and 8.9 µM 
apple procyanidin fraction dp 3.9 for 30 min and 1 h. The cells were lysed and the proteins were separated 
on a NuPAGE gel and probed for the presence of phosphorylated AKT at Ser 473 and total AKT. The data 
is representative of triplicate analysis of five independent experiments. 
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4.5.6 The ability of polyphenols to inhibit VEGFR-2 signalling is 
highly dependent on their structure 
The apple procyanidin fraction dp 3.9, that was used to treat the cells, is not a pure 
fraction as it contains monomers (epicatechin and catechin) and oligomers (dimers to 
heptamers) (Figure 4.18). Therefore the effects of pure (-)-epicatechin, (+)-catechin and 
procyanidin dimer B2 on the VEGF signalling pathway were investigated. When 
HUVECS were treated with epicatechin, catechin or procyanidin dimer B2 there was no 
inhibition of VEGFR-2 phosphorylation at a concentration up to 20 µM, whereas apple 
procyanidin dp 3.9 completely inhibited VEGFR-2 phosphorylation at a concentration of 
0.3 µM (Figure 4.17). This shows that flavanols need to be an oligomer and be at least 
a trimer in order to be able to inhibit the VEGF-induced phosphorylation of VEGFR-2.  
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Figure 4.17: Apple procyanidin fraction dp 3.9, but not epicatechin, catechin, or 
procyanidin B2, inhibits VEGF-induced phosphorylation of VEGFR-2.  
HUVECs were treated with pre-incubated basal medium containing 10 ng/ml (A) or 25 ng/ml (B) of VEGF 
and treated with either epicatechin, catechin, procyanidin dimer B2 or apple procyanidin fraction dp 3.9 for 
5 min. The cells were lysed and the proteins were separated on a NuPAGE gel and probed for the 
presence of phosphorylated VEGFR-2 at the tyrosine 1175 site and for total VEGFR-2 (A) or the amount of 
phosphorylated VEGFR-2 was quantified by a phospho-VEGFR-2 (Tyr1175) ELISA (B). Bars represent 
means ± standard deviation expressed as a percentage of the stimulated cells. ** p <0.01 compared to the 
stimulated cells. The data is representative of triplicate analysis of two independent experiments.  
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Figure 4.18: Polyphenol structures investigated.  
Example of a normal-phase high-pressure liquid chromatography (HPLC) chromatogram of apple 
procyanidin fraction dp 3.9. Normal-phase HPLC is used for the quantification of polymeric flavanols. 
Flavanols were separated according to degree of polymerisation using a Luna silica column (250 x 
4.6 mm2, 5 µM particle size; Pheomenex, Macclesfield, UK) and a mobile phase consisting of a 65 min 
gradient (0 – 30 min, 14.0 – 28.4 % B; 30 – 45 min, 28.4 – 39.6 % B; 45 – 50 min, 39.6 – 86.0 % B; 50 – 55 
min, 86.0 % B; 55 – 65 min, 14.0 % B; with a constant 4 % of C maintained throughout the gradient) where 
solvent A is dichloromethane, B is methanol and C is acetic acid/water (1:1, v/v). Flavanols were detected 
by fluorescence emission at 316 nm, following excitation at 276 nm.  E: epicatechin; C: catechin; dp 2: 
dimers; dp 3: trimers, dp 4: tetramers; dp 5: pentamers; dp 6: hexamers; dp 7: heptamers.  
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In order to examine how polyphenol structures influences the inhibition of VEGF 
induced VEGFR-2 phosphorylation, apple procyanidin fractions dp 3 and dp 4, and 
certain green tea polyphenols were investigated (Figure 4.19). Apple procyanidin 
fraction dp 3 completely inhibited VEGF-induced VEGFR-2 phosphorylation at a 
concentration of 10 µM and with a half inhibitory concentration (IC50) of 0.78 µM. Apple 
procyanidin fraction dp 4 was also able to completely inhibit VEGF-induced VEGFR-2 
phosphorylation at a concentration of 10 µM. However, it was more potent than apple 
procyanidin fraction dp 3 as the IC50 of apple procyanidin fraction dp 4 was 0.28 µM. 
Therefore, indicating that the higher the degree of polymerisation, the greater the ability 
to inhibit VEGFR-2 signalling. The IC50 was determined by using a log (inhibitor) versus 
normalised response – variable slope analysis tool on GraphPad Prism software.  
 
The ability of green tea polyphenols to inhibit VEGFR-2 phosphorylation is also 
dependent on key structural features (Figure 4.19). The green tea catechin, EGCG, 
which is galloylated at the 3-position and contains a trihydroxy B-ring, completely 
inhibited VEGFR-2 phosphorylation at a concentration of 1 µM (Figure 4.20) and the 
IC50 was estimated to be 0.09 µM (Figure 4.19). The phenolics ECG and ellagic acid 
were also able to completely inhibit VEGF-induced VEGFR-2 phosphorylation, while 
EGC and methyl gallate caused a 60 % and 10 % inhibition of VEGF-induced VEGFR-2 
phosphorylation, respectively. The observations that EGC (IC50: 42.9 µM) was a poor 
inhibitor, and ECG (IC50: 0.16 µM) was a better inhibitor than ECG but not as effective 
as EGCG, indicates that both 3-galloylation and the trihydroxy B-ring are important for 
inhibitory activity. Methyl gallate (IC50: >200 µM) did not inhibit phosphorylation, 
showing that a gallate ester is not sufficient for inhibitory activity. Gallic acid 
(IC50: >200 µM) was a weak inhibitor while ellagic acid (a dimer of gallic acid) 
(IC50: 0.23 µM) completely inhibited VEGF signalling. These data show that the ability to 
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inhibit VEGF signalling is highly sensitive to the size of the polyphenol and the number 
of hydroxyl groups.  
 
 
Figure 4.19: Certain phenolics are able to inhibit VEGFR-2 phosphorylation at low 
concentrations.  
HUVECs were treated with pre-incubated basal medium containing 25 ng/ml of VEGF and treated with 
either apple procyanidin fraction dp 3, apple procyanidin fraction dp 4, EGCG, ECG, EGC, ellagic acid or 
methyl gallate for 5 min. The cells were lysed and the amount of phosphorylated VEGFR-2 was quantified 
by a phospho-VEGFR-2 (Tyr1175) ELISA (A). Bars represent means ± standard deviation expressed as a 
percentage of the stimulated cells. ** p <0.01, *** p <0.001 compared to the stimulated cells. HUVECs 
were treated with pre-incubated basal medium containing 25 ng/ml of VEGF and different concentrations 
of polyphenols for 5 min. The cells were lysed and the total amount of phosphorylated VEGFR-2 was 
quantified by a phospho-VEGFR-2 (Tyr1175) ELISA and the half inhibitory concentrations (IC50) were 
determined by using the log (inhibitor) versus normalised response – variable slope analysis tool on 
GraphPad Prism software (B). The IC50 determination for EGCG, ECG, EGC, gallic acid, ellagic acid and 
methyl gallate was carried out by Mark Winterbone (IFR, Norwich). The data is representative of duplicate 
analysis of one independent experiment.  
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Figure 4.20: EGCG inhibits VEGFR-2 phosphorylation. 
HUVECs were treated with pre-incubated basal medium containing 25 ng/ml VEGF and different 
concentrations of EGCG for 5 min. The cells were lysed and the amount of phosphorylated VEGFR-2 was 
quantified by phospho-VEGFR-2 (Tyr1175) ELISA. Bars represent means ± standard deviation expressed 
as a percentage of the stimulated cells. *p < 0.05, **p < 0.01, *** p < 0.001 compared to the stimulated 
cells. This work was carried out by Mark Winterbone (IFR, Norwich).  
 
 
4.6 Discussion 
The data presented in this chapter show that: (1) certain green tea polyphenols are 
able to inhibit VEGF induced VEGFR-2 phosphorylation at dietary relevant 
concentrations; (2) the inhibitory effect of certain polyphenols is highly dependent on 
their structure; (3) the inhibitory action of these polyphenols is due to the polyphenols 
interacting with the VEGF molecule; and (4) the interaction between the polyphenol 
and VEGF molecule is specific as the polyphenol is still able to inhibit VEGF induced 
VEGFR-2 phosphorylation in the presence of FBS and other growth factors. This is the 
first time it has been shown that polyphenols inhibit VEGF induced VEGFR-2 
phosphorylation by binding to the VEGF molecule.  
 
Inhibition of the VEGF signalling pathway, and subsequently angiogenesis, is an 
effective strategy in the treatment of chronic diseases and is currently being used as a 
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therapeutic target in certain types of cancers. Anti-VEGF antibodies, aptamers and 
small molecule VEGFR tyrosine kinase inhibitors are available for the treatment of 
several forms of cancer (Giles, 2001; Ferrara and Kerbel, 2005). Certain polyphenols 
are also able to inhibit VEGF-induced VEGFR-2 phosphorylation (Kondo et al., 2002b; 
Lamy et al., 2002; Tang et al., 2003; Lamy et al., 2006; Mojzis et al., 2008; Wen et al., 
2008; Lu et al., 2010), although the exact mechanism of this inhibition has not been 
fully investigated. In principle, polyphenols may inhibit VEGF induced VEGFR-2 
phosphorylation in three ways; (1) by binding to the VEGF molecule and thus 
preventing VEGF from binding to its receptors; (2) by binding to the VEGF receptor(s) 
and thus preventing VEGF from binding to the receptor(s); or (3) by binding to different 
cellular compartments and thus preventing VEGF from binding to the receptor(s) or by 
inhibiting VEGF’s kinase activity. 
 
Inhibition of VEGF-induced VEGFR-2 phosphorylation may be due to the polyphenol 
binding to the VEGF protein and preventing VEGF from binding to its receptor. 
Kondo et al. (2002) investigated the possibility of catechins interfering with VEGF 
signalling by using an [125I]-labelled VEGF binding assay and concluded that the 
polyphenol (EGCG) inhibited VEGF-induced VEGFR-2 phosphorylation by inhibiting 
the binding of VEGF to VEGFR-2. However the experimental technique preformed was 
to pre-treat HUVECs with the polyphenol for 30 min prior to 90 min exposure of VEGF. 
Therefore while the results show that the polyphenol prevents VEGF binding to its 
receptor by approximately 40 % it can not be deduced whether the inhibition is due to 
the polyphenol interacting with the VEGF molecule, the receptor, or the cellular 
membrane. Other researchers have proposed that polyphenols do not inhibit VEGFR-2 
phosphorylation by interacting with the receptor as there was no reduction in VEGFR-2 
expression in response to the polyphenol treatment (Tang et al., 2003; Rodriguez et al., 
2006). Both of these researchers used the same method: treat the cells with 
polyphenol for 24 h, wash with medium and treat the cells with VEGF for either 30 min 
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or 24 h. Inhibition of intracellular signalling has also been demonstrated by polyphenol-
protein binding with different proteins. For example, in the case of B-cell lymphoma 2 
(Bcl-2) proteins, the polyphenol (EGCG) inhibits the anti-apoptotic function of Bcl-2 
proteins by directly binding to the BH3 pocket of the Bcl-2 (Khan et al., 2006). Direct 
protein binding has also been observed with EGCG and PDGF (Weber et al., 2004).  
 
On the other hand, polyphenols may exert their inhibitory effect by binding to the 
VEGFRs and thus preventing VEGF from binding to its receptor. Previously published 
data has shown that after extended incubations with polyphenols (EGCG and catechin-
gallate or delphinidin), VEGF-induced VEGFR-2 phosphorylation is inhibited as a result 
of interactions between the polyphenol and the receptor (Lamy et al., 2002; Lamy et al., 
2006). This conclusion was based on their experimental method: treating HUVECs with 
the polyphenol in serum free medium for 18 h, replacing the medium with fresh serum 
free medium and treating the cells with VEGF for 1 min. Therefore, concluding that with 
no direct competition of VEGF and polyphenol, the method of interaction must lie 
between the polyphenol and receptor. However a statistically significant difference was 
not observed in the current chapter after a 24 h incubation of apple procyanidin fraction 
dp 3.9 and dp 4 following the same experimental procedures.  
 
Polyphenols may also exert their inhibitory effect by cellular incorporation and therefore 
cause a displacement of VEGF binding. Weber et al. (2004) demonstrated an inhibition 
in PDGF phosphorylation in response to EGCG treatment in vascular smooth muscle 
cells and after at [3H]-labelled EGCG assay an incorporation of EGCG into different 
cellular compartments, including cell surface membranes, was observed. Therefore, it 
was concluded that the incorporation of EGCG into different cellular compartments 
leads to a non-displaceable binding of PDGF to non-receptor binding sites  (Weber et 
al., 2004). The incorporation of anthocyanins into different cellular compartments in 
aortic endothelial cells has also been observed (Youdim et al., 2000). 
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The results presented in the literature have not determined the exact mechanism on 
how polyphenols inhibit VEGF-induced VEGFR-2 phosphorylation, but have presented 
theories based on the experimental design used. Therefore the data presented in this 
chapter has tried to determine the exact mechanism of inhibition. This was 
accomplished by using three different experimental designs in order to establish the 
method of inhibition: (1) pre-treatment of HUVECs with the polyphenol to establish 
whether the polyphenol is inhibiting VEGF-induced VEGFR-2 phosphorylation by 
interacting with the cell membrane; (2) pre-stimulation of HUVECs with VEGF to 
establish whether inhibition of VEGF-induced VEGFR-2 phosphorylation is dependent 
on the interaction between the polyphenol and the VEGF protein; and (3) a pre-
incubation of polyphenol and VEGF protein to determine the length of time it takes to 
inhibit VEGF-induced VEGFR-2 phosphorylation. The data presented show that no 
inhibition of VEGF-induced VEGFR-2 phosphorylation is observed with pre-treatment 
of the cells with the polyphenol between 5 min and 24 h; time dependent inhibition of 
VEGFR-2 phosphorylation is observed with pre-stimulation of the cells with VEGF; and 
immediate inhibition of VEGFR-2 phosphorylation is observed with incubation of 
polyphenol and VEGF prior to cell treatment. These results establish that the 
polyphenol causes the inhibitory effect by interacting with the VEGF molecule rather 
than the cellular membrane. The array data presented by Liu et al. (2008) supports the 
notion that the inhibitory effect of polyphenols is due to the interaction with the VEGF 
molecule. Liu et al. (2008) reported gene expression data for HUVECs pre-treated with 
EGCG (20 µM) for 24 h followed by a 30 min stimulation of VEGF (50 ng/ml). 
Pre-treating the cells with EGCG followed a VEGF stimulation resulted in no 
differentially expressed genes identified when they were compared to VEGF-stimulated 
cells. However when the cells, which were pre-treated with EGCG followed by VEGF 
stimulation were compared to cells that were pre-treated with EGCG, 123 genes were 
reported to be differentially expressed (Liu et al., 2008). The results presented by Liu et 
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al. (2008) shows that pre-treatment of cells with EGCG followed by VEGF stimulation is 
unable to block genes differentially regulated by VEGF, which therefore supports the 
data presented in this chapter showing that polyphenols interact with the VEGF 
molecule. Since the data presented in this chapter shows that the inhibition of VEGF-
induced VEGFR-2 signalling was instantaneous, incorporation of the polyphenol into 
different cellular compartments is unlikely. 
 
Polyphenols are well known for their affinity for protein binding (Baxter et al., 1997; 
Jöbstl et al., 2004; Papadopoulou and Frazier, 2004; Papadopoulou et al., 2005) and 
this characteristic property of polyphenols is responsible for their astringency, enzyme 
inhibition and tanning ability (Ezaki-Furuichi et al., 1987; Luck et al., 1994; Murray et 
al., 1994; Baxter et al., 1997; Bacon and Rhodes, 2000; Jöbstl et al., 2004). The 
protein binding activity is generally non-specific as it is largely independent of the 
nature of the protein. Further experimental designs described here involving different 
types of medium has confirmed that the binding interaction between the polyphenol 
and VEGF molecule is specific as the polyphenol was still able to inhibit VEGF-induced 
phosphorylation of the receptor in the presence or absence of excess BSA, FBS and 
other cytokines and growth factors.  
 
The inhibitory effect of certain polyphenols on VEGF-induced VEGFR-2 
phosphorylation was achieved at physiological concentrations. The data from the 
literature range from very high and physiologically unrealistic doses  (Kondo et al., 
2002b; Kojima-Yuasa et al., 2003; Neuhaus et al., 2004; Wen et al., 2008; Lu et al., 
2010) to physiologically relevant doses (Lamy et al., 2002; Rodriguez et al., 2006). In 
the case of procyanidins the physiological relevance is still unknown as an effective 
plasma analysis method for the detection of procyanidin oligomers has yet to be 
established. It has been stated that cocoa procyanidins are not degraded and can 
reach the intestine and that higher molecular weight procyanidins are poorly absorbed 
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by the intestinal lumen and therefore unlikely to reach the plasma (Rios et al., 2002a; 
Tsang et al., 2005; Appeldoorn et al., 2009b). However procyanidin trimers have been 
detected in rat plasma with a concentration of 4 µM after a high dose (1000 mg/kg of 
an apple procyanidin extract) (Shoji et al., 2006a). Procyanidin trimers have also been 
detected in rat plasma after the consumption of 300 mg/kg grape seed extract (amount 
not quantified) (Prasain et al., 2009) and after the consumption of 1 g/kg grape seed 
procyanidin extract (8.55 µM detected in plasma) (Serra et al., 2009). The detection of 
procyanidins indicated that they are not degraded into monomers (Prasain et al., 2009). 
Data presented here demonstrates that when exposed to VEGF prior to VEGF 
treatment of HUVECs, apple procyanidin trimers and tetramers inhibited VEGF-induced 
VEGFR-2 phosphorylation at low concentrations (IC50 of 0.78 µM and 0.28 µM, 
respectively). These concentrations are lower than the procyanidin concentrations 
described in the literature, 10 µg/ml (approximately 17 µM) (Wen et al., 2008) or 
15 µg/ml (approximately 15 µM) (Lu et al., 2010), that were able to cause an inhibition 
of VEGF induced VEGFR-2 phosphorylation. EGCG has also been shown to inhibit 
VEGF induced VEGFR-2 phosphorylation at physiological concentrations ranging from 
0.01 µM to 2 µM (Lamy et al., 2002; Rodriguez et al., 2006), while the data in this 
chapter has shown an IC50 of 0.09 µM for EGCG inhibition of VEGFR-2 
phosphorylation. The concentrations at which these green tea catechins are able to 
inhibit VEGFR-2 signalling are physiologically relevant as the concentration of 
catechins in plasma, after the consumption of four cups of green tea, is between 
0.2 µM and 1 µM (Lee et al., 1995; Yang et al., 1998b; Tang et al., 2003; Rodriguez et 
al., 2006).  
 
Based on the investigation of different polyphenol structures, it was shown that the 
ability to inhibit VEGF signalling is related to the size of the polyphenol (epicatechin 
polymers with a degree of polymerisation greater than 3), the presence of a gallate 
group at the 3-position and the total number of hydroxyl groups. Therefore the 
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inhibitory effect of certain polyphenols is highly dependent on their structure. This is in 
agreement with what has been stated in the literature. Researchers have concluded 
that since EGCG was the most potent inhibitor, and ECG was the second most potent 
inhibitor, that the gallate group at the 3-position may be responsible for the observed 
inhibitory effect (Kondo et al., 2002b; Khan et al., 2006; Lorenz et al., 2009a). The ester 
bond present in EGCG, ECG, catechin-gallate has also been suggested to have a role 
in the inhibitory effect observed by these polyphenols (Lamy et al., 2002). In the case 
of delphinidin, the presence of three hydroxyl groups at the B-ring and a free hydroxyl 
group at the 3-position appear to be essential for its potency compared to other 
anthocyanidins (Lamy et al., 2006). Therefore, the specific structures of polyphenols 
are crucial for the inhibition of VEGF induced VEGFR-2 phosphorylation and the 
potency of that inhibition.  
 
Confirmation of the inhibition of VEGF intracellular signalling in response to polyphenol 
treatment has been demonstrated by examining two downstream signalling pathways, 
PLCγ1 and AKT. PLCγ is an important protein as it mediates the activation of the 
MAPK/ERK 1/2 cascade and proliferation of endothelial cells. VEGF stimulation of cells 
has been shown to activate PLCγ1 phosphorylation (Xia et al., 1996; Cohen et al., 
1999; Gille et al., 2001; Labrecque et al., 2005), whereas polyphenol treatment has 
inhibited either VEGF or PDGF induced PLCγ1 phosphorylation (Sachinidis et al., 
2000; Weber et al., 2004; Labrecque et al., 2005). The results presented in this chapter 
are in agreement with the previously reported literature data.  
 
However, in the case of AKT phosphorylation, the results presented in this chapter 
contradict those presented in the literature, that AKT phosphorylation was not activated 
by VEGF treatment. AKT is located several steps further downstream in the VEGF 
signalling pathway and it mediates survival of endothelial cells as well as regulating 
nitric oxide production. Others have shown that VEGF treatment of HUVECs induces 
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AKT phosphorylation (Chavakis et al., 2001; Tang et al., 2003; Riesterer et al., 2004; 
Rodriguez et al., 2006; Stangl et al., 2007) and that polyphenol treatment inhibited 
VEGF-induced AKT phosphorylation (Tang et al., 2003; Rodriguez et al., 2006; Stangl 
et al., 2007). However, the data presented in this chapter has shown that (1) VEGF 
alone (10 ng/ml or 25 ng/ml) did not cause an increase in AKT phosphorylation and (2) 
the polyphenol (apple procyanidin fraction dp 3.9), in the presence or absence of 
VEGF, induces AKT phosphorylation. No phosphorylation of AKT was observed when 
chronic lymphocytic leukaemia cells were treated with various doses of VEGF (Lee et 
al., 2004). Previous literature reports have shown that polyphenols are able to induce 
AKT phosphorylation (Wu et al., 2006; Kim et al., 2007; Stangl et al., 2007; Lorenz et 
al., 2009a; Montagut et al., 2010) and part of the cardio-protective effects of 
polyphenols has been attributed to the AKT activation-dependent increase in nitric 
oxide production; an increase of nitric oxide production results in vasorelaxation of the 
endothelium (Dimmeler et al., 1999; Anselm et al., 2007). Therefore, depending on the 
state of the cells (stimulated versus unstimulated), polyphenols can exert opposite 
effects on intracellular signalling (Stangl et al., 2007). However, this does not explain 
why, in the experiments described here, VEGF did not induce AKT phosphorylation.  
 
Therefore based on the results presented in this chapter it can be concluded that 
certain polyphenols are able to inhibit VEGF-induced VEGFR-2 phosphorylation and 
intracellular signalling at physiological conditions and that the inhibition occurs through 
the interactions between the polyphenol and VEGF protein.  
 
4.7 Conclusion  
The results from this chapter have shown that VEGFR-2 phosphorylation is inhibited 
almost instantly once the polyphenol and VEGF are mixed together, and complete 
inhibition is observed after 5 min of incubation. The observed inhibitory effect is due to 
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the polyphenols interacting with the VEGF molecule. This is a specific interaction as the 
polyphenol was still able to inhibit VEGF-induced VEGFR-2 phosphorylation in the 
presence of FBS, cytokines, other growth factors and an excess of BSA. An 
investigation of polyphenol structures in relation to VEGF inhibitory activity has shown 
that the inhibition of phosphorylation is dependent on key structural features 
(epicatechin polymers with a degree of polymerisation greater than 3; 3-galloylation; 
and a trihydroxy B-ring). The most potent inhibitory polyphenols were able to inhibit 
VEGFR-2 phosphorylation at physiological concentrations. These findings are 
significant because they provide a plausible link between consumption of polyphenols 
and a reduced risk of CVD. More importantly this data shows a novel mechanism of 
how polyphenols inhibit VEGF induced VEGFR-2 phosphorylation. While this research 
has only shown an interaction with VEGF, it raises the possibility that polyphenols can 
affect other signalling pathways by interacting with other signalling peptides such as 
growth factors and hormones.  
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Chapter 5 : Binding interactions between polyphenols 
and VEGF 
5.1 Abstract 
The data presented in Chapter 4 demonstrated that certain polyphenols potently inhibit 
VEGF-induced VEGFR-2 phosphorylation by interacting directly with VEGF and not 
with its receptors or the cell membrane. Interactions between proteins and ligands may 
be covalent (the result of a chemical reaction which would form a VEGF-polyphenol 
adduct) or non-covalent (e.g. through hydrogen binding, ionic binding or hydrophobic 
interactions which would result in a VEGF-polyphenol complex). The overall aim of the 
research presented in this chapter was to characterise the nature of the interaction 
between VEGF and inhibitory polyphenols. Extensive dialysis and concentration of 
VEGF-polyphenol adducts/complexes did not restore VEGF activity. This observation 
has shown that the interaction is not an easily reversible dynamic equilibrium between 
bound and unbound forms of VEGF and the observation also supports the formation of 
either a covalent adduct or a strong non-covalent complex. Polyphenol-treated VEGF 
exhibited exactly the same SDS-PAGE migration properties under reducing conditions 
as untreated VEGF which strongly suggests that polyphenol-mediated inhibition of 
VEGF activity is not due to the formation of VEGF-polyphenol adduct(s). LTQ Orbitrap 
mass spectrometry analysis of protease digested VEGF-polyphenol complexes 
identified peptides accounting for approximately 67 % of the full length of the VEGF 
protein, none of which had been covalently modified. Next, the kinetics of polyphenol-
mediated inhibition of VEGF activity was investigated using apple procyanidin fraction 
dp 4. The data showed that the polyphenol-mediated inhibition of VEGF activity was 
time-dependent, providing further evidence that inhibition was not the result of the 
formation of a freely-reversible complex. The log-transformed kinetic data did not fit a 
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simple linear model, but did fit a two-stage model in which an initial rapid, linear phase 
of inhibition (rate constant = 1.29 x 10-3) was followed by a slower linear phase of 
inhibition (rate constant = 0.18 x 10-3). These data show that the inhibition of VEGF 
activity is the result of non-covalent slow-binding of one or more molecules of apple 
procyanidin fraction dp 4 or EGCG to the VEGF protein which results in the formation 
of a tightly bound VEGF-polyphenol complex.  
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5.2 Introduction 
In Chapter 4 it was established that at low (physiological) concentrations, certain 
polyphenols can inhibit VEGF-induced VEGFR-2 phosphorylation by interacting with 
the VEGF molecule and not its receptors. Therefore, the aim of the research covered in 
this chapter was to determine the nature of the binding interaction(s) occurring between 
the polyphenols and VEGF.   
 
Polyphenols are known for their tendency to bind to proteins (Baxter et al., 1997; Jöbstl 
et al., 2004; Papadopoulou and Frazier, 2004; Papadopoulou et al., 2005). This 
characteristic property of polyphenols is responsible for their astringency, enzyme 
inhibition and tanning ability (Ezaki-Furuichi et al., 1987; Luck et al., 1994; Murray et 
al., 1994; Baxter et al., 1997; Bacon and Rhodes, 2000; Jöbstl et al., 2004). The 
understanding of the nature of the interaction (specific versus non-specific, reversible 
versus irreversible, and covalent versus non-covalent) between polyphenols and 
proteins and whether the polyphenol induces conformational changes to the protein is 
important in the understanding of the mechanisms involved in polyphenol-protein 
binding.  
 
5.2.1 Specific versus non-specific binding 
The polyphenol may either bind to the protein specifically or non-specifically 
(Figure 5.1). Specific protein binding involves the interaction of the polyphenol to 
specific amino acid side chains on the protein. For example in the case of enzyme-
substrate binding, the factors that determine substrate specificity for enzymes are 
conformational and chemical compatibility between the substrate and its binding site on 
the enzyme (Hrmova and Fincher, 2001). Non-specific binding involves the interaction 
of polyphenols to numerous hydrophobic side chains or hydrophobic regions on the 
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protein structure. The investigation of the specificity and thermodynamics of tannin-
protein (BSA) binding was previously conducted and based on the general shape of the 
binding isotherms it was concluded that tannins interact non-specifically with BSA 
rather than binding to specific receptor sites on the protein while gelatine-tannin 
interactions involved a two stage binding process (Frazier et al., 2003). The first stage 
involves a specific binding interaction and the second stage involves non-specific 
interactions (Frazier et al., 2003). However, the majority of the literature has focused on 
the ability of polyphenols to bind non-specifically to proteins.  
 
 
Figure 5.1: Schematic model of non-specific and specific protein-polyphenol interactions 
 
5.2.2 Reversible versus irreversible binding 
The specific or non-specific binding of a polyphenol to a protein may also be a 
reversible or irreversible interaction (Figure 5.2). An irreversible binding reaction 
between the polyphenol and protein usually involves the polyphenol covalently 
modifying the protein and the interaction cannot therefore be reversed. Irreversible 
interactions display time-dependent inhibition and their potency cannot be determined 
by an IC50 value. An irreversible binding reaction can also be the result of a very strong 
non-covalent interaction. In this case the polyphenol would bind rapidly to the protein 
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and then undergo a slower rearrangement involving a protein conformational change to 
result in a very tightly bound complex. Non-covalent interactions are associated with a 
reversible interaction and the bound polyphenol can be easily removed by dilution of 
dialysis under these conditions.  
 
The mechanism of protein-polyphenol complexes has generally been regarded as 
reversible (McManus et al., 1985; Luck et al., 1994; Bennick, 2002; Charlton et al., 
2002). The soluble complexes may reach a size where they start to precipitate, but 
these insoluble complexes are usually reversible (Siebert et al., 1996; Siebert, 2006). 
However oxidation, complex formation with metal ions, or changes in pH make the 
precipitation process irreversible (Luck et al., 1994).  
 
The binding interaction between polyphenols and proteins can also involve a 
conformational change to the structure of the protein (Figure 5.2). The conformational 
change of the protein by the polyphenol will result in the loss of the activity of the 
protein. However, it is unlikely that protein conformation is changed by polyphenols. 
The addition of polyphenol (quercetin, rutin, epicatechin or catechin) did not result in a 
change of the conformation of BSA (Papadopoulou et al., 2005).  
 
 
Chapter 5 
 
 
188 
 
 
 
Figure 5.2: Schematic model of reversible, irreversible, conformational change, non-
specific and specific protein-polyphenol interactions 
 
5.2.3 Covalent versus non-covalent binding 
Polyphenols may also bind to proteins non-covalently (involving hydrogen bonds, ionic 
bonds, van der Waals forces and hydrophobic interactions) or covalently (Loomis, 
1974; Butler et al., 1984; Ezaki-Furuichi et al., 1987; Appel, 1993; Bennick, 2002). 
Hydrogen bonds are a weak to moderate intermolecular force (the forces of 
interactions between molecules) that occur between a hydrogen atom that is covalently 
bonded to a very electronegative atom, and a lone pair of electrons on another small 
electronegative atom such as nitrogen, oxygen or fluorine (Figure 5.3 A). For example, 
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hydrogen bonds occur between polyphenols and proteins when hydrogen bonds are 
formed between the hydroxyl groups of polyphenol ‘donor’ and amide carbonyl groups 
of the protein ‘acceptor’ (Loomis, 1974; Appel, 1993; Hagerman et al., 1998; Hofmann 
et al., 2006). Hydrogen bonds are stronger than most other intermolecular forces; 
however they are much weaker than both ionic bonds and covalent bonds. Ionic bonds 
are a chemical bond formed by electrostatic attraction between positive and negative 
ions (Figure 5.3 B), while hydrophobic interactions are the interactions driven by the 
exclusion of non-polar residues from water (Figure 5.3 C). Hydrophobic interactions are 
driven by a decrease in entropy that would result from water molecules being forced to 
become more ordered in order to accommodate the dispersed hydrophobic regions 
(Appel, 1993). Ionic bonds can be formed if the polyphenol is ionized to create a 
phenolate ion with a net negative charge, which can interact with the basic amino acid 
residues of proteins (Loomis, 1974; Appel, 1993). Hydrophobic bonds are formed by 
the attraction of the hydrophobic aromatic rings of the polyphenol and the hydrophobic 
regions of other compounds such as aliphatic and aromatic side chains of amino acids 
or proline residues in proteins (Loomis, 1974; Appel, 1993; Luck et al., 1994; Murray et 
al., 1994). Covalent binding occurs when two or more molecules share electrons 
between atoms, and it is the strongest form of binding (Figure 5.3 D).  
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Figure 5.3: Examples of different types of intermolecular bonds. 
(A) hydrogen binding; (B) ionic binding, (C) hydrophobic interactions, and (D) covalent binding.  
 
 
It has been suggested that hydrogen binding and hydrophobic interactions are the 
major interactions between polyphenols and proteins (Butler et al., 1984), while 
covalent bonds and ionic bonds are less likely to occur (Bennick, 2002). Covalent 
bonds are most likely to occur under oxidizing conditions (Bennick, 2002). Ionic bonds 
are not likely to occur between polyphenols and proteins because it has been 
demonstrated that no interactions between polyphenols and proteins could be 
observed at pH values under which the phenolic hydroxyl groups would be ionized 
(Hagerman and Butler, 1978; McManus et al., 1985). Therefore the main types of 
interactions to occur between polyphenols and proteins are hydrogen bonds and 
hydrophobic interactions; although under certain circumstances covalent bonds can 
occur.  
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A number of reports have provided evidence that the major types of non-specific 
interactions to occur between polyphenols and proteins are hydrophobic interactions, 
and that hydrogen binding occurs as a minor interaction that provides strength and 
stability and reinforces the hydrophobic interactions (Oh et al., 1980; Hagerman and 
Butler, 1981; Luck et al., 1994; Murray et al., 1994; Hagerman et al., 1998; Vergé et al., 
2002; Jöbstl et al., 2004; Papadopoulou et al., 2005; Richard et al., 2006; Diniz et al., 
2008). Proteins or peptides with a high proline and/or arginine content (such as 
bradykinin [BDK] or salivary proline-rich proteins [PRPs]), are relatively large, are 
hydrophobic and possess conformationally open and flexible structures and therefore 
represent good candidates for polyphenol-protein interactions (Hagerman and Butler, 
1981; Butler et al., 1984; Luck et al., 1994; Murray et al., 1994; Bacon and Rhodes, 
2000; de Freitas and Mateus, 2002; Vergé et al., 2002; Jöbstl et al., 2004). In contrast, 
tightly coiled, globular proteins, such as ribonuclease A, cytochrome c, lysozyme and 
myoglobulin have a lower binding affinity for polyphenols (Hagerman and Butler, 1981; 
Luck et al., 1994). Hydrophobic interactions and hydrogen bonds are formed between 
polyphenols and proteins under non-oxidizing conditions (Hagerman et al., 1998; Diniz 
et al., 2008). 
 
Under oxidizing conditions covalent bonds are more likely to occur between 
polyphenols and proteins (Diniz et al., 2008). In oxidizing conditions (for example in 
plasma samples) polyphenols react with reactive oxygen species, such as OH•, O2-• 
and ROO•, (Chen and Hagerman, 2004b) and the reaction products of polyphenols 
(semiquinone radicals or quinones) can form covalent bonds with nucleophiles, such as 
amino acids or thiol groups (Bennick, 2002; Chen and Hagerman, 2004b; Diniz et al., 
2008). The covalent bonds formed between polyphenols and proteins, in oxidizing 
conditions, are resistant to disruption by protein denaturants (Hagerman et al., 1998; 
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Chen and Hagerman, 2004b). It has also been stated that covalent binding is favoured 
by a high pH or by the presence of polyphenol oxidase (Oh et al., 1980). However, the 
exact nature of the binding and the binding affinities between the polyphenol and 
protein is dependent on various parameters, including pH, temperature and structure 
(of the protein or polyphenol) (Luck et al., 1994; de Freitas and Mateus, 2001; Diniz et 
al., 2008).  
 
5.2.4 Polyphenol-protein non-specific binding: the effect of pH 
The pH of the solution may have an influence on the binding affinities between 
polyphenols and proteins. The affinities of proteins for polyphenols were shown to be 
highly dependent on the pH of the solution (Hagerman and Butler, 1981). It has been 
shown that the polyphenol-protein binding affinities are strongest when the pH is near 
the isolectric point (pI) of the protein (Hagerman and Butler, 1981; Ezaki-Furuichi et al., 
1987; Hagerman et al., 1998; Riedl and Hagerman, 2001; Bennick, 2002). Therefore, 
proteins with an acidic pI have a greater affinity for polyphenols at a lower pH and 
proteins with a basic pI have a greater affinity for polyphenols at a higher pH. For 
example acidic proteins, such as bovine serum albumin (BSA) and PRPs, have a 
stronger affinity for polyphenols at pH 4.5 and between pH 3.5 and 5.0, respectively, 
while basic proteins, such as lysozyme have greater affinities at a higher pH 
(Hagerman and Butler, 1981; Ezaki-Furuichi et al., 1987; Hagerman et al., 1998; de 
Freitas and Mateus, 2001). However, different pH values (pH 5.0, 6.2 and 6.8) showed 
a slight upward trend in binding affinity between epicatechin and BSA, but the trend 
was not significant (Papadopoulou and Frazier, 2004). Charlton et al. (2002) also 
observed that binding affinities were unaffected by pH between 3.8 and 6.0. 
 
The pH of the solution also determines the type of binding that occurs between 
polyphenols and proteins. Binding at a low pH is generally favoured by hydrogen 
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bonds, but hydrophobic interactions may also be involved (Barbeau and Kinsella, 
1983). At pHs close to the pI of the protein, hydrophobic interactions are favoured due 
to the minimalisation of charge repulsion (Barbeau and Kinsella, 1983) and covalent 
bonds are favoured by a high pH (Oh et al., 1980).  
 
5.2.5 Polyphenol-protein non-specific binding: the effect of 
temperature 
The binding affinities between polyphenols and proteins have also been reported to be 
affected by temperature. A decrease in binding affinity between BDK and -1,2,3,4,6-
penta-O-galloyl-D-glucose (PGG) and a basic PRP and EGCG or PGG has been 
observed with an increase in temperature (3 ºC to 55 ºC) however increases or 
decreases in binding affinities in response to temperature are dependent on the 
polyphenol or protein under investigation (Charlton et al., 2002). An increase in 
complex formation and precipitation between BSA and PGG and between protein 
isolated from spinach leaves and chlorogenic acid was observed when the temperature 
increased from 4 ºC to 40 ºC (Barbeau and Kinsella, 1983; Hagerman et al., 1998) 
while the complex formation and precipitation of BSA by epicatechin16 (4→8) catechin 
(EC16-C) was not affected by temperature (Hagerman et al., 1998; Hofmann et al., 
2006). Butler et al. (1984) also observed that the complex formed between polyphenols 
and proteins was temperature dependent as well as dependent on the protein under 
investigation. It was observed that the complex between procyanidin-B2 with BSA or 
lysozyme was not affected by differences in temperature, however the complex 
between procyanidin-B2 and trypsin weakened in response to an increase in 
temperature (Butler et al., 1984). An increase in complex formation due to temperature 
differences may be due to temperature-induced conformational changes in the 
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structure of the protein as protein conformational changes are known to alter the 
binding affinity for small ligand molecules (Barbeau and Kinsella, 1983). 
 
5.2.6 Polyphenol-protein non-specific binding: the effect of structure 
Along with pH and temperature, the size and structure of the protein or the polyphenol 
play an important role in polyphenol-protein binding. Polyphenol-protein binding 
affinities are dependent on the size of the protein; proteins which have a molecular 
weight less than 20 kDa have lower polyphenol-protein binding affinities than proteins 
with a molecular weight greater than 20 kDa, with the exception of PRPs (Hagerman 
and Butler, 1981).  
 
The ability of polyphenols to bind to proteins is also dependent on the molecular size of 
the polyphenol (Beart et al., 1985; McManus et al., 1985; Ezaki-Furuichi et al., 1987; 
Bacon and Rhodes, 2000; de Freitas and Mateus, 2001; Bennick, 2002; Brás et al., 
2010). For example, the binding affinity of galloylated D-glucose compounds to BSA 
increases incrementally with the addition of each phenolic ester group and reaches a 
maximum binding strength with β-penta-O-galloyl-D-glucose (Haslam, 1974; Beart et 
al., 1985; McManus et al., 1985). The same was observed with flavan-3-ols; the 
binding affinity was low for the monomers (epicatechin and catechin) and increased 
with the degree of polymerisation for the procyanidins (Ezaki-Furuichi et al., 1987; de 
Freitas and Mateus, 2002; Brás et al., 2010). While an increase in molecular weight of 
the polyphenol results in greater polyphenol-protein binding affinities, the 
conformational mobility and flexibility of the polyphenols is also important in 
polyphenol-protein binding (Beart et al., 1985; de Freitas and Mateus, 2001; Bennick, 
2002). For example, quercetin has a stronger binding affinity to BSA compared to rutin 
(a glycoside of quercetin with the addition of the disaccharide rutinose) (Papadopoulou 
et al., 2005). While the molecular size of rutin is greater than quercetin the addition of 
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rutinonse causes the structure to become less hydrophobic and less flexible than 
quercetin resulting in a lower binding affinity.   
 
Therefore, according to available data in the literature, the interactions between 
polyphenols and proteins are likely to be non-specific and reversible and hydrophobic 
interactions are likely to be the main binding interaction involved between polyphenols 
and proteins with hydrogen binding supporting the hydrophobic interactions. The ability 
of polyphenol-protein binding affinity is also dependent on the pH, temperature, and the 
size and structure of the polyphenol and of the protein. 
 
5.3 Objectives 
In the previous chapter it was established that certain polyphenols inhibit VEGF-
induced VEGFR-2 phosphorylation by interacting with the VEGF molecule. 
Polyphenols are known to interact with and bind to proteins either non-covalently or 
covalently. Therefore, the objectives of this chapter were to achieve an understanding 
of the nature of the interaction between certain polyphenols (apple procyanidin fraction 
dp 3.9 or dp4 and EGCG) and VEGF.   
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5.4 Materials and methods 
5.4.1 Materials 
Human recombinant VEGF165 was obtained from R&D Systems Europe Ltd (Abingdon, 
UK). Purified epigallocatechin gallate (EGCG) was purchased from Extrasynthese 
(Genay, France) and electrophoresis reagents were purchased from Invitrogen. The 
VEGFR-2, phospho-VEGFR-2 (Tyr 1175), the anti-rabbit IgG, HRP-linked antibody and 
the PathScan phospho-VEGFR-2 (Tyr1175) sandwich ELISA kit were from Cell 
Signaling and the VEGF rabbit polyclonal antibody was purchased from Thermo 
Scientific. Apple procyanidin fraction dp 4 was purified from the 2007 apples 
(Chapter 3) provided by Coressence ltd (Herefordshire, UK) as previously described 
(Yanagida et al., 1999; Shoji et al., 2005; Shoji et al., 2006b), with some modifications. 
A brief description of the method can be found in Chapter 4 or a more detailed 
description of the method is located in the Supplementary Information (Supplementary 
Information 1).  
 
5.4.2 Cell culture and flavanol treatments 
5.4.2.1 Cell culture 
The culture of HUVECs is described in Chapter 4, Section 4.4.2.  
 
5.4.2.2 Flavanol treatments 
Flavanol treatments were prepared in Universal tubes prior to adding them to the 
confluent monolayers. Appropriate flavanol concentrations were added to a Universal 
tube containing basal medium and VEGF (25 ng/ml) and incubated at room 
temperature for 5 min. Control treatments were prepared in the same manner. HUVEC 
confluent monolayers were washed twice with warm phosphate buffered saline (PBS), 
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to remove any residual growth factors, and prepared treatments were added to the 
respective wells and incubated for 5 min at 37 ºC under a humidified atmosphere 
containing 5 % CO2. 
 
5.4.3 VEGFR-2 phosphorylation measurement 
The extraction of protein was the same method as described in Chapter 4, Section 
4.4.6 and the measurement of phosphorylated VEGFR-2 by ELISA and Western blot 
followed the same procedure as described in Chapter 4, Section 4.4.7.  
 
5.4.4 Removal of unbound polyphenol from VEGF 
5.4.4.1 Removal of unbound polyphenol from VEGF using dialysis 
Unbound polyphenol was removed from VEGF using a Slide-A-Lyzer MINI Dialysis Unit 
(Thermo Scientific) with a molecular weight cut off (MWCO) of 3500 Da. The 
concentration used for dialysis was increased by a factor of 56 from the control 
samples (the concentration in the control samples were 25 ng/ml VEGF and 0.3 µM 
apple procyanidin fraction dp 3.9 or dp 4). Thus the starting concentration of VEGF was 
1400 ng/ml and 16.8 µM for apple procyanidin fraction dp 3.9 or dp 4. The samples 
were prepared with distilled water and incubated for 5 min, at room temperature, in an 
eppendorf prior to transferring to the dialysis unit. The samples were dialysed, in one 
litre of distilled water, for 2 h at room temperature. The retentate was then diluted in 
4 ml of basal medium to give a final concentration of VEGF of 25 ng/ml. The samples 
were used to treat HUVECs for the determination of phosphorylated VEGFR-2 as 
described in Section 5.4.2. 
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5.4.4.2 Removal of unbound polyphenol from VEGF using centrifugal 
concentration 
Unbound polyphenol was removed from VEGF using a MICROCON spin column 
(MICROCON) with a MWCO of 3000 Da. The concentration used for the spin column 
experiment was increased by a factor of 20 compared to the control samples (the 
concentration in the control samples were 25 ng/ml VEGF and 0.3 µM apple 
procyanidin fraction dp 3.9 or dp 4). Thus the starting concentration of VEGF was 
500 ng/ml and 6 µM for apple procyanidin fraction dp 3.9 or dp4. The samples were 
prepared in basal medium and were incubated for 5 min, at room temperature, prior to 
transferring to the spin column. The solution was concentrated 20 fold by 
centrifugation, the concentrate was then diluted with basal medium and concentration 
was repeated. This process was repeated for a total of three times. The concentrate 
was diluted to the starting volume and then diluted in 4 ml of medium to give a final 
concentration of VEGF of 25 ng/ml. The samples were used to treat HUVECs for the 
determination of phosphorylated VEGFR-2 as described in Section 5.4.2. 
 
5.4.5 SDS-PAGE  
For reducing conditions, sample preparation included incubating 10 ng VEGF 
(761.61 ng/ml) with 30.5 µM apple procyanidin fraction dp 4 or EGCG for 5 min at room 
temperature. NuPAGE LDS Sample Buffer (4x) and DTT were added and the samples 
were denatured at 70 ºC for 10 min. Electrophoresis was carried out in a NuPAGE 
Novex 10% Bis-Tris gel using NuPAGE MES SDS Running Buffer (20x) and NuPAGE 
antioxidant. Proteins were transferred on to a 0.45 µM nitrocellulose membrane. 
Membranes were blocked with 5 % skimmed milk in TBST for 1 h at room temperature. 
The membrane was washed with TBST and followed by an overnight incubation with 
the primary antibody (25 µl VEGF rabbit polyclonal antibody in 5 ml of 5% BSA in 
TBST) at 4 ºC. The membrane was washed with TBST and incubated with the 
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secondary antibody (10 µl anti-rabbit IgG, HRP-linked antibody in 10 ml of 5 % 
skimmed milk in TBST) for 1 h at room temperature. The membranes were developed 
using Pierce SuperSignal West Pico chemiluminescent substrate and the fluorescence 
intensity was measured using a BioRad Fluor-S MultiImager.  
 
The same procedure was used for non-reducing conditions with the exception that no 
DTT or NuPAGE antioxidant were added. Also, 20 ng of VEGF (1273.8 ng/ml) and 
51 µM of apple procyanidin fraction dp 4 or EGCG was used.  
 
5.4.6 Native-PAGE 
VEGF (100 ng or 7843 ng/ml) was incubated with 314 µM of either apple procyanidin 
fraction dp 4 or EGCG for 5 min before the addition of 10 % n-dodecyl-β-D-maltoside 
(DMM) (final concentration 0.001 %) and NativePAGE 5 % G-250 Sample Buffer (4x). 
Electrophoresis was carried out in a NativePAGE Novex 4-16 % Bis-Tris Gel using 
anode buffer (NativePAGE Running Buffer [20x] plus distilled water) and cathode buffer 
(NativePAGE Running Buffer [20x], NativePAGE cathode buffer [20x] and distilled 
water). Before protein transfer on to a polyvinylidene fluoride (PVDF) membrane, the 
gel was incubated in 0.1 % sodium dodecyl sulphate (SDS) in order to create enough 
charge so that the proteins will migrate towards the anode side, and will not denature 
the proteins. Proteins were then fixed on the PVDF membrane by incubating the 
membrane in 20 ml of 8 % acetic acid for 15 min. Membranes were blocked with 5 % 
skimmed milk in TBST for 1 h at room temperature. The membrane was washed with 
TBST and followed by an overnight incubation with the primary antibody (25 µl VEGF 
rabbit polyclonal antibody in 5 ml of 5 % BSA in TBST) at 4 ºC. The membrane was 
washed with TBST and incubated with the secondary antibody (10 µl anti-rabbit IgG, 
HRP-linked antibody in 10 ml of 5 % skimmed milk in TBST) for 1 h at room 
temperature. The membranes were developed using Pierce SuperSignal West Pico 
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chemiluminescent substrate and the fluorescence intensity was measured using a 
BioRad Fluor-S MultiImager.  
 
5.4.7 Isoelectric focusing (IEF) 
VEGF (100 ng or 6666.66 ng/ml) was incubated with 267 µM of either apple 
procyanidin fraction dp 4 or EGCG for 5 min before the addition of Novex IEF Sample 
Buffer pH 3-10 (2x). Electrophoresis was carried out in a Novex pH 3-10 IEF gel using 
Novex IEF Anode Buffer and Novex IEF Cathode Buffer pH 3-10 (10x). The gel was 
equilibrated in a chilled solution of 0.7 % acetic acid for 10 min and then transferred on 
to a PVDF membrane. Membranes were blocked with 5 % skimmed milk in TBST for 
1 h at room temperature. The membrane was washed with TBST and followed by an 
overnight incubation with the primary antibody (25 µl VEGF rabbit polyclonal antibody 
in 5 ml of 5 % BSA in TBST) at 4 ºC. The membrane was washed with TBST and 
incubated with the secondary antibody (10 µl anti-rabbit IgG, HRP-linked antibody in 
10 ml of 5 % skimmed milk in TBST) for 1 h at room temperature. The membranes 
were developed using Pierce SuperSignal West Pico chemiluminescent substrate and 
the fluorescence intensity was measured using a BioRad Fluor-S MultiImager.  
 
5.4.8 Proteolysis and peptide sequencing by mass spectrometry 
VEGF (10 µg) was diluted in 20 mM ammonium bicarbonate (pH 7.0) to give a final 
concentration of 1.4 µg/ml. The solution was then aliquoted into seven eppendorfs; two 
vials were treated as VEGF controls (samples 1 and 2), two were treated with 56 µM 
apple procyanidin fraction dp 4 (samples 3 and 4) and two were treated with 56 µM 
EGCG (samples 5 and 6). The concentration of VEGF used was 56 times greater than 
what was used for cell treatments (25 ng/ml). In order to maintain the VEGF to 
polyphenol concentration ratio, the concentrations of apple procyanidin fraction dp 4 
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and EGCG used to treat the VEGF samples were also increased by a factor of 56. The 
samples were incubated for 19 h at 4 ºC and then at room temperature for 2 h. After 
incubation, the samples were dialysed for 2 h, against one litre of 20 mM ammonium 
bicarbonate (pH 7.0), in a Slide-A-Lyzer MINI dialysis unit. A small portion of the 
sample was diluted in basal medium to give a final concentration of VEGF of 25 ng/ml. 
The samples were used to treat HUVECs for the determination of phosphorylated 
VEGFR-2 as described in Section 5.4.2. The remainder of the samples were 
freeze-dried.  
 
Once the samples were freeze-dried they were given to the IFR Proteomics Platform 
for sample preparation for analysis by mass spectrometry using the LTG Orbitrap 
(Thermo). Briefly, samples were dissolved in protein digest buffer (8M urea, 100 mM 
tris buffer pH 8.0 and 5 mM DTT) and incubated at room temperature for 2 h. Alkylation 
buffer (150 mM iodoacetamide) was added to samples 2, 4 and 6 and distilled water 
was added to samples 1, 3 and 5 and incubated in the dark for 20 min. Enzyme buffer 
(10 ml of 50 mM NH4HCO3 pH 7.8 and 100 µl of 1M CaCl2) was added to each sample 
to give a final urea concentration of 1 M. Trypsin or trypsin plus chymotrypsin were 
added to each sample and incubated at 28 °C overnight. A zip tip was then used to 
clean up the peptides for mass spectrometry using the OMIX protocol (Varian). The 
samples were then centrifuged to dryness using the speed vacuum and subsequently 
diluted in 0.5 % formic acid and analysed on the LTQ Orbitrap. The data derived from 
the LTQ Orbitrap were analysed and interpreted by the IFR Proteomics Platform and 
the resulting sequence information was received.  
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5.5 Results 
5.5.1 VEGF activity is not recovered from the VEGF-polyphenol 
complex following dialysis and dilution 
The first question to be asked in the investigation of the nature of the interaction 
between VEGF and polyphenols was whether the polyphenol could be separated from 
the VEGF-polyphenol complex by dialysis or dilution. If the interaction between VEGF 
and the polyphenol is non-covalent and does not involve a change in protein 
conformation resulting in tight non-covalent binding, then the polyphenol should be 
removed by these methods and the VEGF activity recovered.  
 
All experiments in which VEGF activity was being assessed included a no VEGF 
treatment (vehicle only) and a VEGF only treatment as controls. No phosphorylation of 
VEGFR-2 was observed in vehicle only treated cells while untreated VEGF was able to 
induced VEGFR-2 phosphorylation (Figure 5.4, 5.5 and 5.6). Incubation of apple 
procyanidin fraction dp 3.9 or dp 4 (0.3 µM) with VEGF reduced the ability of VEGF to 
induce VEGFR-2 phosphorylation compared to the VEGF control. An observed 30 % to 
70 % inhibition of VEGF-induced VEGFR-2 phosphorylation was observed with the 
apple procyanidin fraction dp 3.9 and dp 4 treatments which is in keeping with the IC50 
of apple procyanidin fraction dp 3.9 (0.32 µM) and apple procyanidin fraction dp 4 
(0.3 µM) (Chapter 4, Figure 4.13).  
 
After a 2.5 h incubation at room temperature (the period of time used for dialyzing and 
diluting) untreated VEGF still retained its VEGFR-2 activating activity, but 0.3 µM apple 
procyanidin dp 4-treated VEGF was now able to completely inhibit VEGFR-2 
phosphorylation (Figure 5.6). Repeated concentration and dilution of VEGF with a spin 
column reduced the activity of VEGF by approximately 50 % relative to the control 
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(Figure 5.6). This loss of activity was most likely due to non-specific binding of VEGF to 
the spin column membrane, as VEGF still retained its activity after incubation at room 
temperature for 2.5 h. No reduction in VEGF activity was observed when VEGF was 
dialysed. Therefore, based on these results dialysis is a better method in retaining the 
VEGFR-2 activating activity of VEGF.  
 
VEGF-induced VEGFR-2 phosphorylation was completely inhibited in apple 
procyanidin fraction dp 3.9-treated VEGF dialysed and concentrated samples (analysis 
by Western blot; Figure 5.4 and 5.5). Dialysis of apple procyanidin fraction dp 4-treated 
VEGF samples resulted in a 50 % inhibition of VEGF-induced VEGFR-2 
phosphorylation, whereas concentrating the apple procyanidin fraction dp 4-treated 
VEGF samples completely inhibited VEGF-induced VEGFR-2 phosphorylation 
(analysis by ELISA, Figure 5.6). The difference in the amount of retained VEGF activity 
is due to the length of incubation of the polyphenol and protein during the experimental 
procedures. In the case of dialysis, the un-bound polyphenol would have been 
removed in the first 10 min of the dialysis and no further complex formation between 
the polyphenol and protein occurs. Therefore the apple procyanidin fraction dp 4-
treated VEGF samples retained 50 % of the activity of VEGF because the IC50 
concentration was used. One cycle of concentration of VEGF through the use of spin 
columns takes approximately 1 h. Therefore, the polyphenol and VEGF have a longer 
incubation period and further complex formation between the polyphenol and VEGF 
can occur during this time. Thus, VEGF-polyphenol complex formation is dependent on 
the length of incubation.  
 
These results demonstrate that the interaction between VEGF and apple procyanidin 
fraction dp 3.9 and dp 4 is not a standard non-covalent interaction. The interaction 
involved between the VEGF-polyphenol complex may therefore be a covalent 
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interaction or a strong non-covalent interaction which results on the conformational 
change in the protein.  
 
 
Figure 5.4: Inhibition of the VEGFR-2 activation activity of VEGF by apple procyanidin 
fraction dp 3.9 is retained after removal of unbound polyphenol using a centrifugal 
membrane concentrator device. 
HUVECs were treated with pre-incubated basal medium containing 25 ng/ml VEGF and 0.3 µM apple 
procyanidin fraction dp 3.9 or samples prepared by concentrating by spin column for 5 min. For the spin 
column samples, VEGF (500 ng/ml) was incubated with or without apple procyanidin fraction dp 3.9 (6 µM) 
in basal medium for 5 min at room temperature. The solution was concentrated 20 fold by centrifugation 
using a MICROCON spin column. The concentration solution was diluted with basal medium and 
re-constituted. This process was repeated for a total of three times. Finally the concentrate was diluted to 
give a final concentration of VEGF of 25 ng/ml.  The treatments were added to HUVECs and incubated for 
5 min, the cells were then lysed and the proteins were separated on a NuPAGE gel and probed for the 
presence of phosphorylated VEGFR-2 at the tyrosine 1175 site and for total VEGFR-2 levels. (A) Western 
blot data; (B) semi-quantitative data. Bars represent means ± standard deviation expressed as a 
percentage of the stimulated cells. ** p <0.01 compared to the stimulated cells (stimulated = 25 ng/ml 
VEGF). The data presented are representative of two independent experiments.  
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Figure 5.5: Inhibition of the VEGFR-2 activation activity of VEGF by apple procyanidin 
fraction dp 3.9 is retained after removal of unbound polyphenol using a dialysis 
membrane. 
HUVECs were treated with pre-incubated basal medium containing 25 ng/ml VEGF and 0.3 µM apple 
procyanidin fraction dp 3.9 or samples prepared by concentrating by dialysis for 5 min. For the dialysed 
samples, VEGF (1400 ng/ml) was incubated with or without apple procyanidin fraction dp 3.9 (16.8 µM) in 
basal medium for 5 min at room temperature. The solution was dialysed using a Slide-A-Lyzer MINI 
dialysis unit. The retentate was diluted to give a final concentration of VEGF of 25 ng/ml. The treatments 
were added to HUVECs and incubated for 5 min, the cells were then lysed and the proteins were 
separated on a NuPAGE gel and probed for the presence of phosphorylated VEGFR-2 at the tyrosine 
1175 site and for total VEGFR-2 levels. (A) Western blot data; (B) semi-quantitative data. Bars represent 
means ± standard deviation expressed as a percentage of the stimulated cells. *** p <0.001 compared to 
the stimulated cells (stimulated = 25 ng/ml VEGF). The data presented are representative of two 
independent experiments. 
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Figure 5.6: Inhibition of the VEGFR-2 activation activity of VEGF by apple procyanidin 
fraction dp 3.9 is retained after removal of unbound polyphenol using a centrifugal 
membrane concentrator device and a dialysis membrane. 
HUVECs were treated with pre-incubated basal medium containing 25 ng/ml VEGF and 0.3 µM apple 
procyanidin fraction dp 4 or samples prepared by concentrating by spin column or dialysis for 5 min. For 
the spin column samples, VEGF (500 ng/ml) was incubated with or without apple procyanidin fraction dp 4 
(6 µM) in basal medium for 5 min at room temperature. The solution was concentrated 20 fold by 
centrifugation using a MICROCON spin column. The concentration solution was diluted with basal medium 
and re-constituted. This process was repeated for a total of three times. Finally the concentrate was diluted 
to give a final concentration of VEGF of 25 ng/ml. For the dialysed samples, VEGF (1400 ng/ml) was 
incubated with or without apple procyanidin fraction dp 4 (16.8 µM) in basal medium for 5 min at room 
temperature. The solution was dialysed using a Slide-A-Lyzer MINI dialysis unit. The retentate was diluted 
to give a final concentration of VEGF of 25 ng/ml. The treatments were added to HUVECs and incubated 
for 5 min, the cells were then lysed and the amount of phosphorylated VEGFR-2 was quantified by a 
phospho-VEGFR-2 (Tyr1175) ELISA. Bars represent means ± standard deviation expressed as a 
percentage of the stimulated cells. ** p <0.01, *** p <0.001 compared to the stimulated cells; ††† p < 0.001 
compared to VEGF (spin column); and ‡‡‡ p < 0.001 compared to VEGF (dialysis). Unstimulated = no 
VEGF, VEGF = 25 ng/ml VEGF, incubation = 2.5 h. The data presented are representative of duplicate 
biological and duplicate technical replicates of one independent experiment. 
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5.5.2 Possible precipitation of VEGF by polyphenols 
The inhibition of VEGF-induced VEGFR-2 phosphorylation may be the result of the 
aggregation of the VEGF protein by the polyphenol. Therefore experiments were 
conducted in order to investigate the possible precipitation of the VEGF-polyphenol 
complex.  
 
In order to assess whether precipitation occurs as a result of VEGF-polyphenol 
complex formation, 25 ng/ml of VEGF was incubated with either the vehicle, 1 µM 
apple procyanidin fraction dp 4, EGCG or epicatechin in a volume of 2 ml of basal 
medium for 5 min at room temperature. The solution was then centrifuged so that any 
insoluble protein would be located in the pellet and the soluble protein would be located 
in the supernatant. A pellet was not visible in any of the samples; therefore a small 
percentage (~ 100 µl) of the supernatant was retained in order to ensure the pellet was 
not removed. HUVECs were then treated with the supernatant and the reconstituted 
pellets for 5 min.  
 
In the non-polyphenol treated VEGF samples, the majority of the VEGF was located in 
the supernatant and a small percentage was located in the pellet as observed by the 
darker band for VEGFR-2 phosphorylation in the supernatant samples (Figure 5.7). 
The phosphorylation of VEGFR-2 in the VEGF pellet sample was almost certainly due 
to the presence of the residual supernatant.  
 
VEGF-induced VEGFR-2 phosphorylation was inhibited by apple procyanidin fraction 
dp 4 and EGCG in the supernatant and pellet samples (Figure 5.7). Epicatechin, a 
structurally similar polyphenol to apple procyanidin fraction dp 4 and EGCG, which was 
shown to be ineffective in inhibiting VEGF-induced VEGFR-2 phosphorylation 
Chapter 5 
 
 
208 
 
(Chapter 4, Section 4.5.3) did not cause VEGF to precipitate upon centrifugation. The 
majority of VEGF was located in the supernatant and a small percentage of VEGF was 
located in the pellet due to the presence of residual supernatant (Figure 5.7).  
 
 
Figure 5.7: VEGF precipitation test of apple procyanidin fraction dp 4, EGCG and 
epicatechin. 
HUVECs were treated with pre-incubated basal medium containing 25 ng/ml VEGF and 1 µM apple 
procyanidin fraction dp 4 (A & B), EGCG (C & D) or epicatechin (C & D) for five min or with samples 
prepared for the precipitation test. For the precipitation test samples, VEGF (25 ng/ml) was incubated with 
or without apple procyanidin fraction dp 4 (1 µM), EGCG (1 µM), or epicatechin (1 µM) in basal medium for 
5 min and centrifuged for 120 min at 5000 g. The supernatants were collected for the treatments and the 
pellets were re-suspended in 4 ml of basal medium. The cells were lysed and the proteins were separated 
on a NuPAGE gel and probed for the presence of phosphorylated VEGFR-2 at the tyrosine 1175 site and 
for total VEGFR-2 levels. (A & C) Western blot images; (B & D) semi-quantitative data from Western blots. 
The data presented are representative of two independent experiments.  
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However as the cell assay used determines the activity of VEGF through the 
phosphorylation of VEGFR-2, it is unable to detect the location of VEGF in the apple 
procyanidin fraction dp 4 and EGCG treated VEGF samples as these treatments inhibit 
the activity of VEGF. Therefore in order to assess whether the VEGF was located in 
the supernatant or the pellet of the apple procyanidin fraction dp 4 or EGCG treated 
VEGF, the detection of VEGF protein was done using Western blotting (i.e. antibody 
detection of VEGF).  
 
One hundred nanograms of VEGF protein was either incubated with the vehicle 
(0.1 % DMSO) or 350 µM apple procyanidin fraction dp 4 or EGCG for 5 min. The 
experiment was conducted in sterile water and the use of higher concentrations of 
VEGF and polyphenols were required for VEGF antibody detection. After incubation, 
the samples were centrifuged so that any insoluble protein would be located in the 
pellet and the soluble protein would be located in the supernatant. A pellet was not 
visible in any of the samples; therefore a small percentage of the supernatant was 
retained in order to ensure the pellet was not removed. The pellet was then 
reconstituted with water and the samples were run on a SDS-PAGE gel prior to 
antibody detection.  
 
Under reducing conditions, VEGF and apple procyanidin fraction dp 4 treated VEGF 
samples have a molecular weight of approximately 21 kDA (Figure 5.8). After 
centrifugation of the VEGF sample, VEGF was located in the pellet and no VEGF was 
located in the supernatant. This same observation was seen in the apple procyanidin 
fraction dp 4 or EGCG treated VEGF samples. The location of VEGF in the pellet of the 
non-polyphenol-treated VEGF and the polyphenol-treated VEGF samples may be due 
to the high concentrations of VEGF that were used or the poor solubility of VEGF in 
sterile water. Therefore, these experiments have not demonstrated whether or not 
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precipitation of the VEGF-polyphenol complex occurs and further analysis using 
different buffers (e.g. ammonium bicarbonate) may provide evidence to show whether 
the complex is precipitable.   
 
 
Figure 5.8: SDS-PAGE gel (reducing conditions) testing whether polyphenol (apple 
procyanidin fraction dp 4 or EGCG) treatments precipitate the protein (VEGF). 
VEGF (100 ng) was incubated with or without 304.6 µM apple procyanidin fraction dp 4 or EGCG for 5 min 
and then either loaded onto the gel or centrifuged at 13000 x g for 30 min prior to the completion of the 
electrophoresis method described in the Section 5.4.5. This data is representative of two independent 
experiments.  
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5.5.3 Binding interactions between apple procyanidin fraction dp 4 
and EGCG investigated by SDS-PAGE, native-PAGE and isoelectric 
focusing gels 
The effect of incubating VEGF with polyphenols on VEGF gel electrophoretic properties 
was investigated. First, apple procyanidin fraction dp 4 and EGCG treated VEGF was 
analysed using sodium dodecylsufate polyacrylamide gel electrophoresis (SDS-PAGE). 
SDS-PAGE gels separate proteins according to their molecular weight under 
denaturing conditions. SDS is the denaturing agent used and it denatures and unfolds 
the proteins by wrapping around the hydrophobic portions of the protein. The SDS-
PAGE gels were run under both reducing and non-reducing conditions. Under reducing 
conditions, DTT is included which is a strong reducing agent that cleaves protein 
disulfide bonds (cysteine-cysteine bonds). DTT therefore will cleave disulfide bonds in 
the VEGF protein, and cause the reduction of VEGF from a dimer to a monomer.  
 
Under reducing conditions, VEGF has an apparent molecular weight of 21 kDa 
(Figure 5.9A). In the apple procyanidin fraction dp 4 and EGCG treated VEGF samples, 
the apparent molecular weight of the samples was also 21 kDa. Under non-reducing 
conditions, VEGF has an apparent molecular weight of 40 kDa (Figure 5.9B). In the 
apple procyanidin fraction dp 4 and EGCG treated VEGF samples the apparent 
molecular weight of the samples was also 40 kDa. Therefore the polyphenol is not 
causing a modification of the VEGF protein mass under reducing or non-reducing 
conditions and the interaction between VEGF and the polyphenol is most likely not due 
to covalent binding.  
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Figure 5.9: SDS-Page gels of control (VEGF) and treatments (VEGF and apple 
procyanidin fraction dp4 or EGCG). 
VEGF (10 ng) was incubated for 5 min with or without 30.5 µM apple procyanidin fraction dp 4 or EGCG 
prior to reduction and electrophoresis procedure described in Section 5.4.5 (A); or VEGF (20 ng) was 
incubated with or without 51 µM apple procyanidin fraction dp 4 or EGCG for 5 min prior to the 
electrophoresis procedure described in Section 5.4.5 (B).  This data is representative of three independent 
experiments.  
 
Next, the effects of polyphenol treatments on VEGF were examined under native-
PAGE conditions. Native-PAGE gels are preformed under native or non-denaturing 
conditions that maintain the native protein conformation, subunit interaction and 
biological activity. Proteins on native-PAGE gels are separated based on their charge 
to mass ratios. Native-PAGE gels are also run under milder conditions than SDS-
PAGE gels and therefore strong non-covalent binding of the polyphenol to the protein 
may be retained during migration through the gel. The native-PAGE gel results showed 
diffuse bands covering a large molecular weight range that were not suitable for 
detecting small changes in the mass ratios (Figure 5.10).  
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Figure 5.10: Native-PAGE gel of controls (VEGF) and treatments (VEGF and apple 
procyanidin fraction dp 4 or EGCG). 
VEGF(100 ng) was incubated with or without 313.7 µM apple procyanidin fraction dp 4 or EGCG for 5 min 
prior to the electrophoresis procedure described in Section 5.4.6. This data is representative of three 
independent experiments.  
 
The last method used to investigate the effect of polyphenol treatment on VEGF gel 
migration properties was isoelectric focussing (IEF). IEF, similar to native-PAGE, is run 
under milder conditions to SDS-PAGE gels but will detect changes in the pI of a 
protein. The pI is the pH at which a protein has no net charge and will not migrate 
further in an electric field. A dark band was detected in lane 3 (100 ng VEGF + dp 4) 
and faint bands were observed in lane 4 (100 ng VEGF), lane 5 (100 ng VEGF + dp 4) 
and lane 6 (100 ng VEGF, Figure 5.11). The pI range of the pH 3-10 IEF gels used was 
between 3.5 and 8.5 and the pI of VEGF has been reported to be between 8 and 8.5 
(Ferrara et al., 1991; Patterson et al., 2010). Therefore VEGF is located at the upper 
range limit of the gel. Since the pI of VEGF is at the upper range limit of the gel, the 
majority of the VEGF appears to have migrated off the gel. Since a source of higher pH 
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range IEF gels could not be identified, it was not possible to establish whether or not 
the polyphenol treatment of VEGF affected the pI of VEGF.  
 
 
Figure 5.11: IEF gel of controls (VEGF) and treatments (VEGF and apple procyanidin 
fraction dp 4 or EGCG). 
VEGF (100 ng) was incubated with or without 266.8 µM apple procyanidin fraction dp 4 or EGCG prior to 
the electrophoresis method described in Section 5.4.7. This data is representative of two independent 
experiments.  
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5.5.4 Pre-incubation with 0.2 µM apple procyanidin fraction dp 4 
inhibits VEGF induced VEGFR-2 phosphorylation in a time 
dependent manner.   
In Section 5.5.1 it was shown that incubating VEGF with 0.3 µM apple procyanidin 
fraction dp 4 (its IC50) for 2.5 h resulted in complete inhibition of VEGF activity (no 
induction of VEGFR-2 phosphorylation observed in HUVECs). Since a 5 min incubation 
of the apple procyanidin fraction dp 4 with VEGF only resulted in an approximate 50 % 
inhibition of VEGF activity, it appeared that the inhibition of VEGF activity was time-
dependent. In order to investigate the kinetics of the inhibition of VEGF activity by 
apple procyanidin fraction dp 4, a time course was conducted. 
 
Apple procyanidin fraction dp 4 (0.2 µM) was incubated with 25 ng/ml VEGF in basal 
medium for 5, 10, 15, 30, 60 and 120 min prior to cell treatment. A concentration of 
0.2 µM was used because it is below the IC50 of apple procyanidin fraction dp 4 and 
therefore changes in VEGF activity could be monitored over time. The treatment of 
VEGF with 0.2 µM apple procyanidin fraction dp 4 resulted in an inhibition of VEGF-
induced VEGFR-2 phosphorylation in a time-dependent manner (Figure 5.12). 
 
A 5 min pre-incubation of VEGF and apple procyanidin fraction dp 4 resulted in a 30 % 
inhibition of VEGF-induced VEGFR-2 phosphorylation and after a 10 min pre-
incubation, no further inhibition of VEGFR-2 phosphorylation occurred. A pre-
incubation period of 15 min resulted in a 70 % inhibition of VEGFR-2 phosphorylation 
and no further changes in the amount of phosphorylated VEGFR-2 occurred after a 
30 min incubation. A 60 min pre-incubation reduced the amount of phosphorylated 
VEGFR-2 by 75 % and a 120 min pre-incubation resulted in a 90 % inhibition of VEGF-
induced VEGFR-2 phosphorylation. A complete inhibition of VEGFR-2 phosphorylation 
was not achieved during this time course.   
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Figure 5.12: Apple procyanidin fraction dp 4 inhibits VEGF induced VEGFR-2 
phosphorylation in a time dependent manner. 
VEGF (25 ng/ml) and 0.2 µM apple procyanidin fraction dp 4 were pre-incubated in basal medium for 5, 
10, 15, 30, 60 and 120 min. HUVECs were then treated for 5 min with the pre-incubated basal medium 
containing VEGF and apple procyanidin fraction dp 4. The cells were lysed and the amount of 
phosphorylated VEGFR-2 was quantified by a phospho-VEGFR-2 (Tyr1175) ELISA. Bars represent means 
± standard deviation expressed as a percentage of the stimulated cells. *** p <0.001 compared to the 
stimulated cells. The data presented is representative of one independent experiment of biological 
duplicates and technical duplicates. 
 
The data presented in Figure 5.12 appears to show that the inhibition of VEGF activity 
is not linear. Therefore the data were then presented as a scatter plot to determine 
whether the data fits a nonlinear regression model (Figure 5.13). However, the data 
presented in Figure 5.13 show that a nonlinear regression model is not a good fit of the 
data as the 10 min and 15 min time points do not fit the curve.  
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Figure 5.13: Apple procyanidin fraction dp 4 inhibits VEGF induced VEGFR-2 
phosphorylation in a time dependent manner (nonlinear regression fit of the data from 
Figure 5.12). 
 
Further evidence that the kinetic data does not fit a first order reaction model was 
obtained by log transforming the data (Figure 5.14A). By visual inspection, a linear 
model did not fit the data as the data were not normally distributed along the line. 
However, the transformation of the data indicated that a multi-stage binding process 
might occur between the polyphenol and VEGF. The first stage in the binding process 
appears to be rapid and occurs between 0 and 15 min where a 30 % reduction in 
VEGF activity is observed (Figure 5.14B). The second stage, which is slower, occurs 
between 15 min and 120 min where the VEGF activity is reduced from 70 % to 10 % 
(Figure 5.14B). This data suggest that the interaction between VEGF and apple 
procyanidin fraction dp 4 is not a simple process and may involve the conformational 
change of the VEGF protein by apple procyanidin fraction dp 4.   
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Figure 5.14: Apple procyanidin fraction dp 4 inhibits VEGF induced VEGFR-2 
phosphorylation in a time dependent manner (log transform of the data from Figure 5.12).  
 
From the log transform of the data, a rate constant can be determined. A rate constant 
describes the speed of which a reaction occurs. While the determination of the rate 
constant in this instance is only approximate due to the small data set, the reaction in 
the first stage of the binding process has a rate constant of 1.29 x 10-3 s-1 and has a 
half-life of 533 sec (8.9 min) (Figure 5.14B). The reaction in the second stage of the 
binding process has a rate constant of 0.18 x 10-3 s-1 and has a half-life of 3850 sec 
(64.2 min) (Figure 5.14B). This confirms that the first stage occurs at a quicker rate 
than the second stage of the binding process.  
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5.5.5 Analysis of VEGF-polyphenol complexes using mass 
spectrometry  
The final approach used to assess the nature of the interaction between polyphenols 
(apple procyanidin fraction dp 4 or EGCG) and VEGF involved the use of mass 
spectrometry. Mass spectrometry was used to obtain sequence data of VEGF and to 
determine whether there were any modifications in the VEGF sequence after 
polyphenol treatment. VEGF (1.4 µg/ml) was incubated with 56 µM of either apple 
procyanidin fraction dp 4 or EGCG for 21 h and then dialysed for 2 h to remove any 
excess polyphenol. In order to confirm the VEGF activity status of the control and 
treated VEGF samples, VEGF-induced VEGFR-2 phosphorylation was assessed by 
cell culture. The un-treated VEGF samples induced VEGFR-2 phosphorylation but 
VEGF-induced VEGFR-2 phosphorylation was inhibited in the treatment samples 
(VEGF plus apple procyanidin dp 4 or EGCG) (Figure 5.16A&B and 5.17A&B). After 
confirmation of VEGF activity in the control and treatment samples, VEGF and VEGF 
plus apple procyanidin fraction dp 4 or EGCG samples were run on an Orbitrap mass 
spectrometer to determine whether any modification in the mass of VEGF could be 
detected in the polyphenol treated samples.  
 
The VEGF protein was not detected on the Orbitrap mass spectrometer in its native 
state (data not shown), probably because the molecular weight of VEGF was too large 
to be detected. The enzymatic digestion of VEGF and the polyphenol-treated VEGF 
was therefore required to detect any differences in the sequence of VEGF by Orbitrap 
MS. In the first instance trypsin was used as the enzyme. Trypsin cleaves peptide 
chains at the carboxyl side of the amino acids lysine or arginine except when either is 
followed by proline (Figure 5.15). Using trypsin as the enzyme resulted in an 
approximate 33 % coverage of the VEGF sequence (Figure 5.16C). Because only a 
small percentage of the sequence could be detected after trypsin digestion, it could not 
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be determined whether the polyphenol treatment modified the VEGF sequence. 
However, in the areas of the sequence covered, there was no difference between the 
VEGF-control and VEGF-polyphenol treated samples.  
 
MAEGGGQNHH EVVKFMDVYQ RSYCHPIETL VDIFQEYPDE IEYIFKPSCV 
 
PLMRCGGCCN DEGLECVPTE ESNITMQIMR IKPHQGQHIG EMSFLQHNKC 
 
ECRPKKDRAR QENPCGPCSE RRKHLFVQDP QTCKCSCKNT DSRCKARQLE 
 
LNERTCRCDK PRR 
 
   
Figure 5.15: Amino acids on the VEGF sequence where trypsin and chymotrypsin are 
predicted to cleave the peptide chain. 
The peptide chain cleavages occur on the carboxyl side (the right side) of the marked amino 
acids. Trypsin cleaves after amino acids lysine (K) and arginine (R) except when either is 
followed by proline (P) (cleavage sites marked in red). Chymotrypsin cleaves after amino acids 
tyrosine (Y), tryptophan (W) or phenylalanine (F) (cleavage sites are marked in green).  
 
Therefore in order to get more coverage of the VEGF sequence two enzymes, trypsin 
and chymotrypsin, were used in the digestion. Trypsin cleaves amino acids lysine and 
arginine and chymotrypsin cleaves peptide chains at the carboxyl side of the amino 
acids tyrosine, tryptophan or phenylalanine (Figure 5.15). Using both trypsin and 
chymotrypsin in the digestion process resulted in a greater coverage (approximately 
67 % coverage) than just using trypsin alone (Figure 5.17C). However there are still 
large parts in the VEGF sequence (amino acids 52 – 80, 135 – 147, and 155 – 163) for 
which there is a lack of sequence information. In order to be certain if any modifications 
in the VEGF sequence are occurring with the polyphenol treatment, full coverage of the 
VEGF sequence is required.  
 
However, with the coverage achieved with the trypsin and chymotryspin digestion there 
are parts in the VEGF sequence that can be seen with the VEGF samples but not with 
the polyphenol treated samples. The amino acid region 95 – 105 in the un-treated 
VEGF samples are always detected, however in the polyphenol-treated VEGF 
10 20 30 40 50 
60 70 80 90 100 
110 120 130 140 150 
160 163 
Chapter 5 
 
 
221 
 
samples, sometimes the peptide is observed and sometimes it is not. There are 
inconsistencies in whether this region has been detected. In the apple procyanidin 
fraction dp 4-treated VEGF, the amino acid region was not detectable in the first set of 
data (VEGF + dp 4 [3.1] and [3.2]) and in one measurement of the second data set 
(VEGF + dp 4 [4.1]) while in the second measurement the amino acid regions 100 to 
105 are detectable. In the EGCG-treated VEGF, the amino acid regions 95 – 105 are 
only detectable in one set of the measurements of each data set (VEGF + EGCG [5.1], 
[6.1]). These inconsistencies in the observation of the amino acid regions 95 – 105 are 
most likely due to a detection problem rather than do to a potential modification in the 
protein sequence because the duplicate biological replicates and the duplicate 
technical replicates are not consistent.   
 
 222 
 
 
Treatment VEGF Sequence                           
VEGF (1) MAEGGGQNHH EVVKFMDVYQ RSYCHPIETL VDIFQEYPDE IEYIFKPSCV PLMRCGGCCN DEGLECVPTE ESNITMQIMR IKPHQGQHIG EMSFLQHNKC ECRPKKDRAR QENPCGPCSE RRKHLFVQDP QTCKCSCKNT DSRCKARQLE LNERTCRCDK PRR 
VEGF (2) MAEGGGQNHH EVVKFMDVYQ RSYCHPIETL VDIFQEYPDE IEYIFKPSCV PLMRCGGCCN DEGLECVPTE ESNITMQIMR IKPHQGQHIG EMSFLQHNKC ECRPKKDRAR QENPCGPCSE RRKHLFVQDP QTCKCSCKNT DSRCKARQLE LNERTCRCDK PRR 
VEGF + dp 4 (3) MAEGGGQNHH EVVKFMDVYQ RSYCHPIETL VDIFQEYPDE IEYIFKPSCV PLMRCGGCCN DEGLECVPTE ESNITMQIMR IKPHQGQHIG EMSFLQHNKC ECRPKKDRAR QENPCGPCSE RRKHLFVQDP QTCKCSCKNT DSRCKARQLE LNERTCRCDK PRR 
VEGF + dp 4 (4) MAEGGGQNHH EVVKFMDVYQ RSYCHPIETL VDIFQEYPDE IEYIFKPSCV PLMRCGGCCN DEGLECVPTE ESNITMQIMR IKPHQGQHIG EMSFLQHNKC ECRPKKDRAR QENPCGPCSE RRKHLFVQDP QTCKCSCKNT DSRCKARQLE LNERTCRCDK PRR 
VEGF + EGCG (5) MAEGGGQNHH EVVKFMDVYQ RSYCHPIETL VDIFQEYPDE IEYIFKPSCV PLMRCGGCCN DEGLECVPTE ESNITMQIMR IKPHQGQHIG EMSFLQHNKC ECRPKKDRAR QENPCGPCSE RRKHLFVQDP QTCKCSCKNT DSRCKARQLE LNERTCRCDK PRR 
VEGF + EGCG (6) MAEGGGQNHH EVVKFMDVYQ RSYCHPIETL VDIFQEYPDE IEYIFKPSCV PLMRCGGCCN DEGLECVPTE ESNITMQIMR IKPHQGQHIG EMSFLQHNKC ECRPKKDRAR QENPCGPCSE RRKHLFVQDP QTCKCSCKNT DSRCKARQLE LNERTCRCDK PRR 
Figure 5.16: Partial coverage of the VEGF sequence is detected by LTQ Orbitrap using trypsin as the digestion enzyme. 
VEGF (10 µg) was diluted in 20 mM ammonium bicarbonate (pH 7.0) to give a final concentration of 1.4 µg/ml. The solution was aliquoted into eppendorfs and treated with 
either 56 µM of apple procyanidin dp4 (VEGF + dp4 3 and 4) or EGCG (VEGF + EGCG 5 and 6). The solutions were incubated overnight and then subsequently dialyzed 
against ammonium bicarbonate for 2 h. A portion of the sample was diluted to give a final concentration of 25 ng/ml VEGF and applied to HUVECs for subsequent Western 
Blot determination of VEGFR-2 phosphorylation (A) and the semi-quantitative data (B). The remainder of the sample was freeze-dried and digested, alkylated, treated with 
trypsin and analyzed by LTQ Orbitrap (C). The sample preparation for the mass spectrometry work and the mass spectrometry was done by Fran Mulholland as part of the IFR 
Proteomics Platform.  Detected regions are shown in red.  
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Treatment VEGF Sequence                           
VEGF (1) MAEGGGQNHH EVVKFMDVYQ RSYCHPIETL VDIFQEYPDE IEYIFKPSCV PLMRCGGCCN DEGLECVPTE ESNITMQIMR IKPHQGQHIG EMSFLQHNKC ECRPKKDRAR QENPCGPCSE RRKHLFVQDP QTCKCSCKNT DSRCKARQLE LNERTCRCDK PRR 
VEGF (1) MAEGGGQNHH EVVKFMDVYQ RSYCHPIETL VDIFQEYPDE IEYIFKPSCV PLMRCGGCCN DEGLECVPTE ESNITMQIMR IKPHQGQHIG EMSFLQHNKC ECRPKKDRAR QENPCGPCSE RRKHLFVQDP QTCKCSCKNT DSRCKARQLE LNERTCRCDK PRR 
VEGF (2) MAEGGGQNHH EVVKFMDVYQ RSYCHPIETL VDIFQEYPDE IEYIFKPSCV PLMRCGGCCN DEGLECVPTE ESNITMQIMR IKPHQGQHIG EMSFLQHNKC ECRPKKDRAR QENPCGPCSE RRKHLFVQDP QTCKCSCKNT DSRCKARQLE LNERTCRCDK PRR 
VEGF (2) MAEGGGQNHH EVVKFMDVYQ RSYCHPIETL VDIFQEYPDE IEYIFKPSCV PLMRCGGCCN DEGLECVPTE ESNITMQIMR IKPHQGQHIG EMSFLQHNKC ECRPKKDRAR QENPCGPCSE RRKHLFVQDP QTCKCSCKNT DSRCKARQLE LNERTCRCDK PRR 
VEGF + dp 4 (3) MAEGGGQNHH EVVKFMDVYQ RSYCHPIETL VDIFQEYPDE IEYIFKPSCV PLMRCGGCCN DEGLECVPTE ESNITMQIMR IKPHQGQHIG EMSFLQHNKC ECRPKKDRAR QENPCGPCSE RRKHLFVQDP QTCKCSCKNT DSRCKARQLE LNERTCRCDK PRR 
VEGF + dp 4 (3) MAEGGGQNHH EVVKFMDVYQ RSYCHPIETL VDIFQEYPDE IEYIFKPSCV PLMRCGGCCN DEGLECVPTE ESNITMQIMR IKPHQGQHIG EMSFLQHNKC ECRPKKDRAR QENPCGPCSE RRKHLFVQDP QTCKCSCKNT DSRCKARQLE LNERTCRCDK PRR 
VEGF + dp 4 (4) MAEGGGQNHH EVVKFMDVYQ RSYCHPIETL VDIFQEYPDE IEYIFKPSCV PLMRCGGCCN DEGLECVPTE ESNITMQIMR IKPHQGQHIG EMSFLQHNKC ECRPKKDRAR QENPCGPCSE RRKHLFVQDP QTCKCSCKNT DSRCKARQLE LNERTCRCDK PRR 
VEGF + dp 4 (4) MAEGGGQNHH EVVKFMDVYQ RSYCHPIETL VDIFQEYPDE IEYIFKPSCV PLMRCGGCCN DEGLECVPTE ESNITMQIMR IKPHQGQHIG EMSFLQHNKC ECRPKKDRAR QENPCGPCSE RRKHLFVQDP QTCKCSCKNT DSRCKARQLE LNERTCRCDK PRR 
VEGF + EGCG (5) MAEGGGQNHH EVVKFMDVYQ RSYCHPIETL VDIFQEYPDE IEYIFKPSCV PLMRCGGCCN DEGLECVPTE ESNITMQIMR IKPHQGQHIG EMSFLQHNKC ECRPKKDRAR QENPCGPCSE RRKHLFVQDP QTCKCSCKNT DSRCKARQLE LNERTCRCDK PRR 
VEGF + EGCG (5) MAEGGGQNHH EVVKFMDVYQ RSYCHPIETL VDIFQEYPDE IEYIFKPSCV PLMRCGGCCN DEGLECVPTE ESNITMQIMR IKPHQGQHIG EMSFLQHNKC ECRPKKDRAR QENPCGPCSE RRKHLFVQDP QTCKCSCKNT DSRCKARQLE LNERTCRCDK PRR 
VEGF + EGCG (6) MAEGGGQNHH EVVKFMDVYQ RSYCHPIETL VDIFQEYPDE IEYIFKPSCV PLMRCGGCCN DEGLECVPTE ESNITMQIMR IKPHQGQHIG EMSFLQHNKC ECRPKKDRAR QENPCGPCSE RRKHLFVQDP QTCKCSCKNT DSRCKARQLE LNERTCRCDK PRR 
VEGF + EGCG (6) MAEGGGQNHH EVVKFMDVYQ RSYCHPIETL VDIFQEYPDE IEYIFKPSCV PLMRCGGCCN DEGLECVPTE ESNITMQIMR IKPHQGQHIG EMSFLQHNKC ECRPKKDRAR QENPCGPCSE RRKHLFVQDP QTCKCSCKNT DSRCKARQLE LNERTCRCDK PRR 
Figure 5.17: Two-thirds coverage of the VEGF sequence is obtained by LTQ Orbitrap using trypsin and chymotrypsin as the digestion enzymes. 
VEGF (10 µg) was diluted in 20 mM ammonium bicarbondate (pH 7.0) to give a final concentration of 1.4 µg/ml. The solution was aliquoted into eppendorfs and treated with 
either 56 µM of apple procyanidin dp4 (VEGF + dp 4 3 and 4) or EGCG (VEGF + EGCG 5 and 6). The solutions were incubated overnight and then subsequently dialyzed 
against ammonium bicarbonate for 2 h. A portion of the sample was diluted to give a final concentration of 25 ng/ml VEGF and applied to HUVECs for subsequent Western 
Blot determination of VEGFR-2 phosphorylation (A). (B) is the semi-quantitative data from the Western Blot. The remainder of the sample was freeze-dried and digested, 
alkylated, treated with trypsin and chymotrypsin and analyzed by LTQ Orbitrap (C). The sample preparation for the mass spectrometry work and the mass spectrometry was 
done by Fran Mulholland as part of the IFR Proteomics Platform. Detected regions are shown in red.   
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5.6 Discussion 
The investigation of the interaction between polyphenols and VEGF has shown that (1) 
the VEGF-polyphenol complex formation involves non-covalent interactions; (2) the 
interaction is not a freely reversible dynamic equilibrium; and (3) the kinetic analysis of 
the inhibition of VEGF activity by apple procyanidin fraction dp 4 appeared to show a 
two-phase binding process which is consistent with either the binding of polyphenol at 
more than one site on VEGF or slow tight binding which usually involves a change of 
protein conformation. The investigation of the VEGF-polyphenol complex formation 
was not able to determine (1) whether the polyphenol causes the precipitation of 
VEGF; and (2) whether the VEGF-polyphenol complex formation was due to specific or 
non-specific binding. The amount of available protein was the main limitation of the 
investigation, therefore the experimental techniques applied had to account for the 
limited amount of available protein.  
 
Extensive dialysis and concentration of non-polyphenol treated and polyphenol-treated 
VEGF to remove unbound polyphenols has shown that the interaction between 
polyphenols and VEGF is essentially irreversible and either due to covalent binding 
(Figure 2.2B or D) or a strong non-covalent interaction which is typically the result of a 
protein conformational change (Figure 2.2F). If the interaction between polyphenols 
and VEGF was a simple reversible non-covalent interaction (Figure 2.2A or C), VEGF-
induced VEGFR-2 phosphorylation would be observed in the polyphenol-treated VEGF 
samples that were dialysed or concentrated. A strong non-covalent interaction was also 
favoured by the kinetic analysis of the inhibition of VEGF activity by apple procyanidin 
fraction dp 4 as it suggested that the interaction between VEGF and the polyphenol 
involved a two-stage binding process that either involves the binding of the polyphenol 
to more than one site on the VEGF molecule or the slow tight binding which usually 
involves a change of protein conformation (Figure 5.14). The likelihood of a covalent 
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interaction between VEGF and the polyphenol was not favoured by SDS-PAGE gel 
work or mass spectrometry. The polyphenol-treated VEGF did not cause a change in 
the mass of VEGF under reducing or non-reducing conditions (SDS-PAGE, Figure 5.9) 
or cause any covalent modifications in the VEGF sequence (mass spectrometry, 
Figure 5.16).  
 
Non-covalent interactions between polyphenols and proteins are also favoured by the 
literature (Hagerman et al., 1998; de Freitas and Mateus, 2001; Moini et al., 2001; 
Carvalho et al., 2004; Prigent et al., 2009; Cala et al., 2010). Procyanidins are believed 
to mainly bind to proteins via non-covalent interactions (Prigent et al., 2009). 
Procyanidins contain several groups (e.g. aromatic rings and the carbon-hydrogen 
skeleton of the pyranic ring) which provide numerous sites of potential hydrophobic 
regions to interact with proteins (de Freitas and Mateus, 2001). The aromatic rings of 
procyanidins are uncharged, have a flat surface, are hydrophobic in nature and will 
stack face-to-face with the hydrophobic regions of the exposed pyrrolidine rings of 
PRPs (Carvalho et al., 2004). Flavanols are also hydrophilic in nature due to the phenol 
groups present in the structure (Verstraeten et al., 2003; Hofmann et al., 2006) and 
may therefore also involve hydrophilic interactions. It was previously shown that the 
interaction between PGG and BSA is predominately characterised by hydrophobic 
interactions with weak hydrogen binding while hydrogen binding is the primary 
interaction between EC16-C and BSA  (Hagerman et al., 1998). Procyanidins, from a 
French maritime pine bark extract, bind non-covalently to milk xanthine oxidase and 
involves hydrophobic interactions (Moini et al., 2001). Recently, it was also shown that 
for procyanidin concentrations below the critical micelle concentration involved 
hydrophobic interactions between PRPs and procyanidins whereas procyanidin 
concentrations above the critical micelle concentration involved both hydrophobic and 
hydrophilic interactions (Cala et al., 2010). 
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While procyanidins bind to proteins non-covalently, EGCG can either bind covalently 
(Ishii et al., 2008; Cao et al., 2009) or non-covalently (Jöbstl et al., 2006; Hudson et al., 
2009; Hasni et al., 2011; Kanakis et al., 2011) to proteins. It has been suggested that 
covalent binding is more likely to occur between EGCG and proteins as EGCG is prone 
to oxidation in cell culture and in physiological conditions (Cao et al., 2009). EGCG is 
easily oxidized to form a semiquinone radical that rearranges to an o-quinone at either 
the B ring (gallyl) or the D ring (gallate) and the o-quinone then can react with the 
nucleophilic thiol group of cysteine residues to form adducts (Ishii et al., 2008). 
Irreversible covalent interactions were detected by matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) between EGCG and glyceraldehyde-
3-phosphate dehydrogenase and it was shown that EGCG covalently binds to the 
cysteinyl thiol residues (Ishii et al., 2008). Irreversible covalent interactions were also 
detected by MALDI-TOF between EGCG quinine and arginine, cysteine, methionine 
and α-NH2 of the N-terminus of peptides (Cao et al., 2009). EGCG is also known to 
bind strongly to arginine and aromatic residues (Williamson et al., 2006). Non-covalent 
interactions have also been shown to occur between EGCG and proteins; the EGCG-
BSA and EGCG-reduced and carboxymethyalted κ-casein complex formation involves 
hydrophobic interactions (Hudson et al., 2009) and it has been suggested that the 
increase in entropy, as analysed by single molecule force microscopy, between EGCG 
and β-casein is due to hydrophobic interactions (Jöbstl et al., 2006). The interaction 
between EGCG and casein proteins (Hasni et al., 2011) and EGCG and β-lactoglobulin 
(Kanakis et al., 2011) involved both hydrophobic and hydrophilic interactions and the 
interaction between PGG and BSA was the result of a reversible non-covalent 
interaction (Chen and Hagerman, 2004a). Therefore under different circumstances, 
EGCG may bind covalently or non-covalently to proteins. In the case of VEGF-EGCG 
binding, the data presented in this chapter favours a non-covalent interaction.  
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The data presented in this chapter have shown that the interaction between VEGF and 
polyphenols is a non-covalent irreversible reaction. This is in contrast with the literature 
as the mechanism of reported non-covalent protein-polyphenol complexes has 
generally been regarded as reversible (McManus et al., 1985; Luck et al., 1994; 
Bennick, 2002; Charlton et al., 2002). However as the kinetics analysis of the VEGF 
activity appeared to show a two-phase binding process between VEGF and 
polyphenols, the polyphenol may cause a potential irreversible protein conformational 
change. It has been previously reported that polyphenol-protein binding occurs in three 
stages: (1) polyphenols bind to proteins on multiple sties which causes the physical 
size of the protein to decrease and become more spherical and compact; (2) as the 
polyphenol concentration increases, the polyphenols bound to proteins cross-link 
different protein molecules and dimerization and aggregation occurs; and (3) as more 
polyphenol is added to the solution dimers aggregate together and precipitate out of 
solution (Charlton et al., 2002; Jöbstl et al., 2004). This three-phase binding process 
was observed between EGCG and β-casein (Jöbstl et al., 2004) and EGCG and a 
salivary PRP (Pascal et al., 2008). Polyphenols have also been shown to induce 
conformational changes in proteins. The binding of green tea polyphenols to casein 
proteins resulted in the conformational change of the secondary structure which led to 
the unfolding of the protein (Hasni et al., 2011) and the binding of polyphenols 
(resveratrol, genistein and curcumin) to BSA also resulted in the conformational 
change to BSA and led to the partial unfolding of the protein (Bourassa et al., 2010). 
Whereas the secondary structure alteration of β-lactoglobulin by green tea polyphenols 
resulted in stabilization of the protein structure (Kanakis et al., 2011). The tertiary 
structure of elastase was also shown to undergo a moderate structural loosening upon 
procyanidin complexation (Brás et al., 2010). Therefore the multi-stage binding process 
between VEGF and polyphenols, which involves the conformational change of VEGF, 
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may be a consequence of the binding interaction. Further experimental investigation of 
this is required.  
 
However, as proteins are prone to precipitation by polyphenols, it may be possible that 
the inhibition of VEGF activity is due to the precipitation of the protein. The cellular 
determination of the precipitation of VEGF in this chapter was not an appropriate 
method to detect precipitation because apple procyanidin fraction dp 4 and EGCG 
completely inhibit VEGF-induced VEGFR-2 phosphorylation. However, the treatment of 
VEGF with epicatechin did not lead to protein precipitation. Epicatechin is structurally 
related to apple procyanidin fraction dp 4 and EGCG but does not inhibit VEGF activity. 
The fact that epicatechin does not precipitate VEGF suggests that apple procyanidin 
fraction dp 4 or EGCG may not cause VEGF to precipitate. The detection of the 
location (in the pellet or supernatant) of VEGF and polyphenol-treated VEGF by 
Western blot showed that the VEGF was located in the pellet of the un-treated and 
polyphenol-treated VEGF samples. The location of VEGF in the pellets of the VEGF 
samples is either due to the high concentrations of proteins/polyphenols used or the 
use of sterile water instead of a buffer.   
 
The polyphenol to protein ratio used for the detection of VEGF by Western blot was 
1522:1. This is substantially greater than the polyphenol to protein ratios previously 
reported to cause precipitation of proteins. According to Jöbstl et al. (2004) the onset of 
aggregation occurs at a molar ratio of EGCG to β-casein of about 10:1; aggregation 
between EGCG or PGG and a basic PRP occurs at a molar ratio of 5.5:1 and 0.75:1, 
respectively (Charlton et al., 2002); aggregation between EGCG or condensed tannins 
and PRP occurs at a molar ratio of 80:1 and 0.3:1, respectively (Pascal et al., 2008) 
and aggregation between EC16-C or PGG and BSA occurs at a molar ratio of 2.2:1 and 
21.7:1, respectively (Hagerman et al., 1998). Protein aggregation occurs at low molar 
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ratios of polyphenol to protein because β-casein and basic PRPs have large numbers 
of polyphenol binding sites; β-casein has 35 proline residues and 14 aromatic rings 
(another major polyphenol binding site) while basic PRPs have high affinities for 
polyphenols due to their high proline content (Hagerman and Butler, 1981; Bennick, 
1987; Charlton et al., 2002; Jöbstl et al., 2004). 
 
Although the polyphenol to protein ratio used in this chapter was substantially greater 
than what was previously reported to precipitate proteins in the literature, it is possible 
that VEGF is not being precipitated by the polyphenol as polyphenols can bind strongly 
to certain proteins without causing them to precipitate (Bennick, 2002). Precipitation of 
proteins by polyphenols is also related to the proline content of the protein (Lopez and 
Edens, 2005) and VEGF is not a proline rich protein (contains only 11 proline 
residues). However, the investigation of whether polyphenols precipitate VEGF 
remains inconclusive and further experiments need to be conducted.  
 
Therefore based on the data presented in this chapter, it was shown that VEGF-
polyphenol interactions are a result of a potential irreversible non-covalent interaction 
which may involve a protein conformational change. The data were unable to establish 
whether the polyphenol causes the precipitation of VEGF or whether the interaction 
between VEGF and the polyphenol was due to specific or non-specific binding. 
Therefore, in order to gain a full understanding of the interaction involved between 
VEGF and polyphenols further research is required. Experimental techniques such as 
the titration of polyphenols into proteins as assessed by nuclear magnetic resonance 
can be used to characterise the nature of the interaction (e.g. polyphenol self-
association, peptide/polyphenol self association and analysis of the polyphenol 
association state when bound to the peptide) of protein-polyphenol complexes (Baxter 
et al., 1997; Charlton et al., 2002; Cala et al., 2010). Capillary electrophoresis is 
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another method that can be used to characterise the equilibrium binding 
(association/dissociation) constants between polyphenols and proteins (Papadopoulou 
and Frazier, 2004; Diniz et al., 2008). Both the size and the total number of aggregates 
present in the solution can be detected by dynamic light scattering (Brás et al., 2010). 
The application of surface plasmon resonance can be used to determine whether the 
interaction between VEGF and polyphenols is the result of specific or non-specific 
binding (Douat-Casassus et al., 2009). Non-covalent interactions can also be 
characterised by MALDI-TOF mass spectrometry (Chen and Hagerman, 2004a). 
Fourier transform infrared (Bourassa et al., 2010), circular dichroism (Bourassa et al., 
2010; Brás et al., 2010) and fluorescence quenching (Bourassa et al., 2010; Brás et al., 
2010) spectroscopic methods can be used to analyse the polyphenol binding mode, the 
binding constant and the effects on complexation on protein stability and conformation. 
The potential binding sites can also be determined by applying molecular modelling 
(Bourassa et al., 2010; Brás et al., 2010; Cala et al., 2010). 
 
5.7 Conclusions 
The investigation of the interaction between polyphenols and VEGF has shown that (1) 
the VEGF-polyphenol complex formation involves non-covalent interactions; (2) the 
interaction is not a freely reversible dynamic equilibrium; and (3) the kinetic analysis of 
the inhibition of VEGF activity by apple procyanidin fraction dp 4 appeared to show a 
two-phase binding process which is consistent with either the binding of polyphenol at 
more than one site on the VEGF molecule or slow tight binding which usually involves 
a change of protein conformation. The amount of available protein was the main 
limitation of the investigation, therefore the experimental techniques applied had to 
account for the limited amount of available protein. Further investigation (with a larger 
supply of protein) is essential in gaining a full understanding of how polyphenols 
interact with VEGF and inhibit VEGF activity.   
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Chapter 6 : Investigation of gene expression changes 
induced by apple procyanidin fraction dp 4 and VEGF 
treatments using whole genome arrays  
6.1 Abstract  
Data presented in Chapter 4 has shown that apple procyanidin fraction dp 4 inhibits 
VEGF-induced VEGFR-2 phosphorylation at low concentrations. Because apple 
procyanidin fraction dp 4 treatments were shown to completely inhibit VEGF-induced 
activation of the VEGFR-2 receptor, and VEGFR-2 activation is thought to be 
responsible for the majority of VEGF-mediated effects in vascular endothelial cells, it 
was postulated that apple procyanidin fraction dp 4 treatment would block all VEGF-
induced changes in vascular endothelial cells. However, the polyphenol is likely to also 
interact with other receptors, membranes and possibly other cell components such as 
intracellular enzymes. In order to (1) determine if apple procyanidin fraction dp 4 
completely inhibits genes differentially expressed by VEGF and (2) establish whether 
apple procyanidin fraction dp 4 regulates additional genes that are independent of the 
inhibition of VEGF signalling, the investigation of gene expression changes by apple 
procyanidin fraction dp 4 and VEGF treatments using whole genome arrays were 
conducted. Analysis of the microarray data has shown, for the first time, that there were 
no significant differences in transcript profiles between apple procyanidin fraction dp 4 
VEGF complex-treated HUVECs and apple procyanidin fraction dp 4-treated HUVECs. 
This result shows that the apple procyanidin fraction dp 4 treatment completely blocks 
VEGF-regulated genes. The microarray analysis has also shown that the apple 
procyanidin fraction dp 4 treatment regulates genes involved in angiogenesis, 
apoptosis, signalling and transcription that are independent of VEGF. One of the 
VEGF-independent genes regulated by apple procyanidin fraction dp 4 that was of 
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particular interest was Krüppel-like factor 2 as it is recognised to be an important 
transcription factor in the suppression of pro-inflammatory and pro-atherosclerotic 
genes. This finding is investigated further in the next chapter. The results from this 
microarray analysis show that apple procyanidin fraction dp 4 completely blocks the 
genes regulated by VEGF as well as regulating additional genes involved in 
angiogenesis and inflammation independently of VEGF. Therefore the complete 
inhibition of VEGF-mediated genes by apple procyanidin fraction dp 4 provides a 
plausible link between consumption of polyphenols and a reduced risk of CVD. 
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6.2 Introduction 
Data presented in Chapter 4 has shown that at low (physiological) concentrations, 
apple procyanidin fraction dp 4 completely inhibits VEGF-induced VEGFR-2 
phosphorylation. Because apple procyanidin fraction dp 4 treatments were shown to 
completely inhibit VEGF-induced activation of VEGFR-2, and VEGFR-2 activation is 
thought to be responsible for the majority of VEGF-mediated effects in vascular 
endothelial cells (Giles, 2001; Ferrara and Kerbel, 2005; Schweighofer et al., 2009), it 
was postulated that apple procyanidin fraction dp 4 treatments would block all VEGF-
induced changes in vascular endothelial cells. However, apple procyanidin fraction 
dp 4 is likely to interact with other receptors, membranes and possibly other cell 
components as procyanidins have also been shown to induce biological functions in 
vascular endothelial cells that are not dependent on VEGF-induced signalling (Sen and 
Bagchi, 2001; Kenny et al., 2004a; Kenny et al., 2004b; Kaur et al., 2006; Engelbrecht 
et al., 2007; Terra et al., 2007; Miura et al., 2008; Hsu et al., 2009; Caton et al., 2010; 
Terra et al., 2011). Therefore, the aim of the research covered in this chapter was to 
determine whether apple procyanidin fraction dp 4 treatment completely blocks VEGF-
induced changes in vascular endothelial cells and to establish whether apple 
procyanidin fraction dp 4 regulates additional genes that are independent of the 
inhibition of VEGF signalling by investigating the gene expression changes by apple 
procyanidin fraction dp 4 and VEGF treatment using whole genome arrays.  
 
6.2.1 VEGF-regulated intracellular mechanisms 
The binding of VEGF to its receptors leads to downstream signalling cascades involved 
in changes in endothelial cell migration, invasion, proliferation, permeability and tube 
formation in-vivo and in-vitro by inducing genes that regulate angiogenesis (Abe and 
Sato, 2001; Jih et al., 2001; Schweighofer et al., 2009). The previously reported 
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analysis of VEGF-regulated genes identified by microarray analysis showed that the 
angiogenesis related genes directly regulated by VEGF were: alpha-2-macroglobulin 
(A2M), angiotensin 1 converting enzyme (ACE), angiopoietin-2 (ANGPT2), 
bactericidal/permeability-increasing protein (BPI), CD34 molecule, cyclooxygenase 2 
(COX2), cysteine-rich, angiogenic inducer 61 (CYR61), down syndrome critical region 
1 (DSCR-1), early growth response 1 (EGR1), early growth response 3 (EGR3), 
heparin-binding epidermal growth factor (HB-EGF), integrin αv, integrin α5, integrin β1, 
integrin β3, thrombomodulin (THBD), urokinase plasminogen activator (PLAU), VEGF-
C, and vascular cell adhesion molecule 1 (VCAM1) (Zhang et al., 1999; Abe and Sato, 
2001; Weston et al., 2002; Yang et al., 2002; Wary et al., 2003; Minami et al., 2004; 
Schoenfeld et al., 2004). 
 
In addition to inducing angiogenesis, VEGF regulates genes involved in endothelial cell 
survival (Gupta et al., 1999; Jih et al., 2001; Schoenfeld et al., 2004) and inflammation 
(Weston et al., 2002; Schweighofer et al., 2009). VEGF promotes endothelial cell 
survival by regulating anti-apoptotic genes like B-cell lymphoma 2 (Bcl-2), 
serine/theronine kinases (AKT), caspases and extracellular signal regulated kinase 
(ERK) as well as directly and selectively activating the MAPK/ERK pathway (Gupta et 
al., 1999; Jih et al., 2001). VEGF, in contrast to other growth factors, contains a 
significant inflammatory component and therefore may be possible to promote 
inflammation on its own (Schweighofer et al., 2009). Vascular cell adhesion molecule-1 
(VCAM1), inflammatory cell adhesion molecule-1 (ICAM1), interleukin 8 (IL8) E-selectin 
(SELE) are some of the inflammatory genes which are regulated by VEGF (Weston et 
al., 2002; Schweighofer et al., 2009).  
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6.2.2 Procyanidin-regulated intracellular mechanisms 
Procyanidins have been reported to induce numerous biological functions; however 
their most distinct functions include their anti-angiogenic (Kenny et al., 2004a; Kenny et 
al., 2004b; Kaur et al., 2006; Engelbrecht et al., 2007; Miura et al., 2008; Wen et al., 
2008; Hsu et al., 2009; Caton et al., 2010; Lu et al., 2010) and anti-inflammatory 
properties (Sen and Bagchi, 2001; Terra et al., 2007; Terra et al., 2011). The anti-
angiogenic properties of procyanidins include their ability to inhibit VEGF signalling 
(Chapter 4) (Wen et al., 2008; Lu et al., 2010), inhibit proliferation (Kaur et al., 2006; 
Miura et al., 2008; Hsu et al., 2009), induce apoptosis (Kaur et al., 2006; Engelbrecht et 
al., 2007; Miura et al., 2008; Hsu et al., 2009), decrease the expression of V-erb-b2 
erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived 
oncogene homolog (avian) (ErbB2) receptors (Kenny et al., 2004a; Kenny et al., 
2004b), and induce KLF2 expression (Caton et al., 2010). The microarray analysis of 
an apple oligomeric procyanidin fraction showed that the oligomeric procyanidin 
fraction was able to significantly modulate the expression levels of several genes that 
are associated with key angiogenesis-related functions, such as cell proliferation and 
migration (García-Conesa et al., 2009). VEGF, as previously described in Chapter 4, is 
a potent pro-angiogenic growth factor involved in the activation of downstream 
signalling events related to endothelial cell migration, invasion, proliferation, 
permeability (Giles, 2001; Dulak, 2005; Cebe-Suarez et al., 2006). ErbB2 receptors are 
receptors that are important in angiogenesis regulation and over-expression of ErbB2 
receptors results in the induction of VEGF (Kenny et al., 2004a; Kenny et al., 2004b). 
KLF2 is recognised to be an important transcription factor in the suppression of pro-
inflammatory and pro-atherosclerotic genes such as VCAM1, SELE, endothelin-1 
(EDN1) and tissue factor as well as inducing antithrombotic and thrombolytic genes 
(Bhattacharya et al., 2005; Dekker et al., 2006; Caton et al., 2010). Over-expression of 
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KLF2 has also been reported to potently abrogate VEGF-mediated angiogenesis 
(Hamik et al., 2006). 
 
Procyanidins have also been reported to have anti-inflammatory properties. 
Procyanidin anti-inflammatory properties include their ability to reduce NF-κB activity 
(Terra et al., 2007; Terra et al., 2011), reduce markers of systemic inflammation 
(tumour necrosis factor-alpha [TNF-α] and C-reactive protein) (Terra et al., 2011), and 
down-regulate endothelial adhesion molecules (ICAM1 and VCAM1) (Sen and Bagchi, 
2001; Garbacki et al., 2005). NF- κB is one of the most important regulators of pro-
inflammatory gene expression (Tak and Firestein, 2001). Although procyanidins have 
been shown to be effective at preventing the onset of inflammation, it still remains 
unclear whether procyanidins exert anti-inflammatory effects once inflammation has 
been established (Terra et al., 2011) 
 
Procyanidins have been reported to have anti-angiogenic and anti-inflammatory 
properties. VEGF, a potent pro-angiogenic growth factor which contains a significant 
inflammatory component, has been implicated as a key feature in procyanidins anti-
angiogenic properties. In order to determine the extent of the interaction between 
procyanidins and VEGF the investigation of the gene expression changes by apple 
procyanidin fraction dp 4 and VEGF treatments were conducted using whole genome 
arrays. While an investigation of a procyanidin fraction has already been reported, this 
is the first time that the number of differentially expressed genes by a purified 
tetrameric procyanidin fraction (apple procyanidin fraction dp 4) has been described. 
This is important because the procyanidin fraction used in the previous study (García-
Conesa et al., 2009) was a mixture of flavanols (contained flavanol monomers 
[epicatechin and catechin] and oliogmers [dimers to heptamers]) and it could not be 
determined whether a specific compound was responsible for the observed effects or if 
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it was a combined effect. This is also the first report describing differences in gene 
expression following the simultaneous co-treatment of a polyphenol-treated VEGF 
treatment.  
 
6.3 Objectives 
The main aim of the microarray experiment was to (1) determine if a potent VEGF 
inhibitor, apple procyanidin fraction dp 4, completely blocks VEGF-regulated genes; 
and (2) establish whether apple procyanidin fraction dp 4 regulates additional genes 
that are independent of inhibition of VEGF signalling and identify what these genes are.  
 
6.4 Materials and methods 
6.4.1 Materials 
Human recombinant VEGF165 and anti-human VEGF antibody were obtained from R&D 
Systems Europe Ltd (Abingdon, UK). Electrophoresis reagents were purchased from 
Invitrogen and the VEGFR-2, phospho-VEGFR-2 (Tyr 1175), the anti-rabbit IgG, HRP-
linked antibodies were from Cell Signaling. All real time Reverse Transcription 
Polymerase Chain Reaction (RT-PCR) products were from Applied Biosystems. The 
apple procyanidin fraction dp 4 was purified from the 2007 apples (Chapter 3) provided 
by Coressence ltd (Herefordshire, UK) as previously described (Yanagida et al., 1999; 
Shoji et al., 2005; Shoji et al., 2006b), with some modifications. A brief description of 
the method can be found in Chapter 4 or a more detailed description of the method is 
located in Supplementary Information 1.  
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6.4.2 Cell culture and treatments 
6.4.2.1 Cell culture 
The culture of HUVECs is described in Chapter 4, Section 4.4.2.  
 
6.4.2.2 Treatments 
Treatments (control [treated with the vehicle DMSO], VEGF, anti-VEGF antibody, and 
apple procyanidin fraction dp 4) were prepared in Universal tubes and incubated at 
room temperature for 5 min prior to adding them to the confluent monolayers. HUVEC 
confluent monolayers were washed twice with PBS, to remove any residual growth 
factors, and prepared treatments were added to the respective wells and incubated at 
37 ºC under a humidified atmosphere containing 5 % CO2. Treatments were incubated 
for 6 h for the microarray experiment and a time course was conducted for the 
angiopoietin-2 (ANGPT2) gene assay determination. 
 
6.4.3 VEGFR-2 phosphorylation measurement 
The extraction of protein was the same method as described in Chapter 4, Section 
4.4.6 and the measurement of phosphorylated VEGFR-2 by Western blot followed the 
same procedure as described in Chapter 4, Section 4.4.7. 
 
6.4.4 RNA extraction 
After treatment incubation, HUVECs were washed twice with warm PBS and the 
ribronucleic acid (RNA) was extracted using the RNeasy® Mini Kit (Qiagen Ltd, UK) 
according to the manufacturer’s protocol. The homogenization step in the protocol was 
achieved by using a QIAshredder (Qiagen Ltd, UK) and the optional on-column DNase 
digestion was preformed. The quality and quantity of RNA present in the samples was 
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quantified using a Beckman DU-640 spectrometer prior to storage at -80 ºC. For a pure 
and good quality RNA sample the absorbance at 260/280 should be approximately 2; 
this was observed for all the samples.  
 
The quality of the RNA, for the microarray samples, was also assessed by the 
Nottingham Arabidopsis Stock Centre (Nottingham, UK) using an RNA Nano LapChip 
kit and an Agilent 2100 Bioanalyzer. The quality of the RNA is measured by loading the 
samples onto the chip, which then pass through microchannels into the separation 
channel. The RNA fragments are then separated according to their size by means of 
molecular sieving and the fragments are detected by fluorescence at the detection 
point. High quality RNA electropherograms show the following characteristics: clear 
28S and 18S peaks; and low noise between the peaks and minimal low molecular 
weight contamination. Marginally degraded RNA samples include the presence of low 
molecular weight species, noise between 28S and 18S peaks, and a smaller 28S peak 
than an 18S peak. Degraded RNA samples have a lack of 28S and 18S peaks and 
consist only of low molecular weight species.  
 
All samples exhibited high quality RNA electropherograms. An example 
electropherogram of one of the microarray samples is shown in Figure 6.1. 
Chapter 6 
 
 
241 
 
 
Figure 6.1: Example of an electropherogram showing a good quality RNA generated by 
the Agilent 2100 Bioanalyzer. 
 
6.4.5 Real-time Reverse Transcription Polymerase Chain reaction 
Pre-designed gene assays for Angiopoietin 2 (ANGPT2) was purchased from Applied 
Biosystems (Assay ID: Hs00169867_m1). Target gene mRNA levels were determined 
by real time RT-PCR using the ABI Prism 7500 Sequence Detection System (Applied 
Biosystems) and normalised to the housekeeping gene 18S (Sigma). The real time 
RT-PCR reactions were carried out in a Microamp Optical 96-well plate in a total 
volume of 20 µl per well containing TaqMan® RNA-to-CTTM 1-Step Kit, 20 ng total RNA 
and appropriate concentrations of primers and probes. Real time RT-PCR conditions 
were as follows: one cycle of 48 ºC for 30 min, one cycle of 95 ºC for 10 min followed 
by 40 cycles at 95 ºC for 15 sec and one cycle at 60 ºC for 1 min. The concentration of 
RNA was normalised to 18S and the data were analysed as mean ± standard 
deviation. Differences were considered significant at p ≤ 0.05. 
 
Time (sec) 
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6.4.6 Affymetrix GeneChip® Human Exon 1.0 ST Array 
RNA samples were analysed using the Affymetrix GeneChip® Human Exon 1.0 ST 
Array (Affymetrix, Santa Clara, CA). The exon array contains approximately 5.4 million 
features (probes) grouped into 1.4 million probe sets and which are further grouped 
into over 1 million exon clusters. Exon clusters are further grouped into Probe Selection 
Regions (PSRs). A PSR represents a region of the genome that is predicted to act as 
an integral coherent unit of transcriptional behaviour. In most cases, a PSR is an exon; 
however in certain cases, due to overlapping exon structures, several PSRs may form 
contiguous, non-overlapping subsets of a true biological exon. The exon clusters are 
further categorised into transcript clusters; exons which share splice sites, or were 
derived from overlapping exonic sequences, or were single exon clusters bounded on 
the genome by spliced content were annotated to belong to the same transcript cluster. 
A transcript cluster roughly corresponds to a gene.  
 
The design of the Affymetrix GeneChip® Human Exon 1.0 ST Array allows for two 
levels of analysis: gene expression and alternative splicing. For the purposes of this 
chapter only gene expression analysis was investigated.  
 
6.4.6.1 Sample processing, terminal labelling, hybridization and scanning  
Sample processing and hybridization was preformed by the Nottingham Arabidopsis 
Stock Centre according to the Affymetrix protocol. Sample processing including 
generation of sense-strand cDNA from total RNA, fragmentation, labelling and 
hybridization was preformed. Briefly, sense-strand cDNA was synthesised from total 
RNA according to the Ambion WT Expression Kit protocol. After synthesizing sense-
strand cDNA, the sample is fragmented and labelled. During fragmentation, 
Fragmentation Master Mix is added to the samples and incubated at 37 ºC for 60 min, 
93 ºC for 2 min and 4 ºC for 2 min. Subsequently labelling reagents are added to the 
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fragmented single-strand DNA and incubated at 37 ºC for 60 min, 70 ºC for 10 min and 
4 ºC for 2 min. The next step is hybridization; a hybridization cocktail and the 
fragmented and labelled single-strand DNA are prepared. It is then hybridised to the 
probe array for 17 h at 45 ºC in a hybridization oven. After hybridization the 
hybridization cocktail is removed and the probe array undergoes an automated 
washing and staining procedure with streptavidin phycoerythrin conjugate. The probe is 
then scanned using an Affymetrix GeneChip® Scanner 3000. The software defines the 
probe cells and computes intensities for each cell. Each complete probe array image is 
stored in a separate data file identified by the experiment name and is saved with a 
data image file (.dat) extension.  
 
6.4.6.2 Array analysis 
The data was analysed using R (R.Development.Core.Team, 2009) / Bioconductor 
(Gentleman et al., 2004) and the aroma.affymetrix package (Bengtsson et al., 2008b). 
R is a language and environment for statistical computing and graphing, Bioconductor 
provides tools for the analysis and comprehension of high throughput genomic data 
and is based on the R programming language, and aroma.affymetrix is an R package 
for analysing large Affymetrix data sets. All arrays in this study were background 
corrected and quantile normalised together using Robust Multiarray Average (RMA) to 
generate gene-level summaries. For gene annotation, the 20071112 custom chip 
definition file (CDF) file available at the aroma.affymetrix website containing the core 
probesets (18,708 transcript clusters and 284,258 probesets) was used. Subsequent 
statistical analysis to identify differentially expressed genes was preformed using the 
Linear Model for MicroArrays (limma) (Smyth, 2004). Genes were identified as 
differentially expressed at different Benjamini and Hochberg adjusted p-values. The 
Database for Annotation, Visualization and Integrated Discovery v6.7 (DAVID; 
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http://www.david.abcc.ncifcrf.gov/) was used to identify Gene Ontology (GO) categories 
associated with specific gene lists (Huang et al., 2008).  
 
6.4.6.3 Comparison of array data with existing published data 
Generated gene lists were compared with existing published data for VEGF microarray 
analyses as well as apple procyanidin fraction dp 3.9 microarray analyses using the 
data deposited in the NCBI Gene Expression Omnibus (GEO) profiles website 
(http://www.ncbhi.nlm.nih.gov/geo) and ArrayExpress (www.ebi.ac.uk/arrayexpress). 
 
6.4.7 Statistical analysis 
Where indicated, comparisons between mean values and treated samples were carried 
out using a two tailed t-test. A p value < 0.05 was considered significant.  
 
6.5 Results 
6.5.1 Determination of treatment parameters for microarray analysis 
The concentration of apple procyanidin fraction dp 4 and VEGF used in the cell 
treatment for the microarray analysis was 1 µM and 10 ng/ml, respectively. The 
concentrations used were based on the results presented in Chapter 4. One 
micromolar apple procyanidin fraction dp 4 is the lowest concentration that completely 
inhibits VEGF-induced VEGFR-2 phosphorylation after a 5 min treatment and 10 ng/ml 
VEGF induces VEGFR-2 phosphorylation after a 5 min treatment. It was also shown 
that a 10 ng/ml VEGF treatment induced gene expression data in previous microarray 
analyses (Jih et al., 2001; Schoenfeld et al., 2004).  
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The aim of the microarray analysis was to identify the differentially expressed genes 
between treatments. Therefore in order to determine the optimum length of treatment, 
a gene expression assay was conducted for ANGPT2. ANGPT2 was picked as the 
gene of interest because it is a protein growth factor that promotes angiogenesis and 
has been shown to be induced by VEGF (Abe and Sato, 2001; Hiltunen et al., 2002; 
Yang et al., 2002).  
 
HUVECs were treated with VEGF (10 ng/ml) and incubated for 0, 1, 2, 4, 6, 8 and 24 h 
prior to RNA extraction and real-time RT-PCR analysis. A significant increase in 
ANGPT2 expression, compared to the control was observed from 2 h to 24 h 
(Figure 6.2). The ANGPT2 quantity in the control samples also increased with time 
compared to the control at 0 h. Six hours was selected as the time point of interest 
because the increase in ANGPT2 was statistically significant (p < 0.0001) and the 
increase in ANGPT2 expression in the control (p = 0.0043) was not as great as 
compared to the 8 h (p = 0.0012) and 24 h (p < 0.0001) samples. Previously, the 
number of genes which were up-regulated in response to VEGF treatment was shown 
to reach a maximum at 6 h in both HUVECs and myometrial microvascular endothelial 
cells (Jih et al., 2001; Weston et al., 2002) and ANGPT2 was reported to be down-
regulated by apple procyanidin fraction dp 3.9 after a 6 h incubation (García-Conesa et 
al., 2009). Therefore based on the results from the ANGPT2 gene expression assay 
and the information from the literature the time point selected for the microarray study 
was 6 h. 
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Figure 6.2: Angiopoietin-2 quantity in VEGF treated HUVECs. 
HUVECs were treated with 10 ng/ml VEGF and incubated for 0, 1, 2, 4, 6, 8 and 24 h. RNA was extracted 
from the cells using the RNeasy® Mini Kit and the ANGPT-2 quantity was determined by real time 
RT-PCR. Bars represent means ± standard deviation expressed as a quantity of ANGPT-2 normalised 
against 18S. **p < 0.01, *** p < 0.001 compared to the control at each time point. † p < 0.05, †† p < 0.01, 
††† p < 0.001 compared to the control at 0 h.  
 
6.5.2 Confirmation of VEGF induced VEGFR-2 phosphorylation / 
inhibition 
Confirmation of VEGF-induced VEGFR-2 phosphorylation and inhibition of VEGF-
induced VEGFR-2 phosphorylation by apple procyanidin fraction dp 4 and anti-VEGF 
antibody was evaluated by Western blot prior to further processing of the microarray 
samples. Treatments were pre-incubated with the basal medium in a Universal tube for 
5 min followed by a 6 h cellular incubation prior to protein extraction. The experiment 
was conducted in parallel with the microarray experiment to ensure the same 
conditions were applied to both experiments.  
 
In the absence of VEGF, phosphorylation of VEGFR-2 could not be detected in 
HUVECs. However, when HUVECs are exposed to VEGF, VEGFR-2 phosphorylation 
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was induced. Apple procyanidin fraction dp 4 does not induce VEGFR-2 
phosphorylation, but, when treated with 10 ng/ml VEGF, apple procyanidin fraction 
dp 4 completely inhibits VEGF-induced VEGFR-2 phosphorylation. The anti-VEGF 
antibody also completely inhibits VEGF-induced VEGFR-2 phosphorylation. These 
results confirmed that the treatments are working in the correct manner and further 
processing of the microarray samples was continued. 
 
 
Figure 6.3: VEGFR-2 phosphorylation is induced by VEGF and inhibited by apple 
procyanidin fraction dp 4 and anti-VEGF antibody treatments. 
HUVECs were treated with the vehicle (DMSO), 10 ng/ml VEGF, 1 µM apple procyanidin fraction dp 4, 
1 µM apple-procyanidin fraction dp 4-treated VEGF (10ng/ml), or 500 ng/ml anti-VEGF antibody-treated 
VEGF (10 ng/ml) for 6 h. The cells were lysed and the protein was separated on a NuPAGE gel and 
probed for the presence of phosphorylated VEGFR-2 at the tyrosine 1175 site and for total VEGFR-2.   
 
6.5.3 Affymetrix GeneChip® Human Exon 1.0 ST Array data analysis 
Gene expression levels of VEGF, apple procyanidin fraction dp 4, and anti-VEGF 
antibody were examined using Affymetrix GeneChip® Human Exon 1.0 ST Arrays. In 
total, 15 samples were hybridised to the chip from a single experiment during which 
HUVECs were treated, in triplicate biological replicates, with 5 min pre-incubated 
treatments in basal medium followed by a 6 h incubation prior to RNA extraction. There 
were 5 different cell treatments: 1) control (vehicle DMSO); 2) 10 ng/ml VEGF; 3) 1 µM 
apple procyanidin fraction dp 4; 4) 1 µM apple procyanidin fraction dp 4-treated VEGF 
(10 ng/ml); and 5) 500 ng/ml anti-VEGF antibody-treated VEGF (10 ng/ml). All arrays 
were RMA-background corrected and quantile normalised (Bengtsson et al., 2008a). 
Potential array outliers were determined by performing a normalised unscaled standard 
p-VEGFR-2 
(Tyr1175) 
VEGFR-2 
- - + + - - + + + + 10 ng/ml VEGF
500 ng/ml anti-
VEGF antibodyControl 1 µM dp 4
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error (NUSE) plot (Figure 6.4A) and a relative log expression (RLE) plot (Figure 6.4B) 
on RMA and quantile normalised arrays. The NUSE plot identifies any arrays which 
have elevated standard errors relative to other arrays in the data set by standardising 
the standard error across the arrays to have a median of 1 for each gene. Deviating 
arrays are identified by an increased median and generally medians higher than 1.05 
are considered alarming. RLE plots are constructed using log-scale estimates for the 
expression of each probe set on each array. For each probe set and each array, ratios 
are calculated between the expression of a probe set and the median expression of 
this probe set across all arrays of the experiment. It is assumed that, despite biological 
variability, the majority of genes do not change their expression across environmental 
conditions. RLE boxplots are therefore expected to be centred on zero and show a 
small interquartile range. An array with quality problems may result in a box that has a 
relatively greater spread or that is not centred near zero.   
 
Treatments Negctrl_1, Negctrl_2, VEGFandDp4_2 and VEGFandDp4_3 showed a 
greater spread in the RLE plot than the other treatments. Based on the NUSE and RLE 
plots, no arrays were identified as outliers.   
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Figure 6.4: Quality control boxplots. 
NUSE boxplot (A), RLE boxplot (B). Dp 4 = 1 µM apple procyanidin fraction dp 4; Negctrl = control (vehicle 
DMSO); VEGF = 10 ng/ml VEGF; VEGFandAntiVEGFab = 10 ng/ml VEGF plus 500 ng/ml anti-VEGF 
antibody; VEGFandDp4 = 10 ng/ml VEGF and 1 µM apple procyanidin fraction dp 4. 
 
The data was also subjected to hierarchical cluster analysis using MATLAB software to 
establish whether the triplicate biological samples were closely related to one another 
and to reveal any distinctions between the samples. Initially, probes were identified that 
had expression levels with a coefficient of variation (standard deviation / mean) 
between 0.1 and 1000 across all the samples. The probes that met these criteria were 
then used to generate a hierarchical cluster dendrogram using a centroid method of 
linkage. The hierarchical cluster dendrogram shows that for the control, VEGF and 
anti-VEGF antibody-treated VEGF treatments, the biological triplicates of each 
treatment are clustered together to form a separate group with a similar expression 
pattern (Figure 6.5). For the apple procyanidin fraction do 4 and apple procyanidin 
fraction dp 4-treated VEGF treatments, these two treatments are clustered together 
suggesting a similarity between the two treatments. This dendrogram demonstrates the 
A B 
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reproducibility of the array data and highlights the robustness of the biological 
triplicates.  
 
 
Figure 6.5: Hierarchical clustering dendrogram of HUVECs treated with vehicle (DMSO), 
VEGF, apple procyanidin fraction dp 4, apple procyanidin fraction dp-treated VEGF and 
anti-VEGF antibody-treated VEGF in three biological replicates for 6 hours.  
Hierarchical clustering was preformed using MATLAB software. 10878 probes out of 18708 were identified 
to have expression levels with a coefficient of variation (standard deviation / mean) between 0.1 and 1000 
across all the samples.  
 
6.5.4 Identification of the number of differentially expressed genes 
and their biological processes between the treatments  
To identify genes that were differentially expressed, pair-wise comparisons were 
preformed. In total 9 pair-wise comparisons were made between the means of the 
biological replicates: 
1. VEGF versus control (vehicle DMSO) 
2. Apple procyanidin fraction dp 4 versus control 
3. Apple procyanidin fraction dp 4-treated VEGF versus control 
4. Apple procyanidin fraction dp 4 versus VEGF 
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5. Apple procyanidin fraction dp 4-treated VEGF versus VEGF 
6. Apple procyanidin fraction dp 4-treated VEGF versus apple procyanidin fraction 
dp 4 
7. Anti-VEGF antibody-treated VEGF versus control 
8. Anti-VEGF antibody-treated VEGF versus VEGF 
9. Anti-VEGF antibody-treated VEGF versus apple procyanidin fraction dp 4 
 
The number of differentially expressed genes identified by these pair-wise comparisons 
is described in Table 6.1. Genes were identified as differentially expressed at different 
Benjamini and Hochberg adjusted p-values.  
 
Table 6.1: Identification of differentially expressed genes from pair-wise comparisons 
Comparison p < 0.05 
 
p < 0.01 p < 0.001 
 
1. VEGF v Negctrl 
 
890 
(350, 540) 
 
 
337 
(162, 175) 
 
132 
(74, 58) 
2. Dp4 v Negctrl 2689 
(1195, 1494) 
 
446 
(186, 260) 
94 
(37, 57) 
3. VEGFandDp4 v Negctrl 11575 
(7268, 4307) 
 
6825 
(4168, 2657) 
511 
(180, 331) 
4. Dp4 v VEGF 1031 
(454, 577) 
 
524 
(206, 318) 
235 
(83, 152) 
5. VEGFandDp4 v VEGF 3426 
(1675, 1751) 
 
1159 
(370, 789) 
360 
(95, 265) 
6. VEGFandDp4 v Dp4 0 
 
0 0 
7. VEGFandAntiVEGFab v Negctrl 3688 
(2075, 1613) 
 
353 
(170, 183) 
0 
8. VEGFandAntiVEGFab v VEGF 866 
(450, 416) 
 
333 
(139, 194) 
131 
(45, 86) 
9. VEGFandAntiVEGFab v Dp4 271 
(146, 125) 
 
100 
(53, 47) 
37 
(21, 16) 
The up-regulated and down-regulated genes are shown in brackets with the up-regulated gene preceding 
the down-regulated genes (e.g. up-regulated, down-regulated).  
Dp 4 = 1 µM apple procyanidin fraction dp 4; Negctrl = control (vehicle DMSO); VEGF = 10 ng/ml VEGF; 
VEGFandAntiVEGFab = 10 ng/ml VEGF plus 500 ng/ml anti-VEGF antibody; VEGFandDp4 = 10 ng/ml 
VEGF and 1 µM apple procyanidin fraction dp 4. 
 
Chapter 6 
 
 
252 
 
The apple procyanidin fraction dp 4-treated VEGF treatment when compared to the 
control (comparison 3) has the greatest number of genes that are differentially 
expressed. However when compared to the apple procyanidin fraction dp 4 treatment 
(comparison 6) there are no statistically significant genes altered at any p-value. It is 
expected that the number of differentially expressed genes altered by the anti-VEGF 
antibody-treated VEGF compared to the VEGF treatment (comparison 8) would be the 
same as the VEGF treatment compared to the control (comparison 1) because the 
antibody should prevent VEGF from binding to its receptors and therefore be the same 
as the control treatment. The treatments appear to be working correctly as the number 
of differentially expressed genes between comparison 1 and comparison 8 are 
approximately the same. For further analysis regarding the pair-wise comparisons refer 
to Section 6.5.5 for the apple procyanidin fraction dp 4 comparisons and Section 6.5.6 
for the anti-VEGF antibody comparisons.  
 
The GO categories associated with the specific gene lists were identified using the 
DAVID software. The gene list obtained using a p value of < 0.001 was used to 
produce a manageable set of genes to perform more detailed functional analysis. The 
top ten biological processes regulated by the treatments are described in 
Tables 6.2 - 6.8 and the full list of biological processes regulated by the treatments are 
described in the Supplementary Information (Supplementary Information 2: Biological 
processes regulated by the different treatment comparisons). Any biological process 
term which had three or fewer genes associated with that biological process or had a 
fold enrichment of less than 1.5 were not included in the analysis. Those biological 
processes that fit the exclusion criteria were excluded because fold enrichments of 1.5 
and above are only considered as interesting and fold enrichments obtained from terms 
with a few number of genes (three or less) are not as reliable as those obtained from 
larger number of genes (Huang et al., 2008). Fold enrichment measures the magnitude 
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of enrichment and is defined as the ratio of two proportions. For example, if 40 out of 
400 (i.e. 10 %) of the inputted genes are involved in “kinase activity” versus 300 out of 
30000 genes (i.e. 1 %) in the human genome (population background) are associated 
with “kinase activity” then the fold enrichment is tenfold (i.e. 10 % / 1 % = 10) (Huang et 
al., 2008). 
 
The main biological processes regulated by the VEGF treatment (compared to the 
control) are cell migration and angiogenesis (Table 6.2). The top biological processes 
regulated by the apple procyanidin fraction dp 4 treatment (compared to the control; 
comparison 2) are leukocyte and T-cell activation/proliferation (Table 6.3) however 
when it is compared to the VEGF treatment (comparison 4) the main biological 
processes regulated are development and signalling pathways (Table 6.4). When 
VEGF and apple procyanidin fraction dp 4 are treated in combination and compared to 
the control (comparison 3), cell migration and differentiation are the main biological 
process regulated by the treatment (Table 6.5). Whereas when the treatment is 
compared to the VEGF treatment (comparison 5) the main biological processes 
regulated include development and signalling pathways (Table 6.6) which is similar to 
comparison 2. The main biological processes regulated by anti-VEGF antibody-treated 
VEGF compared to the control are signalling pathways and enzyme activity (Table 6.7) 
and when the treatment is compared to the apple procyanidin fraction dp 4 treatment 
the main biological processes regulated are response to stimulus, development and 
angiogenesis (Table 6.8).  
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Table 6.2: Top ten biological processes out of 129 genes regulated by VEGF compared to 
the control. 
The top ten biological processes, out of 132 biological processes, regulated by the VEGF treatment versus 
the control from the p < 0.001 gene list from Table 6.1 were identified using the DAVID software. The top 
biological processes were ranked according to the fold enrichment*. 
Top ten biological processes No. of genes 
involved out 
of 129 
Fold 
Enrichment 
Regulation of endothelial cell migration 4 20.2 
Negative regulation of hydrolase activity 5 12.7 
Regulation of angiogenesis 5 9.8 
Positive regulation of cell migration 6 8.4 
Regulation of caspase activity 5 7.8 
Positive regulation of locomotion 6 7.6 
Positive regulation of cell motion 6 7.6 
Regulation of endopeptidase activity 5 7.5 
Regulation of peptidase activity 5 7.1 
Response to unfolded protein 4 7.1 
*fold enrichment = measures the magnitude of enrichment of the gene members associated with each 
biological process term.   
 
 
Table 6.3: Top ten biological processes out of 92 genes regulated by apple procyanidin 
fraction dp 4 compared to the control. 
Top ten biological processes out of 92 genes regulated by the apple procyanidin fraction dp 4 treatment 
versus the control from the p < 0.001 gene list from Table 6.1 were identified using the DAVID software. 
The top biological processes were ranked according to the fold enrichment*. 
Top ten biological processes  No. of genes 
involved out of 
92 
Fold 
Enrichment* 
Negative regulation of MAP kinase activity 4 19.6 
Negative regulation of leukocyte activation 5 14.7 
Negative regulation of cell activation 5 13.9 
Negative regulation of lymphocyte activation 4 12.4 
Positive regulation of mononuclear cell proliferation 4 11.7 
Positive regulation of leukocyte proliferation 4 11.7 
Positive regulation of cell adhesion 4 11.3 
Positive regulation of T cell activation 5 11.1 
Regulation of lymphocyte differentiation 4 10.8 
Regulation of T cell proliferation 4 10.6 
*fold enrichment = measures the magnitude of enrichment of the gene members associated with each 
biological process term.   
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Table 6.4: Top ten biological processes out of 233 genes regulated by apple procyanidin 
fraction dp 4 compared to VEGF. 
Top ten biological processes out of 233 genes regulated by the apple procyanidin fraction dp 4 treatment 
versus the VEGF treatment from the p < 0.001 gene list from Table 6.1 were identified using the DAVID 
software. The top biological processes were ranked according to the fold enrichment*. 
Top ten biological processes No. of genes 
involved out 
of 233 
Fold 
Enrichment* 
Response to retinoic acid 6 11.7 
Cardiac cell differentiation 4 9.6 
Negative regulation of MAP kinase activity 5 9.5 
Ureteric bud development 5 9.2 
Response to vitamin A 6 9.2 
Negative regulation of defence response 4 7.4 
Metanephros development 5 7.3 
BMP signalling pathway 5 7.3 
Cell-cell junction organization 4 7.2 
ER-nuclear signalling pathway 4 7.2 
*fold enrichment = measures the magnitude of enrichment of the gene members associated with each 
biological process term.   
 
 
Table 6.5: Top ten biological processes out 502 genes regulated by apple procyanidin 
fraction dp 4-treated VEGF compared to the control. 
Top ten biological processes out of 502 genes regulated by the apple procyanidin fraction dp 4-treated 
VEGF treatment versus the control from the p < 0.001 gene list from Table 6.1 were identified using the 
DAVID software. The top biological processes were ranked according to the fold enrichment*. 
Top ten biological processes No. of genes 
involved out 
of 502 
Fold 
Enrichment* 
Mismatch repair 5 7.2 
Regulation of leukocyte migration 4 6.3 
Regulation of striated muscle cell differentiation 6 6.3 
Regulation of skeletal muscle fibre development 4 5.5 
Positive regulation of anti-apoptosis 5 5.4 
Regulation of endothelial cell migration 4 5.3 
Regulation of muscle cell differentiation 6 5.3 
Regulation of nitric oxide biosynthetic process 4 5.0 
Positive regulation of alpha-beta T cell activation 4 5.0 
Cardiac cell differentiation 4 4.9 
*fold enrichment = measures the magnitude of enrichment of the gene members associated with each 
biological process term.   
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Table 6.6: Top ten biological processes out of 355 genes and regulated by apple 
procyanidin fraction dp 4-treated VEGF compared to VEGF. 
Top ten biological processes out of genes regulated by the apple procyanidin fraction dp 4-treated VEGF 
treatment versus the VEGF treatment from the p < 0.001 gene list from Table 6.1 were identified using the 
DAVID software. The top biological processes were ranked according to the fold enrichment*. 
Top ten biological processes No. of genes 
involved out 
of 355 
Fold 
Enrichment* 
Response to retinoic acid 6 8.9 
Ureteric bud development 6 8.4 
Negative regulation of MAP kinase activity 6 8.2 
Cardiac cell differentiation 4 7.0 
Cell-cell junction organization 5 7.0 
Response to vitamin A 6 7.0 
Cell junction organization 8 6.9 
Metanephros development 6 6.7 
Calcium-mediated signalling 5 6.6 
Odontogenesis of dentine-containing tooth 5 6.3 
*fold enrichment = measures the magnitude of enrichment of the gene members associated with each 
biological process term.   
 
 
 
 
Table 6.7: Top ten biological processes out of 129 genes regulated by anti-VEGF 
antibody-treated VEGF compared to VEGF. 
Top ten biological processes out of 129 genes regulated by the anti-VEGF antibody-treated VEGF 
treatment versus the VEGF treatment from the p < 0.001 gene list from Table 6.1 were identified using the 
DAVID software. The top biological processes were ranked according to the fold enrichment*. 
Top ten biological processes No. of genes 
involved out 
of 129 
Fold 
Enrichment* 
ER-nuclear signalling pathway 4 13.5 
Negative regulation of hydrolase activity 4 9.8 
Response to mechanical stimulus 4 8.7 
Response to unfolded protein 5 8.7 
Regulation of caspase activity 5 7.6 
Regulation of endopeptidase activity 5 7.3 
Regulation of peptidase activity 5 6.9 
Response to protein stimulus 6 6.8 
Cartilage development 4 6.6 
Regulation of inflammatory response 4 6.4 
*fold enrichment = measures the magnitude of enrichment of the gene members associated with each 
biological process term.   
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Table 6.8: Top biological processes and regulated by anti-VEGF antibody-treated VEGF 
compared to apple procyanidin fraction dp 4. 
Top biological processes regulated by the anti-VEGF antibody-treated VEGF treatment versus the apple 
procyanidin fraction dp 4 treatment from the p < 0.001 gene list from Table 6.1 were identified using the 
DAVID software. The top biological processes were ranked according to the fold enrichment*. 
Biological process No. of genes 
involved out 
of 37 
Fold 
Enrichment* 
Response to nutrient 4 10.5 
Angiogenesis 4 10.1 
Anti-apoptosis 5 9.1 
Blood vessel morphogenesis 5 8.8 
Response to steroid hormone stimulus 4 7.8 
Blood vessel development 5 7.6 
Response to nutrient levels 4 7.4 
Vasculature development 5 7.4 
Tube development 4 6.8 
Positive regulation of transport 4 6.7 
*fold enrichment = measures the magnitude of enrichment of the gene members associated with each 
biological process term.   
 
While the different comparisons regulate a varied list of biological processes there are 
some similarities between the biological processes regulated by the different 
comparisons. The similar biological processes include cell migration, differentiation, 
signalling pathways, development and angiogenesis. As VEGF is a pro-angiogenic 
growth factor it would be expected that these processes would be regulated by the 
VEGF treatment as they are the main processes involved in angiogenesis. It has also 
been reported that the main biological processes regulated by an apple procyanidin 
fraction dp 3.9 treatment were cell death, cell growth and proliferation, cell migration, 
cell signalling and cell development (García-Conesa et al., 2009). Therefore it would 
also be expected to observe these processes in the apple procyanidin fraction dp 4 
treatments. 
 
Lists of the specific genes that are altered in HUVECs in response to VEGF, apple 
procyanidin fraction dp 4 and anti-VEGF antibody treatments are listed in the 
Supplementary Information (Supplementary Information 3: Genes differentially 
expressed in response to treatments). The genes are ranked into gene ontology groups 
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according to the gene ontology database http://www.geneontology.org/. The genes that 
had more than one gene ontology grouping were ranked according to the amount of 
citations in PubMed (http://www.ncbi.nlm.nih.gov/sites/entrez) for that particular 
function.  
 
6.5.5 Pair-wise comparisons of apple procyanidin faction dp 4-
treated VEGF treatments were conducted in order to establish 
whether apple procyanidin fraction dp 4 negates the effects of VEGF 
Apple procyanidin fraction dp 4 has been shown to inhibit VEGF-induced VEGFR-2 
phosphorylation (Figure 6.3 and Chapter 4), but it is not known whether the treatment 
negates the genes regulated by VEGF. In order to determine whether apple 
procyanidin fraction do 4 negates the effects of VEGF different pair-wise comparisons 
were conducted. In the first comparison, apple procyanidin fraction dp4-treated VEGF 
was compared to apple procyanidin fraction dp 4 (comparison 6). In this pair-wise 
comparison there were no statistically significant genes that were differentially 
expressed at any p-value (Table 6.1). This result shows that apple procyanidin fraction 
dp 4, when treated in combination with VEGF, completely inhibits VEGF-induced 
changes in gene expression.  
 
In the second pair-wise comparison, apple procyanidin fraction dp 4-treated VEGF was 
compared to the control (comparison 3). In this comparison 511 genes were 
differentially expressed (using the most stringent p-value; p < 0.001; Table 6.1). It was 
expected that comparison 3 would have the same number of genes that were 
differentially expressed as the apple procyanidin fraction dp 4 versus control 
comparison (comparison 2) because if the apple procyanidin fraction dp 4 treatment 
was inhibiting VEGF-induced changes in gene expression, comparison 3 would be the 
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same as comparison 2 (i.e. apple procyanidin fraction dp 4-treated VEGF = apple 
procyanidin fraction dp 4). However, there were only 94 genes that were differentially 
expressed in comparison 2 (using the most stringent p-value; p < 0.001; Table 6.1). 
Using Venn diagram analysis it was shown that out of the differentially expressed 
genes in comparisons 2 and 3, 89 genes were common and positively correlated 
between the two groups (Figure 6.6). The majority of the genes regulated by 
comparison 2 are common with comparison 3. Therefore the apple procyanidin fraction 
dp 4-treated VEGF treatment is regulating additional genes than apple procyanidin 
fraction dp 4 alone.  
 
 
Figure 6.6: Comparison between genes differentially expressed by apple procyanidin 
fraction dp 4-treated VEGF versus control and apple procyanidin fraction dp 4 versus 
control (p < 0.001). 
Overlap between genes differentially expressed by apple procyanidin fraction dp 4-treated VEGF when 
compared to the control and by apple procyanidin fraction dp 4 when compared to the control. If all gene 
changes were independent from each other, 3 genes would have been expected to be common between 
the two data sets as opposed to 89. (False discovery rate = number of genes differentially expressed by 
VEGF and Dp 4 v Negctrl divided by number of transcripts [18708] and then multiplied by the number of 
genes differentially regulated by Dp 4 v Negctrl.) Negctrl = control (vehicle DMSO); VEGFandDp4 = 
10 ng/ml VEGF plus 1 µM apple procyanidin fraction dp 4; Dp4 = 1 µM apple procyanidin fraction dp 4.  
 
The third, and final, pair-wise comparison was between apple procyanidin fraction 
dp 4-treated VEGF and VEGF (comparison 5). In this comparison 360 genes were 
differentially expressed (using the most stringent p-value; p < 0.001; Table 6.1). It was 
expected that comparison 5 would have the same number of genes that were 
VEGFandDp4 v Negctrl Dp4 v Negctrl 
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differentially expressed as the apple procyanidin fraction dp 4 versus VEGF 
comparison (comparison 4) because if the apple procyanidin fraction dp 4 treatment 
was inhibiting VEGF-induced changes in gene expression, comparison 5 would be the 
same as comparison 4 (i.e. apple procyanidin fraction dp 4-treated VEGF = apple 
procyanidin fraction dp 4). However, there were only 235 genes that were differentially 
expressed in comparison 4 (using the most stringent p-value; p < 0.001; Table 6.1). 
Using Venn diagram analysis it was shown that out of the differentially expressed 
genes in comparisons 4 and 5, 206 genes were common and positively correlated 
between the two comparisons (Figure 6.7). The majority of the genes regulated by 
comparison 4 are common with comparison 5. Therefore this also suggests that the 
apple procyanidin fraction dp 4-treated VEGF treatment is regulating additional genes 
than apple procyanidin fraction dp 4 alone.  
 
 
Figure 6.7: Comparison between genes differentially expressed by apple procyanidin 
fraction dp 4-treated VEGF versus VEGF and apple procyanidin fraction dp 4 versus 
VEGF (p < 0.001). 
Overlap between genes differentially expressed by apple procyanidin fraction dp 4-treated VEGF when 
compared to VEGF and by apple procyanidin fraction dp 4 when compared to VEGF. If all gene changes 
were independent from each other, 5 genes would have been expected to be common between the two 
data sets as opposed to 206. VEGF = 10 ng/ml VEGF; VEGFandDp4 = 10 ng/ml VEGF plus 1 µM apple 
procyanidin fraction dp 4; Dp4 = 1 µM apple procyanidin fraction dp 4.  
 
 
VEGFandDp4 v VEGF Dp4 v VEGF 
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While the number of genes regulated by the apple procyanidin fraction dp 4-treated 
VEGF treatment versus the control or VEGF treatments are not similar to the number 
of genes regulated by the apple procyanidin fraction dp 4 treatment versus the control 
or VEGF treatments, there are no genes which are differentially regulated in the apple 
procyanidin fraction dp 4-treated VEGF treatment versus apple procyanidin fraction 
dp 4 treatment. This shows that apple procyanidin fraction dp 4 inhibits VEGF-
regulated genes.   
 
6.5.6 Pair-wise comparisons of anti-VEGF antibody-treated VEGF 
treatments were conducted in order to establish whether the anti-
VEGF antibody could be used as a control for the apple procyanidin 
fraction dp 4 treatment  
As apple procyanidin fraction dp 4 was shown to inhibit VEGF-induced VEGFR-2 
phosphorylation (Figure 6.3 and Chapter 4) an anti-VEGF antibody treatment was 
included in the experimental design to serve as a positive control for the apple 
procyanidin fraction dp 4 treatment. The anti-VEGF antibody works by inhibiting VEGF 
from binding to its receptors. Inhibition of VEGF-induced VEGFR-2 phosphorylation 
was observed with a treatment of 500 ng/ml anti-VEGF antibody, therefore in the 
presence of the anti-VEGF antibody, VEGF is unable to induce VEGFR-2 
phosphorylation (Figure 6.3). It is therefore expected that treating the cells with an anti-
VEGF antibody treated-VEGF treatment would be the same as treating the cells with 
the control and no genes would be regulated by the treatment. However, the anti-VEGF 
antibody-treated VEGF treatment versus the control (comparison 7) had more than 
3600 differentially expressed genes at a p value < 0.05 and 353 differentially 
expressed genes at a p value of < 0.01 but at a p value of <0.001 there were no 
differentially expressed genes which were statistically significant (Table 6.1). As the 
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anti-VEGF antibody-treated VEGF versus the control is regulating genes at the two 
higher stringent p-values, it suggests that the anti-VEGF antibody is regulating 
additional genes.   
 
In order to confirm whether the anti-VEGF antibody-treated VEGF treatment was 
regulating additional genes independently of VEGF, a Venn diagram comparison was 
conducted between comparison 1 (VEGF versus control) and comparison 7 (anti-VEGF 
antibody-treated VEGF versus control). Comparison 1 differentially regulated 337 
genes while comparison 7 differentially regulated 353 genes (p < 0.01; Table 6.1). As 
the anti-VEGF antibody-treated VEGF treatment should be the same as the control 
treatment, performing a Venn diagram between these two comparisons will provide an 
indication of the number of differentially expressed genes regulated by the anti-VEGF 
antibody treatment. Between the two comparisons only 29 genes were common 
(Figure 6.8), thus providing further evidence that the anti-VEGF antibody is regulating 
additional genes which are independent of its primary function (inhibition of VEGF 
activity).  
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Figure 6.8: Comparison between the genes differentially expressed by VEGF compared 
to the control and by anti-VEGF antibody-treated VEGF compared to the control 
(p < 0.01). 
Overlap between genes differentially expressed by VEGF when compared to the control and by anti-VEGF 
antibody-treated VEGF when compared to control. If all gene changes were independent from each other, 
6 genes would have been expected to be common between the two data sets as opposed to 29. Negctrl = 
control (vehicle DMSO); VEGF = 10 ng/ml VEGF; VEGFandAntiVEGFab = 10 ng/ml VEGF plus 500 ng/ml 
anti-VEGF antibody.  
 
Further pair-wise comparisons were conducted in order to identify the effect of the anti-
VEGF antibody treatment. In the first pair-wise comparison, the anti-VEGF antibody-
treated VEGF was compared to the VEGF treatment (comparison 8) and 131 genes 
were differentially regulated by this comparison (using the most stringent p-value; 
p < 0.001; Table 6.1). It was expected that comparison 8 would have the same number 
of genes that were differentially expressed as the VEGF versus control comparison 
(comparison 1) because if the anti-VEGF antibody treatment was inhibiting VEGF-
induced changes in gene expression comparison 8 would be the same as 
comparison 1 (i.e. anti-VEGF antibody-treated VEGF = control). Comparison 1 had 132 
genes that were differentially expressed. Therefore the two comparisons have 
essentially the same number of genes being regulated, however only 82 of the genes 
were common between the two treatments (Figure 6.9). If the anti-VEGF antibody was 
working correctly, it would also be expected that the regulated genes from 
comparison 8 would be inversely correlated to comparison 1. The commonly regulated 
VEGF v Negctrl VEGFandAntiVEGFab v Negctrl 
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genes between the two comparisons were all inversely correlated, thus indicating that 
the anti-VEGF antibody is negating some of the effects of VEGF, but is also regulating 
additional genes.  
 
 
Figure 6.9: Comparison between genes differentially expressed by VEGF compared to 
the control or anti-VEGF antibody-treated VEGF treatments (p < 0.001). 
Overlap between genes differentially expressed by VEGF when compared to the control and by anti-VEGF 
antibody-treated VEGF when compared to VEGF. If all gene changes were independent from each other, 
1 gene would have been expected to be common between the two data sets as opposed to 82. 
Negctrl = control (vehicle DMSO); VEGF = 10 ng/ml VEGF; VEGFandAntiVEGFab = 10 ng/ml VEGF plus 
500 ng/ml anti-VEGF antibody.  
 
The second, and final, pair-wise comparison was between anti-VEGF antibody-treated 
VEGF and apple procyanidin fraction dp 4 (comparison 9). In this comparison 37 genes 
were differentially expressed (using the most stringent p-value; p < 0.001; Table 6.1). It 
was expected that comparison 9 would have the same number of genes that were 
differentially expressed as the apple procyanidin fraction dp 4 versus control 
comparison (comparison 2) because if the anti-VEGF antibody was inhibiting VEGF-
induced changes in gene expression comparison 9 would be the same as 
comparison 2 (i.e. anti-VEGF antibody-treated VEGF = control). However, there were 
94 genes that were differentially expressed in comparison 2 (using the most stringent 
p-value; p < 0.001; Table 6.1). Using a Venn diagram analysis it was shown that out of 
VEGF v Negctrl VEGFandAntiVEGFab v VEGF 
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the differentially expressed genes in comparisons 2 and 9, 25 genes were common 
and inversely correlated between the two comparisons (Figure 6.10). 
 
 
Figure 6.10: Comparison between genes differentially expresed by apple procyanidin 
fraction dp4 compared to the control or anti-VEGF antibody-treated VEGF treatments 
(p < 0.001). 
Overlap between genes differentially expressed by anti-VEGF antibody-treated VEGF when compared to 
the apple procyanidin fraction dp 4 treatment and by apple procyanidin fraction dp 4 treatment to the 
control. If all gene changes were independent from each other, 1 gene would have been expected to be 
common between the two data sets as opposed to 25. Negctrl = control (vehicle DMSO); Dp4 = 1 µM 
apple procyanidin fraction dp4 VEGFandAntiVEGFab = 10 ng/ml VEGF plus 500 ng/ml anti-VEGF 
antibody.  
 
Based on these results, it is likely that the anti-VEGF antibody is inhibiting VEGF from 
binding to its receptors as well as regulating additional genes. The regulation of 
additional genes observed in the different pair-wise comparisons are likely due to the 
type of antibody used; the anti-VEGF antibody that was used was a polyclonal 
antibody. Polyclonal antibodies provide certain problems as they are capable of binding 
to several different epitopes on any given antigen (Lipman et al., 2005; Haurum, 2006) 
and therefore may exert additional effects beyond neutralization. Therefore the 
additional regulated genes observed by this treatment are most likely due to the use of 
a polyclonal antibody and the anti-VEGF antibody treatment can not be used as a 
positive control for the apple procyanidin fraction dp 4 treatment.  
 
VEGFandAntiVEGFab v Dp4 Dp4 v Negctrl 
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6.5.7 Identification of angiogenic genes regulated by VEGF confirms 
VEGF is working correctly 
Previous microarray analyses have reported that VEGF induces the following genes: 
A2M, ACE, ANGPT2, BPI, COX2, DSCR-1, EGR1, EGR3, HB-EGF, THBD, PLAU and 
VCAM1 (Arkonac et al., 1998; Abe and Sato, 2001; Weston et al., 2002; Yang et al., 
2002; Wary et al., 2003; Minami et al., 2004; Schoenfeld et al., 2004; Hamik et al., 
2006; Suehiro et al., 2010). Of the angiogenic related genes which have been reported 
to be regulated by VEGF, the microarray analysis in this study has confirmed the up-
regulation of the following genes by VEGF: A2M, ANGPT2, EGR3, PLAU, THBD, IL8 
and VCAM1 (Table 6.9). It was not expected to observe gene expression data for 
COX2, EGR1, CYR61, HB-EGF, BPI and DSCR-1 because the peak expression of 
these genes occurs between 0.5 and 2 h (Abe and Sato, 2001; Minami et al., 2004; 
Suehiro et al., 2010) and the induction of ACE occurs at 12 h (Abe and Sato, 2001). 
Induction of 54 % of the angiogenic genes known to be induced by VEGF confirms that 
VEGF is working correctly in this experiment.  
 
Table 6.9: Fold change of angiogenic, apoptotic, inflammatory, signalling and 
transcription genes differential expressed by the VEGF versus the control comparison. 
 
Microarray fold change 
 
VEGF versus control 
A2M 2.18*** 
ANGPT2 1.81*** 
PLAU 1.25** 
IL8 1.35* 
THBD 2.43*** 
VCAM1 2.28*** 
VEGFC 1.41*** 
* p < 0.05, ** p < 0.01, *** p < 0.001. p = adjusted p-value for multiple comparisons 
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6.5.8 Apple procyanidin fraction dp 4 regulates additional genes that 
are independent of the inhibition of VEGF signalling 
In order to identify the genes which are differentially regulated by the apple procyanidin 
fraction dp 4 treatment that are independent of VEGF signalling a Venn diagram 
analysis was preformed between the VEGF versus control comparison and the apple 
procyanidin fraction dp 4 versus control comparison (Figure 6.11). There were 337 
genes differentially regulated by the VEGF versus control comparison and 446 genes 
differentially regulated by the apple procyanidin fraction dp 4 comparison (p < 0.01, 
Table 6.1) and 75 genes were common between the two groups (Figure 6.11). Of those 
75 genes, 66 were positively correlated and 9 were negatively correlated. Some of the 
positively correlated genes included VEGFC, PLAU, NF-κB2, ADAMTS1, THBD and 
DUSP5 and ANGPT2 were inversely correlated (Table 6.9). 
 
 
Figure 6.11: Comparison between genes differentially expressed by VEGF compared to 
the control and apple procyanidin fraction dp4 compared to the control (p < 0.01). 
Overlap between genes differentially expressed by VEGF compared to the control and apple procyanidin 
fraction dp 4 compared to the control. If all gene changes were independent from each other, 1 gene 
would have been expected to be common between the two data sets as opposed to 75. Negctrl = control 
(vehicle DMSO); Dp4 = 1 µM apple procyanidin fraction dp4 VEGFandAntiVEGFab = 10 ng/ml VEGF plus 
500 ng/ml anti-VEGF antibody.  
 
VEGF v Negctrl Dp4 v Negctrl 
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Of the angiogenic, apoptotic, inflammatory, signalling and transcription genes known to 
be regulated by VEGF (Abe and Sato, 2001; Jih et al., 2001; Hiltunen et al., 2002; 
Schweighofer et al., 2009) and confirmed in this array (Table 6.9), the majority of those 
genes are positively regulated by apple procyanidin fraction dp 4, with the exception of 
IL8, ets variant 1 (ETV1) and ets variant 5 (ETV5) which are negatively regulated by 
apple procyanidin fraction dp 4 (Table 6.10).   
 
Apple procyanidin fraction dp 4 also regulates additional genes that are independent of 
VEGF. These include: angiogenesis related genes: apelin (APLN), bone morphogenic 
protein 4B (BMP4) and angiotensin 1 converting enzyme (ACE); apoptosis related 
gene: caspase 10, apoptosis-related cysteine peptidease (CASP10); signalling 
molecules: connective tissue growth factor (CTGF), cysteine-rich, angiogenic inducer, 
61 (CYR61) and EDN1; and transcription factors: krüppel-like factor 2 (lung) (KLF2) 
and krüppel-like factor 4 (gut) (KLF4) (Table 6.10). ADAMTS1 is a secreted matrix 
metalloproteinase that has been shown to inhibit endothelial cell proliferation. CASP10 
is involved in apoptosis and CYR61 and CTGF are members of the CNN family of 
proteins and are involved in regulating endothelial cell function and promoting cell 
growth and migration. EDN1 is a potent vasoconstrictor that promotes proliferation and 
migration and the genes: bone morphogenetic protein 4 (BMP4), APLN, KIT ligand 
(KITLG), KLF2 and KLF4 have been shown to be involved in angiogenic processes 
and/or vascular function (García-Conesa et al., 2009).  
 
The majority of the genes that are regulated by apple procyanidin fraction dp 4 in 
Table 6.10 are also regulated by the apple procyanidin fraction dp 4-treated VEGF 
treatment with the exception of APLN and Bcl2 which is only regulated by the apple 
procyanidin fraction dp 4 treatment. The genes CASP6 and caspase 8, apoptosis-
related cysteine peptidase (CASP8) are induced by the apple procyanidin fraction dp 4-
Chapter 6 
 
 
269 
 
treated VEGF treatment but not with apple procyanidin fraction dp 4 in the absence of 
VEGF. The anti-VEGF antibody treatment has reduced the induction of the genes 
alpha-2-macroglobulin (A2M) and period homolog 1 (Drosophila) (PER1) and has 
either induced or down-regulated the genes CASP10, intercellular adhesion molecule 1 
(ICAM1), CYR61, dual specificity phosphatase 5 (DUSP5), KLF2, and KLF4 
independent of VEGF. 
 
Table 6.10: Fold change of angiogenic, apoptotic, inflammatory, signalling and 
transcription genes differential expressed by VEGF, apple procyanidin fraction dp 4, 
apple procyanidin fraction dp 4-treated VEGF and anti-VEGF antibody-treated VEGF. 
 Microarray fold change 
 VEGF versus 
control 
dp 4 versus 
control 
VEGF and dp 4 
versus control 
VEGF and anti-
VEGF antibody 
versus control 
Angiogenesis 
A2M 2.18*** 1.22* 1.22** 1.25* 
ACE -- 1.24* 1.21*** -- 
ADAMTS1 1.57*** 1.36** 1.20* -- 
ANGPT2 1.81*** -1.71*** -1.61*** -- 
APLN -- -1.37** -- -- 
BMP4 -- -1.86*** -1.76*** -- 
PLAU 1.25** 1.32** 1.16** -- 
THBD 2.43*** 1.31** 1.34** -- 
VEGFC 1.41*** 1.44*** 1.28*** -- 
Apoptosis 
Bcl2 1.25* 1.26* -- 1.21* 
CASP6 -1.45** -- -1.31** -- 
CASP8 -- -- -1.24** -- 
CASP10 -- -1.62*** -1.88*** -1.27* 
Inflammatory 
SELE 1.65** -- -1.34*  
ICAM1 1.45** 1.89*** 1.78*** 1.51** 
IL8 1.35* -1.31* -1.34* -- 
NF-κB2 1.30** 1.52*** 1.53*** 1.17* 
VCAM1 2.28*** -- -- -- 
Signalling-related molecules 
CTGF -- -1.31** -1.27** -- 
CYR61 -- -1.61*** -1.62*** -1.15* 
DUSP5 1.24** 1.31** 1.32** 1.30** 
EDN1 -- -1.36** -1.35*** -- 
KITLG 1.66** 1.47* -- -- 
Transcription factors 
ETV1 1.32* -1.81*** -1.86** -- 
ETV5 1.33* -1.64*** -1.38** -- 
EGR3 1.33* 1.26* 1.37** -- 
KLF2 -- 1.67*** 1.75*** 1.27** 
KLF4 -- 1.78*** 1.84*** 1.24*** 
HLX 1.30** 1.51*** 1.52*** -- 
MEF2C 1.59*** 1.39** 1.20* -- 
NR4A2 1.65** 1.24* 1.21** -- 
PER1 1.30** 1.22* 1.29** 1.17* 
* p < 0.05, ** p < 0.01, *** p < 0.001. p = adjusted p-value for multiple comparisons 
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6.6 Discussion 
The data presented in Chapter 4 shows that apple procyanidin fraction dp 4 inhibits 
VEGF-induced VEGFR-2 activity at low (physiological concentrations). Procyanidins 
have also been shown to have anti-angiogenic and anti-inflammatory properties that 
are not necessarily dependent on VEGF-induced signalling. Therefore the aims of the 
research presented in this chapter were to determine whether apple procyanidin 
fraction dp 4 blocks VEGF-induced changes in vascular endothelial cells and to 
establish whether apple procyanidin fraction dp 4 regulates additional genes that are 
independent of the inhibition of VEGF signalling. The data presented in this chapter 
shows that apple procyanidin fraction dp 4 (1) completely inhibits VEGF-dependent 
gene expression; and (2) alters the expression of a large number of genes not 
dependent on VEGF, the majority relating to angiogenesis and inflammation which are 
independent of VEGF.  
 
The pair-wise comparison of the apple procyanidin fraction dp 4-treated VEGF cells 
versus the apple procyanidin fraction dp 4-treated cells was conducted in order to 
determine whether apple procyanidin fraction dp 4 completely blocks VEGF-dependent 
gene expression. This pair-wise comparison showed that there were no additional 
genes that were being regulated by the apple procyanidin fraction dp 4-treated VEGF 
treatment compared to the apple procyanidin fraction dp 4 treatment (comparison 6, 
Table 6.1). This result confirms that the apple procyanidin fraction dp 4 treatment 
completely blocks all VEGF-mediated changes in gene expression.  
 
This is the first time that the co-treatment of VEGF and a polyphenol has been shown 
to completely block VEGF-mediated changes in gene expression. After an extensive 
search of the literature, this is the first time that a polyphenol has also been reported to 
completely block a signalling molecule-mediated changes in gene expression. Liu et al. 
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(2008) have previously reported gene expression data for HUVECs pre-treated with 
EGCG (20 µM) for 24 h followed by a 30 min stimulation of VEGF (50 ng/ml). In this 
experimental design, it was shown that there were no differentially expressed genes 
when the cells which were pre-treated with EGCG for 24 h followed by a 30 min VEGF 
stimulation were compared to the cells stimulated with VEGF. However, when cells that 
were pre-treated with EGCG followed by VEGF stimulation were compared to the cells 
that were pre-treated with EGCG, 123 genes were reported to be differentially 
expressed (Liu et al., 2008). The results presented by Liu et al. (2008) shows that pre-
treatment of cells with EGCG followed by VEGF stimulation is unable to block genes 
differentially regulated by VEGF. Therefore, the data presented in this chapter show, 
for the first time, that the co-treatment of a dietary polyphenol (at physiological 
concentrations) completely blocks VEGF-mediated changes in gene expression. The 
comparison of the results presented in this chapter and those by Liu et al. (2008) 
reiterate the point that the inhibition of VEGF signalling is due to the polyphenol 
interacting with the VEGF molecule and not the VEGF receptors (Chapter 4, 
Section 4.5.3). 
 
Because VEGF-induced VEGFR-2 signalling and VEGF-mediated changes in gene 
expression are completely blocked with the treatment of apple procyanidin fraction 
dp 4, apple procyanidin fraction dp 4 treatment may have nutraceutical and 
pharmacological applications for the prevention and treatment of VEGF-induced 
angiogenesis. The current anti-VEGF drugs available have been reported to increase 
blood pressure after prolonged periods of use (Kappers et al., 2010) and the 
systematic reviews and meta-analyses of the anti-VEGF drugs bevacizumab, sorafenib 
and sunitinib have shown an increased risk of developing hypertension among users of 
these drugs (Zhu et al., 2007; Wu et al., 2008b; Zhu et al., 2009). The increased 
susceptibility of developing hypertension is the result of the inhibition of NO production. 
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VEGF has been reported to stimulate the production of NO through the 
phosphorylation of AKT (Chavakis et al., 2001; Tang et al., 2003; Riesterer et al., 2004; 
Rodriguez et al., 2006; Stangl et al., 2007) and the inhibition of VEGF signalling by 
anti-VEGF drugs would therefore be expected to decrease the production of NO (Wang 
et al., 2004). Bevacizumab, a monoclonal anti-VEGF antibody, was shown to 
completely inhibit VEGF-induced NO production in HUVECs (Wang et al., 2004). Apple 
procyanidin fraction dp 3.9, on the other hand, inhibits VEGF signalling but still induces 
NO bioavailability by inducing AKT phosphorylation at 1 h (Chapter 4, 4.5.5). Gene 
expression changes for AKT in the current array analysis was searched, however the 
expression of AKT was not significant in apple procyanidin fraction dp 4-treated cells 
compared to the control at the experimental time point of 6 h. As apple procyanidin 
fraction dp 3.9 and dp 4 are similar in nature, it is highly likely that apple procyanidin 
fraction dp 4 will also induce phosphorylation of AKT. Therefore the inhibition of VEGF 
signalling by apple procyanidin fraction dp 4 may not cause an increase in blood 
pressure or risk of hypertension, as observed for anti-VEGF antibodies, and may be 
more applicable as an anti-VEGF treatment than the current anti-VEGF drugs.  
 
The anti-VEGF drug treatments may also regulate additional functions beyond their 
role in neutralizing the effect of VEGF. The mulit-analyte analysis of aqueous humor 
obtained from patients undergoing bevacizumab injection for VEGF-related ocular 
pathologies showed that the bevacizumab treatment affected the nature of the eye 
beyond what would be expected by neutralization of VEGF alone (Sharma et al., 2010). 
The treatment of rectal cancer cells and tumour-associated macrophages with 
bevacizumab was shown to block VEGF-induced genes but also significantly up-
regulate the expression of genes involved in angiogenesis, independently of VEGF (Xu 
et al., 2009). The data presented in this chapter has also shown that treatment of 
HUVECs with an anti-VEGF polyclonal antibody differentially regulates gene 
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expression independently of its main function of neutralizing VEGF activity 
(Section 6.5.6). Therefore the use of polyclonal antibodies (shown in this chapter) and 
monoclonal antibodies (Xu et al., 2009; Sharma et al., 2010) has been shown to cause 
additional functions beyond the neutralization of VEGF activity. The evidence that 
antibodies exert additional effects beyond their primary function is a problem as the 
antibodies might exert detrimental effects; therefore further research regarding the 
implications of antibody treatments on gene expression and biological processes is 
required. Thus the potential use of procyanidins may be a better treatment therapy as 
they are known to have anti-angiogenic and anti-inflammatory properties.  
 
The data presented in this chapter has shown that apple procyanidin fraction dp 4 
deferentially regulates the expression of genes involved in angiogenesis and 
inflammation that are independent of VEGF induction. These genes include the 
up-regulation of KLF2 and KLF4 and the down-regulation of APLN, BMP4, CASP10, 
CTGF and EDN1. KLF2 and KLF4 belong to the krüppel-like family of transcriptional 
regulators that are involved in the regulation of cellular growth and differentiation 
(Bhattacharya et al., 2005). APLN and BMP4 are genes involved in angiogenesis 
(Kasai et al., 2004; Rothhammer et al., 2007); CTGF is involved in regulating 
endothelial cell function and promoting cell growth and migration (Brigstock, 2002) and 
EDN1 is a potent vasoconstrictor that promotes proliferation and migration (Salani et 
al., 2000).  
 
Out of the VEGF-independent genes regulated by apple procyanidin fraction dp 4, 
KLF2 was considered particularly interesting because over-expression of KLF2 has 
been reported to potently abrogate VEGF-mediated angiogenesis (Hamik et al., 2006). 
KLF2 is recognised to be an important transcription factor in the suppression of 
pro-inflammatory and pro-atherosclerotic genes such as VCAM1, SELE, EDN1 and 
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tissue factor as well as inducing antithrombotic and thrombolytic genes (Bhattacharya 
et al., 2005; Dekker et al., 2006; Caton et al., 2010). KLF2 is also implicated in the 
regulation of cell processes including cell growth, development and differentiation 
(Bhattacharya et al., 2005; Suske et al., 2005; Hamik et al., 2006; Wu et al., 2008a). 
Therefore further investigation of the induction of KLF2 expression by apple 
procyanidin fraction dp 4 was conducted and is reported in Chapter 7.  
 
6.7 Conclusion 
The main aims of the current chapter were to determine if apple procyanidin fraction dp 
4 completely inhibits genes differentially expressed by VEGF and to establish whether 
apple procyanidin fraction dp 4 regulates additional genes that are independent of the 
inhibition of VEGF signalling. The data presented in this chapter showed that apple 
procyanidin fraction dp 4 (1) completely inhibits VEGF-dependent gene expression; 
and (2) alters the expression of a large number of genes not dependent on VEGF, the 
majority relating to angiogenesis and inflammation which are independent of VEGF. 
The array results showed for the first time that apple procyanidin fraction dp 4 (at 
potentially physiological concentrations) completely blocked VEGF-mediated gene 
regulation. Therefore the complete inhibition of VEGF-mediated genes by apple 
procyanidin fraction dp 4 provides a plausible link between consumption of polyphenols 
and a reduced risk of CVD. 
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Chapter 7 : Induction of KLF2 mRNA expression by 
apple procyanidin fraction dp 4 is independent of 
PI3K/AKT activation 
7.1 Abstract 
In the microarray experiment conducted in Chapter 6 it was found that apple 
procyanidin fraction dp 4 induces the transcription of genes related to angiogenesis 
and inflammation which were independent of VEGF. One of those genes that was 
found to be induced by apple procyanidin fraction dp 4 was KLF2. Reports have 
suggested that KLF2 expression is up-regulated in response to increased transcription 
of MEF2 through a PI3K/AKT signalling pathway and it was recently demonstrated that 
ANGPT1 induces KLF2 expression through this pathway (Sako et al., 2009). Therefore 
it was hypothesised that apple procyanidin fraction dp 4 induces KLF2 expression by 
increasing ANGPT1 protein secretion which in turn induces KLF2 expression through 
the stimulation of MEF2 transcription by PI3K/AKT activation. Hence the ability of apple 
procyanidin fraction dp 4 and ANGPT1 to induce AKT phosphorylation and KLF2, 
MEF2A and ANGPT1 transcription was investigated in the presence or absence of 
PI3K inhibitors. Apple procyanidin fraction dp 4 and ANGPT1 induced AKT 
phosphorylation and significantly increased both KLF2 and MEF2A mRNA levels in the 
absence of the PI3K inhibitors. However, apple procyanidin fraction dp 4 did not cause 
an increase in ANGPT1 mRNA levels or protein secretion. These data indicate that 
apple procyanidin fraction dp 4 induction of KLF2 mRNA expression is not dependent 
on the activation of the PI3K/AKT pathway by ANGPT1. In the presence of the PI3K 
inhibitors, apple procyanidin fraction dp 4 and ANGPT1-induced AKT phosphorylation 
was reduced. However, apple procyanidin fraction dp 4 was still able to significantly 
induce both KLF2 and MEF2A mRNA expression, but there was no significant increase 
after ANGPT1 treatment. Therefore, the induction of KLF2 mRNA expression by apple 
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procyanidin fraction dp 4 is independent of the PI3K/AKT signalling pathway and may 
be induced by another pathway such as the MEK5/ERK5, ERK1/2, JNK or p38 kinase 
signalling pathway. Induction of KLF2 expression by apple procyanidin fraction dp 4 
may be an important mechanism explaining how certain polyphenols inhibit 
angiogenesis as well as reducing the risk of cardiovascular disease.  
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7.2 Introduction 
Apple procyanidin fraction dp 4 inhibits the cellular effects exerted by VEGF as well as 
inducing genes related to angiogenesis and inflammation which are independent of 
VEGF, as described in Chapter 6. One of the genes that was found to be induced by 
apple procyanidin fraction dp 4 was Krüppel-like factor 2 (KLF2). KLF2 was identified 
as a gene of interest because it has been recognised as an important transcription 
factor in the suppression of pro-inflammatory and pro-atherosclerotic genes such as 
VCAM1, E-selectin, EDN1 and tissue factor as well as inducing antithrombotic and 
thrombolytic genes (Bhattacharya et al., 2005; Dekker et al., 2006; Caton et al., 2010).  
 
7.2.1 Krüppel-like factor 2 
KLF2 is a member of the Krüppel-like factor (KLF) family of transcription factors. KLFs 
are a subclass of the zinc-family of transcriptional regulators implicated in the 
regulation of cell processes including cell growth, development and differentiation 
(Bhattacharya et al., 2005; Suske et al., 2005; Hamik et al., 2006; Wu et al., 2008a). 
There are more than 15 known family members and the KLFs are named according to 
the tissues in which they were originally shown to be enriched (Bieker, 2001; 
Cullingford et al., 2008). For example, KLF1 was found to be enriched in the erythroid 
and is also known as erythroid KLF; KLF2 is lung KLF; KLF4 is gut KLF; KLF5 is 
intestinal KLF; and KLF15 is kidney KLF (Black et al., 2001; Cullingford et al., 2008). 
 
Members of the KLF family bind to GC-rich or CACCC sequences in the promoter 
region of target genes to regulate transcription (Black et al., 2001; Kaczynski et al., 
2003; Bhattacharya et al., 2005; Lin et al., 2005). Although the KLFs have similar DNA 
binding activities they vary widely in their regulation of transcription. KLFs can either 
function as transcriptional activators or repressors depending on the cellular context in 
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which they function and the promoters to which they bind (Turner and Crossley, 1999; 
Black et al., 2001; Kaczynski et al., 2003; Wu et al., 2008a). However KLFs are 
important transcription factors as expression and gene-knockout studies have shown 
that KLFs regulate fundamental cellular processes such as growth, development, 
apoptosis, angiogenesis, proliferation and differentiation (Black et al., 2001; Suske et 
al., 2005; Cullingford et al., 2008; Hart et al., 2011). 
 
KLF2 has numerous functions in the suppression of pro-inflammatory and 
pro-atherosclerotic genes as well as inducing antithrombotic and thrombolytic genes 
and regulating angiogenesis. KLF2 is expressed at high levels in the lung but is also 
abundant in endothelial cells, T cells, preadipocytes and lymphocytes (Turner and 
Crossley, 1999; Bhattacharya et al., 2005; Dekker et al., 2005; Suske et al., 2005; 
Hamik et al., 2006). In the embryo, KLF2 expression is required for normal vessel 
function and vascular development. KLF2 deficient mice exhibit vascular defects 
despite showing normal angiogenesis and vasculogenesis (Suske et al., 2005; Dekker 
et al., 2006), however these mice die mid gestation due to haemorrhaging as a result of 
defective blood vessel morphology and destabilization of the vessel wall due to the lack 
of KLF2 (Kuo et al., 1997; Turner and Crossley, 1999; Dekker et al., 2005; Lin et al., 
2005; Suske et al., 2005; Hamik et al., 2006). KLF2 has also been shown to suppress 
pro-inflammatory targets such as VCAM1, E-selectin, EDN1 and tissue factor 
(Bhattacharya et al., 2005; Dekker et al., 2005; Caton et al., 2010), induce anti-
inflammatory and anti-thrombotic targets such as eNOS and THBD (Dekker et al., 
2005; Lin et al., 2005; van Thienen et al., 2006), promote T-cell quiescence and 
survival (Turner and Crossley, 1999; Black et al., 2001; Hart et al., 2011), and regulate 
angiogenesis through the inhibition of VEGF mediated angiogenesis via reduction in 
VEGFR2 mRNA and protein expression (Bhattacharya et al., 2005; Dekker et al., 2006; 
Hamik et al., 2006) and the induction of the potent anti-migratory factor SEMA3F 
(Dekker et al., 2006). 
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7.2.2 Induction of Krüppel-like factor 2 expression 
KLF2 mRNA expression has been shown to be induced by steady laminar shear stress 
(Dekker et al., 2002; Groenendijk et al., 2004; Suske et al., 2005; Hamik et al., 2006; 
van Thienen et al., 2006), angiopoietin 1 (ANGPT1) (Sako et al., 2009), EDN1 
(Cullingford et al., 2008), statins (van Thienen et al., 2006) and by apple procyanidin 
extracts (García-Conesa et al., 2009; Caton et al., 2010). It has been reported that 
induction of KLF2 expression is via the activation of transcription factor myocyte 
enhancer factor 2 (MEF2) through the mitogen-activated protein kinase 5 
(MEK5)/ERK5 (Sohn et al., 2005; Parmar et al., 2006; van Thienen et al., 2006; Sako 
et al., 2009; Young et al., 2009) or PI3K/AKT signalling pathway (Huddleson et al., 
2005; van Thienen et al., 2006; Sako et al., 2009).  
 
Recently it has also been demonstrated that phosphorylation of Tie2 by ANGPT1 
stimulated the transcriptional activity of MEF2, through the PI3K/AKT pathway, to 
induce KLF2 expression (Sako et al., 2009). ANGPT1 is a protein that suppresses 
anti-inflammatory and anti-permeability factors and regulates endothelial survival 
(Stoeltzing et al., 2003) and MEF2 is a family of transcription factors, composed of four 
members (MEF2A, MEF2B, MEF2C and MEF2D), known for their regulation in 
vascular function (Ornatsky et al., 1999; van Thienen et al., 2006; Maiti et al., 2008).  
 
In a microarray analysis, apple procyanidin fraction dp 4 was shown to up-regulate 
KLF2, MEF2A and MEF2C gene expression in HUVECs (Chapter 6). The regulation of 
ANGPT1 and AKT gene expression was not significant with the apple procyanidin 
fraction dp 4 at the experimental time point of 6 h (Chapter 6). It was therefore 
hypothesised that apple procyanidin fraction dp 4 induces KLF2 expression through an 
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increase in ANGPT1 protein secretion which in turn causes an increase in KLF2 
expression through the P13K/AKT/MEF2 pathway (Figure 7.1). 
 
Figure 7.1: Proposed mechanism of KLF2 induction by apple procyanidin fraction dp 4.  
It is hypothesised that apple procyanidin fraction dp 4 increases the expression of KLF2 through the 
increase in protein secretion of ANGPT1. ANGPT1/Tie2 signalling causes the activation and 
phosphorylation       of PI3K/AKT which then induces MEF2 transcription which in turn induces KLF2 
expression.  
 
 
 
7.3 Objectives 
The overall aim of the current study was to investigate whether apple procyanidin 
fraction dp 4 induces KLF2 expression by causing an increase in ANGPT1 protein 
secretion which in turn induces KLF2 expression through the stimulation of MEF2 
transcription by PI3K/AKT phosphorylation. The specific aims of the chapter were to: 1) 
evaluate the ability of apple procyanidin fraction dp 4 and ANGPT1 to induce AKT 
phosphorylation; 2) measure the induction of MEF2 and KLF2 mRNA levels by apple 
procyanidin fraction dp 4 and ANGPT1 treatments; 3) determine whether apple 
procyanidin fraction dp 4 increases ANGPT1 mRNA expression and protein secretion; 
and 4) establish whether the increase in KLF2 mRNA expression is dependent on the 
PI3K/AKT pathway. 
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ANGPT1 PI3K/AKT MEF2 KLF2 
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7.4 Materials and methods 
7.4.1 Materials 
Human recombinant angiopoietin-1 and human angiopoietin-1 Quantikine ELISA kit 
was obtained from R&D Systems Europe Ltd (Abingdon, UK). All RT-PCR products 
were from Applied Biosystems. Electrophoresis reagents were purchased from 
Invitrogen. The phospho-AKT (Ser 473) monoclonal antibody, the anti-rabbit IgG HRP-
linked antibody, the PI3K inhibitors LY294002 and wortmannin were from Cell 
Signaling and the KLF2 antibody and bovine anti-goat IgG HRP-linked antibody was 
from Santa Cruz (CA, USA). The apple procyanidin fraction dp 4 was purified from the 
2007 apples (Chapter 3) provided by Coressence ltd (Herefordshire, UK) as previously 
described (Yanagida et al., 1999; Shoji et al., 2005; Shoji et al., 2006b), with some 
modifications. A brief description of the method can be found in Chapter 4 or a more 
detailed description of the method is located in the Supplementary Information 
(Supplementary Information 1).  
 
7.4.2 Cell culture and treatments 
7.4.2.1 Cell culture 
The culture of HUVECs is the same as described in Chapter 4, Section 4.4.2.  
 
7.4.2.2 Treatments 
HUVECs were treated in two different manners, with and without PI3K inhibitors. In the 
absence of PI3K inhibitors flavanol and growth factor treatments were prepared in 
Universal tubes prior to adding them to the confluent monolayers. Apple procyanidin 
fraction dp 4 (1 µM), ANGPT1 (200 ng/ml) or the control (vehicle: DMSO) were added 
to a Universal tube containing basal medium and incubated at room temperature for 5 
min. HUVEC confluent monolayers were washed twice with warm phosphate buffered 
saline (PBS), to remove any residual growth factors, and prepared treatments were 
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added to the respective wells and incubated for 5 min, 1, 4, 6 and/or 24 h for Western 
and mRNA analysis at 37 ºC under a humidified atmosphere containing 5 % CO2. 
 
In the presence of PI3K inhibitors, HUVEC confluent monolayers were washed twice 
with warm phosphate buffered saline (PBS) and prepared basal medium containing the 
PI3K inhibitors were added to the cells for 1 h. The prepared PI3K inhibitor medium 
contained either 50 µM LY294002 or 1 µM wortmannin. After incubation either 1 µM 
apple procyanidin fraction dp 4, 200 ng/ml ANGPT1 or vehicle (DMSO, control) were 
added to the cells and incubated for 5 min, 1, 4, 6 and/or 24 h for Western and mRNA 
analysis at 37 ºC under a humidified atmosphere containing 5 % CO2.  
 
7.4.3 Protein determination 
7.4.3.1 Protein extraction 
The extraction of protein was the same method as described in Chapter 4, 
Section 4.4.6. 
 
7.4.3.2 Western blot 
Phosphorylated AKT expression levels and KLF2 protein levels were detected by 
Western blot. The method of preparing the protein and the gels and the blocking, 
probing, detection and re-probing of the gels was the same method as described in 
Chapter 4, Section 4.4.7.  
 
For the detection of phosphorylated AKT, the primary antibody used was of phospho-
AKT (Ser 473) antibody (5 µl antibody in 5 ml of 5 % BSA in TBST) and the secondary 
antibody was anti-rabbit IgG, HRP-linked antibody (10 µl in 10 ml of 5 % skimmed milk 
in TBST). For the detection of KLF2, the primary antibody used was KLF2 antibody 
(25 µl KLF2 antibody in 5 ml of 5 % skimmed milk in TBST) and the secondary 
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antibody was bovine anti-goat IgG HRP-linked antibody (5 µl in 10 ml of 5 % skimmed 
milk in TBST). 
 
7.4.3.3 Angiopoietin-1 ELISA determination 
ANGPT1 protein levels were measured by ELISA following the manufacturer’s 
instructions using the cell medium to determine ANGPT1 secreted protein levels. After 
the incubation, washing and labelling steps, absorption was measured at 450 nm using 
a Dynex 96 well microplate reader. 
 
7.4.4 RNA extraction 
After treatment incubation, HUVECs were washed twice with warm PBS and the RNA 
was extracted using the RNeasy® Mini Kit (Qiagen Ltd, UK) according to the 
manufacturer’s protocol. The homogenization step in the protocol was achieved by 
using a QIAshredder (Qiagen Ltd, UK). The quality and quantity of RNA present in the 
samples was quantified using a Beckman DU-640 spectrometer prior to storage at 
-80 ºC. For a pure and good quality RNA sample the absorbance at 260/280 should be 
approximately 2; this was observed for all the samples. 
 
7.4.5 Real-time Reverse Transcription Polymerase Chain reaction 
Pre-designed gene assays for KLF2 (Assay ID: Hs00360439_g1), MEF2A (Assay ID: 
Hs01050409_m1) and ANGPT1 (Assay ID: Hs00375822_m1) were purchased from 
Applied Biosystems. Target gene mRNA levels were determined by real time RT-PCR 
as described in Chapter 6, Section 6.4.5.   
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7.4.6 Statistical analysis 
Where indicated, comparisons between mean values between control and treated 
samples were carried out using a two tailed t-test. A p value < 0.05 was considered 
significant.  
 
7.5 Results 
7.5.1 Apple procyanidin fraction dp 4 and angiopoietin-1 both induce 
KLF2 expression 
The microarray analysis in Chapter 6 showed that apple procyanidin fraction dp 4 
induced KLF2 expression (1.67 fold induction) at a p value of < 0.001. Therefore in 
order to test the hypothesis that apple procyanidin fraction dp 4 induces KLF2 
expression through the ANGPT1 signalling pathway and confirm the results of the 
microarray analysis, the KLF2 transcript levels in apple procyanidin fraction dp 4 and 
ANGPT1 treated HUVECs was quantified.  
 
HUVECs were treated with either 1 µM apple procyanidin fraction dp 4, 200 ng/ml 
ANGPT1 or vehicle (DMSO, control) for 5 min, 1, 4, 6 and 24 h and analysed for KLF2 
mRNA transcript levels by RT-PCR. The data show that HUVECs treated with the 
vehicle exhibited an increase in KLF2 mRNA levels at 1 h (Figure 7.2). The expression 
of KLF2, in vehicle-treated cells, at 4 h and 6 h then decreased to below the level at 
5 min and returned to baseline at 24 h. This shows that KLF2 mRNA levels fluctuate 
during a 24 h period.  
 
When HUVECs were treated with apple procyanidin fraction dp 4, a statistically 
significant increase in KLF2 mRNA levels was observed at 4 h (p = 0.01) and 6 h 
(p = 0.01). A statistically significant increase in KLF2 mRNA levels was also observed 
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with ANGPT1 treatment at 1 h (p = 0.043), 4 h (p = 0.01), 6 h (p = 0.01) and 24 h 
(p = 0.008). Based on these results it can be concluded that apple procyanidin fraction 
dp 4 and ANGPT1 induce KLF2 gene expression and that ANGPT1 causes a more 
prolonged induction of KLF2 expression than apple procyanidin fraction dp 4. The 
increase of KLF2 expression by apple procyanidin fraction dp 4 is also consistent with 
the microarray analysis. 
 
 
Figure 7.2: Apple procyanidin fraction dp 4 and ANGPT1 induce KLF2 mRNA 
transcription.  
HUVECs were treated with pre-incubated basal medium containing either 1 µM apple procyanidin fraction 
dp 4, 200 ng/ml ANGPT1 or the vehicle (DMSO, control) for 5 min, 1, 2, 4, 6 and h. RNA was extracted 
from the cells using the RNeasy® Mini Kit and the KLF2 quantity was determined by real time RT-PCR. 
Bars represent means ± standard deviation expressed as a quantity of KLF2 normalised against 18S. *p < 
0.05, ** p < 0.01 compared to the control at each time point. ††† p < 0.001 compared to the control at 0 h. 
Data are representative of three independent experiments with two biological and two technical replicates.  
 
KLF2 protein content was also determined by Western blot. HUVECs were treated with 
either 1 µM apple procyanidin fraction dp 4 or 200 ng/ml ANGPT1 for 5 min, 1, 4, 6 and 
24 h. The data demonstrate that there is no change in protein expression in the vehicle, 
apple procyanidin fraction dp 4 or ANGPT1 treated cells (Figure 7.3).  
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Figure 7.3: Apple procyanidin fraction dp 4 and ANGPT1 do not change the protein 
expression of KLF2.  
HUVECs were treated with pre-incubated basal medium containing either 1 µM apple procyanidin fraction 
dp 4, 200 ng/ml ANGPT1 or vehicle (DMSO, control) for 5 min, 1, 4, 6 or 24 h. The cells were lysed and 
the proteins were separated on a NuPAGE gel and probed for the presence of KLF2 and β-actin (control 
protein). Data are representative of triplicate replicates of three independent experiments.  
 
7.5.2 Apple procyanidin fraction dp 4 and angiopoietin-1 induce 
phosphorylation of AKT 
It has previously been reported that the induction of KLF2 expression is dependent on 
the activation of the PI3K/AKT pathway (Huddleson et al., 2005; van Thienen et al., 
2006; Cullingford et al., 2008; Sako et al., 2009). In order to confirm that the induction 
of KLF2 by apple procyanidin fraction dp 4 and ANGPT1 is dependent on the activation 
of AKT, the effects of these treatments on AKT phosphorylation were evaluated.  
 
HUVECs were treated for 1 h with either 1 µM apple procyanidin fraction dp 4, 
200 ng/ml ANGPT1 or vehicle (DMSO, control) in order to confirm phosphorylation of 
AKT. The data presented show that HUVECs, with no added treatments, do not induce 
phosphorylation of AKT. However, when HUVECs were treated with either apple 
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procyanidin fraction dp 4 or ANGPT1, phosphorylation of AKT was induced 
(Figure 7.4).  
 
Figure 7.4: Apple procyanidin fraction dp 4 and ANGPT1 induce phosphorylation of AKT. 
HUVECs were treated with pre-incubated basal medium containing either 1 µM apple procyanidin fraction 
dp 4, 200 ng/ml ANGPT1 or vehicle (DMSO, control) for 1 h. The cells were lysed and the proteins were 
separated on a NuPAGE gel and probed for the presence of phosphorylated AKT at the serine 473 site and 
β-actin (control protein). Data are representative of triplicate replicates of six independent experiments. 
 
7.5.3 Apple procyanidin fraction dp 4 and angiopoietin-1 induce 
MEF2A expression 
After activation of the PI3K/AKT signalling pathway, the next step in the induction of 
KLF2 expression is the increase in MEF2 expression. In the microarray analysis from 
Chapter 6, apple procyanidin fraction dp 4 was shown to increase MEF2A (1.32 fold 
induction) and MEF2C (1.39 fold induction) expression after a 6 h incubation (p < 0.01). 
To confirm the results of the microarray analysis, the induction of MEF2A transcription 
was determined by RT-PCR.  
 
HUVECs were treated with either 1 µM apple procyanidin fraction dp 4, 200 ng/ml 
ANGPT1 or vehicle (DMSO, control) for 5 min, 1, 4, 6 and 24 h. The quantity of MEF2A 
expression increased in the control samples from 80 to 110 ng during the time period 
5 min to 24 h (Figure 7.5). This shows that MEF2A transcription increases over a 24 h 
period.  
 
When treated with apple procyanidin fraction dp 4, a significant increase in MEF2A 
mRNA levels was observed at the treatment time points of 5 min (p = 0.043), 4 h 
Control
+ + + + +
1 µM dp 4 200 ng/ml ANGPT1
p-AKT 
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(p < 0.0001) and 6 h (p = 0.002) when compared to the control at each time point. A 
significant increase in MEF2A mRNA expression was also observed with the treatment 
of ANGPT1. A significant increase was observed at 4 h (p = 0.036) and 6 h (p = 0.031) 
when compared to the control at each time point. Based on these results in can be 
concluded that apple procyanidin fraction dp 4 and ANGPT1 induce MEF2A 
transcription and that apple procyanidin fraction dp 4 causes a greater induction of 
MEF2A expression than ANGPT1. The increase of MEF2A expression by apple 
procyanidin fraction dp 4 is also consistent with the data from the microarray analysis.  
 
 
Figure 7.5: Apple procyanidin fraction dp 4 and ANGPT1 induce MEF2A mRNA 
transcription.  
HUVECs were treated with pre-incubated basal medium containing either 1 µM apple procyanidin fraction 
dp 4, 200 ng/ml ANGPT1 or the vehicle (DMSO, control) for 5 min, 1, 2, 4, 6 and h. RNA was extracted 
from the cells using the RNeasy® Mini Kit and the MEF2A quantity was determined by real time RT-PCR. 
Bars represent means ± standard deviation expressed as a quantity of MEF2A normalised against 18S. 
*p < 0.05, *** p < 0.001 compared to the control at each time point. † p < 0.05, †† p < 0.01 compared to 
the control at 0 h. Data are representative of three independent experiments with two biological and two 
technical replicates.   
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7.5.4 Apple procyanidin fraction dp 4 does not increase 
angiopoietin-1 protein secretion or induce angiopoietin-1 expression 
In Sections 7.5.1-3 it was shown that apple procyanidin fraction dp 4 induces PI3K/AKT 
phosphorylation and induces MEF2A and KLF2 transcription in the same manner as 
ANGPT1. Therefore the induction of KLF2 by apple procyanidin fraction dp 4 may be 
dependent on apple procyanidin fraction dp 4 increasing the protein secretion of 
ANGPT1.  
 
HUVECs were treated with either 1 µM apple procyanidin fraction dp 4, 200 ng/ml 
ANGPT1 or vehicle (DMSO, control) for 5 min, 1, 4, 6 and 24 h and ANGPT1 
expression was either analysed by RT-PCR or ELISA. Analysis by RT-PCR measures 
the increase in ANGPT1 mRNA levels whereas analysis by ELISA measures the 
quantity of circulating ANGPT1 protein in the medium.   
 
For RT-PCR analysis the data shows that there is an overall decrease in ANGPT1 
mRNA expression in HUVECs treated with the vehicle. The decrease is statistically 
significant at 4 h (p = 0.044), 6 h (p = 0.002) and 24 h (p < 0.0001) when compared to 
the 5 min control time point (Figure 7.6). When HUVECs were treated with apple 
procyanidin fraction dp 4, a statistically significant decrease in ANGPT1 mRNA levels 
was also observed at 4 h (p = 0.025) and 6 h (p < 0.0001). Treating the cells with 
ANGPT1 did not further increase ANGPT1 transcription.  
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Figure 7.6: Apple procyanidin fraction dp 4 does not induce ANGPT1 mRNA 
transcription. 
HUVECs were treated with pre-incubated basal medium containing either 1 µM apple procyanidin fraction 
dp 4, 200 ng/ml ANGPT1 or the vehicle (DMSO, control) for 5 min, 1, 2, 4, 6 and h. RNA was extracted 
from the cells using the RNeasy® Mini Kit and the ANGPT1 quantity was determined by real time RT-PCR. 
Bars represent means ± standard deviation expressed as a quantity of ANGPT1 normalised against 18S. 
**p < 0.01, *** p < 0.001 compared to the control at each time point. †† p < 0.01 compared to the control at 
0 h. Data are representative of three independent experiments with two biological and two technical 
replicates.   
 
The determination of the quantity of ANGPT1 protein circulating by ELISA showed that 
the vehicle and apple procyanidin fraction dp 4 treated HUVECs do not cause an 
increase in the amount of ANGPT1 protein secreted in the medium (Figure 7.7). The 
quantification of these two treatments by ELISA resulted in values below the plate 
blank measurement; therefore the quantities of ANGPT1 were not detectable. The 
amount of ANGPT1 in the medium of ANGPT1 treated HUVECs decreased from 
37.75 ng/ml to 14.75 ng/ml from 5 min to 24 h. Since the HUVECs were treated with 
200 ng/ml of ANGPT1, these data suggest that a large proportion of ANGPT1 is utilised 
by the cells in the first 5 min and this is followed by a slow reduction in ANGPT1 from 
1 h to 24 h.  
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Based on these results it can be concluded that apple procyanidin fraction dp 4 does 
not induce ANGPT1 mRNA expression or increase ANGPT1 protein secretion. 
Therefore the induction of KLF2 by apple procyanidin fraction dp 4 is independent of 
ANGPT1.  
 
 
Figure 7.7: Apple procyanidin fraction dp 4 does not induce ANGPT1 protein secretion.  
HUVECs were treated with pre-incubated basal medium containing either 1 µM apple procyanidin fraction 
dp 4, 200 ng/ml ANGPT1 or the vehicle (DMSO, control) for 5 min, 1, 2, 4, 6 and h. The medium was 
collected, centrifuged and the ANGPT1 protein content was determined by an Angiopoietin-1 Quantikine 
ELISA kit. ANGPT1 content could not be determined as it was below the plate bland measurement. Bars 
represent means ± standard deviation expressed as the quantity of ANGPT1 (pg/ml). Data are 
representative of one independent experiment with two biological and two technical replicates.  
 
7.5.5 Apple procyanidin fraction dp 4 induced KLF2 mRNA 
expression is not dependent on AKT phosphorylation 
Apple procyanidin fraction dp 4-induced KLF2 mRNA transcription has been shown to 
be similar to ANGPT1-induced KLF2 mRNA transcription; both compounds induce AKT 
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phosphorylation and MEF2A and KLF2 expression to a similar extent. However, the 
induction of AKT phosphorylation, and MEF2A and KLF2 mRNA transcription by apple 
procyanidin fraction dp 4 is not a result of increased ANGPT1/Tie2 signalling 
(Section 7.5.4). In order to test whether the induction of KLF2 by apple procyanidin 
fraction dp 4 is dependent on the activation of the PI3K/AKT signalling pathway, 
HUVECs were treated with PI3K inhibitors.  
 
HUVECs were pre-treated with either 50 µM LY294002, 1 µM wortmannin or no 
inhibitors for 1 h to allow for the inhibition of PI3K. Pre-incubated HUVECs with or 
without inhibitors were then treated with either 1 µM apple procyanidin fraction dp 4 or 
200 ng/ml or the vehicle (DMSO, control) for 1 h for Western blot analysis or for 6 h for 
mRNA expression analysis. The data in Figure 7.8 show that when HUVECs were 
treated with the vehicle, AKT phosphorylation is not increased, but when the cells are 
treated with either apple procyanidin fraction dp 4 or ANGPT1, phosphorylation of AKT 
increases substantially (Figure 7.8 A & B). When treated with the PI3K inhibitors 
LY294002 (Figure 7.8 A) or wortmannin (Figure 7.8 B) the induction of AKT 
phosphorylation is reduced compared to the inhibitor-free cell treatments.  
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Figure 7.8: PI3K inhibitors LY294002 and wortmannin reduce apple procyanidin fraction 
dp 4 and ANGPT1-induced AKT phosphorylation.  
HUVECs were treated with either basal medium or medium containing 50 µM LY294002 (A) or 1 µM 
wortmannin (B) for 1 h prior to the addition of treatments. Pre-incubated HUVECs with or without PI3K 
inhibitors were treated with either 1 µM apple procyanidin fraction dp 4, 200 ng/ml ANGPT1 or the vehicle 
(DMSO, control) for 1 h. The cells were lysed and the proteins were separated on a NuPAGE gel and 
probed for the presence of phosphorylated AKT at the serine 473 site and β-actin (control protein). Data 
are representative of triplicate replicates of two independent experiments. 
 
RT-PCR analysis of KLF2 shows that apple procyanidin fraction dp 4 and ANGPT1 
treatments caused a significant increase of KLF2 mRNA levels in the absence of PI3K 
inhibitors (Figure 7.9). PI3K inhibitor LY294002 significantly increased (p < 0.001) 
KLF2 mRNA levels in vehicle treated HUVECs whereas wortmannin significantly 
decreased (p < 0.001) KLF2 mRNA transcription. Apple procyanidin fraction dp 4 was 
still able to induce KLF2 mRNA transcription in the presence of LY294002 (p = 0.009) 
and wortmannin (p = 0.008) while the increase in ANGPT1-induced KLF2 expression 
was not significant (p > 0.05). Western blot analysis of KLF2 protein expression shows 
no difference between treatments (Figure 7.8).  
Control
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Figure 7.9: Apple procyanidin fraction dp 4 induces KLF2 mRNA transcription in the 
presence or absence of the PI3K inhibitors LY294002 and wortmannin.  
HUVECs were treated with either basal medium or medium containing 50 µM LY294002 or 1 µM 
wortmannin for 1 h prior to the addition of treatments. Pre-incubated HUVECs with or without PI3K 
inhibitors were treated with either 1 µM apple procyanidin fraction dp 4, 200 ng/ml ANGPT1 or the vehicle 
(DMSO, control) for 1 h. RNA was extracted from the cells using the RNeasy® Mini Kit and the KLF2 
quantity was determined by real time RT-PCR. Bars represent means ± standard deviation expressed as a 
quantity of KLF2 normalised against 18S. * p < 0.05, **p < 0.01, compared to the control of each treatment 
condition. †† p < 0.01 compared to the control with LY294002. ‡ ‡ p < 0.01 compared to the control with 
wortmannin. Data are representative of two independent experiments with two biological and two technical 
replicates. 
 
The change in MEF2A expression in response to apple procyanidin fraction dp 4 
treatment follows a similar pattern to that of KLF2. PI3K inhibitor LY294002 causes a 
significant decrease (p = 0.005) in MEF2A mRNA levels in vehicle treated HUVECs 
while there is no change (p > 0.05) in MEF2A expression in wortmannin treated cells 
(Figure 7.10). Apple procyanidin fraction dp 4 treatment induces MEF2A expression in 
the absence (p = 0.003) and presence of PI3K inhibitors (LY294002 p < 0.0001; 
wortmannin p = 0.007). No significant increases (p > 0.05) in MEF2A mRNA levels in 
response to ANPGT1 were observed in any of the treatments. Based on this data it can 
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be concluded that the induction of KLF2 expression by apple procyanidin fraction dp 4 
is independent of the activation of the PI3K/AKT signalling pathway. However, since 
ANGPT1 did not cause a significant increase in MEF2A or KLF2 mRNA expression in 
the presence of either of the PI3K inhibitors, it can be concluded that the activation of 
these two transcription factors by ANGPT1 is dependent on PI3K/AKT activation.  
 
 
 
Figure 7.10: Apple procyanidin fraction dp 4 induces MEF2A mRNA transcription in the 
presence or absence of the PI3K inhibitors LY294002 and wortmannin.  
HUVECs were treated with either basal medium or medium containing 50 µM LY294002 or 1 µM 
wortmannin for 1 h prior to the addition of treatments. Pre-incubated HUVECs with or without PI3K 
inhibitors were treated with either 1 µM apple procyanidin fraction dp 4, 200 ng/ml ANGPT1 or the vehicle 
(DMSO, control) for 1 h. RNA was extracted from the cells using the RNeasy® Mini Kit and the MEF2A 
quantity was determined by real time RT-PCR. Bars represent means ± standard deviation expressed as a 
quantity of MEF2A normalised against 18S. ** p < 0.01, ***p < 0.001, compared to the control. ††† p < 
0.001 compared to the control with LY294002. ‡‡ p < 0.01 compared to the control with wortmannin. Data 
are representative of two independent experiments with two biological and two technical replicates. 
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7.6 Discussion 
The data presented in this chapter show that: (1) apple procyanidin fraction dp 4 and 
ANGPT1 activate the PI3K/AKT pathway and induce MEF2A and KLF2 mRNA 
transcription; (2) the induction of KLF2 by apple procyanidin fraction dp 4 was 
independent of ANGPT1; and (3) the induction of KLF2 expression by apple 
procyanidin fraction dp 4 was not dependent on phosphorylation of AKT by PI3K 
whereas induction of KLF2 expression by ANGPT1 was dependent on the activation of 
AKT by PI3K.   
 
KLF2 is an important transcription factor involved in the suppression of 
pro-inflammatory and pro-atherosclerotic genes as well as inducing anti-thrombotic 
genes. KLF2 mRNA has been shown to be induced by a number of factors including 
ANGPT1, apple procyanidin fraction dp 3.9 (García-Conesa et al., 2009) and tetrameric 
and pentameric apple procyanidin fractions (Caton et al., 2010). The induction of KLF2 
expression has been shown to be dependent on the activation of MEF2 transcriptional 
activity (Huddleson et al., 2005; van Thienen et al., 2006; Sako et al., 2009). MEF2 
transcription factors are a subfamily of the MADS box family of transcription factors and 
the MEF2 family members (MEF2A, MEF2B, MEF2C and MEF2D) are best known for 
their critical role in the morphogenesis and myogenesis of skeletal, cardiac and smooth 
muscle cells (Ornatsky et al., 1999; Kumar et al., 2005; Hamik et al., 2006; van 
Thienen et al., 2006; Maiti et al., 2008). Target gene knockdown of MEF2 has been 
shown to reduce KLF2 expression (Kumar et al., 2005; Sen-Banerjee et al., 2005; Sako 
et al., 2009), therefore creating a pivotal role of MEF2 in the induction of KLF2. 
 
MEF2 factors have been implicated as targets for signalling cascades in response to 
serum stimulation and cellular stressors (Ornatsky et al., 1999) and it has been shown 
that the transcriptional activity of MEF2 is increased by the MEK5/ERK5 (Kato et al., 
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1997; Yang et al., 1998a; Ornatsky et al., 1999; Sohn et al., 2005; Parmar et al., 2006; 
Young et al., 2009) or the PI3K/AKT signalling pathways (Huddleson et al., 2005; van 
Thienen et al., 2006; Sako et al., 2009; Zahlten et al., 2010). The present study 
investigated the role of the PI3K/AKT pathway in the induction of MEF2 and KLF2 
expression, partly because AKT had already been shown to be induced by apple 
procyanidins (Chapter 4, Section 4.5.5). It was hypothesised that the induction of KLF2 
expression may be dependent on apple procyanidin fraction dp 4 increasing ANGPT1 
protein secretion. ANGPT1 is an important mediator of angiogenesis through its 
regulation of endothelial cell survival (Stoeltzing et al., 2003) and has been shown to 
induce KLF2 expression through the activation of the PI3K/AKT pathway (Sako et al., 
2009; Fukuhara et al., 2010). ANGPT1 exerts its cellular effects by binding to the 
tyrosine receptor Tie2.  
 
Treatment of HUVECs with apple procyanidin fraction dp 4 and ANGPT1 induced 
phosphorylation of AKT as well as increasing the transcription of MEF2A and KLF2. 
These observations are consistent with previously reported data showing induction of 
AKT phosphorylation by apple procyanidins (Chapter 4, Section 4.5.5) and ANGPT1 
(Sako et al., 2009) as well as the increases in KLF2 expression induced by apple 
procyanidins (Chapter 6) (García-Conesa et al., 2009; Caton et al., 2010) and ANGPT1 
(Sako et al., 2009). However apple procyanidin fraction dp 4 did not increase ANGPT1 
mRNA transcription or protein secretion, therefore the activation of the P13K/AKT 
pathway by apple procyanidin fraction dp 4 was independent of ANGPT1/Tie2 
signalling. In order to establish whether apple procyanidin fraction dp 4-induced KLF2 
expression was dependent on the PI3K/AKT signalling pathway two chemically 
unrelated PI3K inhibitors were investigated. PI3K inhibitor LY294002 is a highly 
selective inhibitor of PI3K and blocks PI3K-dependent AKT kinase activity (Huddleson 
et al., 2006). Wortmannin is a specific and direct inhibitor of PI3K, and inhibition by 
wortmannin is irreversible and non-competitive (Dimmeler et al., 1998).  
Chapter 7 
 
299 
 
 
The induction of KLF2 expression has been shown to be either regulated by the 
PI3K/AKT pathway (Huddleson et al., 2005; Huddleson et al., 2006; Sako et al., 2009; 
Zahlten et al., 2010) or not regulated by the PI3K/AKT pathway (Cullingford et al., 
2008; Sinclair et al., 2008; Young et al., 2009). Zahlten et al. (2010) demonstrated that 
the PI3K inhibitors LY294002 and wortmannin both reduced pneumococci-related 
KLF2 protein expression in human bronchial epithelial cells. LY294002 was also shown 
to reduce the activation of a KLF2 reporter gene in pneumococci-infected lung 
epithelial cells (Zahlten et al., 2010). In HUVECs, wortmannin reduced the basal 
expression of KLF2 as well as inhibiting ANGPT1 induced KLF2 expression (Sako et 
al., 2009). While Huddleson et al. (2005, 2006) showed that induction of KLF2 
expression by shear stress was blocked when human or mouse 
hemangioendothelioma cells and HUVECs were treated with LY294002. In contrast it 
was shown that the PI3K inhibitor LY294002 increased both basal expression of KLF2 
and promoted the increase in KLF2 expression induced by endothelian-1 or H2O2 in 
cardiac myocytes (Cullingford et al., 2008). In CD8+T cells, the mRNA expression of 
KLF2 was significantly increased in the presence of the PI3K inhibitor LY294002 
(Sinclair et al., 2008). Further, the inhibitors LY294002 and wortmannin had little effect 
on shear-induced increases in KLF2 expression in HUVECs (Young et al., 2009). 
 
The present chapter showed that basal expression of KLF2 was reduced in HUVECs 
treated with wortmannin, but an increase in basal expression was observed with the 
PI3K inhibitor LY294002. ANGPT1-induced KLF2 expression was also reduced in 
response to wortmannin and LY294002 treatment, however the apple procyanidin 
fraction dp 4 was still able to induce KLF2 transcription in the presence of both PI3K 
inhibitors. The observed ANGPT1-mediated induction of KLF2 transcription and 
inhibition of KLF2 transcription in response to wortmannin are consistent with the data 
presented by Sako et al. (2009), and it has generally been shown that wortmannin 
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decreases KLF2 expression. However, LY294002 treatment has had opposing effects 
in different cells lines, and both induction and inhibition of KLF2 transcription have been 
reported. Huddleson et al. (2005, 2006) has shown that KLF2 transcription in HUVECs 
was inhibited with LY294002 while in the present study it was shown to be increased in 
response to LY294002. The reason for this discrepancy may be due to differences in 
cell culture/treatment conditions; Huddleson et al. (2005, 2006) used HUVECs exposed 
to shear stress while HUVECs in the present study were investigated in the static state. 
Therefore the induction of KLF2 expression via the PI3K/AKT pathway may be 
dependent on the cell line used and the treatments applied.  
 
KLF2 transcription has been shown to be increased in response to other signalling 
pathways. In addition to the PI3K/AKT pathway, KLF2 has been reported to be 
increased in response to activation of the MEK5/ERK5 signalling pathway. For 
example, resveratrol has been reported to induce KLF2 expression through SIRT and a 
MEK/MEF2-dependent and ERK5-independent pathway (Gracia-Sancho et al., 2010) 
as well as inducing KLF4 expression via a MEK5/MEF2-dependent, ERK5-independent 
pathway (Villarreal et al., 2010). Apple procyanidin fraction dp 4 may induce KLF2 
expression through this pathway, or through the other three families of MAP kinases: 
the extracellular signal-related protein kinase (ERK1/2), c-Jun N-terminal kinase (JNK) 
and p38 kinase (Ornatsky et al., 1999; Kato et al., 2000) or through another not yet 
identified signalling pathway. From the microarray data in Chapter 6, gene expression 
changes for MEK5, JNK, ERK1/2 and p38 kinase were investigated in the list of 
differentially expressed genes by apple procyanidin fraction dp 4 versus control. In this 
list, ERK1/2 was induced 1.12 fold (p = 0.047) and the expression changes of MEK5, 
JNK and p38 kinase were not significant (Chapter 6).  
 
Apple procyanidin fractions have been reported to increase ERK1/2 and JNK 
expression in human colon cancer-derived metastatic SW620 cells (Gossé et al., 
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2005). However, inhibition of ERK1/2 had no effect on KLF2 promoter activation by 
fluid flow (Huddleson et al., 2005) and the inhibition of p38 kinase, ERK1/2 or JNK had 
no effect on KLF2 expression in lung epithelial cells (Zahlten et al., 2010). Therefore 
the effects of these pathways on the induction of KLF2 expression by apple procyanidin 
fraction dp 4 in HUVECs needs to be investigated.  
 
7.7 Conclusions 
The induction of KLF2 expression by apple procyanidin fraction dp 4 is not dependent 
on PI3K/AKT activation of the transcription factor MEF2, in contrast to ANGPT1 
induction of KLF2 transcription, which is dependent on the PI3K/AKT signalling 
pathway. It can be concluded that the induction of KLF2 transcription via the PI3K/AKT 
pathway is dependent on the cell line used and the treatment applied; different stimuli, 
such as ANGPT1 and apple procyanidin fraction dp 4, trigger different signalling 
pathways to stimulate an increase in KLF2 transcription. The induction of KLF2 
transcription has also been shown to be induced via the MEK5/ERK5, ERK1/2, JNK 
and p38 kinase signalling pathway. Therefore apple procyanidin fraction dp 4 may 
induce KLF2 transcription through one of these pathways and further investigation on 
how apple procyanidin fraction dp 4 increases KLF2 transcription is required. The 
induction of KLF2 transcription by apple procyanidin fraction dp 4 may be an important 
mechanism explaining how certain polyphenols inhibit VEGF-induced angiogenesis as 
well as reducing the risk of cardiovascular disease.  
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Chapter 8 : General discussion and recommendations 
for further research 
8.1 Summary of main findings 
The overall aims of this thesis were to (1) assess the potential of apples as a rich 
source of extractable bioactive polyphenols and (2) investigate the bioactivity of apple 
polyphenols with a focus on understanding mechanisms of action in the vascular 
endothelium. The main findings presented in this thesis are as follows: 
 
• It was shown that polyphenol concentrations are highest in small, young fruits 
but total polyphenol yield is highest in large mature fruits, and that polyphenol 
concentrations and yields were inversely associated with growing season 
temperatures and positively associated with growing season rainfall and 
sunlight. These observations provide new insights into the sources of the 
significant inter-seasonal variation in polyphenol content and composition of 
apples. 
 
• Although the hypothesis that microwave heat treating of fresh apples prior to 
pressing would destroy browning enzymes and increase polyphenol yields 
during apple pressing was disproved, it was demonstrated that hot water 
extraction of apple pomace, the by-product of apple juice production, was a 
very effective method of extracting the polyphenols retained in the pomace and 
yielded a polyphenol-rich aqueous extract.  
 
• Consumption of an apple polyphenol-rich extract supplemented apple juice by 
human subjects resulted in small but significant improvements in mean arterial 
Chapter 8 
 
304 
 
stiffness and vascular age, but not in reflective index, compared to a low 
polyphenol apple juice, demonstrating the potential for health benefits from 
consumption of apple polyphenols.  
 
• A novel mechanism by which certain apple polyphenols can alter vascular 
endothelial cell function at physiological concentrations has been demonstrated. 
This involves binding of apple procyanidin fraction dp4 directly to the signalling 
peptide VEGF, which renders VEGF unable to induce signalling through its 
receptor VEGFR-2. Only a few of the polyphenols tested functioned in this way 
and it was shown that inhibition of VEGF function was not due to non-specific 
protein binding. 
 
• Subsequently it was demonstrated that the inhibition of VEGF activity is 
apparently the result of non-covalent slow binding of one or more molecules of 
apple procyanidin fraction dp 4 to the VEGF protein which results in the 
formation of a tightly bound VEGF-polyphenol complex, and that VEGF-apple 
procyanidin fraction dp 4 complexes were unable to induce any of the multiple 
changes in gene transcription observed for untreated VEGF. 
 
• The global analysis of genes altered by apple procyanidin fraction dp 4, VEGF 
or VEGF:apple procyanidin fraction dp 4 complex treatments also demonstrated 
that apple procyanidin fraction dp 4 regulates genes involved with angiogenesis 
and inflammation that are independent of VEGF, including induction of KLF2 
expression. Finally it was demonstrated that the apple procyanidin fraction dp4-
induced up-regulation of KLF2 transcription was not dependent on PI3K/AKT 
activation of the transcription MEF2, in contrast to ANGPT1-mediated induction 
of KLF2 transcription, which is dependent on the PI3K/AKT signalling pathway. 
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The following sections discuss the implications of the major findings of the research 
presented in the previous chapters in the context of the principal objective which was to 
investigate polyphenols in apples and their interactions with vascular endothelial cells.  
 
8.1.1 Does the consumption of dietary polyphenols contribute to the 
health benefits associated with certain foods (e.g. fruits, vegetables and 
cocoa)? 
The consumption of fruits and vegetables is associated with a reduced risk of chronic 
diseases, including cardiovascular disease as discussed in Chapter 1. The protective 
effects of fruits and vegetables are attributed, in part, to the polyphenols present in 
these foods. The intake of fruits, vegetables and cocoa products rich in epicatechin and 
other flavanols have been shown, in vivo, to (1) improve endothelial function of arterial 
vessels (Stein et al., 1999; Agewall et al., 2000; Chou et al., 2001; Duffy et al., 2001; 
Hodgson et al., 2002; Engler et al., 2004a; Grassi et al., 2005b; Schroeter et al., 2006); 
(2) lower blood pressure (Hollenberg et al., 1997; Taubert et al., 2003; Grassi et al., 
2005a; Schroeter et al., 2006); and (3) reduce LDL cholesterol (Hooper et al., 2008; Jia 
et al., 2010). The improvements in endothelial function and blood pressure are due to 
the increase in the bioavailability and bioactivity of NO as a result of the consumption of 
flavanols (Heiss et al., 2003; Grassi et al., 2005b; Schroeter et al., 2006).  
 
The majority of the dietary intervention trials have assessed the effects of soy- or 
soy-isoflavone-products or the effects of flavanols from tea, cocoa/chocolate or red 
wine/grapes on endothelial function. To date there has only been one dietary 
intervention trial assessing the effects of apple polyphenols on endothelial function 
(Auclair et al., 2010). The dietary intervention trial by Auclair et al. (2010) showed that 
there was no significant difference between the long-term consumption of a 
high-polyphenol or a low-polyphenol re-hydrated lyophilised apple sample in 
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hypercholesterolemic subjects. The human intervention trial presented in this thesis 
contributes to the existing data on the effects of flavanols on endothelial function and 
stiffness index as it shows that markers of vascular function (stiffness index and 
vascular age) are improved after the consumption of a polyphenol-rich apple extract 
supplemented drink (~78 mg epicatechin) in nine non-compromised male subjects. The 
consumption of 78 mg epicatechin is the equivalent of eating 6.5 dessert apples 
(average 8.33 mg epicatechin per 100 g), eating 2 cider apples (average 28.67 mg 
epicatechin per 100g), drinking 5 servings of pure apple juice (serving size is 200 ml; 
average 7.76 mg epicatechin per 100 ml) or drinking ~ 2000 servings of apple juice 
from concentrate (average 0.04 mg epicatechin per 100 ml; average epicatechin 
contents in apple products obtained from www.phenol-explorer.eu). The data from the 
human intervention trial in this thesis shows that high polyphenol apples can improve 
vascular function in the same manner as tea, cocoa/chocolate and red wine/grapes.  
 
Flavanols have also been shown, in vitro, to induce numerous cellular effects but their 
ability to (1) increase NO bioavailability by inhibiting NADPH oxidase activity; (2) 
enhance endogenous antioxidant defences by increasing Nrf2 expression; and (3) 
inhibit VEGF-induced angiogenesis most strongly supports their putative role in 
promoting cardiovascular health. However, in-vitro studies do not always take into 
account the bioavailability and metabolism of dietary polyphenols. The majority of cell-
protective research of flavanols has shown a protective effect of flavanols at 
supraphysiological concentrations (Williamson and Manach, 2005). For example, the 
NO-preserving effect of flavanol treatments on endothelial cells was achieved at 
concentrations of 10 µM to 40 µM (Steffen et al., 2005; Steffen et al., 2007). Flavanols 
were shown to inhibit NADPH oxidase activity at concentrations of 10 µM (Steffen et 
al., 2007) and the inhibition of VEGF-induced VEGFR-2 phosphorylation by flavanols in 
endothelial cells was shown to occur at concentrations ranging from 15 µM to 100 µM 
(Kondo et al., 2002b; Neuhaus et al., 2004; Wen et al., 2008; Lu et al., 2010). However, 
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the physiological concentrations of dietary flavanols do not exceed 10 µM in practice, 
and thus the effects of polyphenols in-vitro at concentrations > 10 µM are generally not 
valid (Williamson and Manach, 2005). For example, green tea polyphenols have been 
shown to have antioxidant effects in-vitro at high concentrations that are not achievable 
as plasma concentrations, but no effect on serum lipid concentrations or resistance of 
LDL to oxidation ex-vivo was observed after the daily consumption of 6 cups of green 
or back tea per day for four weeks (van het Hof et al., 1997). The majority of the data 
available from in-vitro studies are also based on the use of flavanol forms which are 
present in foods rather than how they would exist in circulation. As the majority of 
polyphenols are rapidly and extensively metabolised (glucuronidated, sulfated or 
methylated), the in-vitro studies are not representative of what occurs in-vivo (Kroon et 
al., 2004). Therefore it is important to take into account diet relevant protective 
mechanisms of polyphenols when researching their cell-protective effects.  
 
Numerous reports have shown that certain polyphenols are able to inhibit VEGF-
induced VEGFR-2 phosphorylation at high and physiologically unrealistic 
concentrations (15 µM to 100 µM) (Kondo et al., 2002b; Kojima-Yuasa et al., 2003; 
Neuhaus et al., 2004; Wen et al., 2008; Lu et al., 2010) and have not directly 
investigated the mechanisms of how polyphenols inhibit VEGFR-2 signalling. Some 
researchers have proposed that polyphenols do not inhibit VEGFR-2 signalling by 
interacting with the receptor because their was no reduction in VEGFR-2 expression 
following polyphenol treatment (Tang et al., 2003; Rodriguez et al., 2006), while other 
researchers stated that polyphenols may exert their inhibitory effect by binding to 
VEGFR-2 and thus prevent VEGF from binding to its receptor (Lamy et al., 2002; Lamy 
et al., 2006). These two theories were based on the same experimental design: pre-
treat the cells with polyphenols, remove medium, and treat the cells with VEGF. 
Therefore the present literature indicates a lack of knowledge of the exact mechanism 
of how polyphenols inhibit VEGFR-2 signalling. 
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The data presented in this thesis have shown for the first time that an apple 
procyanidin fraction and EGCG were able to specifically inhibit VEGF-induced 
VEGFR-2 phosphorylation by binding directly and non-covalently to the VEGF 
molecule, and that the polyphenol-VEGF complex was important in respect of inhibiting 
VEGFR-2 phosphorylation. Further, this occurred at physiological concentrations 
(EGCG IC50 = 0.09 µM; apple procyanidin fraction dp 4 IC50 = 0.28 µM). The apple 
procyanidin fraction was also shown to completely negate the cellular effects of VEGF 
as well as regulate additional genes (e.g. KLF2) involved in angiogenesis and 
inflammation which are independent of VEGF as assessed by an Affymetrix oligo array. 
These findings are significant because they provide a plausible link between 
consumption of dietary polyphenols and a reduced risk of CVD. More importantly this 
data shows a novel mechanism of how polyphenols inhibit VEGF-induced VEGFR-2 
phosphorylation. While this research has only shown an interaction with VEGF, it raises 
the possibility that polyphenols can affect other signalling pathways by interacting with 
other signalling peptides such as growth factors and hormones.  
 
8.1.2 Potential application of apple polyphenols as nutraceuticals 
and functional foods 
As polyphenols have been shown to have numerous health-related benefits, the 
enrichment of foods and beverages with polyphenols may prove to be beneficial for 
human health. Due to the health-related benefits of polyphenols several companies 
(e.g. Mars Incorporated, Nestlé, Kraft Foods, and Danisco) are currently developing 
and promoting polyphenol-rich products (Mars, www.marsbotanical.com; Nestlé, 
www.research.nestle.com; Kraft Foods, www.kraftbrands.com/kraftnutrition; Danisco, 
www.danisco.com/wps/wcm/connect/www/corporate/media/news/company_news/2008
/october/pressrelease424_en.htm). Functional foods are foods with an additional or 
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enhanced physiological benefit beyond the traditional nutrients it contains (Buttriss, 
2010) and nutraceuticals are any substance that is a food or a part of a food that 
provides health benefits including the prevention or treatment of a disease. 
Polyphenols may be regarded as nutraceuticals or functional foods based on their 
ability to protect lipids from oxidative damage, maintain normal blood pressure, improve 
endothelial function and/or inhibit VEGF-induced angiogenesis.  
 
For example polyphenols could be used as nutraceulticals for the inhibition of VEGF-
induced angiogenesis. The use of polyphenols in reducing VEGF-induced 
angiogenesis may prove to be more beneficial than the current anti-VEGF drugs 
available. Anti-VEGF drugs have been reported to increase blood pressure after 
prolonged periods of use (Kappers et al., 2010) and systematic reviews and meta-
analyses of the anti-VEGF drugs bevacizumab, sorafenib and sunitinib have also 
shown an increased risk of developing hypertension among users of these drugs (Zhu 
et al., 2007; Wu et al., 2008b; Zhu et al., 2009). VEGF stimulates the production of NO 
through the phosphorylation of AKT (Chavakis et al., 2001; Tang et al., 2003; Riesterer 
et al., 2004; Rodriguez et al., 2006; Stangl et al., 2007) and the inhibition of VEGF 
signalling by anti-VEGF drugs would therefore be expected to decrease the production 
of NO (Wang et al., 2004). On the other hand, data presented here have demonstrated 
that certain polyphenols inhibit VEGF signalling but still induce NO bioavailability by 
increasing AKT phosphorylation. Therefore the inhibition of VEGF signalling by certain 
polyphenols may not cause an increase in blood pressure or risk of hypertension, as 
observed for anti-VEGF antibodies, and may be more applicable as an anti-VEGF 
treatment than the current anti-VEGF drugs.  
 
Recently, health claims related to cocoa flavanols and their protection of lipids from 
oxidative damage and maintenance of normal blood pressure was considered by the 
European Food Safety Authority (EFSA) (EFSA Panel on Dietetic Products, 2010).  On 
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the basis of the current published data available in supporting the claim for cocoa 
flavanols and their protection of lipids from oxidative damage and maintenance of 
normal blood pressure, EFSA concluded that a cause and effect relationship had not 
been established (EFSA Panel on Dietetic Products, 2010). Therefore the pursuit of 
polyphenol health claims still continues.  
 
In order to use apple polyphenols as nutraceuticals and functional foods the full 
polyphenol profile of the apple fruit needs to be well defined and the extraction method 
needs to be efficient. When considering the use of apple fruit, harvesting for extraction 
can be based on the optimal yield of the individual polyphenol of interest, while the 
harvesting date of fruit for consumption can not be adjusted because of taste 
characteristics. The investigation of the effect of growth and maturity and seasonal 
variations on the concentration and content of polyphenols in apples has been 
previously reported (Lister et al., 1994; Mayr et al., 1995; van der Sluis et al., 2001; 
Lata et al., 2005; Takos et al., 2006; Lata and Tomala, 2007; Renard et al., 2007; 
Stracke et al., 2009). However the reports were lacking a full apple polyphenol profile 
analysis. The data presented here show, for the first time, a complete quantitative 
HPLC analysis of how all the polyphenols found in apples change during the growing 
season and between growing seasons, and it is the first time a direct effect of seasonal 
variations on individual apples trees has been reported. The results from this research 
show, for the first time, that mean temperature, during the growing season months, was 
negatively correlated with polyphenol content and concentration and that the total 
amount of rainfall was positively correlated with the concentration and content of 
polyphenols in apples. The research presented also show for the first time that the 
polyphenol content and concentration of apples and the percentage of individual 
polyphenols in the apples, from the same tree, is variable between growing seasons. 
Therefore the synthesis of polyphenols in apples is a complex process which is 
dependent on several variables. However the general trends of the changes in 
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concentration and content of polyphenols in apples remains the same between 
different growing seasons. As the taste characteristics of apples are not important 
when extracting polyphenols from apples, the harvesting of apples can therefore be 
based on the optimal yield of the individual polyphenol of interest.  
 
The extraction of polyphenols from apples has been previously reported; however 
these extraction methods do not provide an overall high extraction yield or change the 
taste characteristics of the polyphenol-enriched juice (Spanos et al., 1990; Schols et 
al., 1991; Will et al., 2000; Gerard and Roberts, 2004; Mihalev et al., 2004; van der 
Sluis et al., 2004). The research presented in this thesis showed for the first time that 
the hot water extraction of apple pomace, a by-product of apple juice production, was a 
very efficient method in extracting polyphenols. However the initial pressing of the 
apples, the incubation and second pressing steps resulted in a loss of polyphenols, and 
further investigation is required to improve the recovery of polyphenols during these 
processes. Hot water extraction might be used with different fruits to increase the 
extraction yield of polyphenols. The extracted polyphenols can then either be 
supplemented back into the product (e.g. enriched juice), can be used as a polyphenol 
supplementation in other products or have pharmacological applications (e.g. inhibition 
of VEGF signalling).  
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8.2 Recommendations for further research 
The data presented here show that apple polyphenols interact with vascular endothelial 
cells to improve vascular function and have shown the potential application of apple 
polyphenols as nutraceuticals and functional foods. Isolated apple polyphenols 
(procyanidins) were shown to have a nutraceutical and/or a pharmacological 
application in the inhibition of VEGF signalling. It was identified that the use of apple 
procyanidins may be more applicable than the current anti-VEGF drugs available as 
they may not cause an increase in blood pressure as reported, in the literature, with the 
prolonged use of anti-VEGF antibodies. In order to assess the possibility of 
pharmacological use of apple procyanidins further research is required. In particular 
further research in developing a more sensitive method in analysing the bioavailability 
of procyanidins in humans and determining whether procyanidins are able to reduce 
atherosclerotic plaque progression (for example in an apolipoprotein E/apolipoprotein 
mouse model of atherosclerosis) is required. 
 
Apple polyphenols, through the consumption of an apple polyphenol-rich apple extract 
supplement drink, were also reported here to improve indices of vascular function 
(vascular stiffness index and vascular age). However as a recently published report 
showed no effect on endothelial function after the long-term consumption of lyophilised 
apple extract, further investigation of the effect of the consumption of apple 
polyphenols, from different food matrices, on endothelial function is required. The 
investigation of the acute consumption of apple polyphenol-rich foods in different food 
matrices (for example the consumption of a polyphenol-rich re-hydrated lyophilised 
apple sample compared to the consumption of a polyphenol-rich apple extract 
supplemented drink) will provide further evidence regarding apple polyphenols and 
their vasodilatory effects on endothelial function and the impact on food matrices on 
endothelial function. 
Chapter 8 
 
313 
 
 
In order to use apple polyphenols for a pharmacological product or as a supplement, 
they are required to be efficiently extracted from the apple fruit. Currently the extraction 
of polyphenols from apple pomace, a by-product of apple juice production, does not 
take into account the loss of polyphenols associated with juicing. The data presented 
here show that while a hot water extraction efficiently extracts the polyphenols from the 
apple pomace a large proportion of the polyphenols are lost during juicing. The loss is 
most likely due to polyphenol oxidases present in the apple fruit. Reducing the loss of 
polyphenols associated with fruit juicing will also ultimately result in an increase in the 
polyphenol content of the extracted juice. Food technologists therefore need to 
investigate how to reduce the loss of polyphenols involved in juicing. The investigation 
of alternative methods (for example juicing apples in a reduced oxygen controlled 
environment) which inactivates the polyphenol oxdiase enzymes present in apple fruits 
but also efficiently extracts the polyphenols will also be beneficial in the producing 
apple polyphenol extracts for use as nutraceuticals or functional foods.  
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Purification of apple procyanidin fractions dp 3 and dp 4 
 
Step 1: Removal of flavonoids and phenolics 
The apple procyanidin fractions dp 3 and dp 4 were purified from the 2007 apples 
(Chapter 2) provided by Coressence ltd (Herefordshire, UK). The purification method 
was based on previously published methods (Yanagida et al., 1999; Shoji et al., 2005; 
Shoji et al., 2006b), with some modifications.  
 
Fifty grams of freeze-dried apple powder (Tree C, Week 6 from 2007) was extracted in 
1250 ml of 0.1 % potassium disulphite, shaken and left to stand for 10 min. The 
phenolic profile of sample Tree C from Week 6 is described in Table S1.1. The sample 
was then centrifuged (J6-M1 centrifuge, Beckman Coulter) for 10 min at 4200 x rpm 
and filtered through a miracloth (Calbiochem). The sample was passed through a 
pre-wetted Sepabeads SP-850 (Sigma) column (355 mm x 25 mm). The Sepabeads 
SP-850 column was prepared by transferring the dry resin to a 500 ml glass beaker, 
adding sufficient methanol to cover the resin bed by 1 – 2 inches and stirring gently for 
approximately one 1 min to ensure complete mixing. The material was then allowed to 
stand for 15 min. The majority of the methanol was then carefully removed and distilled 
water was added and left to stand for 5 min. The Sepabeads SP-850 was then 
transferred to column. Samples of each fraction were collected and analysed using two 
different HPLC methods (reverse-phase HPLC analysis and normal-phase HPLC 
analysis) as described in Chapter 2, Section 2.4.5. Example chromatograms of the 
standards are shown in Figure S1.1.  
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Table S1.1: Polyphenol profile of freeze-dried apple sample Tree C (Week 6) from 2007 
Polyphenol mg/kg dry 
weight 
Polyphenol mg/kg dry 
weight 
Epicatechin 4462.5 Chlorogenic acid 3988.4 
Catechin 378.1 Phloridzin  1897.5 
Dimer (dp 2) 3259.8 Rutin 88.2 
Trimer (dp 3) 2974.6 Quercetin-3-galactoside 297.0 
Tetramer (dp 4) 2507.1 Quercetin-3-glucoside 101.2 
Pentamer (dp 5) 1766.9 Quercetin-3-arabinoside 41.0 
Hexamer (dp 6) 1838.6 Quercetin-3-xyloside 100.1 
Heptamer (dp 7) 1468.5 Quercetin-3-rhamnoside 110.1 
Total 25279.7 mg/kg (dry weight) 
 
 
After adding the sample to the Sepabeads SP-850 column, the fraction eluted 
(Fraction: Speabeads filtrate) contained chlorogenic acid only in the sample 
(Figure S1.2). Fractions were eluted by gravitational force only; no vacuum pressure 
was applied. The column was washed with 300 ml of distilled water and the resulting 
fraction (Fraction: Sepabeads distilled water rinse) contained chlorogenic acid and 
epicatechin (Figure S1.3). The crude apple polyphenol fraction was eluted with 200 ml 
of 50 % (v/v) ethanol (Fraction 1). Fraction 1 contained epicatechin, catechin, 
procyanidins dp 2 – 7, chlorogenic acid, phloridzin as well as quercetin glycosides 
(Figure S1.4).  
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Figure S1.1: Example chromatograms for standards.  
Example chromatogram of normal-phase HPLC analysis of an epicatechin standard (A) and the NIST 
chocolate standard (B). Peak IDs: epi = epicatechin and cat = catechin. Example chromatogram of 
reverse-phase HPLC analysis of a mixed standard at 270 nm (C) and 370 nm (D). Peak ID:  
1= chlorogenic acid, 2 = epicatechin, 3 = quercetin-3-O-arabinose, 4 = quercetin-3-O-rutinoside (rutin), 
5 = quercetin-3-O-galactoside, 6 = quercetin-3-O-glucoside, 7 = quercetin-3-O-xyloside, 8 = quercetin-3-O-
rhamnoside. 
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Figure S1.2: HPLC chromatograms of Sepabeads filtrate fraction.  
Normal-phase HPLC analysis chromatogram of the sepabeads filtrate fraction (A). Reverse-phase HPLC 
analysis chromatograms at 270 nm (B) and 370 nm (C) of the sepabeads filtrate fraction.  Peak ID:  1= 
chlorogenic acid. 
 
1 
1 
A 
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Figure S1.3: HPLC chromatograms of Sepabeads distilled water fraction.  
Normal-phase HPLC analysis chromatogram of the sepabeads distilled water fraction (A). Reverse-phase 
HPLC analysis chromatograms at 270 nm (B) and 370 nm (C) of the sepabeads distilled water fraction.  
Peak ID:  1= chlorogenic acid. 
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Figure S1.4: HPLC chromatograms of Fraction 1 (polyphenol fraction). 
Normal-phase HPLC analysis chromatogram of Fraction 1 (A). Peak ID: epi = epicatechin; cat = catechin; 
DP2 = dimers; DP3 = trimers; DP4 = tetramers; DP5 = pentamers; DP6 = hexamers. Reverse-phase 
HPLC analysis chromatograms at 270 nm (B) and 370 nm (C) of Fraction 1. Peak ID:  1= chlorogenic acid, 
2 = epicatechin, 3 = quercetin-3-O-arabinose, 4 = quercetin-3-O-rutinoside (rutin), 5 = quercetin-3-O-
galactoside, 6 = quercetin-3-O-glucoside, 7 = quercetin-3-O-xyloside, 8 = quercetin-3-O-rhamnoside. 
 
Fraction 1 was evaporated on the rotary evaporator at 45 °C to a volume of 
approximately 60 ml and the pH of Fraction 1 was adjusted to 6.5 with 1 N sodium 
hydroxide (starting pH was 3.2).  Meanwhile, the Diaion HP-20ss (Sigma) column was 
prepared in the same manner as the Sepabeads SP-850 column. Fraction 1 was then 
added to the Diaion HP-20ss column (355 mm x 25 mm) and the non-absorbed fraction 
(Fraction 2) was collected. Fraction 2 contained small quantities of epicatechin, 
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catechin, procyanidins, chlorogenic acid, phloridzin and quercetin glycosides 
(Figure S1.5). The column was rinsed with 250 ml of distilled water and the resulting 
fraction (Fraction: Diaion distilled water rinse) contained chlorogenic acid and small 
quantities of epicatechin (Figure S1.6). The procyanidin fraction (Fraction 3) was eluted 
with 700 ml of 25 % (v/v) ethanol (Figure S1.7) and the other flavonoid fraction 
(Fraction 4) was eluted with 400 ml of 50% (v/v) ethanol (Figure S1.8).  
 
 
Figure S1.5: HPLC chromatograms of Fraction 2.  
Normal-phase HPLC analysis chromatogram of Fraction 2 (A). Reverse-phase HPLC analysis 
chromatograms at 270 nm (B) and 370 nm (C) of Fraction 2.  
 
A 
B 
C 
Supplementary Information 1 
 
344 
 
 
Figure S1.6: HPLC chromatograms of Diaion distilled water rinse. 
Normal-phase HPLC analysis chromatogram of the Diaion distilled water rinse fraction (A). Peak ID: epi = 
epicatechin. Reverse-phase HPLC analysis chromatograms at 270 nm (B) and 370 nm (C) of the Diaion 
distilled water rinse fraction. Peak ID:  1= chlorogenic acid, 2 = epicatechin. 
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Figure S1.7: HPLC chromatograms of Fraction 3. 
Normal-phase HPLC analysis chromatogram of Fraction 3 (A). Peak ID: epi = epicatechin; cat = catechin; 
DP2 = dimers; DP3 = trimers; DP4 = tetramers; DP5 = pentamers; DP6 = hexamers. Reverse-phase 
HPLC analysis chromatograms at 270 nm (B) and 370 nm (C) of Fraction 3. 
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Figure S1.8: HPLC chromatograms of Fraction 4. 
Normal-phase HPLC analysis chromatogram (A) of Fraction 4. Reverse-phase HPLC anslysis of 
chromatograms at 270 nm (B) and 370 nm (C) of Fraction 4. Peak ID:  1= chlorogenic acid, 2 = 
epicatechin, 3 = quercetin-3-O-arabinose, 4 = quercetin-3-O-rutinoside (rutin), 5 = quercetin-3-O-
galactoside, 6 = quercetin-3-O-glucoside, 7 = quercetin-3-O-xyloside, 8 = quercetin-3-O-rhamnoside. 
 
From the HPLC data, it can be confirmed that the Fraction 3 (the procyanidin fraction) 
does not contain any chlorogenic acid, phloridzin and qurecetin glycosides. These 
compounds were eluted in Fraction 5.  
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Step 2: Removal of impurities 
Before separating the procyanidins according to their degree of polymerisation on an 
Inertsil PREP-Sil (30 mm x 250 mm) column, a pre-cautionary column guard step was 
undertaken to make sure any impurities remaining in the fraction were removed so that 
any polar substances would not stick to the Inertsil PREP-Sil column (GL Sciences 
Inc). Fraction 3 was concentrated by rotary evaporator and the fraction was 
reconstituted in 3 ml of methanol. The reconstituted fraction was loaded on to a silica 
column insert and dried in the vacuum oven for 1 h. The silica column insert was 
inserted into a pre-wetted Biotage Snap FLASH Purification Cartridge HP-Sil (Biotage) 
and ran on the Medium Pressure Liquid Chromatography (MPLC) (Gilson). The column 
was pre-wetted with Solvent A. The flow rate was set to 45 ml/min and the method 
used a mobile consisting of 82 % dichloromethane, 14 % methanol and 4 % of 50 % 
(v/v) acetic acid (solvent A) and 96 % methanol and 4 % of 50 % (v/v) acetic acid 
(solvent B) with a 120 min gradient (0 – 10 min, 0 % B; 10 – 15 min, 18 % B; 
15 - 18 min, 30 % B; 18 – 20 min 88 % B; 20 – 120 min, 0 % B) and was monitored at a 
wavelength of 280 nm with a DAD detector. 
 
The fractions were collected for the following retention times (RT): Fraction A, 
8 - 10 min; Fraction B, 12 – 14 min; Fraction C, 14 – 16 min; Fraction D, 16 – 17 min; 
Fraction E, 17 – 20 min; Fraction G, 20 – 28 min (Figure S1.9). A sample of each 
fraction was run on the HPLC using reverse-phase and normal-phase methods. 
Fraction A contained epicatechin and catechin (Figure S1.10); Fraction B consisted of 
dimmers (Figure S1.11) while Fraction C contained dimers and trimers (Figure S1.12). 
Fraction D had a combination of trimers, tetramers and pentamers (Figure S1.13) while 
Fraction E had a combination of tetramers, pentamers and hexamers (Figure S1.14).  
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Figure S1.9: Chromatogram of fractions collected on the MPLC using a Biotage Snap 
FLASH Purification HP-Sil cartridge. 
A = Fraction A, RT 8 – 10 min; B = Fraction B, RT: 12 – 14 min; C = Fraction C, RT = 14 – 16 min; 
D = Fraction D, RT 16 – 17 min; E = Fraction E, RT: 17 – 20 min.  
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Figure S1.10: Chromatograms of Fraction A.  
Normal-phase HPLC analysis chromatogram of Fraction A (A). Peak ID: epi = epicatechin, cat = catechin. 
Reverse-phase HPLC analysis chromatograms at 270 nm (B) and 370 nm (C) of Fraction A. Peak ID:  
2 = epicatechin. 
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Figure S1.11: Chromatograms of Fraction B.  
Normal-phase HPLC analysis chromatogram of Fraction B (A). Peak ID: DP2 = dimers. Reverse-phase 
HPLC analysis chromatograms at 270 nm (B) and 370 nm (C) of Fraction B.  
DP2 A 
B
  
C 
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Figure S1.12: HPLC chromatograms of Fraction C.  
Normal-phase HPLC analysis chromatogram of Fraction C (A). Peak ID: DP2 = dimers; DP3 = trimers; 
DP4 = tetramers. Reverse-phase HPLC analysis chromatograms at 270 nm (B) and 370 nm (C) of 
Fraction C. 
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Figure S1.13: HPLC chromatograms of Fraction D.  
Normal-phase HPLC analysis chromatogram of Fraction D (A). Peak ID: DP3 = trimers; DP4 = tetramers; 
DP5 = pentamers. Reverse-phase HPLC analysis chromatograms at 270 nm (B) and 370 nm (C) of 
Fraction D. 
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Figure S1.14: HPLC chromatograms of Fraction E.  
Normal-phase HPLC analysis chromatogram of Fraction E (A). Peak ID: DP4 = tetramers; DP5 = 
pentamers; DP6 = hexamers. Reverse-phase HPLC analysis chromatograms at 270 nm (B) and 370 nm 
(C) of Fraction E. 
 
Fractions B, C, D and E (Combined Fraction) were combined and concentrated by 
rotary evaporator in preparation for the Step 3.  
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Step 3: Separation of apple procyanidins 
The procyanidins in the Combined Fraction were separated according to the degree of 
polymerization by performing normal-phase chromatography using an Inertsil PREP-Sil 
(30 mm x 250 mm) (GL Sciences Inc) column on the preparatory-HPLC (Gilson). The 
combined Fraction was reconstituted in 2 ml of methanol and loaded onto the column. 
The flow rate was 24 ml/min and the method used a mobile phase containing 
hexane/methanol/ethyl acetate in a 8:3:1 ratio (solvent A) and hexane/methanol/ethyl 
acetate in a 2:3:1 ratio (solvent B) with a 185 min gradient (0 – 35 min, 0 % B; 
35 - 185 min, 100 % B) and was monitored at 330 nm with a diode array detector 
(DAD).  
 
The fractions were collected at the following RTs: Fraction I, 23 – 27 min; Fraction J, 
44 – 54 min; Fraction K, 67 – 78 min; Fraction L, 87 – 98 min; Fraction M, 
105 - 111 min; Fraction N, 111 – 115 min; and Fraction O, 119 – 124 min 
(Figure S1.15). A sample of each fraction was run on the HPLC using reverse-phase 
and normal-phase methods. Epicatechin and catechin were eluted in Fraction I, the 
dimers were eluted in Fraction J and the trimers and tetramers were eluted in Fractions 
K and L, respectively (Figure S1.16). No purified compounds were detected in 
Fractions M, N or O (Figure S1.17). Pentamers and hexamers were unable to be 
purified due to low starting material of these compounds. Each procyanidin fraction 
obtained was initially concentrated by rotary evaporator, reconstituted with 2 ml of 
methanol and the further concentrated using a Universal Vacuum System UVS800DDA 
(Thermo Savani) attached to a SPD Speed Vacuum (Thermo Electron Corporation).  
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Figure S1.15: Chromatogram of fractions collected on the Prep-HPLC using the Intersil 
PREP Sil column.  
DAD wavelength detection at 330 nm. Peak IDs: I = Fraction I, RT 23 – 27 min; J = Fraction J, RT: 
44 - 54 min; K = Fraction K, RT = 67 – 78 min; L = Fraction L, RT 87 – 98 min; M = Fraction M, RT: 
105 - 111 min; N = Fraction N, 111- 115 min; O = Fraction O, 119 – 124 min.  
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Figure S1.16: Normal phase chromatograms of purified fractions collected on the Intersil 
Prep Sil column.  
(A) Fraction I; (B) Fraction J; (C) Fraction K; (D) Fraction L. Peak IDs: EPI = epicatechin; CAT = catechin, 
DP2 = dimers; DP3 = trimers; DP4 = tetramers.   
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Figure S1.17: Normal-phase HPLC chromatograms of purified fractions collected on the 
Intersil Prep Sil column.  
(A) Fraction M; (B) Fraction N; (C) Fraction O; (D) Fraction L.  
 
The trimer (Fraction K) and tetramer (Fraction L) fractions were checked for purity by 
mass spectrometry analysis. The mass spectrometry work was preformed and 
interpreted by Mark Philo. Briefly the samples were infused directly from the vial in 
positive electron mode. For the trimer fraction no peak was detected at a mass of 867 
Da (molecular weight of trimers plus a proton), however the sodium adduct at 889 Da 
was detected (Figure S1.18). A peak was detected at a mass of 1155 Da (molecular 
weight of tetramers plus a proton) and the sodium adduct at 1177 Da for the tetramer 
fraction (Figure S1.19).  
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Figure S1.18: Mass spectrometry analysis of the trimer fraction (Fraction K).  
(A) Full scan; (B) area zoomed in of mass of interest.    
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Figure S1.19: Mass spectrometry analysis of the tetramer fraction (Fraction L).  
(A) Full scan; (B) area zoomed in of mass of interest.    
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Supplementary Information 2 
Biological processes regulated by the different treatment 
comparisons 
The GO categories associated with the specific gene lists were identified using the 
DAVID software. The gene list obtained using a p value of < 0.001 was used to 
produce a manageable set of genes to perform more detailed functional analysis. Any 
biological process term which had three or fewer genes associated with that biological 
process or had a fold enrichment of less than 1.5 were not included in the analysis. 
Those biological processes that fit the exclusion criteria were excluded because fold 
enrichments of 1.5 and above are only considered as interesting and fold enrichments 
obtained from terms with a few number of genes (three or less) are not as reliable as 
those obtained from larger number of genes (Huang et al., 2008). Fold enrichment 
measures the magnitude of enrichment and is defined as the ratio of two proportions. 
For example, if 40 out of 400 (i.e. 10 %) of the inputted genes are involved in “kinase 
activity” versus 300 out of 30000 genes (i.e. 1 %) in the human genome (population 
background) are associated with “kinase activity” then the fold enrichment is tenfold 
(i.e. 10 % / 1 % = 10) (Huang et al., 2008). 
 
The biological processes regulated by VEGF versus the control are described in Table 
S2.1. Tables S2.2 and S2.3 describe the biological processes regulated by apple 
procyanidin faction dp 4 versus the control and apple procyanidin fraction dp 4 versus 
VEGF, respectively. The biological processes regulated by apple procyanidin fraction 
dp 4-treated VEGF versus the control and apple procyanidin fraction dp 4-treated 
VEGF versus VEGF are described in Tables S2.4 and S2.5, respectively. Tables S2.6 
and S2.7 describe the biological processes regulated by anti-VEGF antibody-treated 
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VEGF versus the control and anti-VEGF antibody-treated VEGF versus apple 
procyanidin fraction dp 4, respectively.   
 
Table S2.1: Biological processes regulated by VEGF compared to the control.  
Biological processes, regulated by the VEGF treatment versus the control from the p < 0.001 gene list from 
Table 6.1 were identified using the DAVID software. The biological processes were ranked according to 
the fold enrichment score.  
Biological process No. of genes 
involved out 
of 129 
Fold 
Enrichment 
Regulation of endothelial cell migration 4 20.2 
Negative regulation of hydrolase activity 5 12.7 
Regulation of angiogenesis 5 9.8 
Positive regulation of cell migration 6 8.4 
Regulation of caspase activity 5 7.8 
Positive regulation of locomotion 6 7.6 
Positive regulation of cell motion 6 7.6 
Regulation of endopeptidase activity 5 7.5 
Regulation of peptidase activity 5 7.1 
Response to unfolded protein 4 7.1 
Regulation of cell migration 8 6.0 
Response to protein stimulus 5 5.8 
Regulation of locomotion 8 5.2 
Regulation of cell motion 8 5.2 
Transmembrane receptor protein serine/threonine kinase 
signaling pathway 4 4.9 
Regulation of gene-specific transcription 5 4.7 
Response to estrogen stimulus 4 4.7 
Response to nutrient 5 4.4 
Ossification 4 4.3 
Cell migration 9 4.2 
Reproductive structure development 4 4.1 
Bone development 4 4.0 
Wound healing 6 4.0 
Regulation of response to external stimulus 5 4.0 
Response to extracellular stimulus 7 3.9 
Response to metal ion 4 3.9 
Response to inorganic substance 6 3.8 
Localization of cell 9 3.8 
Cell motility 9 3.8 
Leukocyte differentiation 4 3.8 
Response to nutrient levels 6 3.8 
Response to hypoxia 4 3.7 
Negative regulation of transport 4 3.7 
Positive regulation of developmental process 8 3.6 
Di-, tri-valent inorganic cation transport 5 3.6 
Response to oxygen levels 4 3.6 
Response to wounding 15 3.6 
Tube development 6 3.5 
Negative regulation of molecular function 9 3.4 
Enzyme linked receptor protein signaling pathway 9 3.3 
Response to steroid hormone stimulus 5 3.3 
Negative regulation of catalytic activity 7 3.2 
Regulation of cell development 5 3.1 
Response to endogenous stimulus 10 3.1 
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Table S2.1: Biological processes regulated by VEGF compared to the control 
continued 
Biological process No. of genes 
involved out 
of 129 
Fold 
Enrichment 
Inflammatory response 8 3.1 
Regulation of hydrolase activity 8 3.1 
Response to hormone stimulus 9 3.1 
Blood vessel development 6 3.1 
Anti-apoptosis 5 3.1 
Vasculature development 6 3.0 
Response to organic substance 17 3.0 
Negative regulation of programmed cell death 8 2.8 
Negative regulation of cell death 8 2.8 
Positive regulation of transcription 12 2.7 
Cell motion 10 2.7 
Positive regulation of transcription, DNA-dependent 10 2.7 
Positive regulation of RNA metabolic process 10 2.7 
Negative regulation of apoptosis 7 2.5 
Positive regulation of nucleobase, nucleoside, nucleotide and 
nucleic acid metabolic process 12 2.5 
Positive regulation of cell proliferation 8 2.4 
Response to abiotic stimulus 7 2.4 
Regulation of cell proliferation 15 2.4 
Positive regulation of nitrogen compound metabolic process 12 2.4 
Positive regulation of macromolecule biosynthetic process 12 2.3 
Regulation of transcription from RNA polymerase II promoter 13 2.3 
Positive regulation of cellular biosynthetic process 12 2.2 
Positive regulation of macromolecule metabolic process 15 2.2 
Positive regulation of biosynthetic process 12 2.2 
Regulation of programmed cell death 14 2.2 
Regulation of cell death 14 2.2 
Negative regulation of cellular biosynthetic process 9 2.0 
Regulation of apoptosis 13 2.0 
Negative regulation of biosynthetic process 9 2.0 
Ddefense response 9 1.9 
Cell surface receptor linked signal transduction 22 1.6 
Regulation of RNA metabolic process 20 1.5 
Regulation of transcription, DNA-dependent 19 1.5 
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Table S2.2: Biological processes regulated by apple procyanidin fraction dp 4 compared 
to the control.  
Biological processes regulated by the apple procyanidin fraction dp 4 treatment versus the control from the 
p < 0.001 gene list from Table 6.1 were identified using the DAVID software. The biological processes 
were ranked according to the fold enrichment score.  
Biological process 
  
No. of genes 
involved out of 
92 
Fold 
Enrichment 
Negative regulation of MAP kinase activity 4 19.6 
Negative regulation of leukocyte activation 5 14.7 
Negative regulation of cell activation 5 13.9 
Negative regulation of lymphocyte activation 4 12.4 
Positive regulation of mononuclear cell proliferation 4 11.7 
Positive regulation of leukocyte proliferation 4 11.7 
Positive regulation of cell adhesion 4 11.3 
Positive regulation of T cell activation 5 11.1 
Regulation of lymphocyte differentiation 4 10.8 
Regulation of T cell proliferation 4 10.6 
Positive regulation of protein transport 4 10.1 
Negative regulation of immune system process 5 10.0 
Response to vitamin 4 9.9 
Branching morphogenesis of a tube 4 9.9 
Homeostasis of number of cells 6 9.9 
Regulation of mononuclear cell proliferation 5 9.7 
Regulation of leukocyte proliferation 5 9.7 
Morphogenesis of a branching structure 4 8.8 
Regulation of T cell activation 6 8.6 
Positive regulation of lymphocyte activation 5 8.6 
Regulation of leukocyte activation 8 8.1 
Regulation of lymphocyte activation 7 8.0 
Regulation of lymphocyte proliferation 4 7.9 
Negative regulation of protein kinase activity 4 7.9 
Positive regulation of leukocyte activation 5 7.8 
Response to corticosteroid stimulus 4 7.8 
Regulation of cell activation 8 7.7 
Negative regulation of kinase activity 4 7.6 
Positive regulation of cell activation 5 7.5 
Positive regulation of cell migration 4 7.4 
Regulation of MAP kinase activity 6 7.1 
Negative regulation of multicellular organismal process 7 7.1 
Myeloid cell differentiation 4 7.1 
Negative regulation of transferase activity 4 7.1 
Angiogenesis 6 6.8 
Positive regulation of cell motion 4 6.7 
Positive regulation of locomotion 4 6.7 
Regulation of immune effector process 4 6.7 
Positive regulation of cell differentiation 9 6.5 
Regulation of cell adhesion 5 6.2 
Positive regulation of secretion 4 6.2 
Response to nutrient 5 5.9 
Regulation of protein transport 4 5.8 
Regulation of secretion 7 5.8 
Striated muscle tissue development 4 5.6 
Positive regulation of multicellular organismal process 8 5.6 
Response to organic cyclic substance 4 5.5 
Blood vessel morphogenesis 7 5.5 
Regulation of establishment of protein localization 4 5.5 
Positive regulation of developmental process 9 5.3 
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Table S2.2: Biological processes regulated by apple procyanidin fraction dp 4 compared 
to the control continued 
Biological process 
  
No. of genes 
involved out of 
92 
Fold 
Enrichment 
Positive regulation of transport 7 5.2 
Rube morphogenesis 4 5.2 
Response to hypoxia 4 5.0 
Regulation of synaptic transmission 4 5.0 
Regulation of cell migration 5 5.0 
Negative regulation of transport 4 4.9 
Cell fate commitment 4 4.8 
Regulation of protein localization 4 4.8 
Response to oxygen levels 4 4.7 
Blood vessel development 7 4.7 
Regulation of cellular localization 7 4.7 
Vasculature development 7 4.6 
MAPKKK cascade 5 4.6 
Regulation of cytokine production 5 4.6 
Regulation of transmission of nerve impulse 4 4.6 
Wound healing 5 4.5 
Regulation of neurological system process 4 4.4 
Regulation of locomotion 5 4.3 
Response to steroid hormone stimulus 5 4.3 
Regulation of cell motion 5 4.3 
Regulation of phosphorylation 12 4.3 
Regulation of binding 4 4.3 
Positive regulation of immune system process 6 4.3 
Response to nutrient levels 5 4.2 
Response to oxidative stress 4 4.1 
Regulation of phosphorus metabolic process 12 4.1 
Regulation of phosphate metabolic process 12 4.1 
Negative regulation of cell communication 6 4.1 
Positive regulation of cell proliferation 10 4.1 
Regulation of protein kinase activity 8 3.9 
Regulation of protein amino acid phosphorylation 4 3.8 
Hemopoietic or lymphoid organ development 6 3.8 
Endocytosis 5 3.8 
Rube development 5 3.8 
Membrane invagination 5 3.8 
Sensory organ development 5 3.8 
Regulation of kinase activity 8 3.7 
Response to extracellular stimulus 5 3.7 
Negative regulation of cell proliferation 8 3.7 
Blood circulation 4 3.6 
Circulatory system process 4 3.6 
Response to hormone stimulus 8 3.6 
Immune system development 6 3.6 
Regulation of transferase activity 8 3.6 
Hemopoiesis 5 3.5 
Cell activation 6 3.5 
Positive regulation of cell death 9 3.5 
Embryonic morphogenesis 6 3.3 
Response to endogenous stimulus 8 3.3 
Regulation of system process 6 3.3 
Regulation of cell proliferation 15 3.2 
Protein kinase cascade 7 3.2 
Induction of apoptosis 6 3.1 
Induction of programmed cell death 6 3.1 
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Table S2.2: Biological processes regulated by apple procyanidin fraction dp 4 compared 
to the control continued 
Biological process 
  
No. of genes 
involved out of 
92 
Fold 
Enrichment 
Positive regulation of apoptosis 8 3.1 
Positive regulation of programmed cell death 8 3.1 
Membrane organization 7 3.1 
Regulation of cell death 15 3.1 
Cell migration 5 3.1 
Cell-cell signaling 11 3.1 
Cell proliferation 8 3.0 
Regulation of growth 6 3.0 
Enzyme linked receptor protein signaling pathway 6 2.9 
Regulation of apoptosis 14 2.9 
Regulation of programmed cell death 14 2.9 
Response to organic substance 12 2.8 
Response to wounding 8 2.5 
Cell motion 7 2.5 
Apoptosis 8 2.3 
Programmed cell death 8 2.2 
Positive regulation of cellular biosynthetic process 9 2.2 
Positive regulation of biosynthetic process 9 2.2 
Cell death 9 2.1 
Death 9 2.1 
Positive regulation of nitrogen compound metabolic process 8 2.1 
Regulation of transcription, DNA-dependent 16 1.6 
Regulation of RNA metabolic process 16 1.6 
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Table S2.3: Biological processes regulated by apple procyanidin fraction dp 4 compared 
to VEGF.  
Biological processes, regulated by the apple procyanidin fraction dp 4 treatment versus the VEGF 
treatment from the p < 0.001 gene list from Table 6.1 were identified using the DAVID software. The 
biological processes were ranked according to the fold enrichment score.  
Biological process No. of genes 
involved out 
of 233 
Fold 
Enrichment 
Response to retinoic acid 6 11.7 
Cardiac cell differentiation 4 9.6 
Negative regulation of MAP kinase activity 5 9.5 
Ureteric bud development 5 9.2 
Response to vitamin A 6 9.2 
Negative regulation of defense response 4 7.4 
Metanephros development 5 7.3 
BMP signaling pathway 5 7.3 
Cell-cell junction organization 4 7.2 
ER-nuclear signaling pathway 4 7.2 
Odontogenesis 6 7.1 
Regulation of angiogenesis 7 7.1 
Calcium-mediated signaling 4 7.0 
Response to vitamin 7 6.7 
Negative regulation of hydrolase activity 5 6.5 
Odontogenesis of dentine-containing tooth 4 6.4 
Monocarboxylic acid transport 5 6.4 
Mesenchymal cell differentiation 5 6.3 
Mesenchymal cell development 5 6.3 
Ovulation cycle 6 6.2 
Mesenchyme development 5 6.1 
Neuron fate commitment 4 6.1 
Regulation of inflammatory response 7 5.9 
Regulation of smooth muscle cell proliferation 4 5.8 
Ovulation cycle process 5 5.6 
Response to unfolded protein 6 5.5 
Cell junction organization 5 5.5 
Positive regulation of cell adhesion 5 5.5 
Female gonad development 5 5.4 
Regulation of striated muscle tissue development 4 5.2 
Regulation of muscle development 4 5.1 
Female sex differentiation 5 5.0 
Development of primary female sexual characteristics 5 5.0 
Regulation of cell migration 13 5.0 
Response to estrogen stimulus 8 4.9 
Response to estradiol stimulus 4 4.8 
Regulation of locomotion 14 4.7 
Response to mechanical stimulus 4 4.6 
Negative regulation of secretion 4 4.6 
Cardiac muscle tissue development 4 4.6 
Leukocyte migration 4 4.6 
Response to nutrient 10 4.6 
Regulation of response to external stimulus 11 4.5 
Striated muscle tissue development 8 4.4 
Regulation of cell motion 13 4.4 
Cartilage development 5 4.3 
Response to hypoxia 9 4.3 
Negative regulation of cell activation 4 4.3 
Response to protein stimulus 7 4.2 
Cell fate commitment 9 4.2 
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Table S2.3: Biological processes regulated by apple procyanidin fraction dp 4 compared 
to VEGF continued. 
Biological process No. of genes 
involved out 
of 233 
Fold 
Enrichment 
Response to lipopolysaccharide 5 4.2 
Response to oxygen levels 9 4.1 
Muscle tissue development 8 4.1 
Response to glucocorticoid stimulus 5 4.1 
Regulation of caspase activity 5 4.0 
Angiogenesis 9 3.9 
Positive regulation of protein transport 4 3.9 
Positive regulation of response to external stimulus 4 3.9 
Positive regulation of locomotion 6 3.9 
Negative regulation of immune system process 5 3.9 
Regulation of endopeptidase activity 5 3.9 
Skeletal muscle organ development 4 3.9 
Skeletal muscle tissue development 4 3.9 
Branching morphogenesis of a tube 4 3.9 
Regulation of cell adhesion 8 3.9 
Muscle cell differentiation 7 3.8 
Negative regulation of protein kinase activity 5 3.8 
Wound healing 11 3.8 
Striated muscle cell differentiation 5 3.8 
Response to corticosteroid stimulus 5 3.8 
Rransmembrane receptor protein serine/threonine kinase 
signaling pathway 6 3.8 
Response to molecule of bacterial origin 5 3.7 
Cell cycle arrest 6 3.7 
Reproductive structure development 7 3.7 
Response to steroid hormone stimulus 11 3.7 
Negative regulation of kinase activity 5 3.7 
Regulation of peptidase activity 5 3.7 
Rhythmic process 7 3.6 
Gonad development 6 3.6 
Positive regulation of cell migration 5 3.6 
Regulation of I-kappaB kinase/NF-kappaB cascade 6 3.6 
Regulation of Rho protein signal transduction 5 3.6 
Response to nutrient levels 11 3.5 
Negative regulation of transferase activity 5 3.4 
Organelle localization 5 3.4 
Kidney development 5 3.4 
Ossification 6 3.4 
Gland development 7 3.3 
Negative regulation of transport 7 3.3 
Positive regulation of I-kappaB kinase/NF-kappaB cascade 5 3.3 
Blood coagulation 5 3.3 
Negative regulation of response to stimulus 5 3.3 
Coagulation 5 3.3 
Positive regulation of cell motion 5 3.3 
Positive regulation of multicellular organismal process 12 3.2 
Lipid transport 7 3.2 
Regulation of MAP kinase activity 7 3.2 
Negative regulation of cell proliferation 18 3.2 
Response to organic cyclic substance 6 3.2 
Development of primary sexual characteristics 6 3.2 
Response to extracellular stimulus 11 3.2 
Appendage development 5 3.2 
Limb development 5 3.2 
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Table S2.3: Biological processes regulated by apple procyanidin fraction dp 4 compared 
to VEGF continued. 
Biological process No. of genes 
involved out 
of 233 
Fold 
Enrichment 
Carboxylic acid transport 7 3.2 
Negative regulation of multicellular organismal process 8 3.1 
Anti-apoptosis 10 3.1 
Bone development 6 3.1 
Organic acid transport 7 3.1 
Cell migration 13 3.1 
Hemostasis 5 3.1 
Response to wounding 25 3.1 
Blood vessel morphogenesis 10 3.1 
Enzyme linked receptor protein signaling pathway 16 3.0 
Response to hormone stimulus 17 3.0 
Chemotaxis 7 3.0 
Lipid localization 7 3.0 
Raxis 7 3.0 
Regulation of GTPase activity 5 3.0 
Urogenital system development 5 3.0 
Response to peptide hormone stimulus 7 2.9 
Blood vessel development 11 2.9 
Rransmembrane receptor protein tyrosine kinase signaling 
pathway 10 2.9 
Positive regulation of signal transduction 13 2.8 
Muscle organ development 9 2.8 
Vasculature development 11 2.8 
Growth 8 2.8 
Response to oxidative stress 7 2.8 
Localization of cell 13 2.8 
Cell motility 13 2.8 
Reproductive developmental process 11 2.8 
Cell motion 20 2.8 
Inflammatory response 14 2.8 
Regulation of hydrolase activity 14 2.8 
Positive regulation of cell communication 14 2.7 
Response to endogenous stimulus 17 2.7 
Response to organic substance 30 2.7 
Positive regulation of protein kinase cascade 7 2.7 
Tube development 9 2.7 
Sex differentiation 6 2.7 
Regulation of cell activation 7 2.6 
Regulation of secretion 8 2.6 
Epidermis development 7 2.6 
Positive regulation of developmental process 11 2.5 
Positive regulation of hydrolase activity 7 2.5 
Skeletal system development 12 2.4 
Regulation of phosphate metabolic process 18 2.4 
Regulation of phosphorus metabolic process 18 2.4 
Negative regulation of cell differentiation 8 2.4 
Ectoderm development 7 2.4 
Regulation of Ras protein signal transduction 7 2.4 
Regulation of phosphorylation 17 2.4 
Regulation of cellular localization 9 2.3 
Sensory organ development 8 2.3 
Negative regulation of catalytic activity 10 2.3 
Regulation of system process 11 2.3 
Negative regulation of molecular function 12 2.3 
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Table S2.3: Biological processes regulated by apple procyanidin fraction dp 4 compared 
to VEGF continued. 
Biological process No. of genes 
involved out 
of 233 
Fold 
Enrichment 
Regulation of protein kinase cascade 9 2.3 
Regulation of cell proliferation 28 2.3 
Cell-cell signaling 21 2.3 
Regulation of small GTPase mediated signal transduction 8 2.3 
Pattern specification process 9 2.3 
Regulation of protein kinase activity 12 2.2 
Positive regulation of cell differentiation 8 2.2 
Locomotory behavior 9 2.2 
Regulation of kinase activity 12 2.2 
Regulation of cell death 27 2.2 
Cell morphogenesis involved in differentiation 8 2.1 
Regulation of apoptosis 26 2.1 
Positive regulation of cell death 14 2.1 
Regulation of programmed cell death 26 2.1 
Regulation of transferase activity 12 2.1 
Cell morphogenesis 11 2.0 
Negative regulation of apoptosis 11 2.0 
Negative regulation of programmed cell death 11 2.0 
Negative regulation of cell death 11 2.0 
Positive regulation of apoptosis 13 2.0 
Positive regulation of programmed cell death 13 2.0 
Regulation of cell cycle 10 1.9 
Embryonic morphogenesis 9 1.9 
Cell proliferation 13 1.9 
Regulation of growth 10 1.9 
Cell adhesion 19 1.9 
Biological adhesion 19 1.9 
Cellular component morphogenesis 11 1.8 
Reproductive process in a multicellular organism 13 1.8 
Multicellular organism reproduction 13 1.8 
Defense response 16 1.8 
Positive regulation of gene expression 15 1.7 
Positive regulation of biosynthetic process 17 1.6 
Positive regulation of macromolecule biosynthetic process 16 1.6 
Protein amino acid phosphorylation 16 1.6 
Cell death 17 1.6 
Death 17 1.6 
Positive regulation of macromolecule metabolic process 20 1.5 
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Table S2.4: Biological processes regulated by apple procyanidin fraction dp 4-treated 
VEGF compared to the control. 
Biological processes, regulated by the apple procyanidin fraction dp 4-treated VEGF treatment versus the 
control from the p < 0.001 gene list from Table 6.1 were identified using the DAVID software. The 
biological processes were ranked according to the fold enrichment score.  
Biological process No. of genes 
involved out 
of 502 
Fold 
Enrichment 
Mismatch repair 5 7.2 
Regulation of leukocyte migration 4 6.3 
Regulation of striated muscle cell differentiation 6 6.3 
Regulation of skeletal muscle fiber development 4 5.5 
Positive regulation of anti-apoptosis 5 5.4 
Regulation of endothelial cell migration 4 5.3 
Regulation of muscle cell differentiation 6 5.3 
Regulation of nitric oxide biosynthetic process 4 5.0 
Positive regulation of alpha-beta T cell activation 4 5.0 
Cardiac cell differentiation 4 4.9 
Negative regulation of MAP kinase activity 5 4.8 
Positive regulation of cell-substrate adhesion 4 4.7 
Regulation of skeletal muscle tissue development 4 4.7 
Regulation of interferon-gamma production 4 4.5 
Regulation of JUN kinase activity 5 4.4 
Regulation of anti-apoptosis 5 4.3 
Positive regulation of T cell proliferation 5 4.2 
Positive regulation of JUN kinase activity 4 4.1 
Regulation of striated muscle tissue development 6 3.9 
DNA-dependent DNA replication 7 3.9 
Response to retinoic acid 4 3.9 
Response to UV 7 3.9 
Positive regulation of cell adhesion 7 3.9 
Regulation of muscle development 6 3.9 
DNA damage response, signal transduction resulting in 
induction of apoptosis 4 3.8 
Mesenchymal cell differentiation 6 3.8 
Mesenchymal cell development 6 3.8 
Regulation of stress-activated protein kinase signaling pathway 8 3.8 
Regulation of osteoblast differentiation 5 3.8 
Regulation of alpha-beta T cell activation 4 3.7 
Muscle fiber development 4 3.7 
Mesenchyme development 6 3.7 
Positive regulation of cell migration 10 3.6 
Odontogenesis 6 3.6 
Peptidyl-tyrosine phosphorylation 5 3.5 
Regulation of cell-substrate adhesion 5 3.5 
Regulation of JNK cascade 7 3.5 
Negative regulation of leukocyte activation 6 3.4 
Positive regulation of mononuclear cell proliferation 6 3.4 
Positive regulation of leukocyte proliferation 6 3.4 
Peptidyl-tyrosine modification 5 3.4 
Erythrocyte homeostasis 5 3.4 
Positive regulation of cell motion 10 3.3 
Positive regulation of locomotion 10 3.3 
Negative regulation of cell activation 6 3.3 
Striated muscle cell development 5 3.2 
Regulation of T cell proliferation 6 3.1 
Regulation of cell migration 16 3.1 
Regulation of angiogenesis 6 3.1 
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Table S2.4: Biological processes regulated by apple procyanidin fraction dp 4-treated 
VEGF compared to the control continued. 
Biological process No. of genes 
involved out 
of 502 
Fold 
Enrichment 
Negative regulation of lymphocyte activation 5 3.0 
Positive regulation of T cell activation 7 3.0 
Muscle cell development 5 3.0 
Blood coagulation 9 3.0 
Coagulation 9 3.0 
Leukocyte migration 5 2.9 
Cardiac muscle tissue development 5 2.9 
Positive regulation of lymphocyte proliferation 5 2.9 
Branching morphogenesis of a tube 6 2.9 
B cell activation 7 2.9 
Homeostasis of number of cells 9 2.9 
Response to cytokine stimulus 7 2.9 
Regulation of ossification 7 2.9 
Cellular response to insulin stimulus 6 2.8 
Protein amino acid autophosphorylation 7 2.8 
Cytokine-mediated signaling pathway 6 2.8 
Hemostasis 9 2.8 
Regulation of MAP kinase activity 12 2.8 
Muscle cell differentiation 10 2.8 
Striated muscle tissue development 10 2.7 
Negative regulation of immune system process 7 2.7 
Regulation of locomotion 16 2.7 
Regulation of cell motion 16 2.7 
Negative regulation of protein kinase activity 7 2.7 
Regulation of MAPKKK cascade 9 2.7 
Response to hypoxia 11 2.7 
Regulation of leukocyte proliferation 7 2.7 
Striated muscle cell differentiation 7 2.7 
Regulation of mononuclear cell proliferation 7 2.7 
Angiogenesis 12 2.6 
Muscle tissue development 10 2.6 
Negative regulation of kinase activity 7 2.6 
Regulation of cytokine biosynthetic process 6 2.6 
Morphogenesis of a branching structure 6 2.6 
Activation of protein kinase activity 9 2.6 
Response to oxygen levels 11 2.6 
Regulation of cellular response to stress 8 2.5 
DNA replication 14 2.5 
Negative regulation of transferase activity 7 2.4 
Myeloid cell differentiation 7 2.4 
Regulation of body fluid levels 10 2.4 
Positive regulation of lymphocyte activation 7 2.3 
Response to insulin stimulus 7 2.3 
Regulation of T cell activation 8 2.3 
Immune system development 19 2.2 
Positive regulation of MAP kinase activity 7 2.2 
Regulation of cell adhesion 9 2.2 
Response to light stimulus 9 2.2 
Cell activation 19 2.2 
Heart development 14 2.2 
Blood vessel morphogenesis 14 2.2 
Blood vessel development 16 2.1 
Negative regulation of cell differentiation 14 2.1 
Wound healing 12 2.1 
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Table S2.4: Biological processes regulated by apple procyanidin fraction dp 4-treated 
VEGF compared to the control continued. 
Biological process No. of genes 
involved out 
of 502 
Fold 
Enrichment 
Response to peptide hormone stimulus 10 2.1 
Regulation of protein kinase activity 22 2.1 
Vasculature development 16 2.1 
Hemopoiesis 15 2.1 
Positive regulation of protein kinase activity 14 2.0 
Regulation of kinase activity 22 2.0 
Hemopoietic or lymphoid organ development 16 2.0 
Regulation of lymphocyte activation 9 2.0 
Regulation of leukocyte activation 10 2.0 
Positive regulation of kinase activity 14 2.0 
Response to hormone stimulus 22 1.9 
Regulation of protein kinase cascade 15 1.9 
Forebrain development 9 1.9 
Response to endogenous stimulus 24 1.9 
Regulation of transferase activity 22 1.9 
Cell migration 16 1.9 
Regulation of cell activation 10 1.9 
Leukocyte activation 14 1.9 
Positive regulation of transferase activity 14 1.9 
Regulation of protein amino acid phosphorylation 10 1.9 
DNA repair 16 1.9 
Response to DNA damage stimulus 21 1.9 
Response to steroid hormone stimulus 11 1.9 
Localization of cell 17 1.8 
Cell motility 17 1.8 
Regulation of phosphorylation 26 1.8 
Positive regulation of cell proliferation 23 1.8 
Lymphocyte activation 11 1.8 
Tube development 12 1.8 
Cell proliferation 24 1.8 
Positive regulation of multicellular organismal process 13 1.8 
Regulation of phosphorus metabolic process 26 1.8 
Regulation of phosphate metabolic process 26 1.8 
Positive regulation of developmental process 15 1.7 
DNA metabolic process 26 1.7 
Negative regulation of cell proliferation 19 1.7 
Positive regulation of cell differentiation 12 1.7 
Protein kinase cascade 19 1.7 
Response to organic substance 37 1.7 
Positive regulation of cell death 22 1.7 
Protein amino acid phosphorylation 33 1.6 
Cell motion 23 1.6 
Response to wounding 26 1.6 
Inflammatory response 16 1.6 
Positive regulation of apoptosis 21 1.6 
Positive regulation of programmed cell death 21 1.6 
Regulation of cell proliferation 38 1.6 
Ion homeostasis 19 1.5 
Cellular response to stress 26 1.5 
Cell-cell signaling 27 1.5 
Phosphate metabolic process 43 1.5 
Phosphorus metabolic process 43 1.5 
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Table S2.5: Biological processes regulated by apple procyanidin fraction dp 4-treated 
VEGF compared to VEGF.  
Biological processes regulated by the apple procyanidin fraction dp 4-treated VEGF treatment versus the 
VEGF treatment from the p < 0.001 gene list from Table 6.1 were identified using the DAVID software. The 
biological processes were ranked according to the fold enrichment score.  
Biological process No. of genes 
involved out 
of 355 
Fold 
Enrichment 
Response to retinoic acid 6 8.9 
Ureteric bud development 6 8.4 
Negative regulation of MAP kinase activity 6 8.2 
Cardiac cell differentiation 4 7.0 
Cell-cell junction organization 5 7.0 
Response to vitamin A 6 7.0 
Cell junction organization 8 6.9 
Metanephros development 6 6.7 
Calcium-mediated signaling 5 6.6 
Odontogenesis of dentine-containing tooth 5 6.3 
Regulation of endothelial cell proliferation 4 6.1 
Cell junction assembly 5 6.0 
Phospholipid transport 4 6.0 
Cell fate determination 4 6.0 
Establishment of vesicle localization 4 6.0 
ER-nuclear signaling pathway 4 5.6 
Negative regulation of defense response 4 5.5 
Odontogenesis 6 5.5 
Regulation of angiogenesis 7 5.5 
Negative regulation of secretion 6 5.4 
Vesicle localization 4 5.3 
Negative regulation of hydrolase activity 5 5.1 
Positive regulation of cell division 4 5.0 
Response to unfolded protein 7 4.8 
Mesenchymal cell differentiation 5 4.8 
Mesenchymal cell development 5 4.8 
Mesenchyme development 5 4.7 
Neuron fate commitment 4 4.7 
Regulation of inflammatory response 7 4.5 
Negative regulation of protein kinase activity 8 4.5 
BMP signaling pathway 4 4.5 
Response to vitamin 6 4.5 
Ovulation cycle 6 4.4 
Response to mechanical stimulus 5 4.4 
Negative regulation of kinase activity 8 4.4 
Leukocyte migration 5 4.3 
Cytokine production 4 4.3 
Regulation of cell division 4 4.2 
Positive regulation of cell adhesion 5 4.1 
Negative regulation of transferase activity 8 4.1 
Negative regulation of cell activation 5 4.0 
Angiogenesis 12 4.0 
Ovulation cycle process 5 4.0 
Regulation of striated muscle tissue development 4 3.9 
Monocarboxylic acid transport 4 3.9 
Regulation of muscle development 4 3.9 
Female gonad development 5 3.8 
Positive regulation of response to external stimulus 5 3.8 
Striated muscle cell development 4 3.8 
Branching morphogenesis of a tube 5 3.8 
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Table S2.5: Biological processes regulated by apple procyanidin fraction dp 4-treated 
VEGF compared to VEGF continued. 
Biological process No. of genes 
involved out 
of 355 
Fold 
Enrichment 
Response to estrogen stimulus 8 3.7 
Organelle localization 7 3.7 
Regulation of intracellular protein transport 4 3.7 
Regulation of I-kappaB kinase/NF-kappaB cascade 8 3.7 
Response to protein stimulus 8 3.7 
Positive regulation of protein transport 5 3.7 
Response to hypoxia 10 3.7 
Muscle cell differentiation 9 3.7 
Female sex differentiation 5 3.6 
Development of primary female sexual characteristics 5 3.6 
Negative regulation of immune system process 6 3.6 
Positive regulation of I-kappaB kinase/NF-kappaB cascade 7 3.5 
Cell fate commitment 10 3.5 
Regulation of cell migration 12 3.5 
Response to oxygen levels 10 3.5 
Regulation of response to external stimulus 11 3.4 
Lipid transport 10 3.4 
Striated muscle cell differentiation 6 3.4 
Regulation of locomotion 13 3.3 
Morphogenesis of a branching structure 5 3.3 
Cartilage development 5 3.3 
Striated muscle tissue development 8 3.3 
Amino acid transport 6 3.3 
Negative regulation of transport 9 3.3 
Blood vessel morphogenesis 14 3.3 
Cell migration 18 3.2 
Dephosphorylation 10 3.2 
Response to nutrient 9 3.2 
Response to glucocorticoid stimulus 5 3.2 
Muscle tissue development 8 3.1 
Regulation of MAP kinase activity 9 3.1 
Lipid localization 10 3.1 
Regulation of caspase activity 5 3.1 
Wound healing 12 3.1 
Kidney development 6 3.1 
Response to steroid hormone stimulus 12 3.1 
Regulation of cell motion 12 3.1 
Negative regulation of cell cycle 5 3.0 
Regulation of protein transport 7 3.0 
Acute inflammatory response 6 3.0 
Blood vessel development 15 3.0 
Regulation of endopeptidase activity 5 3.0 
Regulation of Rho protein signal transduction 6 3.0 
Protein amino acid dephosphorylation 8 3.0 
Positive regulation of protein kinase cascade 10 2.9 
Vasculature development 15 2.9 
Response to corticosteroid stimulus 5 2.9 
Coagulation 6 2.9 
Blood coagulation 6 2.9 
Localization of cell 18 2.9 
Cell motility 18 2.9 
Regulation of cell adhesion 8 2.9 
Cell cycle arrest 6 2.9 
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Table S2.5: Biological processes regulated by apple procyanidin fraction dp 4-treated 
VEGF compared to VEGF continued. 
Biological process No. of genes 
involved out 
of 355 
Fold 
Enrichment 
Transmembrane receptor protein serine/threonine kinase 
signaling pathway 
6 2.9 
Regulation of peptidase activity 5 2.9 
Regulation of establishment of protein localization 7 2.8 
ATP metabolic process 6 2.8 
Carbohydrate biosynthetic process 6 2.8 
Hemostasis 6 2.7 
Reproductive structure development 7 2.7 
Positive regulation of secretion 6 2.7 
Response to wounding 29 2.7 
Rhythmic process 7 2.7 
Urogenital system development 6 2.7 
Carboxylic acid transport 8 2.7 
Organic acid transport 8 2.7 
Gonad development 6 2.6 
Cell motion 25 2.6 
Inflammatory response 17 2.6 
Regulation of protein kinase activity 18 2.6 
Purine ribonucleoside triphosphate metabolic process 6 2.5 
Ribonucleoside triphosphate metabolic process 6 2.5 
Amine transport 6 2.5 
Positive regulation of signal transduction 15 2.5 
Response to nutrient levels 10 2.5 
Purine ribonucleotide metabolic process 7 2.5 
Regulation of protein localization 7 2.5 
Regulation of kinase activity 18 2.5 
Tube development 11 2.5 
Response to extracellular stimulus 11 2.5 
Negative regulation of cell proliferation 18 2.5 
Regulation of secretion 10 2.4 
Regulation of phosphorus metabolic process 24 2.4 
Regulation of phosphate metabolic process 24 2.4 
Regulation of phosphorylation 23 2.4 
Response to hormone stimulus 18 2.4 
Anti-apoptosis 10 2.4 
Regulation of cellular localization 12 2.4 
Regulation of transferase activity 18 2.4 
Regulation of protein kinase cascade 12 2.4 
Negative regulation of molecular function 16 2.4 
Ribonucleotide metabolic process 7 2.3 
Negative regulation of catalytic activity 13 2.3 
Cell proliferation 20 2.3 
Regulation of cell activation 8 2.2 
Positive regulation of cell communication 15 2.2 
Positive regulation of transport 10 2.2 
Glycoprotein metabolic process 9 2.2 
Tissue morphogenesis 8 2.2 
Response to endogenous stimulus 18 2.2 
Enzyme linked receptor protein signaling pathway 15 2.2 
Response to organic substance 31 2.1 
Muscle organ development 9 2.1 
Regulation of hydrolase activity 14 2.0 
Positive regulation of cell death 18 2.0 
Positive regulation of multicellular organismal process 10 2.0 
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Table S2.5: Biological processes regulated by apple procyanidin fraction dp 4-treated 
VEGF compared to VEGF continued. 
Biological process No. of genes 
involved out 
of 355 
Fold 
Enrichment 
Transmembrane receptor protein tyrosine kinase signaling 
pathway 9 2.0 
Positive regulation of developmental process 11 1.9 
Positive regulation of apoptosis 17 1.9 
Positive regulation of programmed cell death 17 1.9 
Cell-cell signaling 23 1.9 
Reproductive developmental process 10 1.9 
Regulation of cell proliferation 30 1.9 
Induction of apoptosis 12 1.8 
Induction of programmed cell death 12 1.8 
Regulation of cell death 30 1.8 
Regulation of cell cycle 12 1.8 
Regulation of apoptosis 29 1.8 
Regulation of programmed cell death 29 1.8 
Regulation of system process 11 1.8 
Defense response 20 1.6 
Negative regulation of macromolecule biosynthetic process 17 1.5 
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Table S2.6: Biological processes regulated by anti-VEGF antibody-treated VEGF 
compared to VEGF. 
Biological processes regulated by anti-VEGF antibody-treated VEGF treatment versus the VEGF treatment 
from the p < 0.001 gene list from Table 6.1 were identified using the DAVID software. The biological 
processes were ranked according to the fold enrichment score.  
Biological process No. of genes 
involved out 
of 129 
Fold 
Enrichment 
ER-nuclear signaling pathway 4 13.5 
Negative regulation of hydrolase activity 4 9.8 
Response to mechanical stimulus 4 8.7 
Response to unfolded protein 5 8.7 
Regulation of caspase activity 5 7.6 
Regulation of endopeptidase activity 5 7.3 
Regulation of peptidase activity 5 6.9 
Response to protein stimulus 6 6.8 
Cartilage development 4 6.6 
Regulation of inflammatory response 4 6.4 
Response to lipopolysaccharide 4 6.3 
Response to estrogen stimulus 5 5.7 
Response to molecule of bacterial origin 4 5.6 
Positive regulation of cell migration 4 5.4 
Positive regulation of cell motion 4 4.9 
Positive regulation of locomotion 4 4.9 
Transmembrane receptor protein tyrosine kinase signaling 
pathway 9 4.9 
Regulation of response to external stimulus 6 4.6 
Regulation of gene-specific transcription 5 4.6 
Carbohydrate biosynthetic process 4 4.5 
Regulation of cell migration 6 4.3 
Ossification 4 4.2 
Bone development 4 3.9 
Enzyme linked receptor protein signaling pathway 11 3.9 
Rhythmic process 4 3.9 
Response to metal ion 4 3.8 
Response to steroid hormone stimulus 6 3.8 
Regulation of locomotion 6 3.8 
Regulation of cell motion 6 3.8 
Golgi vesicle transport 4 3.7 
Response to inorganic substance 6 3.7 
Response to hypoxia 4 3.6 
Negative regulation of transport 4 3.6 
Cell migration 8 3.6 
Response to extracellular stimulus 6 3.3 
Localization of cell 8 3.3 
Cell motility 8 3.3 
Regulation of nervous system development 5 3.2 
Response to organic substance 19 3.2 
Regulation of system process 8 3.2 
Response to nutrient levels 5 3.0 
Response to abiotic stimulus 9 3.0 
Response to wounding 13 3.0 
Inflammatory response 8 3.0 
Regulation of hydrolase activity 8 3.0 
Blood vessel development 6 3.0 
Anti-apoptosis 5 3.0 
Vasculature development 6 2.9 
Response to endogenous stimulus 9 2.7 
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Table S2.6: Biological processes regulated by anti-VEGF antibody-treated VEGF 
compared to VEGF continued. 
Biological process No. of genes 
involved out 
of 129 
Fold 
Enrichment 
Response to hormone stimulus 8 2.7 
Positive regulation of developmental process 6 2.6 
Negative regulation of transcription, DNA-dependent 7 2.4 
Negative regulation of programmed cell death 7 2.4 
Negative regulation of cell death 7 2.4 
Negative regulation of RNA metabolic process 7 2.4 
Negative regulation of macromolecule biosynthetic process 10 2.3 
Negative regulation of cellular biosynthetic process 10 2.2 
Negative regulation of transcription 8 2.2 
Negative regulation of biosynthetic process 10 2.2 
Cell motion 8 2.1 
Cation transport 9 2.0 
Regulation of phosphorus metabolic process 8 2.0 
Regulation of phosphate metabolic process 8 2.0 
Regulation of programmed cell death 13 2.0 
Regulation of cell death 13 2.0 
Cell surface receptor linked signal transduction 26 1.9 
Regulation of cell proliferation 12 1.9 
Negative regulation of macromolecule metabolic process 11 1.8 
Regulation of apoptosis 12 1.8 
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Table S2.7: Biological processes regulated by anti-VEGF antibody-treated VEGF 
compared to apple procyanidin fraction dp 4.  
Biological processes regulated by anti-VEGF antibody-treated VEGF treatment versus the apple 
procyanidin fraction dp 4 treatment from the p < 0.001 gene list from Table 6.1 were identified using the 
DAVID software. The biological processes were ranked according to the fold enrichment score.  
Biological process No. of genes 
involved out 
of 37 
Fold 
Enrichment 
Response to nutrient 4 10.5 
Angiogenesis 4 10.1 
Anti-apoptosis 5 9.1 
Blood vessel morphogenesis 5 8.8 
Response to steroid hormone stimulus 4 7.8 
Blood vessel development 5 7.6 
Response to nutrient levels 4 7.4 
Vasculature development 5 7.4 
Tube development 4 6.8 
Positive regulation of transport 4 6.7 
Response to extracellular stimulus 4 6.7 
Positive regulation of multicellular organismal process 4 6.2 
Negative regulation of apoptosis 5 5.3 
Negative regulation of programmed cell death 5 5.2 
Negative regulation of cell death 5 5.2 
Response to hormone stimulus 5 5.1 
Embryonic morphogenesis 4 5.0 
Response to endogenous stimulus 5 4.6 
Positive regulation of cell proliferation 5 4.5 
Positive regulation of cell communication 4 4.5 
Enzyme linked receptor protein signaling pathway 4 4.3 
Positive regulation of transcription from RNA polymerase II 
promoter 4 4.1 
Regulation of phosphorylation 5 4.0 
Multicellular organism reproduction 5 4.0 
Reproductive process in a multicellular organism 5 4.0 
Regulation of phosphorus metabolic process 5 3.9 
Regulation of phosphate metabolic process 5 3.9 
Regulation of cell death 7 3.2 
Defense response 5 3.2 
Regulation of transcription from RNA polymerase II promoter 6 3.1 
Cell-cell signaling 5 3.1 
Response to organic substance 6 3.1 
Immune response 5 3.0 
Positive regulation of nitrogen compound metabolic process 5 3.0 
Regulation of apoptosis 6 2.8 
Positive regulation of cellular biosynthetic process 5 2.8 
Regulation of programmed cell death 6 2.8 
Regulation of transcription, DNA-dependent 12 2.7 
Positive regulation of biosynthetic process 5 2.7 
Regulation of RNA metabolic process 12 2.7 
Intracellular signaling cascade 7 2.1 
Regulation of transcription 12 1.8 
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Supplementary Information 3 
Genes differentially expressed in response to treatments  
The genes that are altered in HUVECs in response to VEGF, apple procyanidin fraction 
dp 4 and anti-VEGF antibody treatments are listed in Tables S2.1-7. The gene list that 
represents a p value of <0.001 was used to produce a manageable set of probes to 
perform more detailed functional analysis. The probes are ranked into gene ontology 
groups according to the gene ontology database http://www.geneontology.org/. Those 
probes that had more than one gene ontology grouping were ranked according to the 
amount of citations in PubMed (http://www.ncbi.nlm.nih.gov/sites/entrez) for that 
particular function.  
 
Table S3.1: List of differentially expressed genes in HUVECs after a six hour treatment of 
10 ng/ml VEGF compared to the control (p < 0.001; 132 genes).  
Gene ID Gene 
Symbol 
Gene Name Fold 
Change 
Angiogenesis   
  
NM_001147 ANGPT2 angiopoietin 2 1.81 
NM_005429 VEGFC vascular endothelial growth factor C 1.41 
Apoptosis   
  
NM_002135 NR4A1 nuclear receptor subfamily 4, group A, member 1  1.70 
NM_001066 TNFRSF1B tumor necrosis factor receptor superfamily, member 1B -1.64 
NM_003810 TNFSF10 tumor necrosis factor (ligand) superfamily, member 10  -2.22 
NM_018003 UACA uveal autoantigen with coiled-coil domains and ankyrin 
repeats  1.53 
Binding / Cell Adhesion 
  
NM_001130861 CLDN5 claudin 5  -1.56 
NM_001850 COL8A1 collagen, type VIII, alpha 1 -1.44 
NM_024785 FAM124B family with sequence similarity 124B -1.83 
NM_024582 FAT4 FAT tumor suppressor homolog 4 (Drosophila) -1.66 
NM_016946 F11R F11 receptor -1.36 
NM_130759 GIMAP1 GTPase, IMAP family member 1  -1.68 
NM_015660 GIMAP2 GTPase, IMAP family member 2 -1.83 
NM_018326 GIMAP4 GTPase, IMAP family member 4 -1.61 
NM_024711 GIMAP6 GTPase, IMAP family member 6  -1.44 
NM_175571 GIMAP8 GTPase, IMAP family member 8 -1.71 
NM_022143 LRRC4 leucine rich repeat containing 4  -1.41 
NM_022750 PARP12 poly (ADP-ribose) polymerase family, member 12 -1.30 
NM_001040429 PCDH17 protocadherin 17 1.61 
NM_024787 RNF122 ring finger protein 122 1.39 
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Table S3.1: List of differentially expressed genes in HUVECs after a six hour treatment of 
10 ng/ml VEGF compared to the control (p < 0.001; 132 genes) continued. 
Gene ID Gene 
Symbol 
Gene Name Fold 
Change 
Cell communication 
  
NM_001142481 C5orf13 chromosome 5 open reading frame 13  -1.46 
NM_014421 DKK2 dickkopf homolog 2 (Xenopus laevis) 1.86 
NM_018431 DOK5 docking protein 5  1.84 
NM_012302 LPHN2 latrophilin 2 1.70 
NM_005065 SEL1L sel-1 suppressor of lin-12-like (C. elegans) 1.48 
NM_015144 ZCCHC14 zinc finger, CCHC domain containing 14  1.37 
Cell Cycle / Cell Proliferation 
  
NM_006988 ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 
motif, 1  1.57 
NM_015147 CEP68 centrosomal protein 68kDa -1.62 
NM_001946 DUSP6 dual specificity phosphatase 6 1.39 
NM_001085377 MCC mutated in colorectal cancers -1.37 
NM_006472 TXNIP thioredoxin interacting protein -1.67 
NM_002688 SEPT5 septin 5  1.67 
NM_153618 SEMA6D sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6D 3.90 
NM_145728 SYNM synemin, intermediate filament protein 1.53 
NM_014909 VASH1 vasohibin 1  1.47 
NM_000222 KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog -2.03 
Development   
  
NM_003633 ENC1 ectodermal-neural cortex (with BTB-like domain) -1.74 
NM_006350 FST follistatin 1.84 
NM_002060 GJA4 gap junction protein, alpha 4, 37kDa  -2.55 
NM_005266 GJA5 gap junction protein, alpha 5, 40kDa  -2.12 
NM_003250 THRA thyroid hormone receptor, alpha (erythroblastic leukemia 
viral (v-erb-a) oncogene homolog, avian)  
-1.35 
NM_005450 NOG noggin 2.06 
NM_002360 MAFK v-maf musculoaponeurotic fibrosarcoma oncogene 
homolog K (avian)  1.38 
DNA  Binding / Replication / Repair / Transcription 
NM_014945 ABLIM3 actin binding LIM protein family, member 3 -1.31 
NM_005935 AFF1 AF4/FMR2 family, member 1  -1.36 
NM_001986 ETV4 ets variant 4  1.51 
NM_001134673 NFIA nuclear factor I/A // 1p31.3-p31.2  -1.39 
NM_005378 MYCN v-myc myelocytomatosis viral related oncogene, 
neuroblastoma derived (avian) 1.63 
Immune Response 
  
NM_007074 CORO1A coronin, actin binding protein, 1A 1.55 
NM_005080 XBP1 X-box binding protein 1  1.53 
Metabolic / Biosynthetic Process 
NM_022060 ABHD4 abhydrolase domain containing 4  1.44 
NM_003654 CHST1 carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 -1.42 
NM_015892 CHST15 carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) 
sulfotransferase 15 -1.41 
NM_015892 CHST15 carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) 
sulfotransferase 15  -1.33 
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Table S3.1: List of differentially expressed genes in HUVECs after a six hour treatment of 
10 ng/ml VEGF compared to the control (p < 0.001; 132 genes) continued. 
Gene ID Gene 
Symbol 
Gene Name Fold 
Change 
Metabolic / Biosynthetic Process continued 
NM_032385 C5orf4 chromosome 5 open reading frame 4  -1.57 
NM_000499 CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1  -2.10 
NM_012328 DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 2.16 
NM_006260 DNAJC3 DnaJ (Hsp40) homolog, subfamily C, member 3 1.78 
NM_014674 EDEM1 ER degradation enhancer, mannosidase alpha-like 1  1.50 
NM_019891 ERO1LB ERO1-like beta (S. cerevisiae) 2.19 
NM_007076 FICD FIC domain containing 1.81 
NM_002153 HSD17B2 hydroxysteroid (17-beta) dehydrogenase 2 1.60 
NM_018192 LEPREL1 leprecan-like 1  1.42 
NM_001144967 NEDD4L neural precursor cell expressed, developmentally down-
regulated 4-like 1.62 
NM_004414 RCAN1 regulator of calcineurin 1 2.26 
NM_014746 RNF144A ring finger protein 144A -1.75 
NM_006588 SULT1C4 sulfotransferase family, cytosolic, 1C, member 4 1.96 
NM_032431 SYVN1 synovial apoptosis inhibitor 1, synoviolin 1.69 
Response to stimulus 
  
NM_000014 A2M alpha-2-macroglobulin  2.18 
NM_005409 CXCL11 chemokine (C-X-C motif) ligand 11 -3.69 
NM_001993 F3 coagulation factor III (thromboplastin, tissue factor) 1.59 
NM_005347 HSPA5 heat shock 70kDa protein 5 (glucose-regulated protein, 
78kDa)  1.45 
NM_014685 HERPUD1 homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1 1.90 
NM_006389 HYOU1 hypoxia up-regulated 1  1.42 
NM_006010 MANF mesencephalic astrocyte-derived neurotrophic factor  1.49 
NM_000603 NOS3 nitric oxide synthase 3 (endothelial cell) -1.42 
NM_003155 STC1 stanniocalcin 1 3.76 
NM_000361 THBD thrombomodulin 2.43 
NM_006528 TFPI2 tissue factor pathway inhibitor 2  1.81 
NM_001078 VCAM1 vascular cell adhesion molecule 1 2.28 
Signal Transduction 
  
NM_000020 ACVRL1 activin A receptor type II-like 1 -1.41 
NM_006449 CDC42EP3 CDC42 effector protein (Rho GTPase binding) 3 -1.44 
NM_173515 CNKSR3 CNKSR family member 3 2.03 
NM_138445 GPR146 G protein-coupled receptor 146 -1.74 
NM_001945 HBEGF heparin-binding EGF-like growth factor 1.67 
NM_005204 MAP3K8 mitogen-activated protein kinase kinase kinase 8 1.53 
NM_006186 NR4A2 nuclear receptor subfamily 4, group A, member 2 1.65 
NM_002646 PIK3C2B phosphoinositide-3-kinase, class 2, beta polypeptide -1.46 
NM_007211 RASSF8 Ras association (RalGDS/AF-6) domain family (N-
terminal) member 8 1.51 
NM_016084 RASD1 RAS, dexamethasone-induced 1 1.83 
NM_001010000 ARHGAP28 Rho GTPase activating protein 28 -1.79 
NM_001128615 ARHGEF3 Rho guanine nucleotide exchange factor (GEF) 3 -1.46 
NM_030964 SPRY4 sprouty homolog 4 (Drosophila) -1.82 
NM_015028 TNIK TRAF2 and NCK interacting kinase -1.48 
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Table S3.1: List of differentially expressed genes in HUVECs after a six hour treatment of 
10 ng/ml VEGF compared to the control (p < 0.001; 132 genes) continued. 
Gene ID Gene 
Symbol 
Gene Name Fold 
Change 
Transcription   
  
NM_001200 BMP2 bone morphogenetic protein 2 1.97 
NM_178423 HDAC9 histone deacetylase 9 1.52 
NM_030915 LBH limb bud and heart development homolog (mouse) 1.97 
NM_014368 LHX6 LIM homeobox 6  -1.44 
NM_018717 MAML3 mastermind-like 3 (Drosophila) -1.34 
NM_002397 MEF2C myocyte enhancer factor 2C  1.59 
NM_205860 NR5A2 nuclear receptor subfamily 5, group A, member 2 1.53 
NM_001198 PRDM1  PR domain containing 1, with ZNF domain 2.74 
NM_005686 SOX13 SRY (sex determining region Y)-box 13 -1.45 
Transport   
  
NM_001001396 ATP2B4 ATPase, Ca++ transporting, plasma membrane 4  -1.56 
NM_004827 ABCG2 ATP-binding cassette, sub-family G (WHITE), member 2 -1.91 
NM_198098 AQP1 aquaporin 1 -2.16 
NM_022113 KIF13A kinesin family member 13A 1.42 
NM_138444 KCTD12 potassium channel tetramerisation domain containing 12 -1.66 
NM_152999 STEAP2 six transmembrane epithelial antigen of the prostate 2  -1.46 
NM_003043 SLC6A6 solute carrier family 6 (neurotransmitter transporter, 
taurine), member 6 -1.50 
NM_003045 SLC7A1 solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 1.61 
NM_001128431 SLC39A14 solute carrier family 39 (zinc transporter), member 14  2.07 
Miscellaneous / Other 
  
NM_020437 ASPHD2 aspartate beta-hydroxylase domain containing 2 -1.52 
NM_032866 CGNL1 cingulin-like 1  -1.60 
NM_005851 CDK2AP2 cyclin-dependent kinase 2 associated protein 2 1.55 
NM_001135101 CRELD2 cysteine-rich with EGF-like domains 2 1.57 
NM_014600 EHD3 EH-domain containing 3 3.21 
NM_001130025 FAM115C family with sequence similarity 115, member C 1.37 
NM_173511 FAM117B family with sequence similarity 117, member B  -1.32 
NM_015687 FILIP1 filamin A interacting protein 1  -1.58 
NM_007223 GPR176 G protein-coupled receptor 176  1.50 
NM_001134476 LRRC8B leucine rich repeat containing 8 family, member B 1.57 
NM_173198 NR4A3 nuclear receptor subfamily 4, group A, member 3 1.38 
NM_015993 PLLP plasma membrane proteolipid (plasmolipin) -1.70 
NM_015157 PHLDB1 pleckstrin homology-like domain, family B, member 1 1.39 
NM_001104587 SLFN11 schlafen family member 11 1.75 
NM_022044 SDF2L1 stromal cell-derived factor 2-like 1 1.87 
NM_003898 SYNJ2 synaptojanin 2  -1.37 
NM_005723 TSPAN5 tetraspanin 5 -1.41 
NR_002816 THSD1P 
thrombospondin, type I, domain containing 1 
pseudogene -1.52 
NM_013390 TMEM2 transmembrane protein 2 1.61 
NM_006134 TMEM50B transmembrane protein 50B  1.96 
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Table S3.2: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4 compared to the control (p < 0.001; 94 genes). 
Gene ID Gene 
Symbol 
Gene Name Fold 
Change 
Angiogenesis 
NM_001147 ANGPT2 angiopoietin 2 -1.71 
NM_001202 BMP4 bone morphogenetic protein 4 -1.86 
NM_001554 CYR61 cysteine-rich, angiogenic inducer, 61 -1.61 
NM_002133 HMOX1 heme oxygenase (decycling) 1 1.59 
NM_005924 MEOX2 mesenchyme homeobox 2 -1.66 
NM_005429 VEGFC vascular endothelial growth factor C 1.44 
Apoptosis 
NM_001003940 BMF Bcl2 modifying factor 1.46 
NM_032977 CASP10 caspase 10, apoptosis-related cysteine peptidase  -1.62 
NM_019058 DDIT4 DNA-damage-inducible transcript 4  1.60 
NM_182757 RNF144B ring finger protein 144B  -1.91 
NM_020870 SH3RF1 SH3 domain containing ring finger 1 -1.37 
NM_005092 TNFSF18 tumor necrosis factor (ligand) superfamily, member 18 -2.44 
Binding / Cell adhesion 
NM_001850 COL8A1 collagen, type VIII, alpha 1 -1.64 
NM_001338 CXADR coxsackie virus and adenovirus receptor -1.62 
NM_130759 GIMAP1 GTPase, IMAP family member 1 -1.40 
NM_175571 GIMAP8 GTPase, IMAP family member 8 -1.61 
NM_024787 RNF122 ring finger protein 122 1.74 
Cell Communication 
NM_000863 HTR1B 5-hydroxytryptamine (serotonin) receptor 1B -1.61 
NM_002758 MAP2K6 mitogen-activated protein kinase kinase 6 -1.61 
NM_005923 MAP3K5 mitogen-activated protein kinase kinase kinase 5 -1.57 
NM_024870 PREX2 phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2  -1.66 
NM_032784 RSPO3 R-spondin 3 homolog (Xenopus laevis) -1.57 
NM_015191 SIK2 salt-inducible kinase 2  1.48 
Cell Cycle / Cell Proliferation 
NM_000757 CSF1 colony stimulating factor 1 (macrophage) 1.43 
NM_001946 DUSP6 dual specificity phosphatase 6  -1.49 
NM_004429 EFNB1 ephrin-B1  1.52 
NM_002192 INHBA inhibin, beta A -1.46 
Development 
NM_012242 DKK1 dickkopf homolog 1 (Xenopus laevis)  -2.03 
NM_182964 NAV2 neuron navigator 2  1.69 
NM_013960 NRG1 neuregulin 1  -1.44 
NM_001025252 TPD52 tumor protein D52 -1.43 
NM_005239 ETS2  v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) 1.45 
DNA Binding / Replication / Repair / Transcription 
NM_004956 ETV1 ets variant 1 -1.81 
NM_001515 GTF2H2 general transcription factor IIH, polypeptide 2, 44kDa -1.70 
NM_000270 NP nucleoside phosphorylase  1.42 
NM_005378 MYCN v-myc myelocytomatosis viral related oncogene, 
neuroblastoma derived (avian)  2.01 
NR_027302 XPA xeroderma pigmentosum, complementation group A  -1.63 
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Table S3.2: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4 compared to the control (p < 0.001; 94 genes) 
continued. 
Gene ID Gene 
Symbol 
Gene Name Fold 
Change 
Inflammatory Response 
NM_000201 ICAM1 intercellular adhesion molecule 1 1.89 
NM_000600 IL6 interleukin 6 (interferon, beta 2) -1.92 
NM_002852 PTX3 pentraxin-related gene, rapidly induced by IL-1 beta -2.21 
Immune Response 
NM_014143 CD274 CD274 molecule -2.09 
NM_003954 MAP3K14 mitogen-activated protein kinase kinase kinase 14 1.59 
Metabolic / Biosynthetic Process 
NM_005099 ADAMTS4 ADAM metallopeptidase with thrombospondin type 1 
motif, 4 1.68 
NM_174858 AK5 adenylate kinase 5  -1.96 
NM_007034 DNAJB4 DnaJ (Hsp40) homolog, subfamily B, member 4 -1.80 
NM_024090 ELOVL6 ELOVL family member 6, elongation of long chain fatty acids (FEN1/Elo2, SUR4/Elo3-like, yeast) -2.00 
NM_001097634 GCNT1 glucosaminyl (N-acetyl) transferase 1, core 2 (beta-1,6-N-acetylglucosaminyltransferase)  -1.67 
NM_023112 OTUB2 OTU domain, ubiquitin aldehyde binding 2  1.52 
NM_001159323 PLA2G4C phospholipase A2, group IVC (cytosolic, calcium-independent) 1.76 
NM_000930 PLAT plasminogen activator, tissue 1.48 
NM_000963 PTGS2 
prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and cyclooxygenase) 1.55 
NM_001143676 SGK1 serum/glucocorticoid regulated kinase 1  -1.62 
NM_001130012 SLC9A3R2 solute carrier family 9 (sodium/hydrogen exchanger), 
member 3 regulator 2 1.52 
NM_015028 TNIK TRAF2 and NCK interacting kinase -1.43 
Response to Stimulus 
NM_004827 ABCG2 ATP-binding cassette, sub-family G (WHITE), 
member 2 -1.94 
NM_018948 ERRFI1 ERBB receptor feedback inhibitor 1 -1.51 
NM_002229 JUNB jun B proto-oncogene  1.71 
NM_001128304 PLSCR4 phospholipid scramblase 4 -1.92 
NM_003234 TFRC transferrin receptor (p90, CD71) -2.08 
Signal Transduction 
NM_014391 ANKRD1 ankyrin repeat domain 1 (cardiac muscle) -1.53 
NM_004864 GDF15 growth differentiation factor 15 1.50 
NM_001077494 NFKB2 nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 2 (p49/p100)  1.52 
NM_015368 PANX1 pannexin 1 1.37 
NM_001102445 RGS4 regulator of G-protein signalling 4 -1.61 
NM_005842 SPRY2 sprouty homolog 2 (Drosophila) -1.61 
NM_005841 SPRY1 sprouty homolog 1, antagonist of FGF signalling (Drosophila) -1.57 
NM_005658 TRAF1 TNF receptor-associated factor 1 1.90 
Transcription 
NM_004454 ETV5 ets variant 5 -1.64 
NM_021958 HLX H2.0-like homeobox  1.51 
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Table S3.2: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4 compared to the control (p < 0.001; 94 genes) 
continued. 
Gene ID Gene 
Symbol 
Gene Name Fold 
Change 
Transcription continued  
NM_003884 KAT2B K(lysine) acetyltransferase 2B -1.48 
NM_016270 KLF2  Krüppel-like factor 2 (lung) 1.67 
NM_004235 KLF4 Krüppel-like factor 4 (gut) 1.78 
NM_002398 MEIS1 Meis homeobox 1 -1.55 
NM_032246 MEX3B mex-3 homolog B (C. elegans)  1.41 
Transport 
NM_152999 STEAP2 
six transmembrane epithelial antigen of the prostate 
2 -1.64 
NM_145176 SLC2A12 solute carrier family 2 (facilitated glucose transporter), member 12  -1.59 
NR_024194 TOM1 target of myb1 (chicken) 1.43 
Miscellaneous / Other 
NM_003670 BHLHE40 basic helix-loop-helix family, member e40 1.44 
NM_198545 C1orf187 chromosome 1 open reading frame 187 1.50 
NM_178496 C3orf59 chromosome 3 open reading frame 59 -1.63 
NM_032623 C4orf49 chromosome 4 open reading frame 49 -1.67 
NM_001035254 FAM102A family with sequence similarity 102, member A 1.48 
NM_020116 FSTL5 follistatin-like 5 -1.84 
ENST00000423909 FLJ33996 hypothetical protein FLJ33996 -1.56 
BC004406 KIAA1539 KIAA1539 1.44 
NM_001040078 LGALS9C lectin, galactoside-binding, soluble, 9C 1.45 
NM_001113546 LIMA1 LIM domain and actin binding 1 -1.45 
AY176665 NSAP11 nervous system abundant protein 11 -1.73 
NM_015157 PHLDB1 pleckstrin homology-like domain, family B, member 1 1.36 
NM_001134438 PHLDB2 pleckstrin homology-like domain, family B, member 2 -1.49 
NM_015150 RFTN1 raftlin, lipid raft linker 1  -1.42 
NM_004657 SDPR serum deprivation response (phosphatidylserine binding protein) -1.55 
NM_005723 TSPAN5 tetraspanin 5 -1.51 
NM_021202 TP53INP2 tumor protein p53 inducible nuclear protein 2 1.39 
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Table S3.3: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4-treated VEGF (10 ng/ml) compared to the control 
(p < 0.001; 511 genes). 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Angiogenesis     
 NM_001147 ANGPT2 angiopoietin 2  -1.61 
NM_001202 BMP4 bone morphogenetic protein 4 -1.76 
NM_001554 CYR61 cysteine-rich, angiogenic inducer, 61 -1.62 
NM_002133 HMOX1 heme oxygenase (decycling) 1  1.55 
NM_005924 MEOX2 mesenchyme homeobox 2 -1.55 
NM_194358 RNF41 ring finger protein 41  -1.38 
NM_005429 VEGFC vascular endothelial growth factor C  1.28 
Apoptosis     
 NM_001003940 BMF Bcl2 modifying factor  1.46 
NM_032977 CASP10 caspase 10, apoptosis-related cysteine peptidase -1.88 
NM_019058 DDIT4 DNA-damage-inducible transcript 4  1.44 
NM_021960 MCL1  myeloid cell leukemia sequence 1 (BCL2-
related)  -1.46 
NM_002135 NR4A1 nuclear receptor subfamily 4, group A, member 1  1.60 
NM_182757 RNF144B ring finger protein 144B -1.83 
NM_004760 STK17A serine/threonine kinase 17a  -1.64 
NM_020870 SH3RF1 SH3 domain containing ring finger 1 -1.43 
NM_001561 TNFRSF9  tumor necrosis factor receptor superfamily, 
member 9  1.38 
NM_005092 TNFSF18 tumor necrosis factor (ligand) superfamily, 
member 18 -2.77 
NM_003841 TNFRSF10C 
tumor necrosis factor receptor superfamily, 
member 10c, decoy without an intracellular 
domain  
-1.82 
Binding / Cell Adhesion   
 NM_078481 CD97 CD97 molecule  1.30 
NM_001850 COL8A1 collagen, type VIII, alpha 1 -1.79 
NM_004370 COL12A1 collagen, type XII, alpha 1  -1.63 
NM_001338 CXADR coxsackie virus and adenovirus receptor -1.72 
NM_024582 FAT4 FAT tumor suppressor homolog 4 (Drosophila)  -1.54 
NM_000173 GP1BA glycoprotein Ib (platelet), alpha polypeptide 1.62 
NM_130759 GIMAP1 GTPase, IMAP family member 1 -1.47 
NM_015660 GIMAP2 GTPase, IMAP family member 2  -1.55 
NM_175571 GIMAP8 GTPase, IMAP family member 8 -1.67 
NM_152722 HEPACAM  hepatocyte cell adhesion molecule  1.44 
NM_000210 ITGA6 integrin, alpha 6  -1.43 
NM_000212 ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, 
antigen CD61)  -1.46 
NM_015520 MAGI1 membrane associated guanylate kinase, WW 
and PDZ domain containing 1  -1.46 
NM_015480 PVRL3 poliovirus receptor-related 3  -1.65 
NM_024787 RNF122 ring finger protein 122 1.52 
NM_014000 VCL  vinculin  -1.36 
Cell Communication / Signalling   
 NM_001025105 CSNK1A1 casein kinase 1, alpha 1  -1.56 
NM_001233 CAV2 caveolin 2  -1.37 
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Table S3.3: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4-treated VEGF (10 ng/ml) compared to the control 
(p < 0.001; 511 genes) continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Cell Communication / Signalling continued 
 NM_003607 CDC42BPA CDC42 binding protein kinase alpha (DMPK-like)  -1.51 
NM_005283 XCR1  chemokine (C motif) receptor 1  1.68 
NM_001135597 CCDC88A  coiled-coil domain containing 88A  -1.51 
NM_001258 CDK3  cyclin-dependent kinase 3  1.29 
NM_001259 CDK6 cyclin-dependent kinase 6  -1.44 
NM_004090 DUSP3 dual specificity phosphatase 3  1.30 
NM_002759 EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2  -1.79 
NM_002037 FYN FYN oncogene related to SRC, FGR, YES  -1.49 
NM_020660 GJD2 gap junction protein, delta 2, 36kDa  1.77 
NM_153442 GPR26 G protein-coupled receptor 26  1.47 
NM_015234 GPR116 G protein-coupled receptor 116  -1.72 
NM_020455 GPR126 G protein-coupled receptor 126  -1.60 
NM_002072 GNAQ guanine nucleotide binding protein (G protein), q polypeptide  -1.34 
NM_000863 HTR1B 5-hydroxytryptamine (serotonin) receptor 1B  -1.56 
NM_012302 LPHN2 latrophilin 2  -1.42 
NM_002310 LIFR leukemia inhibitory factor receptor alpha  -1.84 
NM_002758 MAP2K6 mitogen-activated protein kinase kinase 6  -1.65 
NM_002419 MAP3K11 mitogen-activated protein kinase kinase kinase 11  1.34 
NM_153240 NPHP3 nephronophthisis 3 (adolescent)  -1.39 
NM_133494 NEK7  NIMA (never in mitosis gene a)-related kinase 7  -1.69 
NM_001014831 PAK4 p21 protein (Cdc42/Rac)-activated kinase 4  1.36 
NM_024870 PREX2 phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2 -1.94 
NM_017934 PHIP pleckstrin homology domain interacting protein  -1.54 
NM_206907 PRKAA1  protein kinase, AMP-activated, alpha 1 catalytic 
subunit  -1.38 
NM_182948 PRKACB protein kinase, cAMP-dependent, catalytic, beta  -1.45 
NM_014906 PPM1E protein phosphatase 1E (PP2C domain 
containing)  1.43 
NM_000944 PPP3CA protein phosphatase 3 (formerly 2B), catalytic 
subunit, alpha isoform  -1.55 
NM_080683 PTPN13  
protein tyrosine phosphatase, non-receptor type 
13 (APO-1/CD95 (Fas)-associated 
phosphatase)  
-1.36 
NM_152573 RASEF RAS and EF-hand domain containing  1.35 
NM_032784 RSPO3 R-spondin 3 homolog (Xenopus laevis)  -1.62 
NM_015191 SIK2 salt-inducible kinase 2  1.37 
NM_080489 SDCBP2 syndecan binding protein (syntenin) 2  1.45 
NM_001057 TACR2 tachykinin receptor 2  1.47 
NM_003243 TGFBR3 transforming growth factor, beta receptor III  -1.43 
Cell Cycle / Cell Proliferation   
 NM_025009 CEP135  centrosomal protein 135kDa  -1.62 
NM_000757 CSF1 colony stimulating factor 1 (macrophage)  1.33 
NM_057749 CCNE2 cyclin E2  -1.86 
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Table S3.3: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4-treated VEGF (10 ng/ml) compared to the control 
(p < 0.001; 511 genes) continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Cell Cycle / Cell Proliferation continued  
NM_001946 DUSP6  dual specificity phosphatase 6 -1.47 
NM_004429 EFNB1 ephrin-B1 1.45 
NM_032410 HOOK3 hook homolog 3 (Drosophila)  -1.53 
NM_002192 INHBA inhibin, beta A -1.58 
NM_033402 LRRCC1 leucine rich repeat and coiled-coil domain 
containing 1  -1.72 
NM_020310 MNT  MAX binding protein  1.45 
NM_001105078 MECOM MDS1 and EVI1 complex locus  -1.44 
NM_002393 MDM4 Mdm4 p53 binding protein homolog (mouse)  -1.65 
NM_032485 MCM8 minichromosome maintenance complex 
component 8  -1.48 
NM_005923 MAP3K5 mitogen-activated protein kinase kinase kinase 5 -1.68 
NM_001085377 MCC mutated in colorectal cancers -1.47 
NM_012224 NEK1  NIMA (never in mitosis gene a)-related kinase 1  -1.51 
NM_002498 NEK3 NIMA (never in mitosis gene a)-related kinase 3  -1.57 
NM_003999 OSMR oncostatin M receptor  -1.57 
NM_018151 RIF1 RAP1 interacting factor homolog (yeast)  -1.79 
NM_018243 SEP11 septin 11  -1.27 
NM_001060 TBXA2R thromboxane A2 receptor  1.43 
NM_006322 TUBGCP3  tubulin, gamma complex associated protein 3  -1.34 
NM_145314 UCMA upper zone of growth plate and cartilage matrix 
associated  1.42 
NM_000222 KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral 
oncogene homolog  -1.51 
NM_006646 WASF3 WAS protein family, member 3  -1.33 
NM_033131 WNT3A wingless-type MMTV integration site family, 
member 3A  1.51 
Cell Migration 
    
NM_033138 CALD1 caldesmon 1  -1.37 
Development     
 NM_002313 ABLIM1 actin binding LIM protein 1  -1.34 
NM_016441 CRIM1 cysteine rich transmembrane BMP regulator 1 (chordin-like)  -1.31 
NM_012242 DKK1 dickkopf homolog 1 (Xenopus laevis) -1.94 
NM_001405 EFNA2  ephrin-A2  1.46 
NM_004425 ECM1 extracellular matrix protein 1  1.36 
NM_001145772 GPR56 G protein-coupled receptor 56  1.37 
NM_019594 LRRC8A leucine rich repeat containing 8 family, member A  1.31 
NM_018174 MAP1S microtubule-associated protein 1S  1.61 
NM_013960 NRG1 neuregulin 1  -1.38 
NM_182964 NAV2 neuron navigator 2  1.49 
NM_152754 SEMA3D  sema domain, immunoglobulin domain (Ig), 
short basic domain, secreted, (semaphorin) 3D -1.59 
NM_001135599 TGFB2 transforming growth factor, beta 2  -1.48 
NM_020127 TUFT1 tuftelin 1  -1.36 
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Table S3.3: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4-treated VEGF (10 ng/ml) compared to the control 
(p < 0.001; 511 genes) continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Development continued  
NM_001025252 TPD52 tumor protein D52  -1.37 
NM_007124 UTRN utrophin  -1.48 
NM_005239 ETS2 v-ets erythroblastosis virus E26 oncogene homolog 2 (avian)  1.37 
NM_017953 ZNHIT6 zinc finger, HIT type 6  -1.81 
NM_005095 ZMYM4 zinc finger, MYM-type 4  -1.46 
DNA Binding / Replication / Repair / Transcription 
 NM_005224 ARID3A AT rich interactive domain 3A (BRIGHT-like)  1.36 
NM_004956 ETV1 ets variant 1 -1.86 
NM_144571 CNOT6L CCR4-NOT transcription complex, subunit 6-like  -1.50 
NM_015891 CDC40 cell division cycle 40 homolog (S. cerevisiae)  -1.42 
NM_016448 DTL denticleless homolog (Drosophila)  -1.54 
NM_001159936 EBNA1BP2 EBNA1 binding protein 2  -1.55 
NM_000124 ERCC6 excision repair cross-complementing rodent 
repair deficiency, complementation group 6  -1.58 
NM_130398 EXO1 exonuclease 1  -1.44 
NM_014285 EXOSC2 exosome component 2  -1.35 
NM_001515 GTF2H2 general transcription factor IIH, polypeptide 2, 44kDa  -1.81 
NM_018078 LARP1B La ribonucleoprotein domain family, member 1B  -1.57 
NM_020961 METTL14  methyltransferase like 14  -1.50 
NM_002388 MCM3 minichromosome maintenance complex 
component 3  -1.44 
NM_000179 MSH6 mutS homolog 6 (E. coli)  -1.46 
NM_015934 NOP58 NOP58 ribonucleoprotein homolog (yeast)  -1.61 
NM_007362 NCBP2 nuclear cap binding protein subunit 2, 20kDa  -1.68 
NM_001134673 NFIA nuclear factor I/A -1.34 
NM_005596 NFIB nuclear factor I/B -1.33 
NM_000901 NR3C2 nuclear receptor subfamily 3, group C, member 2  -1.46 
NM_000270 NP  nucleoside phosphorylase  1.32 
NM_002526 NT5E 5'-nucleotidase, ecto (CD73)  -1.44 
NM_015342 PPWD1 peptidylprolyl isomerase domain and WD 
repeat containing 1  -1.74 
NM_000534 PMS1 PMS1 postmeiotic segregation increased 1 (S. 
cerevisiae)  -1.41 
NR_003085 PMS2  PMS2 postmeiotic segregation increased 2 (S. 
cerevisiae)  -1.56 
NM_016937 POLA1 polymerase (DNA directed), alpha 1, catalytic 
subunit  -1.51 
NM_007195 POLI polymerase (DNA directed) iota  -1.52 
NM_019014 POLR1B polymerase (RNA) I polypeptide B, 128kDa  -1.60 
NM_033109 PNPT1  polyribonucleotide nucleotidyltransferase 1  -1.72 
NR_027775 PMS2L5 postmeiotic segregation increased 2-like 5  -1.48 
NM_020165 RAD18 RAD18 homolog (S. cerevisiae)  -1.44 
NM_016316 REV1 REV1 homolog (S. cerevisiae)  -1.48 
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Table S3.3: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4-treated VEGF (10 ng/ml) compared to the control 
(p < 0.001; 511 genes) continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
DNA Binding / Replication / Repair / Transcription continued 
 
NM_024945 RMI1 RMI1, RecQ mediated genome instability 1, homolog (S. cerevisiae)  -1.50 
NM_003800 RNGTT RNA guanylyltransferase and 5'-phosphatase  -1.56 
NM_006938 SNRPD1 small nuclear ribonucleoprotein D1 polypeptide 16kDa  -1.49 
NM_003096 SNRPG small nuclear ribonucleoprotein polypeptide G  -2.00 
NM_001142286 SMC6  structural maintenance of chromosomes 6  -1.73 
NM_018419 SOX18 SRY (sex determining region Y)-box 18  1.38 
NM_007114 TMF1 TATA element modulatory factor 1  -1.64 
NM_003598 TEAD2 TEA domain family member 2  1.41 
NM_013293 TRA2A transformer 2 alpha homolog (Drosophila)  -1.41 
NM_020810 TRMT5  TRM5 tRNA methyltransferase 5 homolog (S. 
cerevisiae)  -1.36 
NR_027302 XPA xeroderma pigmentosum, complementation group A  -1.69 
NM_005378 MYCN v-myc myelocytomatosis viral related 
oncogene, neuroblastoma derived (avian) 1.99 
NM_000553 WRN Werner syndrome, RecQ helicase-like  -1.65 
NM_003432 ZNF131 zinc finger protein 131  -1.39 
NM_032819 ZNF341 zinc finger protein 341  1.45 
NM_152320 ZNF641 zinc finger protein 641  -1.39 
Inflammatory Response   
 NM_000201 ICAM1 intercellular adhesion molecule 1 1.78 
NM_000575 IL1A interleukin 1, alpha  -1.64 
NM_000600 IL6 interleukin 6 (interferon, beta 2)  -1.94 
NM_002349 LY75 lymphocyte antigen 75  -1.49 
NM_002852 PTX3 pentraxin-related gene, rapidly induced by IL-1 beta -2.23 
NM_002965 S100A9 S100 calcium binding protein A9  1.63 
NM_003265 TLR3 toll-like receptor 3  -1.49 
Immune Response   
 NM_014143 CD274 CD274 molecule -2.37 
NM_001115152 CD300L CD300 molecule-like family member d  1.56 
NM_005755 EBI3 Epstein-Barr virus induced 3  1.49 
NM_002053 GBP1 guanylate binding protein 1, interferon-inducible, 67kDa  -1.54 
NM_001083539 KIR3DS1 killer cell immunoglobulin-like receptor, three domains, short cytoplasmic tail, 1  1.61 
NM_012312 KIR2DS2 killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2  1.43 
NM_003954 MAP3K14 mitogen-activated protein kinase kinase kinase 14 1.59 
NM_025239 PDCD1LG2 programmed cell death 1 ligand 2  -1.57 
NM_004155 SERPINB9 serpin peptidase inhibitor, clade B (ovalbumin), 
member 9 -1.53 
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Table S3.3: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4-treated VEGF (10 ng/ml) compared to the control 
(p < 0.001; 511 genes) continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Metabolic / Biosynthetic Process   
 NM_020186 ACN9 ACN9 homolog (S. cerevisiae)  -1.84 
NM_005099 ADAMTS4 ADAM metallopeptidase with thrombospondin 
type 1 motif, 4 1.60 
NM_014272 ADAMTS7 ADAM metallopeptidase with thrombospondin 
type 1 motif, 7  1.37 
NM_182920 ADAMTS9 ADAM metallopeptidase with thrombospondin 
type 1 motif, 9  -1.37 
NM_199355 ADAMTS18 ADAM metallopeptidase with thrombospondin 
type 1 motif, 18  -1.46 
NM_174858 AK5 adenylate kinase 5 -2.22 
NM_001126 ADSS adenylosuccinate synthase  -1.64 
NM_000689 ALDH1A1 aldehyde dehydrogenase 1 family, member A1  -1.37 
NM_003659 AGPS  alkylglycerone phosphate synthase  -1.52 
NM_015328 AHCYL2 adenosylhomocysteinase-like 2  -1.37 
NM_001145815 AMDHD2 amidohydrolase domain containing 2  1.40 
NM_005763 AASS aminoadipate-semialdehyde synthase  -1.47 
NM_016201 AMOTL2 angiomotin like 2  -1.42 
NR_027833 APOL3 apolipoprotein L, 3  1.26 
NM_030643 APOL4  apolipoprotein L, 4  1.39 
NM_030817 APOLD1 apolipoprotein L domain containing 1  1.46 
NM_012287 ACAP2 ArfGAP with coiled-coil, ankyrin repeat and PH domains 2  -1.54 
NM_001088 AANAT  arylalkylamine N-acetyltransferase  1.45 
NM_024590 ARSJ arylsulfatase family, member J -1.65 
NM_004674 ASH2L ash2 (absent, small, or homeotic)-like (Drosophila)  -1.42 
NM_014616 ATP11B  ATPase, class VI, type 11B  -1.65 
NM_018371 CSGALNACT1 chondroitin sulfate N-
acetylgalactosaminyltransferase 1  -1.42 
NM_001823 CKB creatine kinase, brain  1.30 
NM_004074 COX8A  cytochrome c oxidase subunit 8A (ubiquitous)  1.44 
NM_000772 CYP2C18 cytochrome P450, family 2, subfamily C, polypeptide 18  1.28 
NM_000774 CYP2F1  cytochrome P450, family 2, subfamily F, polypeptide 1  1.76 
NM_007034 DNAJB4 DnaJ (Hsp40) homolog, subfamily B, member 4 -1.99 
NM_001031723 DNAJB14 
DnaJ (Hsp40) homolog, subfamily B, member 
14  -1.47 
NM_194283 DNAJC21 
DnaJ (Hsp40) homolog, subfamily C, member 
21  -1.65 
NM_018370 DRAM1 DNA-damage regulated autophagy modulator 1  1.35 
NM_024090 ELOVL6 
ELOVL family member 6, elongation of long 
chain fatty acids (FEN1/Elo2, SUR4/Elo3-like, 
yeast)elongation of long chain fatty acids 
(FEN1/Elo2, SUR4/Elo3-like, yeast) 
-2.05 
NM_001442 FABP4 fatty acid binding protein 4, adipocyte  -1.75 
NM_001042762 FIGNL1 fidgetin-like 1  -1.67 
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Table S3.3: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4-treated VEGF (10 ng/ml) compared to the control 
(p < 0.001; 511 genes) continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Metabolic / Biosynthetic Process   
 
NM_001097634 GCNT1 glucosaminyl (N-acetyl) transferase 1, core 2 (beta-1,6-N-acetylglucosaminyltransferase) -1.71 
NM_015554 GLCE glucuronic acid epimerase  -1.29 
NM_004446 EPRS  glutamyl-prolyl-tRNA synthetase  -1.51 
NM_194247 HNRNPA3  heterogeneous nuclear ribonucleoprotein A3  -1.68 
NM_012267 HSPBP1 HSPA (heat shock 70kDa) binding protein, 
cytoplasmic cochaperone 1  1.28 
NM_005575 LNPEP leucyl/cystinyl aminopeptidase  -1.45 
NM_002422 MMP3 matrix metallopeptidase 3 (stromelysin 1, progelatinase)  1.37 
NM_005940 MMP11 matrix metallopeptidase 11 (stromelysin 3)  1.36 
NM_004995 MMP14 
matrix metallopeptidase 14 (membrane-
inserted)  1.33 
NM_014632 MICAL2 microtubule associated monoxygenase, 
calponin and LIM domain containing 2  -1.30 
NM_007208 MRPL3 mitochondrial ribosomal protein L3  -1.49 
NM_015971 MRPS7 mitochondrial ribosomal protein S7  -1.69 
NM_022100 MRPS14 mitochondrial ribosomal protein S14  -1.36 
NM_017971 MRPL20  mitochondrial ribosomal protein L20  -1.44 
NM_017971 MRPL20 mitochondrial ribosomal protein L20  -1.50 
NM_015514 NGDN neuroguidin, EIF4E binding protein  -1.50 
NM_023112 OTUB2 OTU domain, ubiquitin aldehyde binding 2  1.56 
NM_017784 OSBPL10 oxysterol binding protein-like 10  -1.43 
NM_003712 PPAP2C phosphatidic acid phosphatase type 2C  1.54 
NM_003713 PPAP2B phosphatidic acid phosphatase type 2B  1.32 
NM_018290 PGM2  phosphoglucomutase 2  -1.38 
NM_024664 PPCS  phosphopantothenoylcysteine synthetase  -1.39 
NM_001159323 PLA2G4C phospholipase A2, group IVC (cytosolic, 
calcium-independent)  1.49 
NM_002662 PLD1 phospholipase D1, phosphatidylcholine-specific  -1.72 
NM_016518 PIPOX  pipecolic acid oxidase  1.40 
NM_000930 PLAT plasminogen activator, tissue 1.45 
NM_000961 PTGIS  prostaglandin I2 (prostacyclin) synthase  1.32 
NM_006252 PRKAA2 protein kinase, AMP-activated, alpha 2 catalytic 
subunit  -1.70 
NM_024854 PYROXD1 pyridine nucleotide-disulphide oxidoreductase domain 1  -1.42 
NM_017712 PGPEP1 pyroglutamyl-peptidase I  1.44 
NM_002913 RFC1 replication factor C (activator 1) 1, 145kDa  -1.62 
NM_024583 SCRN3  secernin 3  -1.65 
NM_001142298 SQSTM1 sequestosome 1  1.32 
NM_001143676 SGK1 serum/glucocorticoid regulated kinase 1 -1.62 
NM_022733 SMAP2  small ArfGAP2  -1.34 
NM_001130012 SLC9A3R2 solute carrier family 9 (sodium/hydrogen 
exchanger), member 3 regulator 2 1.69 
NM_001128205 SULF1 sulfatase 1  -1.37 
NM_014465 SULT1B1 sulfotransferase family, cytosolic, 1B, member 1  -1.64 
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Table S3.3: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4-treated VEGF (10 ng/ml) compared to the control 
(p < 0.001; 511 genes) continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Metabolic / Biosynthetic Process continued  
NM_015028 TNIK TRAF2 and NCK interacting kinase -1.61 
NM_015017 USP33 ubiquitin specific peptidase 33  -1.56 
NM_032236 USP48 ubiquitin specific peptidase 48  -1.59 
NM_145236 B3GNT7 UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 7  1.42 
NM_003358 UGCG UDP-glucose ceramide glucosyltransferase  -1.55 
NM_003115 UAP1 
UDP-N-acteylglucosamine pyrophosphorylase 
1  -1.57 
NM_207309 UAP1L1 UDP-N-acteylglucosamine pyrophosphorylase 1-like 1  1.58 
NM_018359 UFSP2  UFM1-specific peptidase 2  -1.70 
NM_139281 WDR36 WD repeat domain 36  -1.52 
Response to Stimulus   
 NM_182680 AMELX  amelogenin (amelogenesis imperfecta 1, X-linked)  1.35 
NM_002940 ABCE1  ATP-binding cassette, sub-family E (OABP), 
member 1  -1.68 
NM_004827 ABCG2 ATP-binding cassette, sub-family G (WHITE), 
member 2  -1.84 
NM_001219 CALU  calumenin  -1.44 
NM_004101 F2RL2  coagulation factor II (thrombin) receptor-like 2  -1.56 
NM_004417 DUSP1 dual specificity phosphatase 1  -1.43 
NM_001955 EDN1 endothelin 1  -1.35 
NM_018948 ERRFI1 ERBB receptor feedback inhibitor 1  -1.66 
NM_006732 FOSB FBJ murine osteosarcoma viral oncogene homolog B  1.56 
NM_014905 GLS  glutaminase  -1.52 
NM_002229 JUNB jun B proto-oncogene 1.77 
NM_002276 KRT19 keratin 19  1.51 
NM_006469 IVNS1ABP influenza virus NS1A binding protein  -1.67 
NM_000877 IL1R1 interleukin 1 receptor, type I  -1.75 
NM_004210 NEURL neuralized homolog (Drosophila)  1.51 
NM_006179 NTF4  neurotrophin 4  1.65 
NM_014582 OBP2A odorant binding protein 2A  1.64 
NM_001004450 OR1B1 olfactory receptor, family 1, subfamily B, 
member 1  1.69 
NM_030883 OR2H1  olfactory receptor, family 2, subfamily H, 
member 1  1.46 
NM_001004687 OR2L3  olfactory receptor, family 2, subfamily L, 
member 3  2.00 
NM_001004717 OR4L1 olfactory receptor, family 4, subfamily L, 
member 1  2.20 
NM_001005203 OR8S1 olfactory receptor, family 8, subfamily S, 
member 1  1.46 
NM_001004760 OR51V1 olfactory receptor, family 51, subfamily V, 
member 1  1.91 
NM_021105 PLSCR1 phospholipid scramblase 1  -1.62 
NM_001128304 PLSCR4 phospholipid scramblase 4 -1.95 
NM_000965 RARB retinoic acid receptor, beta  -1.55 
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Table S3.3: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4-treated VEGF (10 ng/ml) compared to the control 
(p < 0.001; 511 genes) continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Response to Stimulus continued   
 NM_003155 STC1 stanniocalcin 1  1.62 
NM_012397 SERPINB13 serpin peptidase inhibitor, clade B (ovalbumin), 
member 13  1.36 
NM_003234 TFRC transferrin receptor (p90, CD71) -2.48 
Signal Transduction   
 NM_005737 ARL4C ADP-ribosylation factor-like 4C  1.40 
NM_014391 ANKRD1 ankyrin repeat domain 1 (cardiac muscle) -1.49 
NM_025045 BAIAP2L2 BAI1-associated protein 2-like 2  1.52 
NM_000710 BDKRB1 bradykinin receptor B1  -1.97 
NM_001014796 DDR2 discoidin domain receptor tyrosine kinase 2  -1.35 
NM_015221 DNMBP dynamin binding protein  -1.40 
NM_020996 FGF6 fibroblast growth factor 6  1.47 
NM_004864 GDF15 growth differentiation factor 15 1.49 
NM_005456 MAPK8IP1  mitogen-activated protein kinase 8 interacting protein 1  1.38 
NM_018945 PDE7B phosphodiesterase 7B  -1.54 
NM_006255 PRKCH protein kinase C, eta  -1.39 
NM_006243 PPP2R5A protein phosphatase 2, regulatory subunit B', 
alpha isoform  -1.62 
NM_001077494 NFKB2 nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 2 (p49/p100) 1.53 
NM_152663 RALGPS2 Ral GEF with PH domain and SH3 binding motif 2  -1.86 
NM_001161616 RGL3 ral guanine nucleotide dissociation stimulator-like 3  1.40 
NM_016084 RASD1 RAS, dexamethasone-induced 1 1.47 
NM_006506 RASA2 RAS p21 protein activator 2  -1.75 
NM_005052 RAC3 ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3)  1.38 
NM_001102445 RGS4 regulator of G-protein signalling 4 -1.81 
NM_005168 RND3 Rho family GTPase 3  -1.61 
NM_004815 ARHGAP29 Rho GTPase activating protein 29  -1.54 
NM_001080479 RGNEF Rho-guanine nucleotide exchange factor  -1.34 
NM_007315 STAT1 signal transducer and activator of transcription 1, 91kDa  -1.50 
NM_005841 SPRY1 sprouty homolog 1, antagonist of FGF signalling (Drosophila)  -1.56 
NM_005842 SPRY2 sprouty homolog 2 (Drosophila)  -1.68 
NM_015595 SGEF Src homology 3 domain-containing guanine 
nucleotide exchange factor  -1.36 
NM_015077 SARM1  sterile alpha and TIR motif containing 1  1.29 
NM_012454 TIAM2 T-cell lymphoma invasion and metastasis 2 -1.40 
NM_005658 TRAF1 TNF receptor-associated factor 1  1.73 
NM_003565 ULK1 unc-51-like kinase 1 (C. elegans)  1.41 
NM_007314 ABL2 v-abl Abelson murine leukemia viral oncogene homolog 2 (arg, Abelson-related gene)  -1.33 
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Table S3.3: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4-treated VEGF (10 ng/ml) compared to the control 
(p < 0.001; 511 genes) continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Transcription     
 NM_014109 ATAD2 ATPase family, AAA domain containing 2  -1.58 
NM_015446 AHCTF1 AT hook containing transcription factor 1  -1.52 
NM_014739 BCLAF1 BCL2-associated transcription factor 1  -1.52 
NM_018429 BDP1 B double prime 1, subunit of RNA polymerase III transcription initiation factor IIIB  -1.46 
NM_001142568 BBX bobby sox homolog (Drosophila)  -1.60 
NM_015125 CIC capicua homolog (Drosophila)  1.37 
NM_001127192 CNBP CCHC-type zinc finger, nucleic acid binding protein  -1.53 
NM_014597 DNTTIP2  deoxynucleotidyltransferase, terminal, interacting protein 2  -1.54 
NM_006494 ERF  Ets2 repressor factor  1.36 
NM_015030 FRYL FRY-like  -1.65 
NM_032575 GLIS2 GLIS family zinc finger 2 1.55 
NM_006582 GMEB1  glucocorticoid modulatory element binding protein 1  -1.42 
NM_021958 HLX H2.0-like homeobox 1.52 
NM_003071 HLTF helicase-like transcription factor  -1.64 
NM_005474 HDAC5 histone deacetylase 5  1.31 
NM_178423 HDAC9  histone deacetylase 9  1.37 
NM_014212 HOXC11  homeobox C11  1.44 
NM_005354 JUND jun D proto-oncogene  1.45 
NM_003884 KAT2B K(lysine) acetyltransferase 2B -1.52 
NM_016270 KLF2 Kruppel-like factor 2 (lung) 1.75 
NM_004235 KLF4 Kruppel-like factor 4 (gut) 1.84 
NM_005583 LYL1 lymphoblastic leukemia derived sequence 1  1.45 
NM_002398 MEIS1 Meis homeobox 1 -1.72 
NM_003926 MBD3 methyl-CpG binding domain protein 3  1.33 
NM_032246 MEX3B mex-3 homolog B (C. elegans)  1.42 
NM_001042539 MAZ MYC-associated zinc finger protein (purine-binding transcription factor)  1.32 
NM_016132 MYEF2 myelin expression factor 2  -1.39 
NM_001146312 MYOCD myocardin  1.40 
NM_152995 NFXL1 nuclear transcription factor, X-box binding-like 1  -1.53 
NM_018137 PRMT6 protein arginine methyltransferase 6  -1.70 
NM_012446 SSBP2 single-stranded DNA binding protein 2  -1.43 
NM_003082 SNAPC1 small nuclear RNA activating complex, polypeptide 1, 43kDa  -1.66 
NM_013306 SNX15 sorting nexin 15  1.32 
NM_005642 TAF7  TAF7 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 55kDa  -1.59 
NM_003201 TFAM  transcription factor A, mitochondrial  -1.45 
NM_016075 VPS36  vacuolar protein sorting 36 homolog (S. 
cerevisiae)  -1.42 
NM_153028 ZNF75A zinc finger protein 75a  -1.38 
NM_001008727 ZNF121 zinc finger protein 121  -1.64 
NM_003441 ZNF141 zinc finger protein 141  -1.42 
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Table S3.3: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4-treated VEGF (10 ng/ml) compared to the control 
(p < 0.001; 511 genes) continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Transcription continued  
NM_001146175 ZNF414  zinc finger protein 414  1.34 
NM_181489 ZNF445 zinc finger protein 445  -1.41 
NM_001136156 ZNF507 zinc finger protein 507  -1.38 
NR_026746 ZNF619 zinc finger protein 619  -1.48 
NM_018293 ZNF654  zinc finger protein 654  -1.55 
NM_133474 ZNF721 zinc finger protein 721  -1.60 
NM_015534 ZZZ3 zinc finger, ZZ-type containing 3  -1.52 
Transport     
 
NM_152565 ATP6V0D2 ATPase, H+ transporting, lysosomal 38kDa, V0 
subunit d2  1.30 
NM_002858 ABCD3 ATP-binding cassette, sub-family D (ALD), 
member 3  -1.67 
NM_000722 CACNA2D1 calcium channel, voltage-dependent, alpha 
2/delta subunit 1  -1.59 
NM_173872 CLCN3 chloride channel 3  -1.49 
NM_001830 CLCN4 chloride channel 4  -1.32 
NM_000744 CHRNA4 cholinergic receptor, nicotinic, alpha 4  1.50 
NM_015018 DOPEY1 dopey family member 1  -1.50 
NM_000810 GABRA5 gamma-aminobutyric acid (GABA) A receptor, 
alpha 5  0.69 
NM_016072 GOLT1B  golgi transport 1 homolog B (S. cerevisiae)  -1.57 
NR_027850 MTX2 metaxin 2  -1.78 
NM_004542 NDUFA3 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 3, 9kDa  1.43 
NM_015938 NMD3  NMD3 homolog (S. cerevisiae)  -1.56 
NM_032523 OSBPL6 oxysterol binding protein-like 6  -1.36 
NM_000466 PEX1 peroxisomal biogenesis factor 1  -1.50 
NM_002234 KCNA5 potassium voltage-gated channel, shaker-
related subfamily, member 5  1.41 
NR_024194 TOM1 target of myb1 (chicken)  1.39 
NM_012288 TRAM2 translocation associated membrane protein 2  -1.30 
NM_079834 SCAMP4 secretory carrier membrane protein 4  0.70 
NM_022754 SFXN1  sideroflexin 1  -1.41 
NM_152999 STEAP2 six transmembrane epithelial antigen of the prostate 2 -1.68 
NM_014191 SCN8A sodium channel, voltage gated, type VIII, alpha 
subunit  -1.47 
NM_017585 SLC2A6 solute carrier family 2 (facilitated glucose 
transporter), member 6  1.27 
NM_145176 SLC2A12 solute carrier family 2 (facilitated glucose 
transporter), member 12  -1.53 
NM_014037 SLC6A16 solute carrier family 6, member 16  1.38 
NM_177550 SLC13A5 solute carrier family 13 (sodium-dependent 
citrate transporter), member 5  1.45 
NM_021194 SLC30A1 solute carrier family 30 (zinc transporter), 
member 1  -1.37 
NM_017964 SLC30A6 solute carrier family 30 (zinc transporter), 
member 6  -1.54 
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Table S3.3: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4-treated VEGF (10 ng/ml) compared to the control 
(p < 0.001; 511 genes) continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Transport continued  
NM_181785 SLC46A3 solute carrier family 46, member 3  -1.39 
NM_003715 USO1 USO1 homolog, vesicle docking protein (yeast)  -1.50 
NM_021083 XK  X-linked Kx blood group (McLeod syndrome)  1.54 
Miscellaneous / Other   
 NM_152326 ANKRD9 ankyrin repeat domain 9  1.39 
NM_025190 ANKRD36B ankyrin repeat domain 36B  -1.48 
NM_020337 ANKRD50 ankyrin repeat domain 50  -1.40 
NM_025190 ANKRD36B ankyrin repeat domain 36B  -1.51 
NM_025190 ANKRD36B ankyrin repeat domain 36B  -1.56 
NM_015379 BRI3 brain protein I3  1.33 
NM_014603 CDR2L cerebellar degeneration-related protein 2-like  1.44 
NM_018372 C1orf103 chromosome 1 open reading frame 103  -1.84 
NM_178550 C1orf110 chromosome 1 open reading frame 110  -1.64 
NM_198545 C1orf187 chromosome 1 open reading frame 187 1.54 
BC034598 C1orf212  chromosome 1 open reading frame 212  -1.50 
NM_178496 C3orf59 chromosome 3 open reading frame 59 -1.84 
NM_001112736 C3orf63 chromosome 3 open reading frame 63  -1.64 
NM_018352 C4orf43 chromosome 4 open reading frame 43  -1.84 
NM_032623 C4orf49 chromosome 4 open reading frame 49  -1.56 
NM_001085411 C5orf33 chromosome 5 open reading frame 33  -1.70 
AK290939 C6orf130 chromosome 6 open reading frame 130  -1.60 
NM_198468 C6orf167 chromosome 6 open reading frame 167  -1.68 
NM_017586 C9orf7 chromosome 9 open reading frame 7  1.39 
NM_153256 C10orf47 chromosome 10 open reading frame 47  1.47 
NM_152261 C12orf23 chromosome 12 open reading frame 23  -1.43 
NM_013300 C12orf24 chromosome 12 open reading frame 24  -1.43 
NM_032366 C16orf13 chromosome 16 open reading frame 13  1.33 
NM_174983 C19orf28 chromosome 19 open reading frame 28  1.35 
NM_033520 C19orf33 chromosome 19 open reading frame 33  1.43 
NM_080608 C20orf165  chromosome 20 open reading frame 165  1.40 
NM_144492 CLDN14  claudin 14  1.39 
NM_003950 F2RL3 coagulation factor II (thrombin) receptor-like 3  1.72 
NM_206833 CTXN1  cortexin 1  1.38 
NM_145056 DACT3 dapper, antagonist of beta-catenin, homolog 3 (Xenopus laevis)  1.51 
NM_006773 DDX18 DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 -1.71 
NM_001007533 DYSFIP1 dysferlin interacting protein 1  1.73 
NM_015252 EHBP1 EH domain binding protein 1  -1.50 
NM_022140 EPB41L4A erythrocyte membrane protein band 4.1 like 4A  -1.54 
NM_001035254 FAM102A family with sequence similarity 102, member A  1.48 
NM_198947 FAM111B family with sequence similarity 111, member B  -1.61 
NM_001130025 FAM115C  family with sequence similarity 115, member C  -1.32 
NM_001105079 FBRS fibrosin  1.43 
BC151150 FLJ25996 FLJ25996 protein  1.51 
NM_001001685 FLJ45079 FLJ45079 protein  1.65 
NM_020116 FSTL5 follistatin-like 5  -1.83 
NM_014170 GTPBP8  GTP-binding protein 8 (putative)  -1.52 
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Table S3.3: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4-treated VEGF (10 ng/ml) compared to the control 
(p < 0.001; 511 genes) continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Miscellaneous / Other continued   
 NM_015473 HEATR5A HEAT repeat containing 5A  -2.12 
NR_026929 DKFZp434L192 hypothetical protein DKFZp434L192  1.89 
ENST00000370520 RP11-93B14.6 hypothetical protein FLJ32154  1.70 
ENST00000423909 FLJ33996  hypothetical protein FLJ33996  -1.44 
NM_178511 LOC255783  hypothetical protein LOC255783  1.52 
ENST00000320322 LOC554207 hypothetical LOC554207  1.49 
NM_001014380 KATNAL1 katanin p60 subunit A-like 1  -1.46 
NM_020803 KLHL8 kelch-like 8 (Drosophila)  -1.63 
NM_213656 KRT39 keratin 39  1.36 
NM_001004325 KRTAP5-2 keratin associated protein 5-2  1.53 
NM_014431 KIAA1274 KIAA1274  1.69 
NM_001142749 KIAA1324L KIAA1324-like  -1.57 
BC004406 KIAA1539  KIAA1539 1.47 
NM_004907 IER2 immediate early response 2  1.44 
NM_022347 IFRG15 interferon responsive gene 15  -1.74 
NM_009587 LGALS9 lectin, galactoside-binding, soluble, 9  1.49 
NM_001040078 LGALS9C lectin, galactoside-binding, soluble, 9C 1.54 
NM_001134476 LRRC8B  leucine rich repeat containing 8 family, member B -1.66 
NM_198565 LRRC33 leucine rich repeat containing 33  1.54 
NM_001113546 LIMA1 LIM domain and actin binding 1 -1.57 
NM_006726 LRBA LPS-responsive vesicle trafficking, beach and 
anchor containing  -1.55 
NM_001017967 MARVELD3 MARVEL domain containing 3  1.57 
NM_012216 MID2 midline 2  -1.35 
NM_018728 MYO5C  myosin VC  -1.58 
NM_018177 N4BP2 NEDD4 binding protein 2  -1.58 
AY176665 NSAP11 nervous system abundant protein 11  -1.64 
NM_183372 RP11-94I2.2  neuroblastoma breakpoint family, member 11-like  -1.34 
NM_144573 NEXN nexilin (F actin binding protein)  -2.09 
NM_198514 NHLRC2  NHL repeat containing 2  -1.48 
NM_173198 NR4A3 nuclear receptor subfamily 4, group A, member 3  1.33 
NM_016167 NOL7  nucleolar protein 7, 27kDa  -1.51 
NM_178507 OAF OAF homolog (Drosophila)  1.44 
NM_024576 OGFRL1 opioid growth factor receptor-like 1  -1.57 
NM_016023 OTUD6B  OTU domain containing 6B  -1.50 
NM_017734 PALMD palmdelphin  -1.53 
NR_002181 PPY2 pancreatic polypeptide 2  1.52 
NM_006457 PDLIM5 PDZ and LIM domain 5  -1.38 
NM_020651 PELI1 pellino homolog 1 (Drosophila)  -1.72 
NM_032728 PPAPDC3 phosphatidic acid phosphatase type 2 domain 
containing 3  1.41 
NM_001134438 PHLDB2 pleckstrin homology-like domain, family B, 
member 2  -1.51 
NM_198859 PRICKLE2 prickle homolog 2 (Drosophila)  -1.42 
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Table S3.3: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4-treated VEGF (10 ng/ml) compared to the control 
(p < 0.001; 511 genes) continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Miscellaneous / Other continued   
 
NM_017607 PPP1R12C protein phosphatase 1, regulatory (inhibitor) 
subunit 12C  1.38 
NM_020700 PPM1H  protein phosphatase 1H (PP2C domain 
containing)  1.56 
NM_015150 RFTN1 raftlin, lipid raft linker 1 -1.50 
NM_001003793 RBMS3 RNA binding motif, single stranded interacting protein  -1.56 
NM_175636 RUNX1T1 runt-related transcription factor 1; translocated 
to, 1 (cyclin D-related)  -1.55 
NM_002962 S100A5 S100 calcium binding protein A5  1.86 
NM_014016 SACM1L SAC1 suppressor of actin mutations 1-like (yeast)  -1.50 
NM_004657 SDPR  serum deprivation response (phosphatidylserine binding protein) -1.55 
NM_174919 SH3D20 SH3 domain containing 20  1.41 
NM_138402 SP140L SP140 nuclear body protein-like  -1.50 
NM_181727 SPATA12  spermatogenesis associated 12  1.56 
NM_152703 SAMD9L sterile alpha motif domain containing 9-like  -1.67 
NM_139215 TAF15 TAF15 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 68kDa  -1.46 
NM_005723 TSPAN5 tetraspanin 5 -1.59 
NM_024753 TTC21B tetratricopeptide repeat domain 21B  -1.68 
NM_144721 THAP6 THAP domain containing 6  -1.75 
NM_172000 TEDDM1  transmembrane epididymal protein 1  1.37 
NM_032824 TMEM87B transmembrane protein 87B  -1.52 
NM_022484 TMEM168 transmembrane protein 168  -1.49 
NM_018241 TMEM184C transmembrane protein 184C  -1.50 
NM_003449 TRIM26 tripartite motif-containing 26  -1.40 
NM_033452 TRIM47 tripartite motif-containing 47  1.45 
NM_145034 TOR1AIP2 torsin A interacting protein 2  -1.58 
NM_207381 TNFAIP8L3 tumor necrosis factor, alpha-induced protein 8-like 3  1.47 
NM_021202 TP53INP2 tumor protein p53 inducible nuclear protein 2  1.38 
NM_175748 UBR7 ubiquitin protein ligase E3 component n-
recognin 7 (putative) -1.62 
NM_014991 WDFY3  WD repeat and FYVE domain containing 3  -1.53 
NM_007086 WDHD1  WD repeat and HMG-box DNA binding protein 1  -1.48 
NM_022828 YTHDC2 YTH domain containing 2  -1.70 
NM_198581 ZC3H6 zinc finger CCCH-type containing 6  -1.57 
AK056855 --- 1.69 
BC033184 1.46 
NA -1.35 
--- --- 1.90 
--- ---   1.63 
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Table S3.4: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4 compared to VEGF (10 ng/ml) (p < 0.001; 235 
genes).  
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Angiogenesis     
 NM_001147 ANGPT2  angiopoietin 2  -3.09 
NM_001202 BMP4  bone morphogenetic protein 4  -2.00 
NM_001554 CYR61  cysteine-rich, angiogenic inducer, 61 -1.71 
NM_002133 HMOX1 heme oxygenase (decycling) 1 1.93 
NM_005924 MEOX2 mesenchyme homeobox 2  -1.75 
NM_194358 RNF41 ring finger protein 41 -1.34 
NM_000459 TEK  TEK tyrosine kinase, endothelial  1.47 
Apoptosis     
 NM_019058 DDIT4  DNA-damage-inducible transcript 4  2.02 
NM_182757 RNF144B  ring finger protein 144B -1.51 
NM_005460 SNCAIP synuclein, alpha interacting protein  -2.21 
NM_198057 TSC22D3  TSC22 domain family, member 3  1.54 
NM_003810 TNFSF10  
tumor necrosis factor (ligand) superfamily, member 
10  1.84 
NM_005092 TNFSF18  
tumor necrosis factor (ligand) superfamily, member 
18  -3.03 
NM_001066 TNFRSF1B  
tumor necrosis factor receptor superfamily, member 
1B  1.44 
NM_033285 TP53INP1  tumor protein p53 inducible nuclear protein 1  1.34 
NM_018003 UACA  uveal autoantigen with coiled-coil domains and 
ankyrin repeats -1.39 
Binding / Cell Adhesion   
 NM_001143668 AMIGO2  adhesion molecule with Ig-like domain 2  -1.43 
NM_078481 CD97  CD97 molecule 1.38 
NM_001130861 CLDN5  claudin 5  1.66 
NM_001338 CXADR coxsackie virus and adenovirus receptor -1.69 
NM_004370 COL12A1 collagen, type XII, alpha 1 -1.64 
NM_001776 ENTPD1 ectonucleoside triphosphate diphosphohydrolase 1 -1.59 
NM_016946 F11R  F11 receptor  1.33 
NM_032876 JUB jub, ajuba homolog (Xenopus laevis)  -1.41 
NM_022143 LRRC4 leucine rich repeat containing 4 1.62 
NM_001143995 LPXN  leupaxin  1.44 
NM_032420 PCDH1 protocadherin 1  1.49 
NM_001040429 PCDH17  protocadherin 17 -1.40 
Cell Communication / Signalling 
 NM_017413 APLN  apelin  -1.66 
NM_001233 CAV2  caveolin 2  -1.45 
NM_014421 DKK2 dickkopf homolog 2 (Xenopus laevis) -1.48 
NM_004438 EPHA4  EPH receptor A4  1.54 
NM_004444 EPHB4  EPH receptor B4  1.41 
NM_000824 GLRB  glycine receptor, beta  -1.64 
NM_207123 GAB1  GRB2-associated binding protein 1  -1.49 
NM_002226 JAG2  jagged 2  1.44 
NM_012302 LPHN2 latrophilin 2  -2.24 
NM_002755 MAP2K1 mitogen-activated protein kinase kinase 1  -1.39 
NM_021724 NR1D1  nuclear receptor subfamily 1, group D, member 1 1.53 
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Table S3.4: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4 compared to 10 ng/ml VEGF (p < 0.001; 235 genes) 
continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Cell Communication / Signalling continued 
 
NM_003629 PIK3R3 phosphoinositide-3-kinase, regulatory subunit 3 (gamma) 1.59 
NM_020182 PMEPA1  
prostate transmembrane protein, androgen induced 
1  1.43 
NM_015191 SIK2  salt-inducible kinase 2 1.58 
NM_005065 SEL1L  sel-1 suppressor of lin-12-like (C. elegans)  -1.63 
Cell Cycle / Cell Proliferation   
 NM_001130914 BTG3  BTG family, member 3 -1.35 
NM_015147 CEP68  centrosomal protein 68kDa  1.64 
NM_001254 CDC6  cell division cycle 6 homolog (S. cerevisiae) -2.39 
NM_000757 CSF1  colony stimulating factor 1 (macrophage) 1.31 
NM_057749 CCNE2  cyclin E2  -1.95 
NM_015097 CLASP2  cytoplasmic linker associated protein 2  -1.42 
NM_001946 DUSP6  dual specificity phosphatase 6  -2.08 
NM_004429 EFNB1  ephrin-B1  1.59 
NM_001001557 GDF6  growth differentiation factor 6 -1.83 
NM_003483 HMGA2 high mobility group AT-hook 2  -1.44 
NM_002192 INHBA  inhibin, beta A  -1.44 
NM_024039 MIS12  MIS12, MIND kinetochore complex component, homolog (S. pombe)  -1.63 
NM_018116 MSTO1  misato homolog 1 (Drosophila)  -1.52 
NM_153618 SEMA6D  sema domain, transmembrane domain (TM), and 
cytoplasmic domain, (semaphorin) 6D  -3.46 
NM_002688 SEPT5 septin 5  -1.65 
NM_014909 VASH1 vasohibin 1  -1.62 
Development     
 
NM_006079 CITED2  Cbp/p300-interacting transactivator, with Glu/Asp-
rich carboxy-terminal domain, 2  -1.65 
NM_012242 DKK1  dickkopf homolog 1 (Xenopus laevis)  -1.89 
NM_006350 FST  follistatin  -1.86 
NM_002060 GJA4  gap junction protein, alpha 4, 37kDa 2.93 
NM_001040167 LFNG  LFNG O-fucosylpeptide 3-beta-N-
acetylglucosaminyltransferase  2.04 
NM_013960 NRG1 neuregulin 1  -1.40 
NM_182964 NAV2  neuron navigator 2  1.71 
NM_005450 NOG  noggin -1.78 
NM_001135599 TGFB2 transforming growth factor, beta 2  -1.44 
NM_020163 SEMA3G sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3G 1.50 
NM_001649 SHROOM2  shroom family member 2 1.38 
NM_005239 ETS2  v-ets erythroblastosis virus E26 oncogene homolog 2 (avian)  1.36 
DNA Binding / Replication / Repair / Transcription 
 NM_194071 CREB3L2 cAMP responsive element binding protein 3-like 2  -1.37 
NM_004956 ETV1  ets variant 1  -2.40 
NM_001986 ETV4  ets variant 4 -1.66 
NM_025081 KIAA1305  KIAA1305  1.39 
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Table S3.4: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4 compared to 10 ng/ml VEGF (p < 0.001; 235 genes) 
continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
DNA Binding / Replication / Repair / Transcription continued 
 NM_021038 MBNL1  muscleblind-like (Drosophila) -1.35 
NM_002526 NT5E  5'-nucleotidase, ecto (CD73)  -1.65 
NM_001135215 ZNF323  zinc finger protein 323 1.47 
NM_153695 ZNF367  zinc finger protein 367  -1.34 
NM_175872 ZNF792 zinc finger protein 792  1.40 
Inflammatory Response   
 NM_000584 IL8  interleukin 8  -1.77 
NM_000450 SELE  selectin E  -2.05 
Immune Response   
 NM_014143 CD274 CD274 molecule  -1.83 
NM_003954 MAP3K14  mitogen-activated protein kinase kinase kinase 14  1.43 
NM_005080 XBP1 X-box binding protein 1  -1.66 
Metabolic / Biosynthetic Process 
 
NM_005099 ADAMTS4  ADAM metallopeptidase with thrombospondin type 1 
motif, 4  1.70 
NM_022060 ABHD4 abhydrolase domain containing 4 -1.37 
NM_174858 AK5 adenylate kinase 5  -2.24 
NR_027833 APOL3 apolipoprotein L, 3  1.55 
NM_030643 APOL4  apolipoprotein L, 4  1.50 
NM_030817 APOLD1 apolipoprotein L domain containing 1 1.54 
NM_024590 ARSJ  arylsulfatase family, member J  -1.51 
NM_018371 CSGALNACT1  chondroitin sulfate N-
acetylgalactosaminyltransferase 1  -1.58 
NM_032385 C5orf4  chromosome 5 open reading frame 4 1.42 
NM_012328 DNAJB9  DnaJ (Hsp40) homolog, subfamily B, member 9  -2.09 
NM_016306 DNAJB11  DnaJ (Hsp40) homolog, subfamily B, member 11  -1.78 
NM_006260 DNAJC3 DnaJ (Hsp40) homolog, subfamily C, member 3  -1.86 
NM_019891 ERO1LB  ERO1-like beta (S. cerevisiae) -2.51 
NM_014674 EDEM1  ER degradation enhancer, mannosidase alpha-like 1  -1.59 
NM_004836 EIF2AK3 eukaryotic translation initiation factor 2-alpha kinase 3  -1.67 
NM_004102 FABP3  fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)  1.43 
NM_007076 FICD FIC domain containing -1.71 
NM_002056 GFPT1  glutamine-fructose-6-phosphate transaminase 1  -1.71 
NM_002153 HSD17B2  hydroxysteroid (17-beta) dehydrogenase 2  -1.86 
NM_018192 LEPREL1  leprecan-like 1  -1.69 
NR_027405 MTHFD2  
methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 2, methenyltetrahydrofolate 
cyclohydrolase 
-1.99 
NM_023112 OTUB2 OTU domain, ubiquitin aldehyde binding 2  1.47 
NM_015288 PHF15  PHD finger protein 15 1.47 
NM_001159323 PLA2G4C  phospholipase A2, group IVC (cytosolic, calcium-independent) 1.55 
NM_000303 PMM2  phosphomannomutase 2  -1.42 
NM_058179 PSAT1 phosphoserine aminotransferase 1 -1.66 
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Table S3.4: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4 compared to 10 ng/ml VEGF (p < 0.001; 235 genes) 
continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Metabolic / Biosynthetic Process continued 
 
NM_000963 PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)  1.50 
NM_004414 RCAN1  regulator of calcineurin 1  -2.41 
NM_000965 RARB  retinoic acid receptor, beta  -1.86 
NM_014746 RNF144A ring finger protein 144A 1.65 
NM_001143676 SGK1 serum/glucocorticoid regulated kinase 1  -1.61 
NM_001142298 SQSTM1  sequestosome 1  1.49 
NM_152996 ST6GALNAC3 
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-
1,3)-N-acetylgalactosaminide alpha-2,6-
sialyltransferase 3  
-1.56 
NM_006588 SULT1C4 sulfotransferase family, cytosolic, 1C, member 4 -1.96 
NM_032431 SYVN1 synovial apoptosis inhibitor 1, synoviolin  -1.47 
NM_017414 USP18  ubiquitin specific peptidase 18  -1.49 
NM_003358 UGCG  UDP-glucose ceramide glucosyltransferase -1.79 
Response to Stimulus   
 NM_000014 A2M  alpha-2-macroglobulin  -1.79 
NM_005409 CXCL11  chemokine (C-X-C motif) ligand 11 3.16 
NM_144601 CMTM3  CKLF-like MARVEL transmembrane domain 
containing 3  1.30 
NM_138410 CMTM7  CKLF-like MARVEL transmembrane domain 
containing 7  1.43 
NM_001993 F3 coagulation factor III (thromboplastin, tissue factor) -1.65 
NM_004417 DUSP1 dual specificity phosphatase 1 -1.60 
NM_005347 HSPA5  heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) -1.62 
NM_014685 HERPUD1 homocysteine-inducible, endoplasmic reticulum 
stress-inducible, ubiquitin-like domain member 1  -1.85 
NM_006389 HYOU1  hypoxia up-regulated 1  -1.46 
NM_002229 JUNB  jun B proto-oncogene 1.52 
NM_006010 MANF mesencephalic astrocyte-derived neurotrophic factor  -1.54 
NM_001130487 NDRG4 NDRG family member 4  1.55 
NM_000603 NOS3 nitric oxide synthase 3 (endothelial cell) 1.42 
NM_001122 PLIN2 perilipin 2  1.41 
NM_001128304 PLSCR4  phospholipid scramblase 4  -1.69 
NM_003155 STC1  stanniocalcin 1  -2.70 
NM_000361 THBD  thrombomodulin  -1.85 
NM_006528 TFPI2 tissue factor pathway inhibitor 2  -1.99 
NR_024168 TLR4  toll-like receptor 4  -1.47 
NM_003234 TFRC  transferrin receptor (p90, CD71) -1.97 
NM_001078 VCAM1  vascular cell adhesion molecule 1 -2.08 
Signal Transduction   
 NM_014391 ANKRD1  ankyrin repeat domain 1 (cardiac muscle) -1.62 
NM_173515 CNKSR3  CNKSR family member 3 -2.32 
NM_001014796 DDR2  discoidin domain receptor tyrosine kinase 2 -1.61 
NM_015221 DNMBP dynamin binding protein  -1.38 
NM_014800 ELMO1  engulfment and cell motility 1 -1.45 
NM_138445 GPR146  G protein-coupled receptor 146  1.67 
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Table S3.4: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4 compared to 10 ng/ml VEGF (p < 0.001; 235 genes) 
continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Signal Transduction continued   
 NM_001945 HBEGF  heparin-binding EGF-like growth factor  -1.95 
NM_003866 INPP4B  inositol polyphosphate-4-phosphatase, type II, 105kDa  -1.41 
NM_015368 PANX1 pannexin 1  1.36 
NM_006255 PRKCH  protein kinase C, eta -1.42 
NM_015149 RGL1 ral guanine nucleotide dissociation stimulator-like 1 -1.61 
NM_007211 RASSF8  Ras association (RalGDS/AF-6) domain family (N-terminal) member 8  -1.69 
NM_016084 RASD1  RAS, dexamethasone-induced 1  -1.38 
NM_001102445 RGS4  regulator of G-protein signalling 4  -1.62 
NM_199282 ARHGAP27  Rho GTPase activating protein 27  1.47 
NM_001128615 ARHGEF3  Rho guanine nucleotide exchange factor (GEF) 3  1.72 
NM_181784 SPRED2  sprouty-related, EVH1 domain containing 2  -1.40 
NM_005658 TRAF1  TNF receptor-associated factor 1  1.67 
NM_005078 TLE3  transducin-like enhancer of split 3 (E(sp1) homolog, Drosophila)  1.36 
NM_005841 SPRY1 sprouty homolog 1, antagonist of FGF signalling (Drosophila)  -2.35 
NM_005842 SPRY2 sprouty homolog 2 (Drosophila)  -1.79 
Transcription     
 NM_024997 ATF7IP2 activating transcription factor 7 interacting protein 2  -1.61 
NM_014109 ATAD2  ATPase family, AAA domain containing 2  -1.76 
NM_001200 BMP2  bone morphogenetic protein 2 -2.17 
NM_006763 BTG2  BTG family, member 2  1.51 
NM_004454 ETV5  ets variant 5  -2.18 
NM_080759 DACH1 dachshund homolog 1 (Drosophila)  -1.64 
NM_016270 KLF2  Kruppel-like factor 2 (lung)  1.50 
NM_004235 KLF4 Kruppel-like factor 4 (gut) 1.54 
NM_030915 LBH  limb bud and heart development homolog (mouse)  -1.66 
NM_014368 LHX6  LIM homeobox 6  1.52 
NM_032246 MEX3B mex-3 homolog B (C. elegans)  1.35 
NM_205860 NR5A2  nuclear receptor subfamily 5, group A, member 2  -1.70 
NM_001080951 PLAGL1 pleiomorphic adenoma gene-like 1  -1.43 
NM_001198 PRDM1 PR domain containing 1, with ZNF domain -2.74 
NM_005686 SOX13  SRY (sex determining region Y)-box 13 1.66 
Transport     
 NM_022735 ACBD3  acyl-Coenzyme A binding domain containing 3 1.34 
NM_170665 ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2  -1.59 
NM_001001396 ATP2B4  ATPase, Ca++ transporting, plasma membrane 4  1.38 
NM_207628 ABCG1 ATP-binding cassette, sub-family G (WHITE), 
member 1 1.49 
NM_198098 AQP1  aquaporin 1 (Colton blood group) 2.06 
NM_022113 KIF13A  kinesin family member 13A  -1.42 
NM_001025579 NDEL1 nudE nuclear distribution gene E homolog (A. 
nidulans)-like 1  -1.38 
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Table S3.4: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4 compared to 10 ng/ml VEGF (p < 0.001; 235 genes) 
continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Transport continued  
NM_138444 KCTD12  potassium channel tetramerisation domain 
containing 12  1.43 
NM_006363 SEC23B  Sec23 homolog B (S. cerevisiae) -1.60 
NM_014822 SEC24D  SEC24 family, member D (S. cerevisiae)  -1.65 
NM_003038 SLC1A4  solute carrier family 1 (glutamate/neutral amino acid transporter), member 4  -1.45 
NM_006931 SLC2A3  solute carrier family 2 (facilitated glucose transporter), member 3  1.45 
NM_003043 SLC6A6 solute carrier family 6 (neurotransmitter transporter, taurine), member 6  1.90 
NM_003045 SLC7A1  solute carrier family 7 (cationic amino acid transporter, y+ system), member 1  -1.70 
NM_003982 SLC7A7  solute carrier family 7 (cationic amino acid transporter, y+ system), member 7  -1.46 
NM_004733 SLC33A1  solute carrier family 33 (acetyl-CoA transporter), 
member 1  -1.57 
NM_001001479 SLC35E4  solute carrier family 35, member E4  1.47 
NM_001128431 SLC39A14  solute carrier family 39 (zinc transporter), member 14  -2.35 
NM_005630 SLCO2A1  solute carrier organic anion transporter family, 
member 2A1 1.50 
Miscellaneous / Other   
 NM_014600 EHD3  EH-domain containing 3  -3.54 
NM_001839 CNN3 calponin 3, acidic  -1.41 
NM_001802 CDR2  cerebellar degeneration-related protein 2, 62kDa -1.43 
NM_198545 C1orf187  chromosome 1 open reading frame 187  1.63 
NM_020130 C8orf4 chromosome 8 open reading frame 4  1.73 
NM_017787 C10orf26  chromosome 10 open reading frame 26 1.39 
NM_032933 C18orf45 chromosome 18 open reading frame 45  -1.55 
NM_020939 CPNE5  copine V  1.43 
NM_001135101 CRELD2  cysteine-rich with EGF-like domains 2 1.42 
NM_178470 DCAF12L1  DDB1 and CUL4 associated factor 12-like 1 -1.45 
NM_014787 DNAJC6  DnaJ (Hsp40) homolog, subfamily C, member 6  -1.63 
AF151906 FAM18B  family with sequence similarity 18, member B  -1.54 
NM_153711 FAM26E  family with sequence similarity 26, member E  1.61 
NM_001130025 FAM115C  family with sequence similarity 115, member C  -1.78 
NM_173511 FAM117B family with sequence similarity 117, member B 1.33 
NM_024785 FAM124B  family with sequence similarity 124B  1.61 
NM_006948 HSPA13 heat shock protein 70kDa family, member 13  -1.46 
NM_009587 LGALS9  lectin, galactoside-binding, soluble, 9  1.61 
NM_001040078 LGALS9C lectin, galactoside-binding, soluble, 9C 1.49 
NM_001134476 LRRC8B  leucine rich repeat containing 8 family, member B  -2.37 
NM_015116 LRCH1  leucine-rich repeats and calponin homology (CH) domain containing 1  -1.67 
NM_017762 MTMR10 myotubularin related protein 10  -1.64 
AY176665 NSAP11  nervous system abundant protein 11 -1.55 
NM_144573 NEXN  nexilin (F actin binding protein)  -2.00 
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Table S3.4: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4 compared to 10 ng/ml VEGF (p < 0.001; 235 genes) 
continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Miscellaneous / Other continued  
NM_001031701 NT5DC3  5'-nucleotidase domain containing 3 -1.43 
NM_021255 PELI2  pellino homolog 2 (Drosophila)  1.44 
NM_001100164 PHACTR2 phosphatase and actin regulator 2 -1.64 
NM_015993 PLLP plasma membrane proteolipid (plasmolipin) 2.17 
NM_001104587 SLFN11  schlafen family member 11  -2.06 
NM_004657 SDPR  serum deprivation response (phosphatidylserine binding protein) -1.33 
NR_002816 THSD1P  thrombospondin, type I, domain containing 1 pseudogene  1.48 
NM_175861 TMTC1  transmembrane and tetratricopeptide repeat 
containing 1  -1.52 
NM_013390 TMEM2  transmembrane protein 2  -1.68 
NM_031442 TMEM47  transmembrane protein 47 -1.35 
NM_006134 TMEM50B  transmembrane protein 50B  -2.29 
NM_080660 ZC3HAV1L zinc finger CCCH-type, antiviral 1-like -1.35 
NM_194250 ZNF804A  zinc finger protein 804A  -1.40 
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Table S3.5: List of differentially expressed genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4-treated VEGF (10 ng/ml) compared to VEGF 
(10 ng/ml) (p < 0.001; 360 genes). 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Angiogenesis     
 NM_000014 A2M  alpha-2-macroglobulin  -1.79 
NM_001147 ANGPT2 angiopoietin 2  -2.93 
NM_001202 BMP4 bone morphogenetic protein 4 -1.89 
NM_001554 CYR61 cysteine-rich, angiogenic inducer, 61  -1.71 
NM_002133 HMOX1 heme oxygenase (decycling) 1  1.88 
NM_002632 PGF placental growth factor 1.42 
NM_025208 PDGFD platelet derived growth factor D -1.47 
NM_005924 MEOX2  mesenchyme homeobox 2 -1.64 
NM_194358 RNF41 ring finger protein 41 -1.40 
NM_006291 TNFAIP2 tumor necrosis factor, alpha-induced protein 2 1.38 
Apoptosis     
 NM_032977 CASP10  caspase 10, apoptosis-related cysteine peptidase  -1.60 
NM_019058 DDIT4 DNA-damage-inducible transcript 4  1.82 
NM_016315 GULP1 GULP, engulfment adaptor PTB domain containing 1 -1.77 
NM_003024 ITSN1 intersectin 1 (SH3 domain protein) -1.34 
NM_002583 PAWR PRKC, apoptosis, WT1, regulator -1.41 
NM_182757 RNF144B ring finger protein 144B  -1.44 
NM_005460 SNCAIP synuclein, alpha interacting protein  -2.16 
NM_003810 TNFSF10  tumor necrosis factor (ligand) superfamily, member 10  1.64 
NM_005092 TNFSF18  tumor necrosis factor (ligand) superfamily, member 18 -3.43 
NM_001066 TNFRSF1B  tumor necrosis factor receptor superfamily, member 1B  1.52 
NM_033285 TP53INP1 tumor protein p53 inducible nuclear protein 1  1.33 
NM_018003 UACA  uveal autoantigen with coiled-coil domains and 
ankyrin repeats  -1.53 
Binding / Cell Adhesion   
 
NM_001712 CEACAM1 carcinoembryonic antigen-related cell adhesion 
molecule 1 (biliary glycoprotein) 1.36 
NM_078481 CD97 CD97 molecule 1.38 
NM_001130861 CLDN5  claudin 5 1.82 
NM_004370 COL12A1 collagen, type XII, alpha 1 -1.83 
NM_001338 CXADR coxsackie virus and adenovirus receptor -1.80 
NM_001776 ENTPD1 ectonucleoside triphosphate diphosphohydrolase 1 -1.74 
NM_000210 ITGA6 integrin, alpha 6 -1.52 
NM_032876 JUB jub, ajuba homolog (Xenopus laevis) -1.38 
NM_022143 LRRC4 leucine rich repeat containing 4  1.60 
NM_032420 PCDH1 protocadherin 1  1.54 
NM_014000 VCL vinculin -1.37 
Cell Communication / Signalling 
 NM_001233 CAV2 caveolin 2  -1.50 
NM_014421 DKK2 dickkopf homolog 2 (Xenopus laevis) -1.44 
NM_004438 EPHA4 EPH receptor A4 1.47 
NM_004444 EPHB4  EPH receptor B4 1.39 
NM_000824 GLRB glycine receptor, beta  -1.66 
NM_004838 HOMER3 homer homolog 3 (Drosophila) 1.32 
NM_002226 JAG2 jagged 2 1.39 
NM_012302 LPHN2  latrophilin 2  -2.40 
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Table S3.5: List of differentially regulated genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4-treated VEGF (10 ng/ml) compared to VEGF 
(10 ng/ml) (p < 0.001; 360 genes) continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Cell Communication / Signalling continued 
 NM_002755 MAP2K1 mitogen-activated protein kinase kinase 1  -1.38 
NM_024717 MCTP1 multiple C2 domains, transmembrane 1 -1.48 
NM_004687 MTMR4  myotubularin related protein 4 -1.37 
NM_016231 NLK nemo-like kinase -1.35 
NM_014840 NUAK1  NUAK family, SNF1-like kinase, 1 -1.42 
NM_021724 NR1D1 nuclear receptor subfamily 1, group D, member 1  1.59 
NM_002742 PRKD1 protein kinase D1 -1.41 
NM_181805 PKIG protein kinase (cAMP-dependent, catalytic) inhibitor gamma 1.54 
NM_002834 PTPN11 protein tyrosine phosphatase, non-receptor type 11 -1.45 
NM_177968 PPM1B protein phosphatase 1B (formerly 2C), magnesium-dependent, beta isoform -1.40 
NM_015191 SIK2 salt-inducible kinase 2 1.46 
Cell Cycle / Cell Proliferation   
 NM_001130914 BTG3 BTG family, member 3 -1.35 
NM_003672 CDC14A CDC14 cell division cycle 14 homolog A (S. 
cerevisiae)  -1.61 
NM_001254 CDC6  cell division cycle 6 homolog (S. cerevisiae)  -2.21 
NM_021873 CDC25B cell division cycle 25 homolog B (S. pombe) 1.32 
NM_015147 CEP68  centrosomal protein 68kDa  1.62 
NM_057749 CCNE2 cyclin E2  -2.10 
NM_015097 CLASP2 cytoplasmic linker associated protein 2  -1.65 
NM_001946 DUSP6 dual specificity phosphatase 6  -2.05 
NM_007036 ESM1 endothelial cell-specific molecule 1 -1.63 
NM_004429 EFNB1 ephrin-B1  1.51 
NM_207123 GAB1 GRB2-associated binding protein 1 -1.65 
NM_002192 INHBA  inhibin, beta A  -1.55 
NM_002357 MXD1 MAX dimerization protein 1 -1.58 
NM_004991 MECOM MDS1 and EVI1 complex locus -1.33 
NM_024039 MIS12  MIS12, MIND kinetochore complex component, homolog (S. pombe)  -2.03 
NM_018116 MSTO1  misato homolog 1 (Drosophila)  -1.57 
NM_005065 SEL1L sel-1 suppressor of lin-12-like (C. elegans) -1.81 
NM_153618 SEMA6D  sema domain, transmembrane domain (TM), and 
cytoplasmic domain, (semaphorin) 6D  -4.23 
NM_002688 SEPT5 septin 5 -1.55 
NM_001048201 UHRF1 ubiquitin-like with PHD and ring finger domains 1 -1.49 
NM_014909 VASH1  vasohibin 1  -1.57 
NM_006887 ZFP36L2 zinc finger protein 36, C3H type-like 2 1.36 
Cell Migration 
    
NM_006505 PVR poliovirus receptor -1.32 
Development     
 
NM_006079 CITED2  Cbp/p300-interacting transactivator, with Glu/Asp-rich 
carboxy-terminal domain, 2  -1.54 
NM_012242 DKK1 dickkopf homolog 1 (Xenopus laevis) -1.80 
NM_004425 ECM1 extracellular matrix protein 1 1.42 
NM_014888 FAM3C family with sequence similarity 3, member C  -1.43 
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Table S3.5: List of differentially regulated genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4-treated VEGF (10 ng/ml) compared to VEGF 
(10 ng/ml) (p < 0.001; 360 genes) continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Development continued  
NM_006350 FST  follistatin  -1.87 
NM_002060 GJA4  gap junction protein, alpha 4, 37kDa  3.18 
NM_001040167 LFNG LFNG O-fucosylpeptide 3-beta-N-
acetylglucosaminyltransferase  1.94 
NM_013960 NRG1 neuregulin 1 -1.35 
NM_182964 NAV2 neuron navigator 2 1.51 
NM_005450 NOG noggin -1.72 
NM_000297 PKD2  polycystic kidney disease 2 (autosomal dominant) -1.55 
NM_152754 SEMA3D sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3D -1.58 
NM_020163 SEMA3G sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3G 1.48 
NM_001649 SHROOM2 shroom family member 2 1.39 
NM_005668 ST8SIA4 ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 4 -1.48 
NM_001135599 TGFB2 transforming growth factor, beta 2  -1.57 
DNA Binding / Replication / Repair / Transcription 
 NM_194071 CREB3L2 cAMP responsive element binding protein 3-like 2 -1.34 
NM_016448 DTL denticleless homolog (Drosophila)  -1.56 
NM_004956 ETV1  ets variant 1 -2.46 
NM_001986 ETV4 ets variant 4  -1.55 
NM_025081 KIAA1305 KIAA1305 1.41 
NM_018078 LARP1B La ribonucleoprotein domain family, member 1B -1.62 
NM_014793 LCMT2 leucine carboxyl methyltransferase 2 -1.38 
NM_021038 MBNL1 muscleblind-like (Drosophila) -1.42 
NM_144778 MBNL2 muscleblind-like 2 (Drosophila) -1.30 
NM_002526 NT5E 5'-nucleotidase, ecto (CD73)  -1.72 
NM_017793 RPP25 ribonuclease P/MRP 25kDa subunit 1.49 
NM_001039697 SNAPC3 small nuclear RNA activating complex, polypeptide 3, 
50kDa -1.41 
NM_007114 TMF1 TATA element modulatory factor 1 -1.72 
NM_003598 TEAD2 TEA domain family member 2 1.39 
NR_027302 XPA xeroderma pigmentosum, complementation group A -1.54 
NM_004926 ZFP36L1 zinc finger protein 36, C3H type-like 1 1.33 
NM_001135215 ZNF323 zinc finger protein 323 1.40 
NM_032819 ZNF341 zinc finger protein 341 1.36 
NM_152320 ZNF641 zinc finger protein 641 -1.38 
Inflammatory Response   
 NM_000575 IL1A interleukin 1, alpha -1.59 
NM_000584 IL8 interleukin 8 -1.81 
NM_002852 PTX3 pentraxin-related gene, rapidly induced by IL-1 beta -1.50 
NM_000450 SELE  selectin E  -2.22 
Immune Response   
 NM_014143 CD274 CD274 molecule -2.07 
NM_001114752 CD55 CD55 molecule, decay accelerating factor for 
complement (Cromer blood group) -1.45 
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Table S3.5: List of differentially regulated genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4-treated VEGF (10 ng/ml) compared to VEGF 
(10 ng/ml) (p < 0.001; 360 genes) continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Immune Response continued   
 NM_003954 MAP3K14 mitogen-activated protein kinase kinase kinase 14  1.43 
NM_003326 TNFSF4 tumor necrosis factor (ligand) superfamily, member 4 -1.54 
NM_005080 XBP1 X-box binding protein 1 -1.50 
Metabolic / Biosynthetic Process 
 NM_022060 ABHD4 abhydrolase domain containing 4 -1.36 
NM_005099 ADAMTS4 ADAM metallopeptidase with thrombospondin type 1 
motif, 4  1.62 
NM_014272 ADAMTS7 ADAM metallopeptidase with thrombospondin type 1 
motif, 7 1.34 
NM_182920 ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 
motif, 9 -1.38 
NM_174858 AK5  adenylate kinase 5  -2.53 
NM_002860 ALDH18A1 aldehyde dehydrogenase 18 family, member A1  -1.44 
NR_027833 APOL3  apolipoprotein L, 3  1.52 
NM_030643 APOL4  apolipoprotein L, 4  1.49 
NM_030817 APOLD1 apolipoprotein L domain containing 1  1.60 
NM_024590 ARSJ arylsulfatase family, member J  -1.64 
NM_005603 ATP8B1 ATPase, class I, type 8B, member 1 -1.41 
NM_014616 ATP11B ATPase, class VI, type 11B -1.68 
NM_003654 CHST1 carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 1.37 
NM_018371 CSGALNACT1 chondroitin sulfate N-acetylgalactosaminyltransferase 1 -1.55 
NM_032385 C5orf4  chromosome 5 open reading frame 4 1.41 
NM_000774 CYP2F1 cytochrome P450, family 2, subfamily F, polypeptide 1 1.78 
NM_013352 DSE dermatan sulfate epimerase -1.43 
NM_003647 DGKE diacylglycerol kinase, epsilon 64kDa -1.61 
NM_007034 DNAJB4 DnaJ (Hsp40) homolog, subfamily B, member 4 -1.49 
NM_012328 DNAJB9  DnaJ (Hsp40) homolog, subfamily B, member 9  -2.27 
NM_016306 DNAJB11 DnaJ (Hsp40) homolog, subfamily B, member 11 -1.74 
NM_006260 DNAJC3  DnaJ (Hsp40) homolog, subfamily C, member 3 -2.17 
NM_024090 ELOVL6 ELOVL family member 6, elongation of long chain fatty acids (FEN1/Elo2, SUR4/Elo3-like, yeast) -1.79 
NM_014674 EDEM1  ER degradation enhancer, mannosidase alpha-like 1  -1.63 
NM_019891 ERO1LB  ERO1-like beta (S. cerevisiae) -2.81 
NM_004836 EIF2AK3 eukaryotic translation initiation factor 2-alpha kinase 3  -1.87 
NM_001442 FABP4 fatty acid binding protein 4, adipocyte -1.82 
NM_017946 FKBP14 FK506 binding protein 14, 22 kDa -1.84 
NM_007076 FICD FIC domain containing -1.78 
NM_002056 GFPT1 glutamine-fructose-6-phosphate transaminase 1  -1.87 
NM_002153 HSD17B2  hydroxysteroid (17-beta) dehydrogenase 2  1.66 
NM_005530 IDH3A isocitrate dehydrogenase 3 (NAD+) alpha -1.41 
NM_018192 LEPREL1 leprecan-like 1  -1.74 
NM_032121 MAGT1 magnesium transporter 1 -1.45 
NM_014730 MLEC malectin -1.32 
NR_027405 MTHFD2 
methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 2, methenyltetrahydrofolate 
cyclohydrolase 
-2.02 
NM_000240 MAOA monoamine oxidase A -1.40 
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Table S3.5: List of differentially regulated genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4-treated VEGF (10 ng/ml) compared to VEGF 
(10 ng/ml) (p < 0.001; 360 genes) continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Metabolic / Biosynthetic Process continued 
 NM_018946 NANS N-acetylneuraminic acid synthase -1.52 
NM_001146276 NCEH1 neutral cholesterol ester hydrolase 1  -1.41 
NM_012229 NT5C2 5'-nucleotidase, cytosolic II -1.41 
NM_023112 OTUB2 OTU domain, ubiquitin aldehyde binding 2 1.50 
NM_018233 OGFOD1 2-oxoglutarate and iron-dependent oxygenase domain containing 1 -1.38 
NM_015288 PHF15 PHD finger protein 15 1.45 
NM_003712 PPAP2C  phosphatidic acid phosphatase type 2C 1.49 
NM_000303 PMM2  phosphomannomutase 2 -1.51 
NM_058179 PSAT1  phosphoserine aminotransferase 1  -1.72 
NM_014819 PJA2 praja ring finger 2 -1.58 
NM_004414 RCAN1  regulator of calcineurin 1  -2.39 
NM_014746 RNF144A ring finger protein 144A  1.73 
NM_001143676 SGK1  serum/glucocorticoid regulated kinase 1 -1.61 
NM_001142298 SQSTM1 sequestosome 1 1.46 
NM_001136258 SGMS2 sphingomyelin synthase 2 -1.69 
NM_152996 ST6GALNAC3 
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-
1,3)-N-acetylgalactosaminide alpha-2,6-
sialyltransferase 3 
-1.59 
NM_015589 SAMD4A sterile alpha motif domain containing 4A -1.37 
NM_001128205 SULF1 sulfatase 1 -1.45 
NM_006588 SULT1C4 sulfotransferase family, cytosolic, 1C, member 4  -2.31 
NM_032431 SYVN1 synovial apoptosis inhibitor 1, synoviolin -1.40 
NM_014305 TGDS TDP-glucose 4,6-dehydratase -1.50 
NM_017414 USP18 ubiquitin specific peptidase 18  -1.65 
NM_003358 UGCG  UDP-glucose ceramide glucosyltransferase  -1.92 
NM_003115 UAP1 UDP-N-acteylglucosamine pyrophosphorylase 1  -1.63 
NM_207309 UAP1L1 UDP-N-acteylglucosamine pyrophosphorylase 1-like 1 1.49 
Response to Stimulus   
 NM_005409 CXCL11 chemokine (C-X-C motif) ligand 11 2.45 
NM_138410 CMTM7  CKLF-like MARVEL transmembrane domain 
containing 7 1.45 
NM_001993 F3 coagulation factor III (thromboplastin, tissue factor) -1.41 
NM_004417 DUSP1 dual specificity phosphatase 1  -1.70 
NM_018948 ERRFI1 ERBB receptor feedback inhibitor 1 -1.51 
NM_005347 HSPA5  heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)  -1.65 
NM_014685 HERPUD1 homocysteine-inducible, endoplasmic reticulum 
stress-inducible, ubiquitin-like domain member 1 -1.97 
NM_006389 HYOU1  hypoxia up-regulated 1  -1.56 
NM_001144878 IMPA1 inositol(myo)-1(or 4)-monophosphatase 1 -1.52 
NM_002229 JUNB jun B proto-oncogene 1.57 
NM_002276 KRT19 keratin 19 1.46 
NM_006010 MANF  mesencephalic astrocyte-derived neurotrophic factor -1.55 
NM_001130487 NDRG4 NDRG family member 4  1.62 
NM_000603 NOS3  nitric oxide synthase 3 (endothelial cell) 1.53 
NM_001122 PLIN2 perilipin 2 1.35 
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Table S3.5: List of differentially regulated genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4-treated VEGF (10 ng/ml) compared to VEGF 
(10 ng/ml) (p < 0.001; 360 genes) continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Response to Stimulus continued  
NM_001128304 PLSCR4  phospholipid scramblase 4  -1.72 
NM_000965 RARB retinoic acid receptor, beta -2.06 
NM_003155 STC1  stanniocalcin 1  -2.33 
NM_006528 TFPI2  tissue factor pathway inhibitor 2  -2.12 
NM_000361 THBD  thrombomodulin  -1.81 
NR_024168 TLR4 toll-like receptor 4  -1.57 
NM_003234 TFRC  transferrin receptor (p90, CD71) -2.34 
NM_001078 VCAM1 vascular cell adhesion molecule 1 -2.55 
Signal Transduction   
 NM_014391 ANKRD1 ankyrin repeat domain 1 (cardiac muscle) -1.58 
NM_003567 BCAR3 breast cancer anti-estrogen resistance 3 1.34 
NM_173515 CNKSR3 CNKSR family member 3  -2.62 
NM_001014796 DDR2 discoidin domain receptor tyrosine kinase 2 -1.82 
NM_015221 DNMBP dynamin binding protein -1.46 
NM_014800 ELMO1 engulfment and cell motility 1  -1.52 
NM_138445 GPR146 G protein-coupled receptor 146 1.64 
NM_001945 HBEGF heparin-binding EGF-like growth factor -1.86 
NM_003866 INPP4B inositol polyphosphate-4-phosphatase, type II, 105kDa -1.40 
NM_018945 PDE7B phosphodiesterase 7B -1.57 
NM_025179 PLXNA2 plexin A2 -1.74 
NM_006255 PRKCH  protein kinase C, eta -1.52 
NM_006266 RALGDS ral guanine nucleotide dissociation stimulator 1.37 
NM_015149 RGL1  ral guanine nucleotide dissociation stimulator-like 1  -1.79 
NM_007211 RASSF8 Ras association (RalGDS/AF-6) domain family (N-
terminal) member 8  -1.76 
NM_001102445 RGS4  regulator of G-protein signalling 4  -1.82 
NM_024605 ARHGAP10 Rho GTPase activating protein 10  -1.52 
NM_199282 ARHGAP27 Rho GTPase activating protein 27 1.49 
NM_001128615 ARHGEF3 Rho guanine nucleotide exchange factor (GEF) 3 1.56 
NM_005841 SPRY1  sprouty homolog 1, antagonist of FGF signalling (Drosophila) -2.34 
NM_005842 SPRY2  sprouty homolog 2 (Drosophila) -1.87 
NM_030964 SPRY4  sprouty homolog 4 (Drosophila) -1.56 
NM_181784 SPRED2 sprouty-related, EVH1 domain containing 2 -1.42 
NM_005078 TLE3 transducin-like enhancer of split 3 (E(sp1) homolog, Drosophila) 1.36 
Transcription     
 NM_024997 ATF7IP2 activating transcription factor 7 interacting protein 2  -1.81 
NM_014109 ATAD2  ATPase family, AAA domain containing 2  -1.94 
NM_001200 BMP2  bone morphogenetic protein 2 -2.03 
NM_006763 BTG2 BTG family, member 2 1.49 
NM_080759 DACH1 dachshund homolog 1 (Drosophila)  -1.67 
NM_004454 ETV5 ets variant 5  -1.83 
NM_016270 KLF2  Kruppel-like factor 2 (lung) 1.58 
NM_004235 KLF4 Kruppel-like factor 4 (gut) 1.59 
NM_014368 LHX6  LIM homeobox 6  1.58 
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Table S3.5: List of differentially regulated genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4-treated VEGF (10 ng/ml) compared to VEGF 
(10 ng/ml) (p < 0.001; 360 genes) continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Transcription continued  
NM_030915 LBH  limb bud and heart development homolog (mouse)  -1.58 
NM_005583 LYL1 lymphoblastic leukemia derived sequence 1 1.46 
NM_032246 MEX3B mex-3 homolog B (C. elegans) 1.36 
NM_016132 MYEF2 myelin expression factor 2 -1.39 
NM_205860 NR5A2  nuclear receptor subfamily 5, group A, member 2  -1.87 
NM_001080951 PLAGL1 pleiomorphic adenoma gene-like 1 -1.50 
NM_001198 PRDM1  PR domain containing 1, with ZNF domain  -2.53 
NM_003082 SNAPC1 small nuclear RNA activating complex, polypeptide 1, 
43kDa -1.77 
NM_005686 SOX13  SRY (sex determining region Y)-box 13  1.66 
NM_022117 TSPYL2 TSPY-like 2  -1.42 
NM_016206 VGLL3 vestigial like 3 (Drosophila) -1.61 
Transport     
 NM_022735 ACBD3 acyl-Coenzyme A binding domain containing 3 -1.42 
NM_014570 ARFGAP3 ADP-ribosylation factor GTPase activating protein 3 -1.47 
NM_001113738 ARL17P1 ADP-ribosylation factor-like 17 pseudogene 1 -1.80 
NM_170665 ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2  -1.75 
NM_020453 ATP10D ATPase, class V, type 10D -1.58 
NM_207628 ABCG1 ATP-binding cassette, sub-family G (WHITE), 
member 1 1.45 
NM_198098 AQP1 aquaporin 1 (Colton blood group) 1.98 
NR_026745 COG6 component of oligomeric golgi complex 6 -1.68 
NM_007235 XPOT exportin, tRNA (nuclear export receptor for tRNAs) -1.42 
NM_016072 GOLT1B  golgi transport 1 homolog B (S. cerevisiae) -2.02 
NM_006855 KDELR3 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 3 -1.42 
NM_022113 KIF13A  kinesin family member 13A  -1.59 
NM_003826 NAPG N-ethylmaleimide-sensitive factor attachment protein, gamma  -1.48 
NM_001025579 NDEL1  nudE nuclear distribution gene E homolog (A. 
nidulans)-like 1 -1.46 
NM_138444 KCTD12 potassium channel tetramerisation domain containing 12  1.48 
NM_198686 RAB15 RAB15, member RAS onocogene family -1.34 
NM_004580 RAB27A RAB27A, member RAS oncogene family  -1.34 
NM_006363 SEC23B  Sec23 homolog B (S. cerevisiae) -1.75 
NM_014822 SEC24D SEC24 family, member D (S. cerevisiae)  -1.72 
NM_004170 SLC1A1 solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1 -1.64 
NM_003038 SLC1A4 solute carrier family 1 (glutamate/neutral amino acid 
transporter), member 4 -1.50 
NM_003043 SLC6A6  solute carrier family 6 (neurotransmitter transporter, 
taurine), member 6 1.64 
NM_003045 SLC7A1 solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 1  -1.70 
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Table S3.5: List of differentially regulated genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4-treated VEGF (10 ng/ml) compared to VEGF 
(10 ng/ml) (p < 0.001; 360 genes) continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Transport continued  
NM_003982 SLC7A7  solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 7  -1.51 
NM_001029998 SLC10A7 solute carrier family 10 (sodium/bile acid 
cotransporter family), member 7  -1.37 
NM_001046 SLC12A2 solute carrier family 12 (sodium/potassium/chloride 
transporters), member 2  -1.45 
NM_030780 SLC25A32  solute carrier family 25, member 32 -1.45 
NM_004733 SLC33A1 solute carrier family 33 (acetyl-CoA transporter), 
member 1 -1.78 
NM_005827 SLC35B1 solute carrier family 35, member B1 -1.45 
NM_001001479 SLC35E4 solute carrier family 35, member E4  1.43 
NM_001128431 SLC39A14  solute carrier family 39 (zinc transporter), member 14  -2.54 
NM_013306 SNX15 sorting nexin 15 1.30 
NM_139164 STARD4 StAR-related lipid transfer (START) domain 
containing 4 -1.62 
Miscellaneous / Other   
 NM_015379 BRI3 brain protein I3 1.41 
NM_015916 CALHM2 calcium homeostasis modulator 2 1.37 
NM_001839 CNN3 calponin 3, acidic -1.44 
NM_001802 CDR2 cerebellar degeneration-related protein 2, 62kDa -1.45 
NM_198545 C1orf187  chromosome 1 open reading frame 187 1.68 
NM_173552 C3orf58 chromosome 3 open reading frame 58 -1.34 
NM_024315 C7orf23 chromosome 7 open reading frame 23 -1.55 
NM_020130 C8orf4 chromosome 8 open reading frame 4 1.56 
NM_017782 C10orf18 chromosome 10 open reading frame 18 -1.47 
NM_017787 C10orf26  chromosome 10 open reading frame 26 1.33 
NM_024942 C10orf88  chromosome 10 open reading frame 88  -1.61 
NM_152261 C12orf23 chromosome 12 open reading frame 23 -1.56 
NM_020456 C13orf1 chromosome 13 open reading frame 1  -1.40 
NM_032933 C18orf45 chromosome 18 open reading frame 45  -1.67 
NM_144492 CLDN14  claudin 14 1.42 
NM_138357 CCDC109A coiled-coil domain containing 109A  -1.44 
NM_030627 CPEB4 cytoplasmic polyadenylation element binding protein 4 -1.56 
NM_020939 CPNE5 copine V 1.38 
NM_178470 DCAF12L1 DDB1 and CUL4 associated factor 12-like 1 -1.42 
NM_006773 DDX18 DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 -1.54 
NM_014787 DNAJC6 DnaJ (Hsp40) homolog, subfamily C, member 6 -1.62 
NM_020354 ENTPD7 ectonucleoside triphosphate diphosphohydrolase 7  -1.56 
NM_014600 EHD3  EH-domain containing 3 -3.84 
NM_198947 FAM111B family with sequence similarity 111, member B -1.70 
NM_001130025 FAM115C  family with sequence similarity 115, member C -1.81 
NM_024785 FAM124B family with sequence similarity 124B  1.58 
AF151906 FAM18B  family with sequence similarity 18, member B  -1.76 
NM_153711 FAM26E family with sequence similarity 26, member E  -1.71 
NM_033387 FAM78A family with sequence similarity 78, member A 1.34 
NM_144963 FAM91A1  family with sequence similarity 91, member A1 -1.46 
NM_144963 FAM91A1 family with sequence similarity 91, member A1 -1.59 
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Table S3.5: List of differentially regulated genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4-treated VEGF (10 ng/ml) compared to VEGF 
(10 ng/ml) (p < 0.001; 360 genes) continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Miscellaneous / Other continued  
NM_058229 FBXO32 F-box protein 32 -1.98 
NM_032892 FRMD5 FERM domain containing 5  -1.39 
NM_180989 GPR180 G protein-coupled receptor 180 -1.57 
NM_006948 HSPA13 heat shock protein 70kDa family, member 13 -1.73 
NM_152230 IPMK inositol polyphosphate multikinase -1.52 
NM_022347 IFRG15 interferon responsive gene 15 -1.62 
NM_020888 KIAA1522 KIAA1522 1.39 
NM_009587 LGALS9 lectin, galactoside-binding, soluble, 9 1.65 
NM_001040078 LGALS9C lectin, galactoside-binding, soluble, 9C  1.59 
NM_015116 LRCH1  leucine-rich repeats and calponin homology (CH) domain containing 1  -1.90 
NM_001134476 LRRC8B leucine rich repeat containing 8 family, member B  -2.61 
NM_198565 LRRC33 leucine rich repeat containing 33 1.56 
NM_019556 MOSPD1 motile sperm domain containing 1 -1.45 
NM_017762 MTMR10 myotubularin related protein 10 -1.66 
NM_018177 N4BP2 NEDD4 binding protein 2 -1.67 
NM_144573 NEXN nexilin (F actin binding protein)  -2.31 
NM_198514 NHLRC2 NHL repeat containing 2  -1.56 
NM_001031701 NT5DC3 5'-nucleotidase domain containing 3 -1.62 
NM_005013 NUCB2 nucleobindin 2 -1.64 
NM_024576 OGFRL1  opioid growth factor receptor-like 1  -1.57 
NM_020651 PELI1 pellino homolog 1 (Drosophila) -1.75 
NM_021255 PELI2 pellino homolog 2 (Drosophila) 1.37 
NM_001100164 PHACTR2  phosphatase and actin regulator 2  -1.73 
NM_015993 PLLP plasma membrane proteolipid (plasmolipin)  2.20 
NM_153026 PRICKLE1 prickle homolog 1 (Drosophila) -1.38 
NM_130809 PRRC1 proline-rich coiled-coil 1 -1.35 
NM_153020 RBM24 RNA binding motif protein 24 1.50 
NM_014016 SACM1L SAC1 suppressor of actin mutations 1-like (yeast) -1.53 
NM_001104587 SLFN11  schlafen family member 11 -2.24 
NM_144682 SLFN13  schlafen family member 13 -1.46 
NM_004657 SDPR  serum deprivation response (phosphatidylserine binding protein) -1.33 
NM_024745 SHCBP1 SHC SH2-domain binding protein 1 -1.47 
NM_022648 TNS1 tensin 1 1.29 
NM_015914 TXNDC11 thioredoxin domain containing 11 -1.30 
NR_002816 THSD1P thrombospondin, type I, domain containing 1 pseudogene 1.45 
NM_138786 TM4SF18  transmembrane 4 L six family member 18 -1.37 
NM_175861 TMTC1  transmembrane and tetratricopeptide repeat 
containing 1  -1.66 
NM_152588 TMTC2 transmembrane and tetratricopeptide repeat 
containing 2 -1.46 
NM_013390 TMEM2  transmembrane protein 2 -1.84 
NM_018266 TMEM39A transmembrane protein 39A -1.55 
NM_031442 TMEM47 transmembrane protein 47 -1.38 
NM_006134 TMEM50B  transmembrane protein 50B  -2.53 
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Table S3.5: List of differentially regulated genes in HUVECs after a six hour treatment of 
1 µM apple procyanidin fraction dp 4-treated VEGF (10 ng/ml) compared to VEGF 
(10 ng/ml) (p < 0.001; 360 genes) continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Miscellaneous / Other continued  
NM_145041 TMEM106A  transmembrane protein 106A 1.40 
NM_175748 UBR7  ubiquitin protein ligase E3 component n-recognin 7 (putative) 1.55 
NM_173834 YIPF6 Yip1 domain family, member 6  -1.49 
NM_001005404 YPEL2 yippee-like 2 (Drosophila) -1.46 
NM_080660 ZC3HAV1L zinc finger CCCH-type, antiviral 1-like -1.45 
--- --- --- 1.87 
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Table S3.6: List of differentially expressed genes in HUVECs after a six hour treatment of 
500 ng/ml anti-VEGF antibody-treated VEGF (10 ng/ml) compared to VEGF (10 ng/ml) 
(p < 0.001; 131 genes). 
Gene ID 
Gene 
Abbreviation Gene Name 
Fold 
Change 
Angiogenesis 
   NM_001147 ANGPT2 angiopoietin 2  -1.82 
NM_005429 VEGFC vascular endothelial growth factor C -1.36 
Apoptosis 
   NM_005460 SNCAIP synuclein, alpha interacting protein -1.63 
NM_003810 TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 2.09 
NM_001066 TNFRSF1B tumor necrosis factor receptor superfamily, member 1B 1.57 
NM_018003 UACA uveal autoantigen with coiled-coil domains and 
ankyrin repeats -1.56 
Binding / Cell Adhesion 
  NM_001130861 CLDN5 claudin 5  1.76 
NM_024711 GIMAP6 GTPase, IMAP family member 6 1.45 
NM_022143 LRRC4 leucine rich repeat containing 4 1.38 
Cell Communication 
  NM_019074 DLL4  delta-like 4 (Drosophila) 1.55 
NM_018431 DOK5  docking protein 5 -1.77 
NM_014421 DKK2 dickkopf homolog 2 (Xenopus laevis) -1.56 
NM_207123 GAB1  GRB2-associated binding protein 1 -1.59 
NM_012302 LPHN2 latrophilin 2 -2.05 
NM_021724 NR1D1 nuclear receptor subfamily 1, group D, member 1  1.61 
NM_005065 SEL1L sel-1 suppressor of lin-12-like (C. elegans) -1.71 
Cell Cycle / Cell Proliferation 
 
NM_006988 ADAMTS1  ADAM metallopeptidase with thrombospondin type 1 
motif, 1 -1.56 
NM_003672 CDC14A  CDC14 cell division cycle 14 homolog A (S. 
cerevisiae)  -1.55 
NM_015147 CEP68 centrosomal protein 68kDa 1.71 
NM_015097 CLASP2 cytoplasmic linker associated protein 2 -1.70 
NM_001946 DUSP6  dual specificity phosphatase 6 -1.44 
NM_005524 HES1 hairy and enhancer of split 1, (Drosophila) 1.64 
NM_018116 MSTO1 misato homolog 1 (Drosophila) -1.51 
NM_001142393 NEDD9  neural precursor cell expressed, developmentally down-regulated 9  1.39 
NM_153618 SEMA6D sema domain, transmembrane domain (TM), and 
cytoplasmic domain, (semaphorin) 6D -3.64 
NM_002688 SEPT5 septin 5 -1.46 
NM_145728 SYNM synemin, intermediate filament protein -1.49 
NM_006472 TXNIP thioredoxin interacting protein 1.56 
NM_000222 KIT  v-kit Hardy-Zuckerman 4 feline sarcoma viral 
oncogene homolog 1.65 
Development 
   NM_014888 FAM3C  family with sequence similarity 3, member C  -1.66 
NM_006350 FST  follistatin -2.10 
NM_005266 GJA5  gap junction protein, alpha 5, 40kDa 2.64 
NM_002060 GJA4  gap junction protein, alpha 4, 37kDa 3.87 
NM_001002295 GATA3 GATA binding protein 3 1.42 
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Table S3.6: List of differentially expressed genes in HUVECs after a six hour treatment of 
500 ng/ml anti-VEGF antibody-treated VEGF (10 ng/ml) compared to VEGF (10 ng/ml) 
(p < 0.001; 131 genes). 
Gene ID 
Gene 
Abbreviation Gene Name 
Fold 
Change 
Development continued 
NM_003250 THRA thyroid hormone receptor, alpha (erythroblastic leukemia viral (v-erb-a) oncogene homolog, avian)  1.41 
DNA Binding / Replication / Repair / Transcription 
NM_006734 HIVEP2 human immunodeficiency virus type I enhancer binding protein 2 -1.74 
NM_021038 MBNL1 muscleblind-like (Drosophila)  -1.39 
NM_025081 KIAA1305  KIAA1305 1.45 
Immune Response 
NM_005080 XBP1 X-box binding protein 1  -1.41 
Metabolic / Biosynthetic Process 
NM_022060 ABHD4 abhydrolase domain containing 4 -1.35 
NM_003654 CHST1  carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 1.53 
NM_015892 CHST15 carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) 
sulfotransferase 15  1.57 
NM_015892 CHST15 carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) 
sulfotransferase 15 1.66 
NM_032385 C5orf4 chromosome 5 open reading frame 4  1.53 
NM_000499 CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1  2.03 
NM_013352 DSE  dermatan sulfate epimerase  -1.50 
NM_152879 DGKD  diacylglycerol kinase, delta 130kDa -1.62 
NM_012328 DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 -2.34 
NM_006260 DNAJC3 DnaJ (Hsp40) homolog, subfamily C, member 3 -1.91 
NM_014674 EDEM1  ER degradation enhancer, mannosidase alpha-like 1 -1.79 
NM_019891 ERO1LB ERO1-like beta (S. cerevisiae)  -2.46 
NM_004836 EIF2AK3 eukaryotic translation initiation factor 2-alpha kinase 3 -1.76 
NM_007076 FICD  FIC domain containing -1.59 
NM_000158 GBE1  glucan (1,4-alpha-), branching enzyme 1 -1.54 
NM_002056 GFPT1  glutamine-fructose-6-phosphate transaminase 1  -1.82 
NM_030792 GDPD5 glycerophosphodiester phosphodiesterase domain 
containing 5 1.41 
NM_018192 LEPREL1  leprecan-like 1 -1.71 
NM_001080424 KDM6B lysine (K)-specific demethylase 6B  1.60 
NM_001144967 NEDD4L neural precursor cell expressed, developmentally down-regulated 4-like  -1.44 
NM_004414 RCAN1 regulator of calcineurin 1 -2.25 
NM_014746 RNF144A ring finger protein 144A 1.76 
NM_006588 SULT1C4 sulfotransferase family, cytosolic, 1C, member 4 -2.16 
NM_032431 SYVN1  synovial apoptosis inhibitor 1, synoviolin  -1.36 
Response to Stimulus 
NM_000014 A2M alpha-2-macroglobulin  -1.75 
NM_005409 CXCL11 chemokine (C-X-C motif) ligand 11 3.22 
NM_001993 F3  coagulation factor III (thromboplastin, tissue factor) -1.49 
NM_005347 HSPA5  heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)  -1.51 
NM_014685 HERPUD1 homocysteine-inducible, endoplasmic reticulum 
stress-inducible, ubiquitin-like domain member 1 -1.85 
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Table S3.6: List of differentially expressed genes in HUVECs after a six hour treatment of 
500 ng/ml anti-VEGF antibody-treated VEGF (10 ng/ml) compared to VEGF (10 ng/ml) 
(p < 0.001; 131 genes). 
Gene ID 
Gene 
Abbreviation Gene Name 
Fold 
Change 
Response to Stimulus continued 
NM_006389 HYOU1 hypoxia up-regulated 1  -1.48 
NM_006010 MANF mesencephalic astrocyte-derived neurotrophic factor -1.65 
NM_000603 NOS3 nitric oxide synthase 3 (endothelial cell) 1.36 
NM_001122 PLIN2 perilipin 2 1.40 
NM_003155 STC1 stanniocalcin 1  -3.05 
NM_000361 THBD thrombomodulin  -2.11 
NM_006528 TFPI2 tissue factor pathway inhibitor 2  -1.97 
NR_024168 TLR4  toll-like receptor 4  -1.36 
NM_001078 VCAM1  vascular cell adhesion molecule 1 -2.13 
Signal Transduction 
NM_004041 ARRB1 arrestin, beta 1  1.42 
NM_173515 CNKSR3 CNKSR family member 3 -2.16 
NM_001014796 DDR2 discoidin domain receptor tyrosine kinase 2 -1.72 
NM_138445 GPR146 G protein-coupled receptor 146 1.89 
NM_032553 GPR174 G protein-coupled receptor 174 1.37 
NM_001945 HBEGF heparin-binding EGF-like growth factor  -1.71 
NM_006186 NR4A2 nuclear receptor subfamily 4, group A, member 2 -1.53 
NM_006266 RALGDS ral guanine nucleotide dissociation stimulator  1.44 
NM_007211 RASSF8  Ras association (RalGDS/AF-6) domain family (N-terminal) member 8  -1.64 
NM_016084 RASD1  RAS, dexamethasone-induced 1  -1.44 
NM_024605 ARHGAP10  Rho GTPase activating protein 10 -1.59 
NM_001010000 ARHGAP28 Rho GTPase activating protein 28 1.71 
NM_015149 RGL1  ral guanine nucleotide dissociation stimulator-like 1 -1.64 
Transcription 
NM_001200 BMP2  bone morphogenetic protein 2  -1.78 
NM_014368 LHX6  LIM homeobox 6  1.49 
NM_030915 LBH limb bud and heart development homolog (mouse)  -1.80 
NM_002397 MEF2C myocyte enhancer factor 2C -1.79 
NM_205860 NR5A2 nuclear receptor subfamily 5, group A, member 2  -1.83 
NM_001198 PRDM1 PR domain containing 1, with ZNF domain  -2.38 
Transport 
NM_170665 ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 -1.56 
NM_020453 ATP10D  ATPase, class V, type 10D  -1.75 
NM_198098 AQP1  aquaporin 1 (Colton blood group) 2.19 
NM_022113 KIF13A kinesin family member 13A -1.73 
NM_138444 KCTD12 potassium channel tetramerisation domain containing 12 1.69 
NM_014822 SEC24D SEC24 family, member D (S. cerevisiae)  -1.63 
NM_006363 SEC23B Sec23 homolog B (S. cerevisiae)  -1.47 
NM_003045 SLC7A1 solute carrier family 7 (cationic amino acid transporter, y+ system), member 1  -1.53 
NM_001046 SLC12A2 solute carrier family 12 (sodium/potassium/chloride transporters), member 2 -1.70 
NM_004733 SLC33A1 solute carrier family 33 (acetyl-CoA transporter), 
member 1 -1.72 
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Table S3.6: List of differentially expressed genes in HUVECs after a six hour treatment of 
500 ng/ml anti-VEGF antibody-treated VEGF (10 ng/ml) compared to VEGF (10 ng/ml) 
(p < 0.001; 131 genes). 
Gene ID 
Gene 
Abbreviation Gene Name 
Fold 
Change 
Transport continued 
NM_001128431 SLC39A14 solute carrier family 39 (zinc transporter), member 14 -2.47 
NM_013306 SNX15 sorting nexin 15 1.34 
Miscellaneous / Other 
NM_001613 ACTA2 actin, alpha 2, smooth muscle, aorta  1.59 
NM_032933 C18orf45  chromosome 18 open reading frame 45  -1.51 
NM_058187 C21orf63 chromosome 21 open reading frame 63 1.42 
NM_020939 CPNE5 copine V 1.41 
NM_030627 CPEB4  cytoplasmic polyadenylation element binding protein 4 -1.62 
NM_014787 DNAJC6 DnaJ (Hsp40) homolog, subfamily C, member 6  -1.53 
NM_020354 ENTPD7 ectonucleoside triphosphate diphosphohydrolase 7  -1.54 
NM_014600 EHD3 EH-domain containing 3 -3.28 
NM_033387 FAM78A  family with sequence similarity 78, member A 1.50 
NM_001130025 FAM115C  family with sequence similarity 115, member C -1.64 
NM_024785 FAM124B family with sequence similarity 124B 1.57 
NM_015687 FILIP1 filamin A interacting protein 1  1.51 
NR_024042 GUCY2E guanylate cyclase 2E 1.63 
NM_006948 HSPA13 heat shock protein 70kDa family, member 13  -1.54 
NM_001134476 LRRC8B leucine rich repeat containing 8 family, member B -2.01 
NM_015993 PLLP plasma membrane proteolipid (plasmolipin) 2.14 
NM_001104587 SLFN11 schlafen family member 11 -2.00 
NM_144682 SLFN13 schlafen family member 13  -1.46 
NR_002816 THSD1P thrombospondin, type I, domain containing 1 pseudogene 1.48 
NM_013390 TMEM2 transmembrane protein 2 -1.83 
NM_006134 TMEM50B transmembrane protein 50B -1.88 
NM_015271 TRIM2 tripartite motif-containing 2 -1.48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Information 3 
 
424 
 
Table S3.7: List of differentially expressed genes in HUVECs after a six hour treatment of 
500 ng/ml anti-VEGF antibody-treated VEGF (10 ng/ml) compared to apple procyanidin 
fraction dp 4 (1 µM) (p < 0.001; 37 genes).  
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Angiogenesis 
   NM_001147 ANGPT2 angiopoietin 2  1.70 
NM_001202 BMP4 bone morphogenetic protein 4 1.81 
NM_005924 MEOX2 mesenchyme homeobox 2 1.64 
NM_005429 VEGFC vascular endothelial growth factor C -1.38 
Apoptosis 
   NM_182757 RNF144B ring finger protein 144B 1.63 
NM_005092 TNFSF18 tumor necrosis factor (ligand) superfamily, member 18 1.95 
Binding / Cell Adhesion 
  NM_002982 CCL2 chemokine (C-C motif) ligand 2 1.43 
NM_024787 RNF122 ring finger protein 122 -1.49 
Cell Communication 
  NM_017413 APLN apelin 1.63 
NM_015191 SIK2 salt-inducible kinase 2 -1.43 
Cell Cycle / Cell Proliferation 
  NM_001946 DUSP6 dual specificity phosphatase 6 1.44 
Development 
   
NM_006079 CITED2 Cbp/p300-interacting transactivator, with Glu/Asp-rich 
carboxy-terminal domain, 2 1.42 
NM_012242 DKK1 dickkopf homolog 1 (Xenopus laevis)  2.05 
NM_001002295 GATA3 GATA binding protein 3 1.51 
NM_182964 NAV2 neuron navigator 2  -1.69 
DNA Binding / Replication / Repair / Transcription 
 NM_004956 ETV1 ets variant 1 1.65 
NM_005378 MYCN v-myc myelocytomatosis viral related oncogene, 
neuroblastoma derived (avian) -1.64 
Inflammatory Response 
  NM_002852 PTX3 pentraxin-related gene, rapidly induced by IL-1 beta 1.67 
Immune Response 
  NM_003954 MAP3K14 mitogen-activated protein kinase kinase kinase 14 -1.39 
Metabolic / Biosynthetic Process 
 
NM_005099 ADAMTS4 ADAM metallopeptidase with thrombospondin type 1 
motif, 4 -1.58 
NM_018371 CSGALNACT1 chondroitin sulfate N-acetylgalactosaminyltransferase 1  1.50 
NM_001097634 GCNT1 glucosaminyl (N-acetyl) transferase 1, core 2 (beta-1,6-N-acetylglucosaminyltransferase) 1.64 
NM_001159323 PLA2G4C phospholipase A2, group IVC (cytosolic, calcium-independent) -1.51 
NM_000963 PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) -1.79 
NM_001142298 SQSTM1 sequestosome 1 -1.41 
Signal Transduction 
  NM_014391 ANKRD1 ankyrin repeat domain 1 (cardiac muscle) 1.51 
NM_015368 PANX1 pannexin 1 -1.42 
NM_005842 SPRY2 sprouty homolog 2 (Drosophila) 1.60 
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Table S3.7: List of differentially regulated genes in HUVECs after a six hour treatment of 
500 ng/ml anti-VEGF antibody-treated VEGF (10 ng/ml) compared to apple procyanidin 
fraction dp 4 (1 µM) (p < 0.001; 37 genes) continued. 
Gene ID Gene Symbol Gene Name 
Fold 
Change 
Signal Transduction continued 
  
NM_005841 SPRY1 sprouty homolog 1, antagonist of FGF signalling (Drosophila) 1.72 
Transcription 
   NM_004454 ETV5 ets variant 5 1.90 
NM_002397 MEF2C myocyte enhancer factor 2C -1.56 
NM_022157 RRAGC Ras-related GTP binding C -1.47 
NM_020245 TULP4 tubby like protein 4 -1.37 
NM_152320 ZNF641 zinc finger protein 641 1.53 
Transport 
   
NM_003043 SLC6A6 solute carrier family 6 (neurotransmitter transporter, taurine), member 6 -1.70 
NM_003046 SLC7A2 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 -1.78 
Miscellaneous / Other 
  
NM_004657 SDPR serum deprivation response (phosphatidylserine binding protein) 1.35 
 
 
 
 
 
 
